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 The introduction of antibiotics revolutionized modern medicine. Surgical procedures 
became safer to perform, neonatal fatalities plummeted, and the risk of death from simple injuries 
was virtually eliminated. Since their initial discovery and introduction to the clinic in the 1940s, a 
steady supply of new agents helped establish this “antibiotic era.” In large part due to their 
remarkable success, antibiotics are today expected to be safe, cheap, and effective at a level 
unparalleled by any other class of drugs. The expansive use and misuse of antibiotics has caused 
a rise in antibiotic microbial resistance (AMR) at a time that new antibiotic discovery has slowed 
to a crawl. The time of picking low-hanging fruit has ended. New approaches to antibiotic 
discovery are sorely needed to avoid entering the “post-antibiotic era.” One critical component of 
any new strategy is a better understanding of how to get drugs into bacterial cells. A combined 
effort featuring complex molecule synthesis, microbiology, and cheminformatics has led to the 
development of guidelines that enable compound entry. These guidelines can jump-start stalled 
antibiotic projects and help usher new classes of drugs into the clinic. Several initial examples of 
converting gram-positive-only antibiotics into broad-spectrum agents shown here demonstrate the 
potential impact of this kind of approach. 
 Poly(ADP-ribose) (PAR) signaling is an important component of DNA damage repair, cell 
division regulation, and initiation of controlled cell death. Despite extensive knowledge and a 
powerful toolkit available for studying the synthesis of PAR (including several approved drugs), 
significantly less is known about the degraders of PAR. This lack of knowledge is attributed to a 
lack of tool compounds and assays that can inhibit or measure the activity of the major PAR 
degraders (PARG and ARH3). Towards filling this need, novel fluorogenic substrates of PARG 
and ARH3 were designed and synthesized. Using these tools, the first continuous enzyme activity 
assays for PARG and ARH3 were developed for use with purified enzymes and in cell lysate. 
Critically, a substrate selective for ARH3 was utilized to identify an endogenous inhibitor of 
ARH3, ADP-ribosylated arginine. This compound is produced in cells treated with cholera toxin 
and is a potent and selective inhibitor of ARH3. With a new activity assay for measuring PARG 
and ARH3 activity and the first selective inhibitor of ARH3, we now have the tools necessary to 






 I have had the great privilege to work with many excellent scientists while working in 
graduate school. In particular, I would like to thank my advisor Prof. Paul Hergenrother for leading 
my research and education. Paul’s confidence in my ability and optimism in every project I worked 
on was critical to my success. He taught me how to think about big problems and remain focused 
on the larger context of our research.  
 I am grateful for the support of my thesis committee. Professors Burke, Zimmerman, and 
Silverman have challenged me while encouraging my development. I have had the privilege to 
collaborate with several excellent laboratories. In particular, I thank Prof. Ivan Ahel and Dr. 
Johannes Rack from Oxford University as well as Prof. Gee Lau from University of Illinois 
College of Veterinary Medicine. I would like to thank Prof. Daniel Burden and Prof. Lisa Burden, 
my advisors from Wheaton College, who introduced me to research at the interface of chemistry 
and biology and encouraged me to attend chemistry graduate school. 
I would like to thank Dr. Rob Huigens, Dr. Matthew Brichacek, Dr. Michael Lambrecht 
for training me in synthetic organic chemistry. I was supported by many people on the poly(ADP-
ribose) project including Matt, Mike, Dr. Tomohiro Shirai, Dr. Claire Knezevic, Dr. Bryan 
Yestrepsky, Lydia Boike, and Aya Kelly. In studying bacterial accumulations, I am greatly 
indebted to Dr. Michelle Richter, Dr. Andrew Riley, Emily Geddes, Alfredo Garcia, Sarah 
Perlmutter, and Riley Svec. While working on converting antibiotics, it was supported by Dr. Erica 
Parker, Dr. Stephen Motika, Dr. Sarah Tasker, Emily Geddes, Alfredo Garcia, Sarah Perlmutter, 
Martin Chavez, and Kristen Munoz. Thank you all for creating a fun and supportive working 
environment. I am also thankful for my parents, Stephen and Ellen Drown, who supported me 
from afar through this long degree. Finally, thank you Betsy for emotion and scholastic support; 
you help keep me excited about science. 
 iv 
TABLE OF CONTENTS 
CHAPTER 1 INTRODUCTION ..................................................................................................... 1 
1.1. Status of antibiotic resistance crisis ...................................................................................... 1 
1.2. Mechanisms of intrinsic resistance ....................................................................................... 6 
1.2.1. Structure of outer membrane ......................................................................................... 6 
1.2.2. Porins ............................................................................................................................. 7 
1.2.3. Efflux pumps ................................................................................................................. 8 
1.3. Design principles for gram-negative drugs .......................................................................... 9 
1.3.1. The eNTRy rules for gram-negative accumulation ..................................................... 10 
1.3.2. Strategy for expanding spectrum of activity for existing antibiotics ........................... 10 
1.4. Conversion candidates from FDA-approved drugs ............................................................ 12 
1.4.1. Linezolid ...................................................................................................................... 13 
1.4.2. Fusidic acid .................................................................................................................. 15 
1.4.3. Clindamycin ................................................................................................................. 17 
1.5. Conversion candidates from clinical pipeline .................................................................... 18 
1.5.1. Zoliflodacin ................................................................................................................. 19 
1.5.2. Afabicin ....................................................................................................................... 20 
1.5.3. Iclaprim ........................................................................................................................ 24 
1.6. Candidates from pre-clinical pipeline ................................................................................ 26 
1.6.1. Indolmycin ................................................................................................................... 26 
1.6.2. Ribocil ......................................................................................................................... 27 
1.6.3. FtsZ inhibitors .............................................................................................................. 28 
1.6.4. AccC inhibitors ............................................................................................................ 31 
1.6.5. MurC inhibitors ........................................................................................................... 33 
1.6.6. LolCDE inhibitors ....................................................................................................... 36 
1.6.7. RNAP inhibitors .......................................................................................................... 37 
1.7. Concluding remarks ............................................................................................................ 38 
1.8. References .......................................................................................................................... 38 
CHAPTER 2 PREDICTION OF GRAM-NEGATIVE ACCUMULATION ............................... 53 
2.1. Introduction ........................................................................................................................ 53 
2.1.1. Predictive modeling in drug discovery ........................................................................ 53 
2.1.2. Existing models for bacterial accumulation ................................................................ 54 
 v 
2.2. Development of predictive guidelines ................................................................................ 55 
2.2.1. Assembly of accumulation training set ....................................................................... 55 
2.2.2. Overview of properties ................................................................................................ 58 
2.2.3. Data preprocessing ...................................................................................................... 60 
2.2.4. Regression model of accumulation .............................................................................. 61 
2.2.5. Classification model of accumulation ......................................................................... 63 
2.2.6. Case-studies to support findings .................................................................................. 66 
2.3. Web application for predicting accumulation .................................................................... 68 
2.3.1. Survey of conformer generation techniques ................................................................ 69 
2.3.2. Implementation of globularity calculation ................................................................... 70 
2.3.3. Overview of MVC Rails framework ........................................................................... 71 
2.3.4. Implementation of queuing system with AWS SQS ................................................... 73 
2.3.5. Walk-through of entry-way ......................................................................................... 75 
2.4. Molecular dynamics for OmpF .......................................................................................... 75 
2.5. Conclusions ........................................................................................................................ 80 
2.6. Materials and methods ........................................................................................................ 81 
2.7. References .......................................................................................................................... 85 
CHAPTER 3 CONVERSION OF NARROW SPECTRUM ANTIBIOTICS .............................. 89 
3.1. Afabicin .............................................................................................................................. 89 
3.1.1. Alternative FabI inhibitors ........................................................................................... 89 
3.1.2. Design of derivatives ................................................................................................... 91 
3.1.3. Synthesis of FabI inhibitors ......................................................................................... 94 
3.1.4. Antimicrobial susceptibility to Debio-1452-NH3 ....................................................... 94 
3.1.5. Resistance to FabI inhibitors ....................................................................................... 96 
3.1.6. In vitro FabI assay ....................................................................................................... 98 
3.1.7. In vivo activity ............................................................................................................. 99 
3.2. Zoliflodacin ...................................................................................................................... 100 
3.2.1. Synthesis of zoliflodacin and derivatives .................................................................. 101 
3.2.2. Evaluation of zoliflodacin derivatives ....................................................................... 104 
3.3. Indolmycin ........................................................................................................................ 104 
3.4. Zantrin Z3 ......................................................................................................................... 110 
3.5. Conclusion ........................................................................................................................ 118 
 vi 
3.6. Materials and methods ...................................................................................................... 118 
3.6.1. Biology assays ........................................................................................................... 118 
3.6.2. Synthesis of zoliflodacin derivatives ......................................................................... 123 
3.6.3. Synthesis of indolmycin derivatives .......................................................................... 133 
3.6.4. Synthesis of FtsZ inhibitors ....................................................................................... 140 
3.7. References ........................................................................................................................ 147 
CHAPTER 4 PROBES FOR POLY(ADP-RIBOSE) REGULATORS ...................................... 154 
4.1. Introduction ...................................................................................................................... 154 
4.1.1. Canonical PAR signaling ........................................................................................... 155 
4.1.2. PAR-hydrolyzing enzymes ........................................................................................ 156 
4.1.3. PARG assays ............................................................................................................. 157 
4.2. Design and synthesis of PARG substrates ........................................................................ 157 
4.2.1. Design of an ARH3-selective substrate ..................................................................... 160 
4.3. Utilizing PARG substrates ............................................................................................... 163 
4.3.1. In vitro processing of substrates ................................................................................ 163 
4.3.2. Measuring ARH3 activity assay in cell culture ......................................................... 166 
4.3.3. Survey of cancer cell lines ......................................................................................... 168 
4.3.4. Mechanism of ARH3 inhibition by ADP-ribosyl-arginine ....................................... 169 
4.4. Synthesis and evaluation of ADP-HPD and analogues .................................................... 172 
4.4.1. Synthesis of ADP-HPD ............................................................................................. 173 
4.4.2. Synthesis of ADP-HPM ............................................................................................. 175 
4.4.3. Differential inhibition by ADP-HPD and ADP-HPM ............................................... 176 
4.5. Future directions ............................................................................................................... 177 
4.5.1. Improved substrate design ......................................................................................... 177 
4.5.2. Screen for synthetic lethality with ARH3 .................................................................. 177 
4.5.3. ARH3 inhibitors inspired by ADPr-Arg .................................................................... 177 
4.5.4. MacroD1 substrates ................................................................................................... 179 
4.6. Materials and methods ...................................................................................................... 180 
4.6.2. Synthesis of PARG substrates ................................................................................... 187 
4.6.3. Synthesis of amino sugar PARG inhibitors ............................................................... 207 




CHAPTER 1 INTRODUCTION 
1.1. Status of antibiotic resistance crisis 
Antibiotic microbial resistance is a global health crisis that has slowly yet relentlessly 
marched forward in recent years. With the establishment of resistance surveillance networks in the 
early 2000s, the US, Europe, and China have been able to more accurately measure the scope of 
the problem and found they face different challenges.1-3 In the US, 80-85% Enterococcus faecium 
infections are vancomycin resistant while only 8% are vancomycin resistant in Europe.4,5 In 
Europe, co-resistance to carbapenems, fluoroquinolones, and aminoglycosides is the most 
common resistance phenotype, particularly in Klebsiella pneumoniae.6 China is unique in that 
colistin resistant Enterobacteriaceae has reached an alarming average rate of 15% with local rates 
as high as 32% in some provinces.7 Given the potential for these resistant populations to rapidly 
move across the globe, the WHO attempted to focus attention on pathogens that pose a global risk 
by harmonizing individual government reports.8  
The resulting report classifies pathogens into three levels of urgency. The highest level, 
termed “critical priority”, consists of Acinetobacter baumannii, Pseudomonas aeruginosa, and 
Enterobacteriaceae species, all gram-negative bacteria (Table 1.1). These priority pathogens 
account for one-third of acute hospital-acquired infection (greater than 40% in intensive care 
units).4,9 The WHO surveyed a panel of experts to determine the most important criteria for 
measuring priority and concluded the most important factors are: treatability, mortality, health-
care burden, and 10-year trend of resistance. This most critical factor, treatability, is prescient 
when considering trends in production of antibiotics effective against gram-negative infections. 
Table 1.1 Bacterial pathogens identified as high priority for public health. 
IDSA ESKAPE Pathogens – 2008   
   Enterococcus faecium Gram-positive 
   Staphylococcus aureus Gram-positive 
   Klebsiella pneumoniaea Gram-negative 
   Acinetobacter baumannii Gram-negative 
   Pseudomonas aeruginosa Gram-negative 
   Enterobacter genusb Gram-negative 
WHO Priority Pathogens – 2017   
   Acinetobacter baumannii Gram-negative 
   Pseudomonas aeruginosa Gram-negative 
   Enterobacteriaceae familyc Gram-negative 
aEscherichia coli is often associated due to high similarity 
bIncludes E. cloacae and E. aerogenes 




Figure 1.1 Taxonomy of several medically relevant bacteria. ESKAPE pathogens are highlighted in red and 
WHO priority pathogens are bolded. 
Several years earlier, the Infectious Disease Society of America identified a group of 
microorganisms that they acronymically referred to as the “ESKAPE pathogens.”10,11 The 
ESKAPE pathogens were so called because of their capacity of escape the biocidal activity of 
typical antibiotics and represent microorganisms with hitherto unparalleled pathogenicity, 
transmission, and resistance (Table 1.1). These pathogens are over represented among hospital-
acquired infections, particularly amongst critically ill and immunocompromised patients.12 
Strikingly, 4 out 6 ESKAPE pathogens are gram-negative, which reiterates the critical need for 
new treatment options for gram-negative bacteria. The ESKAPE pathogens list does not explicitly 
include E. coli, but this species is often associated with this list due to its close relationship to 
Enterobacter and Klebsiella (Figure 1.1). 
The last class of antibiotics with efficacy against gram-negative bacteria to be introduced 



















































been approved for use against gram-positive infections. This dichotomy is not likely to change 
given the current state of the antibiotic clinical pipeline. Of the drugs currently in clinical 
development only one new class of compounds is expected to have efficacy against a “critical 
priority” pathogen.13 This compound, murepavadin, is only active in P. aeruginosa and lacks 
activity in other gram-negatives.14,15 The majority of new drugs approved and currently in the 
clinic are advanced generations of existing drug classes. This is best exemplified by b-lactams for 
which derivatives are designed that can circumvent the principle mode of resistance, expression of 
b-lactamases. While some these compounds have clear value in that they resensitize bacteria that 
had become resistant to earlier generations, a much more effective strategy for dealing with 
resistance is to utilize drugs with orthogonal mechanisms of action and thereby avoiding cross-
resistance. This tendency to revisit existing drug classes is due in part to the unique challenges 
associated with developing novel gram-negative drugs and in part the regulatory environment for 
antibiotics.  
Table 1.2 Classes of antibiotics and their date of introduction to the clinic. Gram-positive only classes 
introduced after the last gram-negative class are in red. 
Gram-positive Only  Broad spectrum 
Name Date Introduced  Name Date Introduced 
Macrolides 1952  b-lactams 1942 
Glycopeptides 1955  Aminoglycosides 1944 
Fusidates 1962  Tetracyclines 1950 
Aminocoumarins 1964  Sulfonamides/Trimethoprim 1961 
Ansamycins 1968  Quinolones 1967 
Lincosamides 1968    
Mupirocin 1986    
Dalfopristin 1999    
Oxazolidinones 2000    
Daptomycin 2003    
Pleuromutilins 2007    
 
There are unique regulatory challenges in the antibiotic area. Superiority clinical trials of 
MDR infections would be most desirable for evaluating the efficacy of investigational new drugs.16 
These types of trials are technically challenging to administer and are ethically problematic as 
placebo treatment of acute infections can result in rapid complications or even death.16,17 
Additionally, recruitment of patients with MDR infections is challenging due to low incidence 
rates. For decades, non-inferiority trials have been preferred in which new drugs are compared to 
an active control. As it is important that non-inferiority is evaluated in challenging acute infections 
in which antibiotic intervention is necessary, the FDA has provided specific guidance for trial 
design for several types of infection: acute bacterial skin and skin structure infection (ABSSSI),18 
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community and hospital acquired pneumonia,19 ventilator-associated pneumonia,20 complicated 
intra-abdominal infection,21 and complicated urinary tract infection.22 While non-inferiority is a 
useful benchmark in that it allows antibiotics with potential activity against MDR infections to be 
introduced into the clinic ahead of MDR outbreaks, this standard can be a distorted filter in some 
cases. Drugs that have efficacy against MDR strains yet cannot compete with existing drugs in 
wild-type strains will perform poorly under this regime. Meanwhile, antibiotics with the same 
spectrum of activity as approved drugs can gain approval. 
  
Figure 1.2 Antibiotics approved by the FDA 1980-2009 but then subsequently withdrawn by 2013. Figure 
adapted from Ref. 23. *Sales discontinued prior to 1993; exact date was unavailable. 
The poor financial return on investment is often cited as a major motivation for the 
departure of major pharmaceutical companies from the antibiotic development area for three 
reasons.24 First, antibiotics treat acute conditions and are commonly prescribed for relatively short 
periods of time.25 Second, prices for new antibiotics must compete with historically low prices for 
older, generic drugs that are efficacious in most circumstances. Third, the onset of resistance can 
be quite rapid meaning a drug can only remain on the market for a limited period of time before 





































































the third highest earning drug class, bringing in $25 billion to $45 billion per year.26 The 
profitabilities of individual antibiotics greatly vary. Not all antibiotics are as profitable as 
daptomycin, which earned $1 billion in 2013 and $382 million in revenue in 2017. Between 1980 
and 2009, the FDA approved 61 systemic antibiotics, representing 11-16% of all approvals by 
decade.27 By 2013, twenty six (43%) had been withdrawn from the market, representing the highest 
rate among drug classes (Figure 1.2). While some of these withdrawals were due to safety, the 
majority of withdrawals were voluntary. Sales data shows that only three of the withdrawn 
compounds were commercial successes, and only two were granted FDA’s priority review status.23 
Although it is difficult to speculate the precise reasons for each withdrawal, sales data suggests 
that these drugs could not compete with similar preexisting antibiotics bearing similar properties. 
Developing new antibiotics can be a profitable enterprise as long as the new agent addresses an 
unmet clinical need as evidenced by the recent financial success of linezolid, azithromycin, and 
daptomycin. 
 
Figure 1.3 Hit to lead development of compounds coming from high-throughput screen programs. MurC,28 
DNA ligase,29 and AccC30,31 inhibitors all originated from target-based screens and did not provide clinical 
candidates. MetRS32,33 and FabI34-36 inhibitors also originated from target-based screens but produced clinical 
candidates for gram-positive indications. Zoliflodacin originated from a whole-organism screen with the 
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Even in the face of this regulatory environment, pharmaceutical companies have made a 
concerted effort to discover new classes of gram-negative antibiotics. Large genomic studies have 
revealed essential genes in E. coli,40 K. pneumoniae,41 A. baumannii,42 and P. aeruginosa.43,44 
These genomic data were then used to design and execute high-throughput screens against 
putatively essential protein targets. AstraZeneca and GlaxoSmithKline both conducted 
retrospective analyses of these screening campaigns.45-49 Both companies were successful in 
identifying hits and leads after screening a combined 5 million compounds in 135 screens. Despite 
the ability to translate hit compounds into leads with potent activity against purified protein, none 
of these leads had appreciable gram-negative cellular activity (Figure 1.3). In the course of this 
work and elsewhere, however, new chemotypes were discovered that potently inhibit exciting new 
targets in bacteria as evidenced by the advancement of several of these into the clinic for gram-
positive infections. As demonstrated by whole-cell antibacterial activity in ∆tolC strains, these 
compounds have the potential to be novel gram-negative antibiotics if only sufficient cellular 
accumulation could be achieved. With a better understanding of how gram-negative bacteria limit 
accumulation, we anticipate that many of these newly discovered compounds can become effective 
antibiotics. 
1.2. Mechanisms of intrinsic resistance 
While proliferation of acquired resistance via horizontal gene transfer is a critical public 
health concern, gram-negative bacteria are uniquely challenging to develop effective therapies 
against due to their intrinsic resistance to most small-molecule antibiotics. Gram-negative bacteria 
employ a number of strategies to evade exposure to xenotoxins. The most well conserved across 
species are: exclusive outer membrane, selective porins, and active efflux transporters (Figure 1.4). 
1.2.1. Structure of outer membrane 
The defining feature of gram-negative bacteria that differentiate them from gram-positive 
organisms is the presence of a second outer membrane (Figure 1.4). Critically, the outer membrane 
is not symmetric. The nearly three-quarters of the outer leaflet of the outer membrane consists of 
lipopolysaccharide (LPS) molecules, the remaining area filled by proteins.50 LPS is a modular 
molecule containing three portions: a highly acylated di-glucosamine (lipid A) connected to a 
conserved oligosaccharide Kdo/heptose core followed by a repeating polysaccharide (O-
antigen).51 While some gram-negative organisms can survive without LPS synthesis (e.g. 
Neisseria, Moraxella, and Acinetobacter),52-54 the minimal structure for most others is Kdo2-lipid 
A (Figure 1.4).55,56 Strains can be engineered to present this truncated LPS by knockout of rfaC 
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(gene encoding for glycosyltransferase that transfers innermost heptose to Kdo2, UniProt 
P24173).57 These strains are hypersensitive to antibiotics due to the enhanced rate of diffusion 
across the outer membrane.58 
The ability of LPS-containing membranes to exclude small-molecules has been known for 
quite some time, but the mechanism by which diffusion is slowed has remained a matter of debate. 
The permeability of the asymmetric outer membrane is about 1% of that of a typical phospholipid 
bilayer.59 Much like gram-positive bacteria, the peptidoglycan layer was long regarded as the 
principle source of strength and rigidity for gram-negative bacteria. Recent work has revised this 
paradigm and points to the outer membrane as the primary load-bearing element for gram-negative 
organisms.60 LPS has more numerous, shorter acyl tails compared to phosphatidylglycerol and 
consequently pack tighter and result in a stiffer membrane. 61 The attached oligosaccharides are 
also highly charged, bearing both phosphates and carboxylic acids (Figure 1.4). The resulting 
environment is too polar for most drug-like molecules to cross. Whether through increased rigidity 
or presentation of a highly charged shield, bacterial LPS is an effective barrier against most drugs. 
 
Figure 1.4 Architecture of bacterial cellular envelopes. Gram-positive bacteria possess a single membrane 
constructed from phospholipids and a thick yet loosely cross-linked peptidoglycan layer. Most lipophilic 
small-molecules can passively diffuse across this barrier. Gram-negative bacteria possess an additional outer 
membrane composed of LPS molecules that limit the passive diffusion of small-molecules across the 
membrane. Instead, molecules must traverse porins. Once inside the cell, small-molecules are subject to 
removal by promiscuous efflux pumps. The minimally viable LPS molecule is Kdo2-Lipid A. Figure adapted 
with permission from Annals of the New York Academy of Sciences, Ref. 62 © 2018 John Wiley and Sons. 
1.2.2. Porins 
Because gram-negative bacteria protect themselves from small-molecules passively 






















































survive. While some essential metals are scavenged by specialized ligands called siderophores and 
the specific receptors, most nutrients enter cells via integral membrane proteins called porins. The 
wide diversity and function of porins have been reviewed extensively elsewhere.57,63-66 The 
majority of approved antibiotics enter bacteria through porins. Most porins are characterized by 
an hourglass shape that features a constriction site near the center. This constriction site features 
charge segregation: a basic ladder consisting of arginine and lysine residues on one side and acidic 
residues on the other side. This charge separation forms an electric field perpendicular to the 
direction of translocation. As a result, compounds possessing dipoles that can align with the 
constriction site electric field have greater propensity to cross the porin. The precise orientation 
and flexibility of charged residues in and around the constriction site influence the selectivity of 
porins. 
The availability of high-quality crystal structures of bacterial porins has led to molecular 
modeling of these proteins and the translocation of molecules across them. While the ionic 
selectivity of porins have been extensively explored in detail,67,68 the slower process of antibiotic 
translocation is much more challenging to study due the intense computational requirements. 
Instead, effort has focused on case studies of individual antibiotics traversing porins.69-72    In these 
simulations, E. coli OmpF is the predominantly studied porin, in part due to the availability of 
experimental data.67,68,73-80 Further complicating the understanding of porin transport is the role of 
water and ions play; Mg2+ has been implicated in facilitating the translocation of fluoroquinolones 
across OmpF.70 While more recent attention has been focused on the more specific porins of P. 
aeruginosa, OmpF is a good model for the “general” porins in Enterobacteriaceae, which 
significantly contribute to the AMR crisis. 
1.2.3. Efflux pumps 
Even after successfully traversing the outer membrane of bacteria through porins or via 
self-promoted uptake, small-molecules are still susceptible to removal from the cell by active 
transporters called efflux pumps. While substrate specific efflux pumps can be important for 
conferring high level resistance to some classes of antibiotics (e.g. tetracyclines and 
macrolides),81,82 promiscuous efflux pumps that provide intrinsic resistance is a more persistent 
problem in developing new drugs. The most prominent class such of efflux pumps in gram-
negative bacteria are resistance-nodulation-cell division (RND) transporter complexes, which 
includes AcrAB-TolC in E. coli and MexAB-OprM in P. aeruginosa.63,83-87 The RND type efflux 
pumps are tripartite assemblies comprised of a substrate antiporter (e.g. AcrA), an adaptor protein 
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(e.g. AcrB), and an access-regulated efflux duct (e.g. TolC). This class of efflux pumps utilize the 
proton-motive force to transport a broad range of small-molecule substrates. A key observation 
was that knockout of tolC generally leads to increased sensitivity to antibiotics that otherwise have 
very little activity against gram-negatives. The efflux ratio (ratio of wild type MIC to ∆tolC MIC) 
has been used to support the notion that efflux is the main driver of poor accumulation. As a result, 
several researchers have tried to discern the substrate recognition of efflux pumps through 
molecular dynamics, cheminformatic, and reconstituted systems.83,88-92 This interpretation fails to 
consider that influx rate can still impact efflux ratios as shown by the impact of knocking out rfaC 
(Table 1.3).49,93 While the efficacy of antibiotics are certainly limited by the action of general 
efflux pumps, the impact of poor influx is much more deleterious to their translation into drugs. 
Table 1.3 Relationship of E. coli susceptibility to efflux and influx. Data was acquired in-house. 
 MIC (µg/mL)  Susceptibility Ratio 
Agent MG1655 ∆tolC ∆rfaC  ∆tolC ∆rfaC 
Rifampin 8 4 1  2 8 
Fusidic Acid 1024 2 16  512 64 
Erythromycin 16 1 0.5  16 32 
Azithromycin 1 0.25 0.032  4 32 
Vancomycin 128 128 128  1 1 
Ciprofloxacin 0.016 0.004 0.008  4 2 
Novobiocin 512 0.5 16  1024 32 
Linezolid 256 8 32  32 8 
Debio-1452 >32 0.032 1  >1024 >32 
Zantrin-Z3 >32 2 n.d.  >16 n.d. 
Ribocil-C 32 0.5 1  64 32 
Indolmycin 64 4 16  16 4 
 
1.3. Design principles for gram-negative drugs 
Retrospective analyses of drug development programs have identified a fundamental 
challenge in antibiotic development, which is the translation of candidate compounds with good 
in vitro activity to agents active against wild-type organisms.46-49 The prevailing assumption was 
that gram-negative antibiotics occupy a part of chemical space separate from most other drug 
classes. Even when describing the “rule of 5,” Lipinski identified antibiotics as an exception.94 The 
most influential treatise on the properties necessary for bacterial accumulation, by O’Shea and 
Moser, suggested that gram-negative antibiotics generally have a lower moleculear weight, are 
more polar, and have a higher relative polar surface area than gram-positive drugs.95 This analysis 
was restricted to FDA approved drugs and consequently limited to relatively few compound 
classes. More recent analyses have appreciated the importance of directly measuring compound 
accumulation but still are limited to relatively few compounds; additionally, these studies have 
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largely reiterated previous findings that small and polar compounds more easily traverse the outer-
membrane.96 Reanalysis by others suggests that these physiochemical properties are more 
indicative of protein target than antibiotics generally.97 Several medicinal chemistry campaigns 
trying to implement this strategy have not provided gram-negative active agents, highlighting the 
poor actionability of these guidelines derived from the retrospective studies. 
1.3.1. The eNTRy rules for gram-negative accumulation 
We sought to develop general guidelines for compound design that would predict a higher 
likelihood of accumulation in gram-negative bacteria. Informed by the limitation of previous 
studies, this project was intentionally prospective, featured a large and diverse compound 
collection, and directly measured compound accumulation.98 This approach is described in detail 
in Chapter 2. Briefly, E. coli cells were individually exposed to a library of complex and diverse 
compounds. After a short incubation, extracellular compounds was removed, cells were lysed, and 
intracellular compound concentration was determined by LC-MS/MS quantification. 
Cheminformatic analysis of results from these experiments led to the formalization of a new set of 
guidelines, termed the eNTRy rules. Higher accumulation is correlated with compounds that 
possess an ionizable nitrogen, have low three-dimensionality (globularity ≤ 0.25), and have few 
rotatable bonds (RB ≤ 5). These findings were consistent with existing gram-negative agents and 
were confirmed with several test conversions. 
1.3.2. Strategy for expanding spectrum of activity for existing antibiotics 
While a new class of antibiotics with efficacy against gram-negative bacteria has not been 
introduced into the clinic for decades, a sizeable arsenal of antibiotics has been assembled with 
efficacy against gram-positive organisms. In most cases, their limited spectrum of activity is due 
to the inability to penetrate gram-negative bacteria. If key chemical features that enable 
accumulation could be identified, then a significant number of new antibiotics could be ushered 
into the development pipeline. With judicial application of the eNTRy rules, many gram-positive 
antibiotics are anticipated to gain activity against gram-negative bacteria. 
As not all gram-positive antibiotics are deemed suitable for conversion, the selection 
criteria for conversion candidates includes the known bioactivity as well as the chemical structure 
itself. First, accumulation should be the sole reason a candidate compound does not exhibit activity 
against gram-negative bacteria. This can be predicted through genetic methods: target homology 
between gram-positive and gram-negative orthologs, lethal knockout of target, and absence of 
redundant pathways. Observing susceptibility in strains that enable compound accumulation is a 
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far more diagnostic experiment. This can be accomplished by knocking out efflux pumps (∆tolC), 
mutation in LPS biosynthesis (∆lpxC or ∆rfaC), potentiation by colistin, or a combination of 
approaches. Knockout of efflux pumps and colistin potentiation rarely causes susceptibility to the 
same extent as against gram-positive bacteria; the MIC is typically 2-4 fold higher. While others 
regard the ratio of MIC against wild-type E. coli and ∆tolC E. coli (often called the efflux ratio) 
as an indication that efflux is the primary barrier to efficacy, this interpretation disregards the 
nature of MIC determination experiments. CLSI guidelines dictate that bacteria should be exposed 
for 16-20 hours before growth inhibition determination.99 In these steady-state conditions, 
compounds with rapid influx may accomplish similar target exposure regardless of efflux rates 
resulting in the same MIC.49 Conversely, a compound with slow influx may be able to slowly 
diffuse across the outer-membrane over the course of several hours. With a competent efflux 
system, bacteria can keep the intracellular concentration sufficiently low as to evade death. In this 
case, the rate of influx may be the primary determinant of efficacy rather than efflux. At the very 
least, MIC ratios are poor tools for making conclusions about kinetics. We use activity in ∆tolC E. 
coli solely as indicative that an antibiotic’s molecular target is conserved in gram-negative 
bacteria. 
The second most significant factor in conversion candidate selection is an in-depth 
understanding of structure-activity relationship (SAR). The introduction of a primary amine is not 
trivial and has the potential to be disruptive to target binding. We have frequently observed that a 
high accumulating derivative can be made that loses all antibacterial activity due to poor target 
engagement. In most cases, the real challenge in a conversion is to retain the ability to bind to the 
target. This difficulty can be greatly mitigated by choosing a candidate with a well-documented 
SAR. Most medicinal chemistry programs reveal portions of a compound that are more tolerant to 
substitution. Special attention should be given to derivatives that include polar substituents 
(hydroxyl, primary amides, acids) that may be good locations for amine replacement. The most 
valuable piece of data is co-crystal structure of the candidate compound with its protein target. 
Solvent exposed regions of the candidate compound are often good starting points for introducing 
an amine as it may mitigate unfavorable contacts.  
If the candidate compound has more than five rotatable bonds, then tying up rotatable 
bonds with the introduction of rings can productively reduce flexibility. Introducing rings as a 
means to conformationally constrain a drug molecule is a common strategy in medicinal chemistry 
campaigns meant to improve entropy of binding. One of these compounds may be a better 
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candidate for conversion than the antibiotic that was ultimately moved forward as a lead. However, 
once rotatable bonds are removed, the compound must still be able to adopt the same binding pose 
with the target, and the binding poses revealed by X-ray structures should be compared to any 
restrained derivatives. Whether introducing a primary amine, reducing rotatable bonds, or both, 
careful examination of SAR is an important step in prioritizing candidates and planning a synthetic 
strategy.  
 
Figure 1.5 Evaluation of gram-positive-only antibiotics that lack an ionizable nitrogen at different stages of 
development. 
The antibiotic development literature was searched for potential conversion candidates. 
Gratifyingly, many of these antibiotics possessed the necessary physiochemical properties for 
accumulation except lacking a primary amine (Figure 1.5). Evaluating these leads by the criteria 
above, several of these were determined to have good potential for conversion into new gram-
negative antibiotics and are discussed here. 
1.4. Conversion candidates from FDA-approved drugs 
As discussed above, many of the drug classes approved to treat bacterial infections are not 
effective against gram-negative bacteria. Many of these classes, particularly those produced by 
NRPSs, are not anticipated to be good candidates for conversion due to their size and high 
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Figure 1.6 FDA approved gram-positive only antibiotics as candidates for conversion to broad spectrum 
agents. 
1.4.1. Linezolid 
Linezolid, a prototypical oxazolidinone antibiotic, was granted FDA approval in 2000 
(Figure 1.7). Linezolid demonstrates exemplary activity against all clinically relevant gram-
positive pathogens with little cross-resistance with other antibiotics, even others that target the 
ribosome. Tedizolid was more recently approved for the same indications and is 4-to-16-fold more 
potent against staphylococci and enterococci than linezolid. Recent medicinal chemistry efforts 
with oxazolidinones are aimed towards improving the overall safety has been spurred by the class’s 
activity against MDR Mycobacterium tuberculosis.100 Unfortunately, myelosuppression by 
linezolid typically limits the course of treatments to under 14 days.101 Exceptions are made for 
serious infections of vancomycin-resistant enterococci, where dosage is extended to 28 days.101 
While longer treatment regimens (18 months) have shown good success rates against M. 
tuberculosis, >80% of patients face adverse events.102 Consequently, significant efforts have been 
made to design oxazolidinones with improved safety profiles. Sutezolid was initially developed in 
parallel with linezolid at Pfizer but eventually was superseded by the latter compound.103,104 
Despite facing licensing problems, sutezolid development has been rebooted with recent clinical 
trials sponsored by Sequella and the TB Alliance.105,106 In an effort to discover new chemical 
matter LegoChem Biosciences and MicuRx examined new heterocycles to replace the C-ring of 
linezolid, which led to delpazolid and contezolid, respectively.107-111 Several other oxazolidinones 
that made it into clinical trials but were not ultimately approved (radezolid, eperezolid, and 
posizolid) are C-ring modified oxazolidinones, and further reinforce the observation that the 











































Figure 1.7 Approved oxazolidinones and those in late-stage development. Ring system naming convention 
is overlaid on structure of linezolid in blue. Atom numbering of ring C is indicated in red. 
Several amine-containing oxazolidinones have already been reported in the literature. In 
an expansive SAR, Aggen and coworkers discovered a limited number of amines with bioactivity 
although with unremarkable potency (DP-60, DP-326, and DP-44, Figure 1.8).112,113 In a 
collaboration between Merck and NIAID, the amine L-005578844 was shown to have excellent 
potency against M. tuberculosis but not S. aureus.114 This surprising selectivity was later 
rationalized with the discovery that the amine is acylated by Rv0133 in cells.115 From these studies, 
it seems clear that introducing an amine via C-5 chain modification is deleterious to target 






















































































































Figure 1.8 Amine-containing oxazolidinones. 
Several compound series have been synthesized and derivatized by previous members of 
the Hergenrother lab (Figure 1.9). Dr. Michelle Richter (MFR) synthesized an analogue of 
eperezolid by replacing the C-ring 2-hydroxyamide with glycineamide. Dr. Sarah Tasker (SZT) 
synthesized several ring-restrained oxazolidinones modeled after PF-708093. The activity trends 
observed here are similar to those above. Introducing an amine via C-5 chain modification is 
wholly intolerable. Some activity can be retained by introducing the amine on ring B although this 
does not translate to an acceptable E. coli MIC despite decent accumulation (SZT-1-228). 
Although several amine-containing compounds have been evaluated already, the partial success of 
DP-326 provides some hope that other derivatives may be more efficacious. At the same time, the 
limited potency of linezolid in ∆rfaC E. coli (MIC = 32 µg/mL) suggests that a high-accumulating 
oxazolidinone may only have limited efficacy in gram-negative bacteria. 
 
Figure 1.9 Preliminary efforts to develop gram-negative oxazolidinones. Work was performed by Dr. 
Michelle Richter (MFR) and Dr. Sarah Tasker (SZT). Accumulation measured as nmol per 1012 CFUs. 
1.4.2. Fusidic acid 
Fusidic acid is a gram-positive only antibiotic that inhibits protein synthesis through a 
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fusidic acid is an excellent complement to antibiotics that directly target the ribosome 
(aminoglycosides, oxazolidinones, etc.). Fusidic acid has been in clinical use since the 1960s, 
primarily in Europe, for the treatment of staphylococci infections.116 Although approval in the US 
was never sought, the rise of methicillin-resistant S. aureus has renewed interest in agents without 
cross-resistance. Consequently, Cempra Inc. has conducted two clinical trials in the US that have 
both demonstrated non-inferiority to linezolid (ClinicalTrials.gov, NCT00948142, 
NCT02570490).117 In 2013, fusidic acid was granted orphan drug designation from the FDA for 
the indication of prosthetic joint infections, which has initiated another Phase 3 trial 
(NCT02569541). Fusidic acid is remarkably well tolerated as evidenced by the 1500 mg dose in 
recent clinical trials. The primary limitation of fusidic acid is the relatively high resistance rate 
(~1x10-6), yet resistance surveillance programs have continued to identify significant susceptible 
populations despite continued use since the 1960s. 
 
Figure 1.10 A. Structure of fusidic acid and key antimicrobial susceptibility data. B. Positions on fusidic acid 
that are predicted to be tolerant to modification based on existing SAR and molecular docking.  
Fusidic acid appears to be a good candidate for conversion. It inhibits a currently 
unexploited protein target in gram-negative bacteria and would constitute a valuable addition to 
the current collection of available antibiotics. The excellent tolerability of fusidic acid also 
suggests that the resulting MIC in gram-negative bacteria may not need to be below 1 µg/mL for 
efficacy. While the available SAR for fusidic acid is limited, detailed review of the literature and 
molecular docking suggests several points for derivatization (Figure 1.10B).118 A key hurdle will 
be reduction of flexibility. While this might be accomplished by truncation of the alkyl chain, the 
length of this moiety appears to be necessary. Reduction of flexibility could be instead achieved 
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The lincosamides are a class of natural products and semisynthetic derivatives that target 
the 50S subunit of the ribosome and bind to the same site as chloramphenicol and macrolides.119 
This compound class was founded by two natural products, lincomycin and celesticetin (Figure 
1.11).120,121 Celesticetin has about 2-fold less active than lincomycin, and therefore, has not 
garnered nearly the attention of lincomycin.122,123 Many semisynthetic lincosamides have been 
described, the most prominent of these being clindamycin (Figure 1.11). On the basis of their 
gram-positive activity, lincomycin and clindamycin have both been approved. The improved 
spectrum of activity and bioavailability of clindamycin over lincomycin resulted in dramatically 
increased prescription rates for clindamycin (1.5 million Medicare Part D claims in 2016) than 
lincomycin (134 in 2016). Additionally, pirlimycin, marketed solely for veterinary use, 
demonstrates how rotatable bonds can be reduced via replacement of the pyrrolidine ring with a 
piperidine ring. Clindamycin is efficacious against ∆acrB E. coli (MIC = 8 µg/mL) but not wild-
type E. coli (MIC = 256 µg/mL), which demonstrates its potential for conversion.124 
 
Figure 1.11 Structures of prevalent lincosamides and relevant physiochemical properties. Lincomycin and 
celesticetin are both natural products. Clindamycin and lincomycin are both approved for gram-positive 
infections in humans although clindamycin is much more commonly used due to improved activity and 
absorption. Pirlimycin is only approved for use in animals. 7-(S)-amino-7-deoxylincomycin demonstrates 
reduced activity against gram-positive bacteria. 
Analysis of the crystal structure of clindamycin bound to the ribosome reveals an intricate 
network of hydrogen bonds between the thioglycoside and the ribosome (Figure 1.12).119 The 
chloroethyl sidechain appears mostly solvent exposed, making it a potential site for modification. 

















































































or amine retains activity in gram-positive bacteria.125,126  The activity against gram-negative 
species has not be reported. Based on this preliminary evidence, gram-negative activity may be 
attainable through introduction of an amine at this position combined with reducing rotatable 
bonds by replacing the 1-methyl-4-propylpyrrolidine ring with the 4-ethylpiperidine ring from 
pirlimycin.  
  
Figure 1.12 X-ray structure of clindamycin (magenta) bound to E. coli ribosome (PDB: 4V7V). Polar contacts 
are rendered as yellow dashes. 
1.5. Conversion candidates from clinical pipeline 
Several drugs are currently in clinical development as antibiotics. While the majority of 
compounds belong to classes of antibiotics with members possessing activity against gram-
negatives (e.g. b-lactams and fluoroquinolones), several investigational drugs appear to be 
excellent candidates for conversion. Current antibiotic development trends largely reflect the needs 
highlighted by the WHO Priority Pathogen list with the major exception of programs geared 
towards gram-negative antibiotic development due to the still-unsolved problem of penetrance. 
The rate of MDR Neisseria gonorrhoeae has risen dramatically in Europe with cases of third-
generation cephalosporin resistance combined with fluoroquinolone resistance becoming 
common.6 Although N. gonorrhoeae is a gram-negative pathogen, it has an atypical architecture 
for its outer membrane, which many small-molecule drugs are still capable of traversing. 127 
Current drugs in clinical development to combat MDR N. gonorrhoeae include zoliflodacin and 
gepotidacin (Figure 1.13). Of notable interest is the recent medicinal chemistry optimization of 
gepotidacin to include primary amines, which conferred gram-negative activity to this previously 
gram-positive only class of antibiotics.128  
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Even though several classes of compounds in the clinical pipeline hit targets that are 
exploited by approved drugs, many do so via different binding modes and therefore avoid cross-
resistance. While the incidence of hospital-associated methicillin-resistant Staphylococcus aureus 
(MRSA) has decreased in recent years due to improved hygiene, new strains of community-
associated MRSA have emerged that cause more pneumonia and invasive infections than 
nosocomial MRSA strains do.129 As a result, new agents with unique mechanisms of action that 
can circumvent the evolution of drug-resistant staphylococci are badly needed. Currently 
antibiotics in development for the treatment of MRSA include afabicin (Debio-1450), CG400549, 
and iclaprim. 
 
Figure 1.13 Conversion candidates from clinical pipeline. 
1.5.1. Zoliflodacin 
Zoliflodacin (formerly ETX0914 and AZD0914) is the first-in-class spiropyrimidenetrione 
currently developed by Entasis Therapeutics for the treatment of MDR N. gonorrhoeae. 
Zoliflodacin targets DNA gyrase by engaging the protein in a binding mode unique to the widely 
prescribed fluoroquinolones. As a consequence, no cross-resistance has been observed for 
zoliflodacin in a large collection of clinical isolates.130 Although the MIC of zoliflodacin has not 
been determined against efflux-deficient gram-negative bacteria, earlier derivatives were highly 
potent against ∆tolC E. coli but not wild-type E. coli (Figure 1.14). With a well-validated protein 
target, unique mechanism of action, low globularity, and only one rotatable bond, zoliflodacin is 
an excellent candidate for conversion. 
An extensive medicinal chemistry effort for optimization of the spiropyrimidinetrione 
scaffold spanned several years and pharmaceutical companies, culminating in the discovery of 
zoliflodacin. The spiropyrimidinetrione scaffold was first discovered in a whole-cell high-
throughput screen conducted by Pharmacia and Upjohn Co. in which QPT-1 (PNU-286607) was 
identified as a hit (Figure 1.14).37 QPT-1 demonstrated broad activity against drug-resistant gram-
positive bacteria. Although exhibiting modest activity against wild-type E. coli, QPT-1 showed 






































































its molecular target to be DNA gyrase and that it induced the same double-strand breaks in DNA 
as fluoroquinolones. Later, a co-crystal structure of QPT-1 with DNA gyrase showed that the 
molecule binds in the same site as fluoroquinolones yet makes significantly different binding 
interactions.131 After Pharmacia was acquired by Pfizer, several patents filed by Pfizer show some 
progress in improving QPT-1 potency via introducing halogens and pendant heterocycles (Zol-
1).132,133 At some point, AstraZeneca started their own program, and Basarab and coworkers 
developed an enantioselective route and found that a benzisoxazole was an effective isostere for 
fluorine (Zol-2).134,135 Zol-2 demonstrated bone marrow toxicity and genotoxicity, but a series of 
N-linked oxazolidinone substituents greatly improved pharmacokinetic and toxicity attributes, 
which ultimately led to zoliflodacin.38,136,137 
 
Figure 1.14 Summary of medicinal chemistry leading to zoliflodacin.  
The existing SAR for zoliflodacin clearly suggests that the “northwestern” portion of the 
molecule is most amenable to derivatization. While over 100 oxazolidinones have been 
synthesized, none contained a primary amine or possessed gram-negative activity. Further 
exploration of this portion of SAR is likely to provide an accumulating compound. The conversion 
of the zoliflodacin scaffold is discussed further in Section 3.2. 
1.5.2. Afabicin 
Bacterial fatty acid synthesis (FAS) has long been a target for antibiotics due to its central 
role in proliferation and divergence from mammalian FAS. Mammals and fungi utilize type I FAS 
in which large, multidomain complexes carry out multiple steps to synthesis palmitic acid from 
acetyl-CoA, malonyl-CoA, and NADPH. Nascent fatty acids are shuttled to various domains that 
perform the necessary transformations. Bacteria and archaea utilize type II FAS in which discrete 
enzymes perform each transformation (Figure 1.15). While chemical transformations involved in 
FASII are highly conserved across bacteria, the enzymes that catalyze these reactions are quite 



































































tolerate FASII inhibition. Vigorous debate at the beginning of the decade concerning the 
applicability of FASII inhibition for gram-positive antibiotics has largely been resolved and 
resulted in a better understanding of the conditions under which gram-positive species can bypass 
FASII inhibition.138-141 The potential problem of exogenous fatty acid uptake is avoided with gram-
negative bacteria since no mechanism exists to convert these fatty acids into b-hydroxy-fatty acids 
used for the synthesis of lipid A, a key component of the outer-membrane (Figure 1.15,  Figure 
1.4).141 Further, supplementing with b-hydroxy-fatty acids does not rescue cells because LpxA 
only recognizes b-hydroxy-fatty acids loaded onto an acyl carrier protein (ACP).142 Regardless, 
the diversity of FASII systems potentially limits the spectrum of activity of antibiotics inhibiting 
this pathway, which warrants careful consideration when trying to convert a gram-positive only 
antibiotic into an agent with gram-negative activity. Alternatively, this diversity can be leveraged 
to design agents with targeted spectra of activity. 
 
Figure 1.15 Schematic of FASII pathway. FabI (highlighted in blue) is an enoyl-ACP reductase that catalyzes 








































































The last step of fatty acid elongation is performed by enoyl-ACP reductases. While some 
organisms have redundant enoyl-ACP reductases (e.g. B. subtilis and P. aeruginosa), FabI is the 
sole isoform to catalyze this reaction in S. aureus, M. tuberculosis, and Enterobacteriaceae species 
(summary of isoforms in Table 1.4). Despite some diversity regarding usage, the sequence of FabI 
is well conserved across bacterial species (Figure 1.16, Table 1.5). As a result, intensive research 
has focused on the development of potent FabI inhibitors. While many have been reported, only 
three have advanced into clinical trials: afabicin, CG400549, and MUT056399 (Figure 1.13, Table 
3.1). MUT056399 is an analogue of triclosan sponsored by FAB Pharma that entered a Phase I 
clinical trial in 2009.143,144 Results from this trial have not been released and no further 
development seems to be occurring. While largely speculative, it is possible MUT056399 suffered 
from the same poor selectivity that limits the clinical utility of triclosan. CG400549, a remarkably 
narrow spectrum FabI inhibitor developed by CrystalGenomics Inc., has completed two Phase I 
and one single-arm Phase IIA clinical trial in 2012 (ClinicalTrials.gov, NCT01085578, 
NCT01848470, NCT01593761).145 Although limited data from these trials have been reported, 
CG400549 appears to be well tolerated and effective. Unfortunately, CG400549 is highly selective 
for S. aureus FabI over the E. coli ortholog, making conversion to a gram-negative-active version 
unlikely.146 
Table 1.4 Summary of Enoyl-ACP Reductase Isoforms found in relevant bacteria. 
Species FabI FabK FabL FabV 
S. aureus147 X    
E. coli147 X     
A. baumannii42,148,149 X    
K. pneumoniae41,148 X    
P. aeruginosa150 X   X 
B. subtilis151  X  X  
S. pneumoniae147  X   
C. difficile148  X   
M. tuberculosis InhI    
 
Afabicin (also Debio-1450) represents the latest generation of inhibitors of enoyl-ACP-
reductase (FabI) currently in clinical development. Sponsored by Debiopharm, afabicin has 
completed five Phase I clinical trials (ClinicalTrials.gov, NCT02162199, NCT02214433, 
NCT02595203, NCT03209648, NCT02726438)152,153 and one Phase II trial (ClinicalTrials.gov, 
NCT02426918). Afabicin is a phosphate prodrug and rapidly converts to the active agent, Debio-
1452 (also AFN-1250), shortly after entering the bloodstream. The prodrug derivativization 
strategy was necessary due to the poor solubility and bioavailability of the parent, Debio-1452. 
Afabicin was recently granted orphan drug status for osteomyelitis and is anticipated to be 
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approved for staphylococcal infections. The abundance of SAR data,35,154-156 published X-ray 
structures bound to its target,157 and compelling bioactivity data makes Debio-1452 an excellent 
candidate for conversion. This conversion is discussed further in Section 3.1. 
 
Figure 1.16 Sequence alignment of FabI proteins for relevant bacterial species. Residues responsible for 
resistance are indicated by red (E. coli) and blue (S. aureus) arrows.  Alignment was performed with Clustal 
Omega 1.2.4158 and visualized with ESPript 3.0.159 Secondary structure generated with DSSP from E. coli 
FabI (PDB 4JQC). Protein sequences obtained from Uniprot: E. coli (P0AEK4), K. pneumoniae (A6T7Z6), 
A. baumannii (A0A077GA87), P. aeruginosa (Q9ZFE4), E. faecalis (Q820V5), S. aureus (Q6GI75), B. 
subtilis (P54616). 
Table 1.5 Percent identity matrix for FabI. 
 Ec Kp Ab Pa Ef Sa Bs 
E. coli 100 93.13 64.5 69.47 47.18 43.7 51.37 
K. pneumoniae 93.13 100 66.41 69.47 47.18 42.52 49.8 
A. baumannii 64.5 66.41 100 71.1 48.79 47.24 50 
P. aeruginosa 69.47 69.47 71.1 100 44.4 42.97 48.64 
E. faecalis 47.18 47.18 48.79 44.4 100 51.6 51.6 
S. aureus 43.7 42.52 47.24 42.97 51.6 100 57.81 
B. subtilis 51.37 49.8 50 48.64 51.6 57.81 100 
aProtein sequences and alignment conditions same as Figure 1.16 
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E_faecalis  YN MG AKASL   V Y A        RVN  SAG I TL   G               P         VG     L S   M  I     ET  K L LA I   GI    K  AVT V Y QLI NERT KT VT EE  T AF  A FE ADK A KD D SIS D G I N C V D
S_aureus    YN MG AKASL   V Y A        RVN  SAG I TL   G               P         VG     L S   V  V     EA  K L LG I   AI    R  SAK V F TIL EERA KR VD VE  T AY  N LD PDN P GG N KEI L N Q K A L D
B_subtilis  YN MG AKASL   V Y A        RVN  SAG I TL   G               P         VG     L S   V  V     DA  K L LG I   SI    R  SAK I F SIL EERA RR TT EE  T AF  S AD KEN P SD N KDI L T P D A F D
                                                                                E_coli      
  240       250       260                                                       
E_coli         G  G    VD G                                                                 SA IS EVV    F IAL H G S AMNELELK..
K_pneumoniae    G  G    VD G                                                                 SA IS EVV    F IAL H G N AMNELELK..
A_baumannii    G  G    VD G                                                                 AS IT EIL    F TVW Y A N GMSQSMMDDE
P_aeruginosa    G  G    VD G                                                                 AS IS EIL    F TTL Y G N AMGPLDDD..
E_faecalis     G  G    VD G                                                                 AS VV DII    V LTL Y K H ..........
S_aureus       G  G    VD G                                                                 SS VT ENI    F AIL H S H K.........
B_subtilis     G  G    VD G                                                                 SR IT ENL    F ITM H S H AR........
β1 α1 β2 α2 β3 α3 
β4 η1 α4 α5 α6 η2 β5 η3 





Dihydrofolate reductase (DHFR) has been exploited as both an antimicrobial 
(trimethoprim) and anticancer (methotrexate) therapeutic target for decades. Because the 
biosynthetic pathway for tetrahydrofolate is conserved among humans and bacteria, inhibitors of 
DHFR must be highly selective for the prokaryotic variant. 
 
Figure 1.17 A. Tetrahydrofolate biosynthetic pathway. DHFR inhibitors are often used in combination with 
sulfonamides because of linear synergy. B. Reduction of dihydrofolate to tetrahydrofolate catalyzed by 
DHFR. C. Trimethoprim, iclaprim, and methotrexate are substrate mimics used as antibiotics and anticancer 
agents. 
Although effective against E. coli, trimethoprim is susceptible to high rates of resistance, 
and is commonly prescribed in combination with sulfamethoxazole, which hit the same pathway 
(Figure 1.17). Unfortunately, the sulfonamides are not well tolerated, often leading to 
hypersensitivity, blood dyscrasias, and life-threatening hyperkalemia.160,161 In response to the low 
tolerability of sulfonamide cotreatment, iclaprim was developed so that sulfonamide co-therapy 
would be unnecessary. In a structure guided effort, iclaprim was designed to bind to trimethoprim-
resistant DHFR by engaging in additional hydrophobic contacts with the substrate binding 
pocket.162 As a consequence, iclaprim is approximately 8-fold more potent against gram-positive 
bacteria, in particular S. aureus. This added hydrophobicity seems to have diminished gram-
negative penetrance, and iclaprim shows poor efficacy against gram-negative pathogens despite 
being able to hit the target.163 After completing two Phase 3 clinical trials against complicated skin 

































































































































and European regulatory bodies indicated that iclaprim would not be approved citing poor efficacy, 
preexisting resistance, and potential cardiotoxicity.164,165 Two more trials were conducted with 
iclaprim for ABSSSI in which non-inferiority was successfully demonstrated compared to 
vancomycin.164-166 Based on these data, iclaprim is anticipated to be approved for ABSSSI. 
While this anticipated approval would fulfill a clear clinical need by providing an 
additional option in treating MRSA, the potential for a DHFR inhibitor tolerant of trimethoprim-
induced resistance active in gram-negative bacteria remains unrealized. Iclaprim or other late-
generation DHFR inhibitors bear potential as starting points for the development of amine-
containing analogues that can penetrate gram-negative outermembranes. Development of novel 
DHFR inhibitors has continued while maintaining the pyrimidine-2,4-diamine pharmacophore 
(Table 1.6). As the most rotationally constrained inhibitors, a series of benzimidazole containing 
compounds (e.g. DHFR-1) would be excellent starting points.167 Dennis Wright’s lab has worked 
extensively in the area of new types of DHFR inhibitors and has developed a series of propargyl 
linked compounds (e.g. PLA-10R and UCP1021) with excellent potency.168-173 Interestingly, they 
showed species selectivity with the placement of charged functional groups on a biphenyl 
framework (PLA-10R and UCP1021).168,169 Carboxylic acid-containing compounds failed to kill 
gram-negative bacteria due to insufficient influx and not efflux as evidenced by the comparison of 
activity in wild-type, ∆imp, and ∆acrB E. coli strains. The pyridine-containing analogue showed 
activity against K. pneumoniae but antimicrobial activity against other gram-negative bacteria was 
not reported. This activity might be improved by conversion of this pyridine to methylpyridinium 
or benzylamine. Although many derivatives of trimethoprim have been evaluated since its 
discovery, this existing SAR will greatly aid in the development of the a DHFR inhibitor effective 












Table 1.6 Recent development for DHFR inhibitors. 
Agent In vitro Inhibition Antimicrobial Activity 
 
Trimethoprim 
Ki = 1.2 nM (saDHFR a) 
Ki = 19 µM (hsDHFR b)  
MIC = 1-4 µg/mL (S. aureus)174 
MIC = 0.5-2 µg/mL (E. coli) 174 
MIC = 0.01 µg/mL (E. coli ∆imp) 170 
Iclaprim Ki = 0.08 nM (saDHFR) 
Ki =  775 nM (hsDHFR) 
MIC = 0.06-0.25 µg/mL (S. aureus) 174 
MIC = 1-4 µg/mL (E. coli) 174 
Methotrexate Ki = <4 pM (saDHFR) 
Ki =  <4 pM (hsDHFR) 




Ki = 2 pM (saDHFR)167 
Ki =  93 nM (hsDHFR)167 




Ki = 32 nM (saDHFR)170 
Ki = 3 nM (ecDHFRc)170 
Ki =  450 nM (hsDHFR)170 
MIC = 0.03 µg/mL (S. aureus)170 
MIC = 32 µg/mL (E. coli WT)170 
MIC = 0.002 µg/mL (E. coli ∆imp)170 
MIC = 32 µg/mL (E. coli ∆acrB)170 
IC50 = > 100 µM (MCF10A)170 
 
UCP1021 
IC50 = 19 nM (saDHFR)168 
IC50 = 180 nM (spDHFRd)168 
IC50 = 16 nM (kpDHFRe)169 
IC50 = 1.3 µM (hsDHFR)169 
MIC = 0.09 µg/mL (S. aureus)168  
MIC = 0.012 µg/mL (S. pyogenes)168 
MIC = 1.25 µg/mL (K. pneumoniae)169 
IC50 = 85 µM (MCF10A)169 
aS. aureus DHFR, bH. sapiens DHFR, cE. coli DHFR, dS. pyogenes DHFR, eK. pneumoniae DHFR 
 
1.6. Candidates from pre-clinical pipeline 
1.6.1. Indolmycin 
Indolmycin was identified early as an excellent candidate for expansion of activity against 
gram-negative bacteria. A natural product isolated from Streptomyces albus,175 indolmycin is a 
selective inhibitor of tryptophanyl-tRNA synthetase (TrpRS)176 with potent activity against gram-
positive bacteria (MIC 0.3 µg/mL, S. aureus ATCC 13150).177 Because no approved antibiotics 
target TrpRS, indolmycin attracted interest from several pharmaceutical companies leading to 
development of an extensive structure-activity-relationship.174-178 Despite these efforts, no 
derivatives have been discovered with activity against gram-negative pathogens. This failure was 
not due to poor target conservation as demonstrated by in vitro inhibition of purified E. coli 
TrpRS178 and whole-cell activity against a permeability mutant of E. coli.177,179 
In addition to having a promising target and encouraging bioactivity, indolmycin has 
chemical properties ideal for conversion to a broad-spectrum agent. Indolmycin has low three-
dimensionality and flexibility (Glob = 0.12, RB = 3). Further, the recently reported co-crystal 




















Previous SAR studies and structural biology together suggest one primary site for derivatization. 
While the oxazolinone ring makes critical water-mediate H-bonding interactions with the catalytic 
Mg2+ ion, the pendant methylamine is solvent exposed. Further, previous medicinal chemistry 
efforts have demonstrated that some substitutions are tolerated at this position.180,181 
Computational modeling of one such molecule in the binding site of TrpRS suggests this 
modification will be well tolerated (Figure 1.18). The conversion of indolmycin is discussed in 
Section 3.3. 
   
Figure 1.18 Computational modeling of indolmycin (cyan) and derivative (pink) in the binding site of TrpRS. 
Small-molecules were docked into co-crystal of indolmycin and TrpRS (PDB: 5DK4) using Glide SP. Top 
ranked poses were visualized using PyMol. 
1.6.2. Ribocil 
Although many drugs target the RNA portion of ribosomes, therapeutics that bind to other 
RNA-containing elements are rare. The first chemotype that inhibits the flavin mononucleotide 
(FMN) riboswitch was recently described.182,183 The FMN riboswitch controls the expression of 
de novo riboflavin (vitamin B2) biosynthetic machinery and is nearly ubiquitously expressed in 
bacteria. While gram-negative species are capable of bypassing de novo synthesis by uptake of 
exogenous riboflavin in vitro, the concentration of riboflavin is sufficiently low in vivo such that 
∆ribA E. coli are significantly less pathogenic.182 
Ribocil was discovered in a screen against efflux-deficient E. coli and counter-screened in 
the presence of riboflavin. Two compounds were disclosed (ribocil-B and ribocil-C, Figure 1.19) 
that showed excellent activity against strains of E. coli that were engineered to be hyper-
permeabilized or poses deficient efflux systems. The FMN riboswitch is fairly conserved across 
gram-negative bacteria although ribocils do not appear to bind to P. aeruginosa FMN 





















conversion candidates. Although the available SAR is fairly limited in scope, the availability of a 
co-crystal structure of ribocil-B bound to F. nucleatum FMN riboswitch does provide insight for 
potential sites amenable to derivatization (Figure 1.20). The pyrimidine and piperidine rings of 
ribocil-C appear fairly solvent accessible and are excellent starting points for modification. 
 
Figure 1.19 Bioactivity of inhibitors of FMN riboswitch. Riboflavin inhibition refers to inhibition of 
biosynthesis by E. coli MB5746. MIC measurements were performed in minimal media. Knockout strains 
are as follows: MB5008 (∆lpxC), MB5747 (∆tolC), MB5746 (∆lpxC/∆tolC). FMN riboswitch from 
Acinetobacter baumannii was introduced to MB5746 to assess the ability of ribocil to bind to A. baumannii 
riboswitch. 
 
Figure 1.20 Co-crystal structure of ribocil derivative bound to F. nucleatum FMN riboswitch (PDB: 5KX9). 
A. Full view of complex. Ribocil is depicted in magenta. B. Detailed view of molecular interactions between 
riboswitch and ribocil. C. Ligand interaction diagram of complex. 
1.6.3. FtsZ inhibitors 
FtsZ is an essential protein involved in bacterial cell division, and is homologous to 
eukaryotic tubulin yet plays a role unique to bacteria. Most bacteria divide via the formation of a 
Z-ring at the midpoint of the cell. This Z-ring is a multiprotein complex with FtsZ as the backbone. 
The assembly, movement, and constriction of the Z-ring is mediated by the polymerization or 
depolymerization of FtsZ through a mechanism similar to tubulin dynamics. While the exact 



















E. coli (∆lpxC) MIC
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initial assembly of the Z-ring is the rate-limiting step in bacterial cell division and proper function 
of FtsZ is essential for division to occur. As a consequence of its central role in the bacterial life 
cycle, ftsZ is remarkably conserved among bacteria (Figure 1.22). Conditional knockdown of ftsZ 
results in the filamentation of rod-like bacteria (e.g. E. coli) and eventual lysis. Cocci bacteria (e.g. 
S. aureus) typically swell and likewise lyse. A wealth of genetic evidence point to FtsZ as an 
excellent antibiotic target. 
Similar to tubulin, inhibitors of the function of FtsZ act either as stabilizers or destabilizer. 
These tip the balance of (de)polymerization and cause the protein to mislocate and ultimately fail 
to assemble a Z-ring. Despite having distinct mechanisms of actions, FtsZ stabilizers and 
destabilizers are both described as FtsZ inhibitors in literature. While several natural products have 
been suggested as FtsZ inhibitors and later shown to be non-specific,184,185 the first series of bona 
fide FtsZ inhibitors are the difluorobenzamides (Figure 1.21).186 After lead optimization, a 
derivative of PC190723 (TXA709) was licensed to Taxis Pharmaceuticals and is a promising 
narrow spectrum antibiotic.187-189 
  
Figure 1.21 FtsZ inhibitors externally validated as not acting through aggregation. TXA709 is a prodrug that 
hydrolyzes to a primary amide. 
The narrow spectrum of activity for the difluorobenzamides has been attributed to 
important differences in the sequence of FtsZ. Although FtsZ is highly conserved across bacteria, 
the difluorobenzamides bind to a cleft between a1 and b10 whose solvent exposure is dependent 
on the presence or absence of a salt bridge (Figure 1.22). In the case of S. aureus and B. subtilis, 
this salt bridge is absent so PC190723 can successfully bind to FtsZ. In the case of E. faecalis, S. 
pneumoniae, and Enterrobacter spp., an arginine-glutamate salt bridge occludes this cleft and 
prevents binding.190 Consequently, the only gram-negative species anticipated to be sensitive to 
difluorobenzamides are A. baumannii and P. aeruginosa (although unconfirmed with efflux-
deficient strains). The eNTry rules are not predictive of P. aeruginosa accumulation and have 















































is not a good starting point for conversion until more predictive guidelines have been developed 
for these species. 
Other screening efforts to discover in vitro FtsZ disruptors have uncovered many 
candidates but most have acted non-specifically. The two most commonly utilized in vitro assays 
for FtsZ, polymerization and GTPase, are both highly sensitive to aggregators. In 2012, the Shaw 
group reevaluated putative FtsZ inhibitors.184 Surprisingly, only zantrin Z3 demonstrated robust 
activity against E. coli and B. subtilis FtsZ in the presence of Triton X-100 (a common additive 
that prevents aggregation). Zantrin Z3 was discovered in a high-throughput screen for GTP-
dependent FtsZ polymer assembly and demonstrated modest activity against efflux-deficient E. 
coli.191 Unlike other validated FtsZ inhibitors, zantrin Z3 did not induce filamentation, both 
possibly pointing to an alternative mechanism of action. Further, no resistant mutants have been 
reported. More recent structure optimization studies have shown that modification of the pendant 
aliphatic amine is possible.184,192 Regardless of the exact mechanism of action zantrin Z3 is an 
excellent candidate for conversion. Structurally, however, reduction of rotatable bonds is desirable 
so that proposed analogues fit within the conversion guidelines. Existing SAR suggests that this is 
possible without significant loss in activity. 
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Figure 1.22 Sequence alignment of FtsZ proteins for relevant bacterial species. Residues responsible for 
fluorobenzamide selectivity are indicated by red (H33) and blue (V307) arrows.  Alignment was performed 
with Clustal Omega 1.2.4158 and visualized with ESPript 3.0.159 Secondary structure generated with DSSP 
from S. aureus FtsZ (PDB 5XDT). Protein sequences obtained from Uniprot: S. aureus (P0A031), B. subtilis 
(P17865), E. faecalis (O08439), S. pneumoniae (A0A0B7LA49), S. pyogenes (J7MAP3), E. coli (P0A9A6), 
K. pneumoniae (A6T4N8), A. baumannii (A0A1G5IET6), P. aeruginosa (P47204). 
1.6.4. AccC inhibitors 
Biotin carboxylase (AccC) is one part of the multi-component bacterial acetyl coenzyme-
A carboxylase (ACCase) which carries out the first step in fatty acid synthesis (Figure 1.15). 
Specifically, AccC utilizes bicarbonate to carboxylate a prosthetic biotin that eventually transfers 
                                    TT                                          S_aureus    
 1       10        20        30        40        50        60        70         
S_aureus                A  KVIGVGGGG NA   M       VE    NTD QAL         Q G   T GLGAG  PE G LE F  TL           VN  I MNN  FI I   G   N SKA SKI I L R     AN  I K.M FEQG NHL N R DHG A L E EK
B_subtilis              A  KVIGVGGGG NA   M       VE    NTD QAL         Q G   T GLGAG  PE G LE I  SI           VN  I VQG  YI V   A   N SKA VKM I L R     AN  V K.M FETN DGL N R ENE A L E AK
E_faecalis              A  KVIGVGGGG NA   M       VE    NTD QAL         Q G   T GLGAG  PE G FS I  VI           VN  I VKG  FI A   V   K SKA TVI L Y R     SQ  V QME LDNN NNG G R EEN T H E PK
S_pneumoniae             A  KVIGVGGGG NA   M       VE    NTD QAL         Q G   T GLGAG  PE G FS A  VI           IN  V VTG  FI A   V   S TKA TVI L L R     GQ  V RMT FDTA AQG G R DEG A S E PK
S_pyogenes              A  KVIGVGGGG NA   M       VE    NTD QAL         Q G   T GLGAG  PE G FS S  II           IN  I VAG  FI A   I   S SKA TVI L L R     GQ  V RMA FDTA IQG G R DEG A S E PK
E_coli                  A  KVIGVGGGG NA   M       VE    NTD QAL         Q G   T GLGAG  PE G FE L  VI           VE  V IEG  FF V   A   R TAV QTI I I K     AN  V R.M PM.E TND G H RER A K G SG
K_pneumoniae             A  KVIGVGGGG NA   M       VE    NTD QAL         Q G   T GLGAG  PE G FE L  VI           VE  V IEG  FF V   A   R TAV QTI I I K     AN  V R.M PM.E TND G H RER A K G SG
A_baumannii             A  KVIGVGGGG NA   M       VE    NTD QAL         Q G   T GLGAG  PE G FE I  VI           VN  A VEG  FI A   A   K IAA TVL L V K     AN  V R.M LVDN AQT G H KNN C N R PG
P_aeruginosa             A  KVIGVGGGG NA   M       VE    NTD QAL         Q G   T GLGAG  PE G FE I  VI           VN  A VEG  FI A   A   K IAA TVL L V K     AN  V R.M LVDN AQT G H KNN C N R PG
                         TT                                                     S_aureus    
80        90       100       110       120       130       140       150         
S_aureus     AA E          GADM F   GMGGG GTGAAP  A  AK  G LTV VVT PF FEG KR   A  G       VDK   REQIEDAIQ    V VTS     T      VV KI  M A      R       T  A VEAMKA   E S E G S R Q Q A A
B_subtilis   AA E          GADM F   GMGGG GTGAAP  A  AK  G LTV VVT PF FEG KR   A  G       VDK   KEQIEEALK    V VTA     T      VI QI  L A      R       L  G ISAMKE   E S D G T R Q Q A A
E_faecalis   AA E          GADM F   GMGGG GTGAAP  A  AK  G LTV VVT PF FEG KR   A  G       VDK   EQVISESLQ    I ITA     T      VV KI  L A      R       R  E IALLKE   E S E G S P G F A N
S_pneumoniae  AA E          GADM F   GMGGG GTGAAP  A  AK  G LTV VVT PF FEG KR   A  G       VDK   EETLTEAIS    V ITA     S      VI RI  L A      R       Q  E INQLRE   E S D G G S G F V H
S_pyogenes   AA E          GADM F   GMGGG GTGAAP  A  AK  G LTV VVT PF FEG KR   A  G       VDK   EEILTEALT    V ITA     S      VI RI  L A      R       N  E IEELRE   E S S A G N G F I Q
E_coli       AA E          GADM F   GMGGG GTGAAP  A  AK  G LTV VVT PF FEG KR   A  G       VDN   RDALRAALE    V IAA     T      VV EV  L I      K       A  Q ITELSK   D D D A N K M F E H
K_pneumoniae  AA E          GADM F   GMGGG GTGAAP  A  AK  G LTV VVT PF FEG KR   A  G       VDN   REALRAALD    V IAA     T      VV EV  L I      K       A  Q ITELSK   D D D A N K M F E H
A_baumannii  AA E          GADM F   GMGGG GTGAAP  A  AK  G LTV VVT PF FEG KR   A  G       VDQ   RERISEVLE    V ITT     T      II EV  M I      R       Q  E IRALAE   L D E A P R M I D S
P_aeruginosa  AA E          GADM F   GMGGG GTGAAP  A  AK  G LTV VVT PF FEG KR   A  G       VDQ   RERISEVLE    V ITT     T      II EV  M I      R       Q  E IRALAE   L D E A P R M I D S
               TT                                                               S_aureus    
160       170       180       190       200       210       220       230         
S_aureus     L  I N   L           A   A  VL   V GI   I   G  N DFADV T M   G A MG G   G  R  ET IV  RL IV K T MM  F E D   R  Q  SDL AVS V L     K I SN   L  I SS  AV P D D D S P E K N QG E Q S V EN
B_subtilis   L  I N   L           A   A  VL   V GI   I   G  N DFADV T M   G A MG G   G  R  ET IV  RI IV K T ML  F E D   R  Q  SDL ATP I L     K I SN   L  I AT  AA P D E D N P E R N QG L K S I EN
E_faecalis   L  I N   L           A   A  VL   V GI   I   G  N DFADV T M   G A MG G   G  R  ET LI  RL VV K T ML  F E D   R  Q  SDL TAP V L     K V EN   L  I AS  VI S N E D K P E R N QG Y Q T V EE
S_pneumoniae  L  I N   L           A   A  VL   V GI   I   G  N DFADV T M   G A MG G   G  R  ET LI  NL IV K T LL  L E D   R  Q  TDL TNP I L     K V AN   L  I GS  VV S N E D K P E S N QG L K N I EE
S_pyogenes   L  I N   L           A   A  VL   V GI   I   G  N DFADV T M   G A MG G   G  R  ET LI  NL IV K T LL  L E D   R  Q  TDL TSP I L     K V AN   L  I GS  IV S N E D K P E S N QG L K N I EE
E_coli       L  I N   L           A   A  VL   V GI   I   G  N DFADV T M   G A MG G   G  R  ES IT  KL VL R I LL  F A N   K  Q  AEL TRP M V     R V SE   M  S AS  AE P D K G G S D G D GA L M Y V ED
K_pneumoniae  L  I N   L           A   A  VL   V GI   I   G  N DFADV T M   G A MG G   G  R  ES IT  KL VL R I LL  F A N   K  Q  AEL TRP M V     R V SE   M  S AS  AE P D K G G S D G D GA L M Y V ED
A_baumannii  L  I N   L           A   A  VL   V GI   I   G  N DFADV T M   G A MG G   G  R  ES IT  KL IL K A LL  F K D   A  R  SDI KRP I V     K V SE   M  T AS  AR P E T G D S A A D GA M M M C PN
P_aeruginosa  L  I N   L           A   A  VL   V GI   I   G  N DFADV T M   G A MG G   G  R  ES IT  KL IL K A LL  F K D   A  R  SDI KRP I V     K V SE   M  T AS  AR P E T G D S A A D GA M M M C PN
                TT           TT                  TT          TT                 S_aureus    
240       250        260       270       280       290       300       310        
S_aureus    A   AI  PLLE     GA     N T G    L E                    G        D   VTV ATG     AK   S    I   Q VLM I  SLS  Q A IV D A VNM F TVI L  EI    I   FK S T.S V G G E F A E AD Q A DED I NPE Q V DDK
B_subtilis  A   AI  PLLE     GA     N T G    L E                    G        D   VTV ATG     AK   S    I   Q VLM I  NLS  Q A IV S S VNM F SVI L  EI    I   FK S A.A D G G T Y V E AD A A DQD I NEN K V IEQ
E_faecalis  A   AI  PLLE     GA     N T G    L E                    G        D   VTV ATG     TK   S    I   E VLL I  DMT  Q A IV N A VNI L TSI L  EI    I   IK S T.S D Q G L F A D SD T A SGD I NED G R DES
S_pneumoniae A   AI  PLLE     GA     N T G    L E                    G        D   VTV ATG     AR   S    I   E VIV V  DLT  E A IV Q A VNI L TSI M  EI    V   VK Y T.T D D G L I A E SQ N A GQG W DES R R RQD
S_pyogenes  A   AI  PLLE     GA     N T G    L E                    G        D   VTV ATG     AR   S    I   Q VIV V  DMT  E A IV Q A VNI L TSI M  DI    V   VK Y T.T D D G L T A E SE G A GQG W DDT K R RQE
E_coli      A   AI  PLLE     GA     N T G    L E                    G        D   VTV ATG     AE   S    L   R VLV I  DLR  E V TI A A ATV I TSL M  EL    V   IM S DID S G A F D F T GN R F SDN V DPD N R GMD
K_pneumoniae A   AI  PLLE     GA     N T G    L E                    G        D   VTV ATG     AE   S    L   R VLV I  DLR  E V TI A A ATV I TSL M  EL    V   IM S DID S G A F D F T GN R F SDN V DPD N R GMD
A_baumannii A   AI  PLLE     GA     N T G    L E                    G        D   VTV ATG     TE   N    L   R ILV I  DLS  S V II Q A ATV V TVI M  EL    V   LA R DVN Q G A P G Y D GN E F SEH K DAD R H GAR
P_aeruginosa A   AI  PLLE     GA     N T G    L E                    G        D   VTV ATG     TE   N    L   R ILV I  DLS  S V II Q A ATV V TVI M  EL    V   LA R DVN Q G A P G Y D GN E F SEH K DAD R H GAR
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320        330                         340                    350                
S_aureus     T                                                                              P SHGRKSGS.TGFG..................TSVNTSSN.............ATSKDESFTSN...............
B_subtilis   K                                                                              E DVTKPQ.R.PSLN..................QSIKTHNQ.............SVPKREPKR.................
E_faecalis   K                                                                              K DRKPHRQ......................TRQAVQPMQQTTQSVE..............MDQPKSQEEASAFGDWDIR
S_pneumoniae  V                                                                              R EKVVAPQARS...A.............TNYRETVKPAHSHGFDRHFDMAETVELPKQNP..RRLEPTQASAFGDWDLR
S_pyogenes   A                                                                              K EQVSGFRQPRTFTQTNAQQVAGAQYASDQAKQSVQPGFDRRSNFDFDMGESREIPSAQKVISNHNQNQGSAFGNWDLR
E_coli       R                                                                              K PEITLVTNKQV.............................................QQPVMDR.YQQHGMA....PLT
K_pneumoniae  R                                                                              K PEITLVTNKQV.............................................QQPVMDR.YQQHGMS....PLT
A_baumannii  E                                                                              L KPVKVVDNTVQGS................ATQAAAPAQREQQSVNYRDL.......DRPTVMR.NQSHGSA....A..
P_aeruginosa  E                                                                              L KPVKVVDNTVQGS................AAQAAAPAQREQQSVNYRDL.......DRPTVMR.NQSHGSA....A..
                                                                                S_aureus    
                     360         370       380       390                        
S_aureus                                           P F                                      K DDI  IRNR...............SSNAQATDSVSE..RTHTT E S EERRSRRTRR
B_subtilis                                         P F                                      D LDI  LRNR................EEPQQQNTVSRHTSQPAD T T NKRG......
E_faecalis                                         P F                                      D LST  FRRKREQNTRPKVDESSLEQVDKKEFDTFHREEPNHND E P R.........
S_pneumoniae                                        P F                                      D LDT  FKNRRESIVRTTDSVVSP....VERFE..A..PISQDE E P ..........
S_pyogenes                                         P F                                      D LET  FKNRRDNISRPTEGELDN....HLNMSTFS..ANDDSD E P ..........
E_coli                                             P F                                      D LDI  LRKQ.............QEQKPVAKVVNDNAPQTAKEP Y A AD........
K_pneumoniae                                        P F                                      D LDI  LRKQ.............QEQKPAAKVVNDNTPQTAKEP Y A AD........
A_baumannii                                        P F                                      D LDI  LRRQ.......................TAAKLNPQDDL Y A AD........
P_aeruginosa                                        P F                                      D LDI  LRRQ.......................TAAKLNPQDDL Y A AD........
β1 α1 β2 α2 β3 α3 α4 
α5 β4 α6 β5 η1 α7 
β6 η2 α8 α9 β7 
α10 β8 α11 β9 β10 
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the carboxylate to form malonyl-CoA from acetyl-CoA. AccC has been demonstrated to be 
essential for gram-negative bacteria.193 Several AccC inhibitors have been described, and while 
their bioactivity is only modest, many are good conversion candidates. Schering-Plough 
discovered a series of benzimidazoles in an affinity selection-mass spectrometry screen as ligands 
for E. coli AccC (Figure 1.23).30 Although the scope of available bioactivity data is limited, AccC-
2 and AccC-3 show sub-microgram per milliliter MIC against hyper-permeabilized E.coli and a 
co-crystal structure of AccC-4 bound to AccC was solved (PDB: 3JZI). 
 
Figure 1.23 AccC inhibitors developed by Schering-Plough. Compounds were evaluated in a radiometric 
ACCase assay for inhibition of malonyl-CoA formation. A proprietary permeabilized strain of E. coli with 
deficient efflux pumps (HS294) was used in MIC determination. All compounds did not demonstrate activity 
in wild-type E. coli. 
In a separate program, Pfizer discovered a series of pyridopyrimidines in a high-throughput 
screen against efflux-deficient E. coli (Figure 1.24).194,195 Although the lead compound, AccC-5, 
shows potent cellular activity, it also broadly inhibited human kinases. Derivatives with fewer off-
target activity (AccC-6 and AccC-7) unfortunately are less active against AccC. A scaffold-
hopping program led to aminooxazole AccC-8 that possessed potent in vitro activity that failed to 
translate into cellular activity.196 While the limited antimicrobial activity against S. aureus may 
initially seem discouraging, the disparity in activities may be attributed to the ability of many 
gram-positive bacteria to utilize exogenous fatty acids. The activity of inhibitors of de novo fatty 
acid synthesis is both target and species dependent.138 
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Despite limited availability of bioactivity for known AccC inhibitors, several stand out as 
good candidates for conversion. The benzimidazoles (Figure 1.23) offer particular promise due to 
their potent bioactivity, substituent tolerability of the cycloalkane, and adherence to 
physiochemical property guidelines. The pyrimidopyrimidines (Figure 1.24) are an excellent 
starting point for developing compounds with increased potential for accumulation. However, the 
existing reports of non-specific activity and lower potency reduces enthusiasm for this compounds 
class. Finally, the aminooxazoles are likely not ideal candidates due to their high globularity and 
flexibility. 
1.6.5. MurC inhibitors 
Muramyl ligases are essential for the successful biosynthesis of bacterial peptidoglycan. 
MurC (UniProt P17952) is responsible for the first of several amino acid additions to UDP-
MurNAc (Figure 1.25). MurC is remarkably well conserved among gram-negative pathogens 
(Figure 1.26). Given the long-standing success of b-lactams in inhibiting the final stages of 
peptidoglycan synthesis, inhibition of the first step is also anticipated to be effective as 
demonstrated by fosfomycin, which inhibits the earliest step in the cell wall pathway, MurA. 
Temperature-dependent knockout of MurC shows that it is essential for growth. Early MurC 
inhibitor development produced transition-state mimics197,198 and compounds with poor drug-like 
properties,199,200 all without cellular activity. To date, no MurC inhibitor has demonstrated 
antimicrobial activity against wildtype gram-negative bacteria. Despite this shortfall, the genetic 
support for MurC as a validated target combined with other existing scaffolds make MurC 
inhibitors promising candidates for conversion. 
 
Figure 1.25 Biosynthesis of UDP-MurNAc pentapeptide, the building block of the peptidoglycan layer. UDP-
MurNAc is synthesized from N-acetylglucosamine by MurAB (not shown). A series of muramyl ligases 












































Figure 1.26 Sequence alignment of MurC from gram-negative organisms. Red arrows indicate site mutations 
that confer resistance in P. aeruginosa.28 Alignment was performed with Clustal Omega 1.2.4158 and 
visualized with ESPript 3.0.159 Secondary structure generated with DSSP from E. coli MurC (PDB 2F00). 
Protein sequences obtained from Uniprot: E. coli (P17952), K. pneumoniae (A6T4N4), A. baumannii 
(B7GV74), and P. aeruginosa (Q9HW02). 
The first unique chemotypes with activity against MurC came from target-based high-
throughput screens. Pfizer conducted a HTS that detected the consumption of ATP by E. coli MurC 
and discovered MurC-1.201 MurC-1 showed surprisingly selective activity against MurC from 
Enterobacteriaceae over other gram-negative organisms (e.g. H. influenzae and P. aeruginosa). 
MurC-1 did not show activity against wild-type E. coli but did show very weak activity (MIC = 
64 µg/mL) against a double mutant (∆imp and ∆tolC). This poor antimicrobial activity could 
partially be explained by MurC-1 being a competitive inhibitor of ATP. 
A more promising scaffold comes from a HTS performed by AstraZeneca, in this case 
against P. aeruginosa MurC. The pyrazolopyridine hit compound (MurC-2, Figure 1.27) was 
                   TT                                                           E_coli      
   1       10        20        30        40        50        60        70       
E_coli                        MRR   IHFVGIGGAGM GIAEVL N GY  SGSD      T  L   G      H  EN  LAK IV E   VR                  A E  QI    LA N V QQ  ATIY  R   V...MNTQQ LRS P H G P P MNL FN P R
K_pneumoniae                   MRR   IHFVGIGGAGM GIAEVL N GY  SGSD      T  L   G      H  EN  LAK IV E   VR                  A E  QI    LA N V QQ  ATIY  R   V...MNTQD LRS P H G P P SQL FN P R
A_baumannii                   MRR   IHFVGIGGAGM GIAEVL N GY  SGSD      T  L   G      H  EN  QAK KV E   IK                  A Q  KI    IK S T QQ  IKVY  E   IMSPTTAAN KLI P H C A K EEN IG A K
P_aeruginosa                   MRR   IHFVGIGGAGM GIAEVL N GY  SGSD      T  L   G      H  EN  VKE VT T   IR                  L L  EV    LK S V ER  AQIF  Q   A.......M PNG R R C A A EKF IG A D
        TT                                                                      E_coli      
 80        90       100       110       120       130       140       150       
E_coli       A V VVS AI   NPE   A E RIP   RAEML ELMR RHGIA AGTHGKTTTT       A   LDPT V GG     V   S     IVA  A   VI          F     I          AMVSS  E     F   LVD S SAD H R A IY AG N K
K_pneumoniae  A V VVS AI   NPE   A E RIP   RAEML ELMR RHGIA AGTHGKTTTT       A   LDPT V GG     V   S     IVA  A   VI          F     I          AMVSS  E     F   LVD S SAD H R A IY AG N K
A_baumannii  A V VVS AI   NPE   A E RIP   RAEML ELMR RHGIA AGTHGKTTTT       A   LDPT V GG     L   T     VKA  Q   IV          Y     V          SLLTT  E     Y   LLN N DPE I R G ML EN I N
P_aeruginosa  A V VVS AI   NPE   A E RIP   RAEML ELMR RHGIA AGTHGKTTTT       A   LDPT V GG     L   S     VAS  R   VV          Y     V          SLIAS  A     F   RLG D NRA L P A VF GG I N
                    TT                                           TT             E_coli      
160       170       180       190       200       210       220       230       
E_coli        G  A LG  R   AEADESDASFL LQPM A VTNI ADHM TY G F  LK TF  FLHNLPFYG AV C DD   RAA V  R   YLI               V I                IN              VI H HG H E D Q D EN Q R M V P
K_pneumoniae   G  A LG  R   AEADESDASFL LQPM A VTNI ADHM TY G F  LK TF  FLHNLPFYG AV C DD   RAA V  R   YLI               V I                IN              VI H HS H E D H D EN Q R M V P
A_baumannii   G  A LG  R   AEADESDASFL LQPM A VTNI ADHM TY G F  LK TF  FLHNLPFYG AV C DD   RST V  A   FIV               A I                VQ              NI N ES Y D D E S DK D L V G A
P_aeruginosa   G  A LG  R   AEADESDASFL LQPM A VTNI ADHM TY G F  LK TF  FLHNLPFYG AV C DD   RAA T  Q   YLV               V V                VE              VV N AS H D A G D NK K L M V P
                TT           TT        TT                                       E_coli      
240       250       260       270       280       290       300       310       
E_coli      E LP   R   TYG   D D R     Q G    F   R          N PG HN LN  A    AT EG  D AI    L  RV  TT   FSE A V VE Q  Q  TLL KE M VTL     A  AA AV V    I  E  LRG Q DY I P GH QD P R A R A E D A
K_pneumoniae E LP   R   TYG   D D R     Q G    F   R          N PG HN LN  A    AT EG  D AI    L  RV  IT   FSD A V VE R  Q  RLV KA L VTL     A  AA AV V    I  R  LRG Q DY V A GH QD I Q A R A E D A
A_baumannii E LP   R   TYG   D D R     Q G    F   R          N PG HN LN  A    AT EG  D AI    I  RV  VI   FNE N I AI E  R  TVL RE L LTI     V  AL AI V    V  E  SRG P DV D M SH KG P R Q L G D S A
P_aeruginosa E LP   R   TYG   D D R     Q G    F   R          N PG HN LN  A    AT EG  D AI    I  QI  TV   LSE A V AI R  R  TVL RE L VSV     V  SL TI I    I  E  VQA P NI E M TW PE P D M L V D S G
       TT                                                                       E_coli      
320       330       340       350       360       370       380       390       
E_coli      L  F G GRRF   GE          G   L DDYGHHP EV A IKA R   P   LVM  QPHR  RTRD   DF  V E  Q T      F L  TA  V       T   T   A  DK    LF    FT    YD  AN S DFL P EPVNGKS M D AGW N L
K_pneumoniae L  F G GRRF   GE          G   L DDYGHHP EV A IKA R   P   LVM  QPHR  RTRD   DF  V E  Q T      F L  SA  I       T   T   A  DK    VF    YT    YD  AN S DFL P AEVNGKP M D AGW N L
A_baumannii L  F G GRRF   GE          G   L DDYGHHP EV A IKA R   P   LVM  QPHR  RTRD   DF  V K  S V      F L  NV  V       K   T   A  DR    LF    YS    FD  IE G QVQ E G.....E K E QSH R C
P_aeruginosa L  F G GRRF   GE          G   L DDYGHHP EV A IKA R   P   LVM  QPHR  RTRD   DF  V S  Q V      L V  SV  V       R   V   I  ER    VY    YT    YE  VQ G QVY Q E.....G M A GGW R L
                    TT                                                          E_coli      
400       410       420       430       440        450       460       470      
E_coli      L     LL   VYPAGE PI GADSR L   IR RG   PI                L   D  L QGAG  G     L  QV T  MLE      A       S T    KID  VA MLA V T  LI     I IA  AT D P CR G LVPD.PAR E P GN V N K RS
K_pneumoniae L     LL   VYPAGE PI GADSR L   IR RG   PI                L   D  L QGAG  G     L  QV A  MLD      A       S T    KVD  AA MLA V T  LV     I IA  AT D P CR G LVPD.STQ E S GN V N K RH
A_baumannii L     LL   VYPAGE PI GADSR L   IR RG   PI                L   D  L QGAG  G     L  QV Q  LLE      K       T S    QVE  LQ IMQ V Q  LL     V IS  AS D V AR L LIDPVEGN N N PN T N A VE
P_aeruginosa L     LL   VYPAGE PI GADSR L   IR RG   PI                L   D  L QGAG  G     L  EA V  LME      E       Q S    QLD  LA LVK L R  IL     V LA  IG N P CH Q YFER.DAD P P AG C D G PQ
                                                                                E_coli      
 480       490                                                                  
E_coli         L                                                                            E  IK KPQTPEEEQHD
K_pneumoniae    L                                                                            E  IK IPQKTEEERHG
A_baumannii    L                                                                            Q  HH YVK........
P_aeruginosa    L                                                                            K  NP FAGKGGKGA..
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rapidly optimized into a series of compounds with nanomolar potency against MurC in vitro 
(MurC-3, MurC-4, and MurC-5).28,202 Despite this impressive activity against purified enzyme, 
these analogues showed only moderate activity against efflux-deficient mutants of E. coli and P. 
aeruginosa. Researchers at AstraZeneca assumed that the limiting factor was bacterial 
accumulation and observed that lipophilicity had increased during lead optimization (Figure 1.28). 
In response, carbamate-linked polar groups were introduced to reduce cLogD (MurC-6, MurC-7, 
MurC-8). Notably two primary amine containing molecules were synthesized and evaluated. The 
introduction of primary amines was accompanied with increased flexibility which likely precluded 
accumulation. Potent MurC inhibitors with low globularity and few rotatable bonds (e.g. MurC-5) 
still may be promising conversion candidates. The promise for this compound series is slightly 
moderated by the recent disclosure that while the accumulation of the pyrazolopyrimidines was 
low, it was sufficiently high to anticipate >90% MurC inhibition.203 
 
Figure 1.27 Promising MurC inhibitors as candidates for conversion to gram-negative antibiotics. Eco524 




IC50 (E. coli) = 30.2 µM
IC50 (K. pneumoniae) = 26.4 µM
IC50 (H. influenzae) >200 µM




























IC50 (E. coli) = 12 nM
IC50 (P. aeruginosa) = 0.7 nM
MIC (E. coli WT) = 200 µM
MIC (Eco524) = 12.5 µM
MIC (P. aeruginosa WT) > 200 µM
MIC (Pae546) = 6 µM
IC50 (P. aeruginosa) = 1.0 µM IC50 (E. coli) = 1 nM
IC50 (P. aeruginosa) = <5 nM
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Figure 1.28 Relationship of cLogD and efficacy against P. aeruginosa MurC during the course of structure 
optimization. Figure was reprinted by permission from Nature Reviews Drug Discovery Ref. 48 © (2015) 
Springer Nature. 
While a co-crystal structure of MurC bound inhibitors is not available, several structures 
are available of H. influenzae bound to ATP analogues. Docking reported for MurC inhibitors and 
potential analogues into the ATP binding pocket does provide insight into potential positions for 
modification.28 
1.6.6. LolCDE inhibitors 
The lipoprotein trafficking is an essential pathway for gram-negative bacteria. In order to 
traffic lipoproteins across the periplasm, the Lol system shuttles these proteins via the carrier 
protein LolA. While the components of this pathway have been known for quite some time, their 
reconstitution in assays amenable for HTS has not been successful. Recent phenotypic screening 
efforts have revealed a promising lead that inhibits the LolCDE complex. The AstraZeneca 
compound collection (~1.2 million compounds) was evaluated for growth inhibition of a 
permeablized E. coli strain (W3110 ∆waaP) and discovered Lol-1 and Lol-2 (Figure 1.29).204 
Genentech separately screened their compound library against efflux-defficient E. coli (∆tolC) 
with a secondary gene reporter screen that detects the sE stress response and discovered 
pyrrolopyrimidinedione G0507.205 Although the structure LolCDE has not been solved, both 
compound series share resistance mutations in LolC (Q258K/L, N265K) and LolE (L371P, P372L) 
and share a core pharmacophore which suggests these compounds may be binding to the same site. 
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for hydrophobic binding sites that favour 
intrinsic binding energetics, which further 
bias molecules towards having LogD values 
above what is normally seen for marketed 
antibacterial agents. Although many pro-
gressable hits were identified for most of the 
AstraZeneca screening targets, the progres-
sion of these projects into lead optimiza-
tion proved extremely difficult, as hits were 
typically ~3–4 log units more hydrophobic 
than the average hydrophobicity of a typical 
antibacterial agent (FIG. 2).
In response to the lack of molecules 
with whole-cell activity for use as starting 
molecules in our programmes, conven-
tional wisdom amongst medicinal chem-
ists often supported design strategies that 
drive biochemical potency to nanomolar 
levels to achieve meaningful activity (typi-
cally single-digit micromolar) against intact 
bacteria, often with this observation extend-
ing to include even hypersensitive mutant 
strains. Although this may have been an 
accepted strategy in the field during the HTS 
era of antibacterial drug discovery, several 
examples presented here demonstrate the 
limitations of this approach. For example, 
for inhibitors of UDP-N-acetylmuramate-l-
alanine ligase (MurC) or CoaD, nanomolar 
activity was achieved without marked anti-
bacterial activity. Conversely, the strategy 
of only d ivin  potency against the target 
has not received universal support. Indeed, 
privileged scaffolds or targets exist for 
which good antibacterial activity can be 
achieved without large differences between 
the target-binding and whole-cell activity 
potencies. One such example is the group of 
benzoxoborole-derived inhibitors that target 
leucyl-tRNA synthetase22. These inhibitors 
typically had only micromolar biochemical 
activity but nonetheless exhibited impres-
sive antibacterial potency. Clearly, a detailed 
understanding of the cellular context of the 
target, and whether or not its correspond-
ing biochemical assay adequately represents 
physiological conditions, is key for successful 
execution of this strategy.
Although it is simple to suggest that 
teams should focus on designing com-
pounds with a low LogD as well as simulta-
neously increasing the biochemical potency, 
in our experience, lipophilicity typically 
increases with potency. This tendency is 
highly dependent on the nature of the target 
binding site; however, lipophilic compounds 
are difficult to avoid for targets with large 
hydrophobic active sites. For example, in 
identifying compounds that inhibit MurC 
(FIG. 2), chemists that were designing an  
synthesizing compounds over the course  
of the project encountered a very common  
problem: the most potent compounds 
that the teams generated tended to be very 
hydrophobic (FIG. 2). Efforts to reduce lipo-
philicity are generally met with reduced 
biochemical potency (FIG. 2), which further 
exacerbates the separation between their 
activity and the MICs in important patho-
gens23. Teams may eventually give up trying 
to find hydrophilic compounds and focus 
on the hydrophobic compounds, hoping to 
identify compounds potent enough to negate 
the loss of activity due to outer membrane 
permeability barriers. We have found that this 
approach generally does not work.
The AstraZeneca team also screened 
several diverse chemical libraries with a 
range of physical properties and character-
istics outside of the typical screening col-
lection with the hopes of overcoming some 
of the abovementioned issues. Phenotypic 
screens were also pursued in an attempt to 
identify compounds with cceptable MICs 
from the start of the programme. Neither 
target-based nor phenotypic scr ening 
approaches against these diverse libraries 
yielded any substantial differences in hit 
frequency when compared to the standard 
AstraZeneca proprietary screening sets 
used in the 65 high-throughput screens 
highlighted above. In many of these efforts 
hydrophobicity remained an issue, such that 
the most interesting molecules identified 
still exhibited a LogD >3, even when present 
in smaller numbers among the original 
screening sets18.
It should also be noted that having  
chemical series in the appropriate physical  
property space does not automatically 
increase the probability of finding whole-cell 
active compounds. For example, compounds 
that inhibit β-ketoacyl-(acyl carrier protein) 
synthase III (FabH) had favourable physical 
properties (FIG. 1), but only a few examples 
exhibited very weak activity in Gram-positive 
strains and no activity in Gram-negative 
strains. There ar  several obvious reasons f r 
this observation, including a lack of target 
Figure 2 | The relationship over time between the biochemical potency against Pseudomonas  
aeruginosa MurC and the cLogD of newly synthesized programme compounds. As chemists 
were designing and synthesizing compounds over the course of the project (shown as sequential 
compou d r gistrations on the x axis) the most p tent examples t ended towards having a high hydro-
phobicity (dark red squares). Efforts to reduce the hydrophobicity were generally met with reduced 
biochemical potency (green squares). The molecules are grouped by hydrophobicity, as measured by 
‘computed’ LogD (cLogD) values, calculated using AstraZeneca’s proprietary predictive model, 
AZlogD
7.4
, as indicated in the key. 
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Figure 1.29 LolCDE inhibitors discovered in HTS efforts at Astrazeneca and Genentech. 
All of the LolCDE inhibitors are good candidates for conversion with low globularity and 
few rotatable bonds. While Lol-4 has some activity against wild-type E. coli, the high efflux ratio 
suggests that there is significant room for improving cellular activity by increasing accumulation. 
Already on the verge of being having clinically useful efficacy, these compounds would make 
compelling antibiotics with even modest improvements in accumulation. The modular structure 
should allow for the rapid exploration of SAR to leading to an amine-containing compound with 
good activity. Overall, the LolCDE inhibitors are one of the most promising conversion candidates. 
1.6.7. RNAP inhibitors 
RNA polymerase (RNAP) is a validated antibacterial target. Currently, two classes of 
approved natural product antibiotics act through inhibition of RNAP: rifamycins (rifampin, 
approved 1999) and lipiarmycins (fidaxomicin, approved 2011). More recently, nucleoside natural 
products have been discovered as effective RNAP inhibitors.206 These classes of compounds have 
been useful for drug-resistant gram-positive infections, particularly C. difficile. To date, no RNAP 
inhibitors are effective against gram-negative pathogens. As the above drugs are of a substantial 
size to be considered for conversion via the introduction of an amine, the best chance for a gram-
negative RNAP inhibitor is from the conversion of synthetically derived small-molecules. 
The best scaffold for conversion comes from a HTS performed by Merck.207 A HTS had 
been performed against hyper-permeabilized E. coli. Hits from this screen were subjected to AS-
MS to find ligands for RNAP. Although increased target potency would be desirable, MRL-436 is 
an unoptimized hit and an accumulating derivative would provide precedent to further explore the 






























































Figure 1.30 Bioactivity for RNAP inhibitor MRL-436. Strains: E. coli MB5746 (∆tolC, ∆lpxC), E. coli 
(∆tolC, ∆rfa), identity of wild-type E. coli strain was not reported. 
1.7. Concluding remarks 
The current AMR crisis has fueled a critical need for new antibiotic classes with orthogonal 
mechanisms of action. The promise that the genomic era would deliver new druggable targets and 
therapies has failed to be realized; ultimately, this shortcoming arises from the difficulty in 
translating a potent inhibitor of purified protein into ones with adequate cellular activity. This 
problem is primarily attributed to a poor understanding of how to incorporate features into 
compounds that position them for sufficient accumulation in gram-negative bacteria. Following 
the codification of the eNTRy rules, we are now poised to revisit many of these stalled antibiotic 
development projects. Here, the strategy for approaching the most promising candidates for 
conversion into gram-negative antibiotics was discussed. Successful application of the eNTRy 
rules to these scaffolds will require careful drug design to achieve accumulation while maintaining 
sufficient target engagement. With a new strategy in place, a newfound optimism exists that many 
of the compounds discovered from target-based screening can be coopted to introduce new 
antibiotics with meaningful activity against priority pathogens. 
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CHAPTER 2 PREDICTION OF GRAM-NEGATIVE ACCUMULATION 
Portions of this Chapter are reprinted with permission from Richter, M.F.; Drown, B.S.; 
Riley, A.P.; Garcia, A.; Shirai, T.; Svec, R.L.; Hergenrother, P.J., Predictive compound 
accumulation rules yield a broad-spectrum antibiotic. Nature 2017, 545, 299-304, © 2017 Springer 
Nature. Contributions of others are noted where applicable. 
2.1. Introduction 
2.1.1. Predictive modeling in drug discovery 
Predictive modeling permeates modern life. Predictive models are at the heart of email 
spam filters, movie recommendations from Netflix, fraud detection by credit card companies, and 
patient diagnosis. Predictive modeling is the process of developing a mathematical tool or model 
that generates an accurate prediction.1 These models are most useful for dealing with an 
overwhelming amount of data or uncovering relationships not initially apparent at first glance. To 
build a predictive model, a collection of observations is annotated with a series of predictors and 
outcome of interest. A mathematical model is then developed to describe the relationship between 
predictors and outcome. 
The drug discovery process is an excellent opportunity to apply predictive modeling. A 
commonly described mantra in the industry is “fail early, fail cheap.” The longer it takes to 
recognize that a particular target or compound is not viable, the higher the cost of developing the 
eventual drug. Further, drug companies have large annotated collections of compounds that have 
been scrutinized in a wide variety of bioassays, which can be leveraged to produce predictive 
models. The features that ultimately lead to decisions about a target or drugs promise can often be 
expensive or at least laborious to determine. In early lead generation, screening hits can be ranked 
based on predicted properties associated with good drugs. These properties can be as simplistic as 
water solubility2 and protein binding3 or as complex as susceptibility to first-pass metabolism4 and 
liver toxicity.5  
The fundamental assumption in cheminformatics is that the properties of a molecule are 
determined by the number, type, and structural arrangement of the atoms. According to this theory 
if the structure of molecules can be described by some quantitative metric, a relationship can be 
determined between that structure and a property of interest. This thinking can clearly be seen in 
the increasingly sophisticated models for predicting the boiling point of alkanes. In 1842, Kopp 
observed the addition of methyl groups increased a molecule’s boiling point.6 Through to the 
1930s, boiling point prediction was accomplished with increasingly complex equations involving 
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molecular weight, number of carbons, and empirical constants.7-9 These approaches failed to 
account for constitutional isomers until Harry Weiner’s seminal paper in 1947 applying graph 
theory.10 Although boiling point may seem less relevant today, the work by Weiner showed that 
the structural arrangement of carbons can be summarized as a single number (now called the 
Weiner index) and that this number can be directly related to a physiochemical property.  
The discoveries by Weiner coincided with an expansion of computing capacity which led 
to an explosion in molecular descriptors used to power new predictive models. In addition to the 
topological indices developed by Weiner and others, molecules can be described with molecular 
fingerprints,11 molecular interaction fields,12,13 and surfaces.14 These primary descriptors can be 
used to predict common physiochemical properties (e.g. logP, molar refractivity, dipole moment). 
Today, hundreds to thousands of molecular descriptors can be rapidly calculated and used to build 
predictive models. These predictive models are most commonly quantitative structure-activity 
relationship (QSAR) models.15 Using this approach, a biological response (growth inhibition, 
binding constant to target, etc.) is predicted by small changes in structure. Widely practiced by 
drug companies, QSAR can prioritize compounds for synthesis and therefore saves time and 
money. While predictive modeling can be highly successful in analyzing closely related structures 
(as is the case in QSAR), it is rarely applied to diverse compound collections to understand wider 
trends in compound behavior. Here, we apply predictive modeling along with molecular dynamics 
to assist in discovering new determinants of bacterial accumulation. 
2.1.2. Existing models for bacterial accumulation 
Drug accumulation into gram-negative bacteria has long been recognized as a major 
limitation in the development of gram-negative antibiotics. Consequently, several approaches to 
understanding the physiochemical basis of compound accumulation have been described. In a 
landmark paper, O’Shea and Moser looked retrospectively at 147 antibiotics and calculated seven 
physiochemical properties (molecular weight, cLogP, cLogD7.4, polar surface area, relative polar 
surface area, hydrogen bond donor count, and hydrogen bond acceptor count).16 In general, gram-
negative antibiotics were smaller (as measured by molecular weight) and more polar (as measured 
by cLogD7.4) than gram-positive only antibiotics (Figure 2.1A). However, these two properties 
were much more indicative of structural class (i.e. fluoroquinolone vs. aminoglycoside) than 
spectrum of activity (Figure 2.1B). The limited structural diversity, reliance on antimicrobial 
activity over accumulation data, and retrospective nature of this study ultimately limits the 
predictive power of this model as demonstrated by examples discussed in Chapter 1. 
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Figure 2.1 Retrospective analysis of physiochemical properties of antibiotics by O’Shea and Moser. 
Compounds are labeled according to spectrum of activity (A) and compound class (B). Reprinted with 
adaptation with permission from Ref. 16, © 2008 American Chemical Society. 
A limited number of prospective studies have been performed. Some feature large, diverse 
compounds collections but rely on bioactivity17,18 while others directly measure accumulation but 
feature small, focused compound sets.19-22 In many of these studies the finding of O’Shea and 
Moser have simply been reiterated. To our knowledge, no prospective analysis of gram-negative 
bacterial accumulation has been conducted with a large and diverse compound collection. Our 
overall goal was to perform this kind of study and better understand the molecular determinants of 
gram-negative accumulation. 
2.2. Development of predictive guidelines 
2.2.1. Assembly of accumulation training set 
The gold standard for measuring bacterial accumulation has been the use of radioisotopic 
labelling of molecules.23 While numerous methods have been developed (e.g. fluorescent 
tagging,21,24 enzyme coupled reactions,25 incorporation of bio-orthogonal handles,22 liposomal 
swelling,26 patch clamp27), these methods either lack generality or fail to consider the whole cell.28 
While these reductionist approaches can be helpful for individual drug design projects, we sought 
to develop predictive guidelines that were useful for whole organisms and a wider range of 
compounds. We turned to mass spectrometry as a tag-free method with high sensitivity. 
The accumulation assay developed by Dr. Michelle Richter has been described in detail 
elsewhere.29-31 Briefly, compounds are individually incubated with bacteria for a brief period of 
time, extracellular compound is removed, cells are lysed, and the concentration of compound in 
lysate is quantified by LC-MS/MS (Figure 2.2). Although laborious, this method was found to 
accurately measure the accumulation of a wide variety of compounds. The only limitations are that 
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compounds that ionize poorly by ESI cannot be quantified and test compounds must be sufficiently 
soluble in aqueous media.  
 
Figure 2.2 Workflow for bacterial accumulation assay. After a culture of bacteria is grown to mid‐log phase, 
bacteria are harvested and washed with sterile phosphate‐buffered saline (PBS). The pellet is then 
resuspended in a much smaller volume of PBS and aliquoted into Eppendorf tubes. The cultures are then 
incubated with compound of interest for 10 minutes. To separate the bacteria from extracellular compound, 
cultures are layered on cold silicone oil and centrifuged. The oil forms a layer between the bacterial pellet 
and the supernatant. After disposal of both the supernatant and oil, the pellets are resuspended in water and 
the bacteria are lysed by freeze–thawing. The lysate is centrifuged to remove cellular debris, and the 
supernatant is analyzed by LC–MS/MS. Figure is reprinted with permission from Annals of the New York 
Academy of Sciences, Ref. 29 © 2018 John Wiley and Sons. 
To understand the physicochemical properties that influence small-molecule accumulation 
in E. coli, a collection of diverse compounds was required. Given that most antibacterial drugs are 
natural products or derivatives, critical to this effort would be access to a collection of compounds 
that possess natural-product-like properties, but also are synthetically accessible so that various 
properties can be tuned, enabling SAR studies. Thus, these compounds were produced using the 
‘complexity-to-diversity’ strategy, whereby diverse compounds are constructed from readily 
available natural products.32-34 To begin the analysis, a set of 100 compounds, including positively 
charged, negatively charged and neutral compounds, were synthesized and tested. As retrospective 
studies suggest that compound accumulation is related to ClogD7.4, the accumulation data for all 
100 compounds were plotted against ClogD7.4 (Figure 2.3). These results differ starkly from the 
conclusions reached in retrospective studies. Within this set of 100 compounds, charge is the 
 57 
primary factor dictating accumulation in E. coli. The positively charged compounds are the most 
likely to accumulate, with 12 of 41 positively charged compounds showing a significant level of 
accumulation compared to the low-accumulating controls. In contrast, 0 of 39 neutral compounds 
and 0 of 20 negatively charged compounds show significant accumulation. Notably, even 
carboxylic acids with strongly negative ClogD7.4 values (<−5) do not accumulate. 
 
Figure 2.3 Assessment of 100 compounds for accumulation, labelled by ionic state. Statistical significance 
was determined by using a two-sample Welch’s t-test (one-tailed test, assuming unequal variance) relative 
to the negative controls. P values relative to the average of the low-accumulating controls; *P < 0.05, **P < 
0.01. 
Primary amines showed the highest level of accumulation among positively charged 
compounds, and systematic modification (to mono, di, and trimethylated species) showed the 
superiority of primary amines. Additional primary amine-containing compounds were then 
obtained and their accumulation in E. coli was assessed; these compounds are both ‘complexity-
to-diversity’ compounds and commercially available primary amines that more closely mimic the 
types of compounds found in commercial screening libraries. For the total set of 68 primary 
amines, accumulation does not increase with lower ClogD7.4 (Figure 2.4a), and there is also no 
correlation between accumulation and molecular weight (Figure 2.4b). SAR analysis on several of 
these compounds also demonstrated the importance of the amine for accumulation (not shown).  
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Figure 2.4 ClogD7.4 and molecular weight do not correlate with accumulation of primary amines. a, b, The 
accumulation of 68 primary amine containing compounds in E. coli MG1655 compared to ClogD7.4 (a) and 
molecular weight (b). High-accumulating controls (black x) = tetracycline, ciprofloxacin and 
chloramphenicol; low-accumulating controls (open circles) = novobiocin, erythromycin, rifampicin, 
clindamycin, mupirocin and fusidic acid, clindamycin and ampicillin. Statistical significance was determined 
by using a two-sample Welch’s t-test (one-tailed test, assuming unequal variance) relative to the negative 
controls. P values are relative to the average of the low-accumulating controls. *P < 0.05, **P < 0.01. All 
samples were performed in biological triplicate. 
2.2.2. Overview of properties 
Although the presence of a primary amine is clearly important for accumulation in E. coli, 
it is not sufficient: although 36 of the primary amines within the test set do accumulate, 32 of them 
do not. Therefore, a chemoinformatic approach was implemented to understand which factors 
contribute to amine accumulation. For this set of 68 primary amines, 297 molecular descriptors 
were calculated for each compound, which were used to train several prediction models. 
Before any models were built, the distribution of variables was considered. As the 
physiochemical properties were all on different scales, the distribution of variables among 
accumulation classes was evaluated by the separation index (ratio of variance between and within 























A method for calculating separation index was implemented in R and used to calculate the 
separation of all properties in the training set (Figure 2.5). The properties with the highest 
separation are more likely to be related to accumulation. The four properties with the highest 
separation (ast_fraglike, Kier3, ast_fraglike_ext, and std_dim2) all are related to the shape of 
molecules. Even with this crude method of feature selection, it seems molecular shape is important. 
Although several shape indices were highly ranked (e.g. Kier and Weiner) the lowest ranked 
property (Balaban’s J index) is a similar topology index. While these shape indices can be powerful 
metrics for integrating molecule shape into QSAR models, interpreting their relationship to guide 
medicinal chemistry is challenging. 
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Figure 2.5 Separation of variables among accumulation classes. A high separation index suggests that there 
is high variance between classes but low variance within each class. The full set refers to all calculated 
properties. The reduced set refers to only properties following data preprocessing (see Section 2.2.3. for 
details). 
2.2.3. Data preprocessing 
Many prediction models are sensitive to aberrantly distributed variables. Most models 
perform optimally when variables are normally distributed and are not correlated, but many 
physiochemical properties do not fulfill these requirements. Many physiochemical properties 
strongly correlate with molecular weight or lipophilicity. Other correlations are less obvious but 
still present in training sets. This problem can be mitigated by removing highly cross-correlated 
variables (Figure 2.6), but this does not guarantee that linear combinations of variables are not 
correlated. Using principal component analysis (PCA) for pre-processing will guarantee that the 
resulting predictors and combinations thereof will not be correlated. Unfortunately, the 
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components resulting from PCA are linear combinations of the original variables, so practical 
interpretation is challenging. While PCA was used in some cases to preprocess data for regression 
models (Section 2.2.4.  below), we chose to simply remove variables with near-zero variance or 
high cross-correlation (threshold set to 0.8 Pearson coefficient). 
 
Figure 2.6 Correlation matrix of properties before (left) and after (right) preprocessing. Pearson coefficients 
are used for hierarchical clustering of properties. 
2.2.4. Regression model of accumulation 
Initially, regression models were trained to predict accumulation. These kinds of models 
predict numeric outcomes. Examples of regression models in medicinal chemistry are cLogP, 
cLogBB, and cLogS (although they do not need to be on a logarithmic scale). In the case of 
modeling bacterial accumulation, the number of properties is greater than the number of 
observations, so a typical linear regression would be more prone to overfitting. To this end, several 
methods were evaluated that are less prone to overfitting. Partial least squares (PLS) performs 
dimension reduction prior to fitting and is a popular method. Several related penalized linear 
models were employed: ridge, least absolute shrinkage and selection operator (LASSO), and 
elastic net (enet). Finally several non-linear regression models were included: support vector 
machines (SVM), k-nearest neighbor (k-NN), and random forest (RF). All models were trained 
with 10-fold cross-validation so that out-of-bag observations could be used to measure the 
accuracy of the models (Figure 2.7). 
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Figure 2.7 Comparison of regression model performance. Performance is measured by mean absolute error 
(MAE), root mean square error (RMSE), and R squared. Lower values for MAE and RMSE are better and 
higher R squared values are better. The linear model is not included in this figure because it performed so 
much more poorly (average RMSE = 12,000). 
 
Figure 2.8 Predictions by regression models of accumulation. Compounds that accumulate significantly 
above negative controls are shown in blue while low accumulators are shown in pink. 
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While the performance metrics described in Figure 2.7 are helpful for quickly comparing 
models, the raw values of these metrics do not give a sense for how the models are performing. By 
predicting accumulation for the training set (Figure 2.8), it becomes clear how some models (e.g. 
linear and SVM) are severely overfit. Further, all of the models perform more poorly for the highest 
accumulating compounds. Given that most antibiotics must simply reach a threshold level of 
accumulation in order to have their biological effect, we decided that a binary classification of 
compounds may be more appropriate for this application. Encouraged by the performance of the 
RF regression model, a RF classification model was anticipated to perform well. 
2.2.5. Classification model of accumulation 
An alternative mode of prediction modeling is to classify observations. Many of the same 
regression methods can be converted into classification models by simply setting thresholds for 
assigning a class. For example, linear discriminant analysis is analogous to linear regressions in 
that a scoring function is created from a linear combination of variables. Other methods are 
naturally suited for classification, because they already partition elements (e.g. k-NN or random 
forest). 
As discussed above, antibiotics must reach a threshold level of accumulation in order to 
have a biological response. This is evidenced by many high-accumulating antibiotics that do not 
have significantly higher activity upon knockout of tolC (Table 1.3). Compounds in the training 
dataset were classified as high accumulators if they had statistically significantly higher 
accumulation than low-accumulating control compounds (two-sample Welch’s t-test, one-tailed 
test, assuming unequal variance). With a training set of 36 high-accumulators and 32 low-
accumulators, a RF classification model was built. The RF classification model involves growing 
and pruning a “forest” of decision trees. Each tree is given a random subset of all variables with 
which to construct the best tree to classify the training data. When performing a prediction, each 
tree in the forest casts a vote to predict the class of a query. If the number of votes reaches a 
threshold value, then the model gives a positive class prediction. 
Because of the small size of the training set, several cross-validation (CV) methods were 
evaluated to ensure that accuracy is not influenced by CV method. The performance of models 
was measured by the area under the curve of a receiver-operator curve (ROC). The ROC plot 
shows the relationship between vote threshold, sensitivity, and false positive rate. The Y-axis is 
the true-positive rate while the X-axis is the false-positive rate. By lowering the vote threshold, 
more high-accumulating compounds can be captured but at the cost of false positives. As shown 
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in Figure 2.9A, the CV method has little impact on the overall performance of the model. The 
tuning plot (Figure 2.9B) suggests that decision trees can perform well with fewer assigned 
variables. Overall, the model performed with 75% accuracy (sum of true-positive and true-
negative rates, Figure 2.9C). 
 
Figure 2.9 Training and performance of random forest classification model. A. ROC plot comparing cross-
validation methods in training classification model. B. Tuning plot optimizing for number of selected 
predictors. C. Confusion matrix of classification model using repeated tenfold cross-validation (n = 20). D. 
Predictors with the highest relative importance as measured by the permutation method. Predictors related to 
flexibility, shape, and amphiphilicity are highlighted in red. 
One of the benefits of building a RF prediction model is the ability to measure the relative 
importance of each variable. There are two ways to measure variable importance for RF models. 
Accuracy-based importance is based on how much accuracy decreases when the variable is 
excluded. The second measure is unique to tree models and is based on the decrease in Gini 
impurity when a variable is chosen to split a node. Although mean decrease in Gini impurity is 
useful, we favored variable importance linked to overall accuracy. Many of the variables with the 
highest importance were related to the shape and flexibility of molecules (Figure 2.9D). 
Additionally, the most important variable, vsurf_A, is a measure of a molecule’s amphiphilicity. 
Several metrics of flexibility were evaluated (Kier flexibility and number of conformers), 
but number of rotatable bonds (RB) was chosen due to its intuitive relationship to flexibility. 
True Class
Prediction High Low
High 578 (42.5%) 198 (14.6%)





































































Several measures of molecular shape were also considered. Principle moment of inertia (PMI) is 
a common  method for describing molecular shape, and the second normalized PMI ratio (npr2) 
was identified as an important variable.35 The plane of best fit (PBF) was also considered as it was 
identified as an important variable.36 Another shape metric that was not included in the initial 
analysis, globularity (Glob), was found to work well with RB to discriminate high and low 
accumulators (Figure 2.10A). Glob is the inverse condition number of the covariance matrix of 
atomic coordinates. Glob can be calculated by performing PCA on the atomic coordinates and 
dividing the smallest eigenvalue by the largest eigenvalue. Perfectly spherical molecules (e.g. 
adamantane) have a Glob of 1 and perfectly flat molecules (e.g. benzene) have a Glob of 0. 
Although initially calculated using MOE, Glob was eventually implemented using open source 
tools (see Section 2.3.2. on page 70). 
 
Figure 2.10 Flexibility and globularity are important for accumulation in E. coli. A. Flexibility (as measured 
by the number of rotatable bonds) plotted against globularity for the primary amines with proper amphiphilic 
moment and amine steric hinderance. B. Flexibility versus globularity for antibiotics. Antibiotics included 
are gram-positive-only drugs containing ionizable nitrogens (circles) and gram-negative actives that are 
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As alluded to above, plotting RB vs. Glob results in a clear separation of high and low 
accumulators (Figure 2.10A). Gratifyingly, this trend was also observed for existing antibiotics 
that were not part of the training set (Figure 2.10B). b-lactams seem to occupy an intermediate 
space, likely because late-generation b-lactams are more resistant to b-lactamases and therefore 
do not need high accumulation to be effective.37 Importantly, these findings point to a new 
understanding of the molecular features that are required for a compound to accumulate in gram-
negative bacteria. The presence of an ionizable nitrogen (particularly primary amines) is a strong 
driver of accumulation.  Beyond this basic requirement, molecules with low flexibility, low 
globularity, and high amphiphilic moment are more likely to accumulate. These general 
observations are borne out in individual scaffolds where physiochemical properties are 
systematically adjusted. 
2.2.6. Case-studies to support findings 
Case studies demonstrate the importance of flexibility and globularity for accumulation of 
the primary amines: as shown in Figure 2.11A, amine 2-1 with four rotatable bonds accumulates 
well; however, amine 2-2, a compound of similar molecular weight and globularity but with 13 
rotatable bonds, shows virtually no accumulation. Analogous results are observed in Figure 2.11B, 
when comparing a compound with low globularity (2-3, globularity = 0.14) to a compound with 
similar functional groups, molecular weight and rotatable bonds, but with high globularity (2-4, 
globularity = 0.49); the globularity of each compound is most easily observed in its three-
dimensional model (Figure 2.11B).  
Although, in general, primary amines with five or fewer rotatable bonds and a globularity 
of 0.25 or less have a markedly higher likelihood of accumulation, two additional factors related 
to the placement of the primary amine are important. First, the random forest model identified 
increased amphiphilic moment, which measures the distance between hydrophobic and 
hydrophilic portions of a compound 2-14, as favoring accumulation. Notably, although mono-
amine isomannide (2-5) does not accumulate, derivatives with increased amphiphilic moment 
(vsurf_A) do accumulate (2-6 to 2-10), and similar trends are observed for other compound classes 
(2-11 to 2-14) (Figure 2.11C). Accordingly, some degree of hydrophobicity appears necessary for 
accumulation, although in practice most organic compounds possess this feature. Second, two 
compounds in this set with sterically encumbered primary amines are not high accumulators (2-15 
and 2-16; Figure 2.11D); both have low flexibility and globularity but contain a primary amine on 
a tetra-substituted carbon. This result is consistent with the increased accumulation of compounds 
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in which the primary amine is systematically extended from a sterically congested ring system (2-
17 < 2-18 < 2-19) (Figure 2.11E).  
 
Figure 2.11 Physiochemical properties affecting small-molecule accumulation in E. coli. A,B. Case studies 
comparing the importance of flexibility (A) and globularity (B). C. Derivative sets demonstrate how 
accumulation can rise as amphiphilic moment (vsurf_A) increases within a structural class. D. Two 
compounds with primary amines attached to tertiary centers, both are low accumulators. E. Systemic 
separation of the primary amine from a sterically congested ring system results in increased compound 
accumulation. Accumulation in E. coli MG1655 is reported in nmol per 1012 CFUs. All experiments were 
performed in biological triplicate. The s.e.m. is reported for accumulation values. 
In the course of this study, it became clear that many compound collections do not contain 
primary amines despite the clear benefit of a primary amine in favoring accumulation. This 
observation was quantified by measuring the percent abundance of several functional groups 
within screening collections (Figure 2.12). Although carboxylic acids are relatively abundant in 
screening collections, primary amines were the least abundant functional group searched. The 
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Chembridge Microformat) was vanishingly small (<1%). The dearth of primary amines is 
understandable given the challenge in purifying them, a luxury not afforded when assembling a 
large compound library. This observation perhaps explains the failure of high throughput screening 
against wild-type gram-negative bacteria to provide any tractable hits. The underrepresentation of 
primary amines in compound libraries stands in stark contrast to their comparably high prevalence 
(~8%) in approved drugs.38 
 
Figure 2.12 Prevalence of primary amines in screening collections. Comparison of the abundance of primary 
amines, secondary amines, tertiary amines, and carboxylic acids in the natural products subset of the ZINC 
database, the Molecular Libraries Small-molecule Repository – Natural Products (MLSMR-NP), and the 
Chembridge Microformat Library. 
2.3. Web application for predicting accumulation 
Having identified the importance of physiochemical properties for determining compound 
accumulation in gram-negative bacteria, it became apparent that the routine calculation of these 
parameters would be necessary when applying these findings in medicinal chemistry optimization 
of gram-negative antibacterials. The initial method for generating molecular descriptor data 
involved extensive work with command line interfaces and custom scripts. While this approach is 
accessible to some medicinal chemists, these factors are significant barriers for others. To solve 
this problem, the process of calculating physiochemical properties was automated in a web 
application. 
There are several challenges in implementing a web application that will predict the 
accumulation of small-molecules. First a program must be written that will perform the 
physiochemical property calculations necessary for a prediction. This program must then be 
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wrapped in a user interface that allows non-experts to perform calculations. Behind the scenes, a 
relational database and queuing system must manage user permissions, molecule ownership, and 
job execution. All of these pieces were brought together to develop the web application entry-way. 
2.3.1. Survey of conformer generation techniques 
The quality of three-dimensional physiochemical properties is critically dependent upon 
the quality of input conformers. While it may be less computationally expensive to perform all 
calculations on an energy-minimized structure, this approach fails to appreciate that molecules 
adopt many conformations when in solution. Thus, the first hurdle was to develop a rapid and 
accurate method for generating an ensemble of molecule conformers. 
Several approaches and implementations have been described to this problem (Table 2.1).39 
Conformer generation methods are broadly divided into systematic and stochastic approaches. In 
systematic methods, conformer space is explored by incrementing all rotatable bonds. This is a 
rapid method for small-molecules but can become impractical for molecules with many rotatable 
bonds. In stochastic methods, conformers are randomly generated by simulated annealing, genetic 
algorithms, and distance geometry. Many modern methods also utilize some knowledge-based 
algorithm to make an initial guess at a molecule’s structure. Fragments of a query molecule are 
compared to experimentally determined reference structures (e.g. Cambridge Structural Database) 
and reconstructed. In many of these approaches, the resulting conformers are scored based on their 
relative energies to eliminate unlikely conformers. 
For the initial development of the eNTRy rules, low mode molecular dynamics (MOE) was 
used to generated ensembles of conformers.40 This method gave high-quality conformers but at a 
high computational cost (Figure 2.13A). Deploying this method on a web server would be 
inappropriate because it is too slow and presents licensing restrictions. Instead, we intended to 
deploy an open-source method for conformer generation. Several of these methods were evaluated 
for their ability to rapidly generate high quality conformer ensembles (Table 2.1). In terms of 
speed, Confab and RDkit processed molecules much faster than other methods (Figure 2.13A). 
The globularity for each conformer was calculated and averaged for each molecule in order to 
compare their ability to recapitulate data generated from MOE. All but RDkit provided good 
correlation with MOE (Figure 2.13C). Finally, the reproducibility to globularity measurements 
was evaluated by running conformer generation three times. In this way, Balloon performed poorly 
(Figure 2.13D) with some molecules having quite variable shapes. By these three metrics (speed, 
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correlation with MOE, and reproducibility) Confab outperformed other methods and was utilized 
to generate conformers in entry-way. 
Table 2.1 Methods for conformer generation. 
Tool Method Cost/License Distribution 
MOE40 Systematic, stochastic, low mode MD Commercial Binary 
MacroModela Stochasitc Commercial Binary 
Confab41 Systematic GNU GPL Source 
OpenBabel Stochastic GNU GPL Source 
Balloon42 Stochastic Free/Proprietary Binary 
RDKit39,43 Stochastic BSD Source 
Corinaa Stochastic Commercial Binary 
OMEGAa Systematic Commercial Binary 
aNot included in analysis 
 
 
Figure 2.13 Analysis of open-source conformer generation methods. A. Time required to generate conformers 
for 100 molecules running on a single processor. B. Number of conformers generated by each method. 
Confab is not shown as it is off-scale. C. Correlation matrix of glob scores from conformer ensembles 
generated by each method, Pearson correlation coefficients shown. D. Reproducibility of calculated glob for 
each method. Conformer ensembles were generated three times from the same starting structure. 
Reproducibility is measured by standard deviation in calculated glob. Confab generated conformers via a 
systematic approach, so outcome is the same each time. 
2.3.2. Implementation of globularity calculation 
As is the case for conformer generation, globularity calculations were initially performed 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































implemented outside the context of MOE. The user manual of MOE defines Glob, “Globularity, 
or inverse condition number (smallest eigenvalue divided by the largest eigenvalue) of the 
covariance matrix of atomic coordinates. A value of 1 indicates a perfect sphere while a value of 
0 indicates a two- or one-dimensional object.” This description was sufficient to write a short 
Python program that calculates globularity. This script relies on OpenBabel for reading structure 
files and NumPy for performing the necessary linear algebra. The accuracy of this new method 
was tested by calculating the globularity of 992 drug-like molecules using both MOE and Python. 
Gratifyingly, the results show perfect agreement (Figure 2.14). 
 
Figure 2.14 Comparison of glob calculated by MOE and Python script. 992 drug-like molecules were 
evaluted R2 = 1.0. 
2.3.3. Overview of MVC Rails framework 
We considered the relative benefits for deploying entry-way as part of a platform such as 
Galaxy or as a stand-alone service. Deploying entry-way as a tool in Galaxy would benefit from 
the robust infrastructure for job handling but must also conform to existing standards. As a stand-
alone service, the production environment can be more optimally configured for our desired use. 
In constructing a front-end for entry-way there are almost endless options. While single-page 
applications (e.g. Reaxys, Chemicalize, Benchling) implemented with JavaScript frameworks (e.g. 
AngularJS, React, and other AJAX methods) are currently quite popular, the latency inherent in 
conformer calculations makes client-side calculations inappropriate. Instead, a more traditional 
thin client model-view-controller (MVC) architecture was favored (Figure 2.15). The Ruby on 
Rails framework was chosen to implement a MVC because of its excellent active record pattern. 
Ruby on Rails applications also benefit from being easy to deploy to production through tools like 
Heroku or Elastic Beanstalk on Amazon Web Services (AWS).  














Figure 2.15 Model-view-controller architecture. The Model represents the application’s dynamic data that is 
used to construct a View (in this case a web page) that is displayed to the user. The User provides input that 
is interpreted and validated by the Controller, which modifies the Model and determines which View to show 
using data given by the Model. Although originally developed for desktop graphical user interfaces, MVC 
frameworks are now the most common type of web application. 
The first critical step in developing entry-way was to formalize the model. In MVC 
architecture, models access and manipulate data. Models also define their relationship to other 
models and what kinds of attributes are available. The object-relational mapping system in Ruby 
is called ActiveRecord and greatly simplifies building models since they can be written from an 
object-oriented perspective. The relationships and attributes for models used in entry-way are 
described in Figure 2.16.  
 
Figure 2.16 Database scheme used by entry-way. Database tables are depicted as rectangles. Private keys 
(PK) are unique identifiers for each row and foreign keys (FK) are identifiers used to define relationships. 
The delay_jobs table was used for development and testing environments only. AWS SQS was used for job 










2.3.4. Implementation of queuing system with AWS SQS 
Web development best practices dictate that computational intensive processes should be 
off-loaded to workers so that the responsiveness of a web page is not impacted. Common tasks 
that are off-loaded are sending emails, reformatting images for thumbnails, and preparing 
downloads. Rails has built-in functionality for running jobs called Active Job, which packages 
particular processes so that they can be run separately. A major advantage of Active Job is that it 
standardizes the interface to a number of queuing options. For development and testing, Delayed 
Job was used for scheduling jobs. Delayed Jobs uses a table in the database as a queue that contains 
all the necessary information to run each job (Figure 2.16). 
We decided early on to deploy entry-way on Amazon Web Services. This decision was 
made in part due to convenience and practicality. An existing agreement between Amazon and the 
University of Illinois makes account management and billing relatively straightforward. AWS 
features a robust internet infrastructure while still being remarkably configurable. An Elastic 
Beanstalk environment was created with separate web server and worker tiers, which were 
connected by a Simple Queuing System (SQS) queue (Figure 2.17). With this environment 
established, two types of jobs were created, MoleculesCalcJob and BatchProcessJob (Figure 2.18). 
BatchProcessJob reads a list of SMILES strings and creates a database entry for each molecule 
and then launches a MoleculesCalcJob for each molecule. Once the individual calculations are 
complete, BatchProcessJob writes a CSV file that contains the physiochemical properties of all the 
molecules. MoleculesCalcJob launches a Python program through a system call, which generates 
an ensemble of conformers and calculates physiochemical properties. For a typical drug-like 
molecule, this whole process occurs in less than a second thereby having little impact on the 
experience of the user. 
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Figure 2.17 Organization of Elastic Beanstalk environment for running jobs. Two environments are created 
tasked either as web service or workers. The web server tier is exposed to the internet and handles requests 
from users. When a molecule is submitted, an SQS message is created and sent to the SQS queue. On each 
instance in the worker tier, an sqsd daemon is subscribed to the same SQS queue. When it receives the 
message, sqsd sends a HTTP POST, which is interpreted by the Rails application and the job is performed. 
Once the job is completed, the Rails application informs the SQS queue that the job is complete via POST. 
Both tiers have access to a database so that molecule properties can be updated (not shown). The health of 
workers is monitored by CloudWatch, and additional instance can be created automatically under high load. 
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2.3.5. Walk-through of entry-way 
The web application entry-way is currently accessible at entry-way.org. Visitors are asked 
to register an account in order to run calculations. Once logged in, users can submit individual 
molecules as SMILES strings or batches of molecules as text files containing a series of SMILES 
strings (Figure 2.19). Individual SMILES strings are most conveniently generated by ChemDraw, 
and batch files can be rapidly produced by MOE or OpenBabel. By selecting the “View Molecules” 
tab, the results of calculations are displayed in a regularized format. The status of each eNTRy 
guideline is shown to the right of structure. Batch results can be downloaded as a CSV file or 
individual molecules in the batch can be viewed in a similar manner to single submissions.   
 
Figure 2.19 Screenshots of two modes of compounds submission to entry-way. Individual molecules can be 
submitted as SMILES strings or text files that contain compound names and SMILES strings can be uploaded. 
2.4. Molecular dynamics for OmpF 
A critical step towards understanding small-molecule accumulation in bacteria is 
understanding how molecules enter the cell. A subset of compounds was evaluated in a strain of 
E. coli in which knockout of ompR leads to down-regulation of two porins (ompF and ompC). 
Accumulation was significantly reduced in the ∆ompR strain for a majority of these compounds 
(Figure 2.20), which suggests that the major route for influx is via porins. A large body of literature 
points to OmpF as the major means of entry into E. coli for most antibiotics.44-48 Given the central 
role of OmpF in compound influx, we sought to investigate whether the eNTRy rules described 
above (particularly ionizable nitrogens) have any bearing on way molecules interact with OmpF. 
 76 
The porin OmpF has already been the subject of several molecular dynamics (MD) 
studies.27,48-52 In these works, the ionic selectivity and antibiotic binding sites have been examined. 
From this work, there is a general understanding that the electric field formed by dipolar residues 
in the constriction site acts as a filter for molecules (Figure 2.21). This is perhaps best demonstrated 
by the b-lactams, many of which are zwitterions. The antibiotic’s dipole can align with the electric 
field within the constriction site, lower the energetic barrier, and achieve entry.53 While this seems 
reasonable for zwitterionic molecules, we hypothesized that a similar mechanism could allow 
amine-containing molecules to traverse porins. This possibility was supported by a strong 
dependence on amphiphilic moment for accumulation.  
 
Figure 2.20 Accumulation dependence on porins. Isogenic strains of E. coli in which ompR was knocked out.  
To test this hypothesis, we turned to steered molecular dynamics (SMD) to monitor the 
pathway of molecules as they traverse the OmpF porin. SMD differs from standard MD in that an 
external harmonic potential is applied to an atom in the simulation. The center of this harmonic is 
moved at a constant velocity along a reaction coordinate (in this case through the porin). By 
applying this external potential, processes that occur at long timescales are accelerated into a 
regime that modern high performance computing can reasonably handle. Ampicillin has been 
experimentally determined to cross OmpF in ~300 µs.27 This process can be accelerated to ~10 ns 
with SMD. An unfortunate by-product of SMD is that quantitative measures of the energy 
landscape are not possible in the same way as MD under equilibrium conditions. We therefore can 
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only get a qualitative picture of the way molecules interact with the porin as they enter cells. A 
model was built by embedding the OmpF monomer into a lipid bilayer. 
 
Figure 2.21 Overview of porin structure. Substrate selectivity is derived from interactions with residues 
within the constriction site. Three acidic residues (D113, D121, and E117) colored red. Three basic residues 
(R42, R82, and R132) colored blue. 
As we were primarily interested in the role of the amine in contributing to compound 
accumulation, so the compounds included in SMD simulations were paired with those lacking 
amines (Figure 2.22). SMD simulations of these compounds were performed while pulling on the 
center of mass for each molecule, five replicates for each. Snapshots from the obtained trajectories 
show that the amines of 2-18 and 6DNM-NH3 make critical interactions with Asp113 while 
traversing the porin (Figure 2.23). Closer analysis of SMD trajectories showed that the amines of 
2-18 and 6DNM-NH3 made extensive hydrogen bonding interactions with acidic residues 
throughout the simulation (Figure 2.24A, D). Molecules without an amine (2-20 and 6DNM) 
instead displace constriction site residues from their initial configuration (Figure 2.24C, F). While 
SMD does not allow for quantification of energy barriers, the observation of hydrogen bonding by 
amines and displacement by non-amines suggests that amines have a unique permeation pathway 
that is unavailable to non-amines. 
 

















Figure 2.23 Snapshots of SMD simulation of compound translocation through OmpF. A. Compound 2-18 is 
capable of making a key interaction with Asp113 (purple) that assists in movement past constriction site. 
This finding is in accord with previous reports of the importance of Asp113 in producing the cation selectivity 
of OmpF. B. Same pose as A, viewed from above. C. Compound 13 makes no interactions with Asp113 and 
thus faces additional barriers to penetrance. D. Same pose as C, viewed from above. E. 6DNM-NH3 makes 
key H-bonding interactions with Asp113 (purple) that assists in the molecule’s passage through the 
constriction site. F. Same pose as E, viewed from above. G. 6DNM requires larger movement by peptide 
backbone in order to pass through constriction site. Asp113 is appreciably displaced by 6DNM. H. Same 
pose as G, viewed from above. In all simulations, the largest barrier to translocation is a series of stacked 
arginine residues (Arg 42, 82, and 132) that are depicted in blue.  
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Figure 2.24 A. Distance of primary amine of compound 2-18 and constriction site residues in course of 
simulation. Stabilized distance at 2Å is indicative of hydrogen bonding. In repeated simulations molecules 
adopted similar pathways for traversing the porin while often hydrogen bonding with different hydrophilic 
reisudes. B. Displacement of Arg42 by compound 2-18 relative to initial coordinates was measured during 
course of simulation. C. Displacement of Arg42 by compound 2-20. D. Distance of primary amine of 6DNM-
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Poor understanding the molecular determinants of bacterial accumulation has been a major 
impediment to antibiotic drug development. Here some of the first inroads are made toward 
developing a rational framework for drug design. In the first large-scale prospective study of 
compound accumulation in E. coli, key molecular features were identified that are highly 
correlated with successful accumulation. The three major features were used to formalize the 
eNTRy rules: an ionizable Nitrogen, low Three-dimensionality, and few Rotatable bonds. A series 
of steered molecular dynamics simulations suggest how the presence of an ionizable nitrogen can 
enable entry. 
We anticipate that these rules can be used in the process of discovering new chemotypes 
or in converting gram-positive-only antibiotics into broad spectrum agents. As the three-
dimensionality metrics are harder to calculate than the components of Lipinski’s rules, a web 
application was developed that can enable researchers to test prospective compounds. This tool, 
entry-way, has already facilitated the development of several conversion projects as discussed in 
Chapter 3. As the understanding of compound accumulation in more species of bacteria is 
improved, we expect that many antibiotic discovery programs can be restarted. 
Our work with steered molecular dynamics provides a theoretical basis for the benefit of 
primary amines for accumulation. Recently, Ceccerelli and coworkers used a reductionist approach 
to develop a permeability scoring function.54 Their scoring function utilized molecular parameters 
derived from molecular dynamics simulations of four porins (including OmpF). When fitting the 
scoring function to experimental data from these four porins with ten b-lactams, they found that 
three parameters could accurately predict permeability: overall charge (more positive permeates 
better), minimal projection area (a measure of three dimensionality), and transverse dipole 
moment. Interestingly, they applied their scoring function to predict the permeability of seven 
molecules from our accumulation test set and found good agreement with experimentally 
determined accumulation. The molecular features that Ceccerelli and coworkers found to be 
important are strikingly similar the ones we found (charge vs. ionizable nitrogen, projection area 
vs. Glob, and dipole moment vs. amphiphilic moment). We regard these findings as further support 
for our model of bacterial accumulation. 
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2.6. Materials and methods 
Calculation of physiochemical properties 
Data sets of chemical structures were created and managed using Canvas (Version 2.6, 
Schrödinger, LLC). Initial structure preparation and 3D minimization was performed with LigPrep 
(Version 3.6, Schrödinger, LLC) using OPLS_2005 force fields. Tautomeric and protonation states 
were determined using Epik (Version 3.4, Schrödinger, LLC) at pH 7.4. Generation of ensembles 
of conformations was performed using Conformational Search in MOE 2015.10 using the 
LowModeMD method with default settings.  
Physiochemical descriptors (297, both 2D- and 3D-based) were calculated using MOE for each 
conformation. Descriptors were averaged (unweighted mean) across all conformations for each 
molecule. Data with descriptors were used to train a random forest classification prediction model 
using the R package caret. The random forest model offers many advantages for this application 
including resistance to over-fitting and the ability to measure descriptor importance. Preprocessing 
of data removed descriptors with near-zero variance or high co-correlation with other descriptors. 
Source code for data analysis and model training can be found at 
https://github.com/HergenrotherLab/GramNegAccum.  
An additional approximation of three-dimensionality, average distance to the plane of best fit 
(PBF), was calculated using a custom Python program. The PBF algorithm was implemented in 
Python with SDfile I/O and structure representation being handled by libraries from Schrödinger. 
For each compound, the PBF algorithm determines the plane that best fits a set of 3D coordinates 
that represent the positions of all heavy atoms in the molecule using single value decomposition. 
The distance of each heavy atom to this plane is measured in angstroms and averaged. This Python 
program was incorporated into the Maestro GUI for convenient use. Source code can be found at 
https://github.com/HergenrotherLab/GramNegAccum.  
ClogD7.4 values were calculated using the online compound property calculation software 
FAFdrugs3 (http://fafdrugs3.mti.univ-paris-diderot.fr/index.html).  
Sources 
Chemical structure data for the MicroFormat library was obtained from the ChemBridge website. 
Chemical structure data for the ZINC Natural Products library was obtained from 
http://zinc.docking.org/browse/catalogs/natural-products. Chemical structure data for the 
MLSMR-NP library was obtained from PubChem.  
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Identification of predicted accumulators in commercial libraries 
Compounds containing particular functional groups were identified and counted by substructure 
filtering with Open Babel, using the following SMARTS queries: primary aliphatic amine, 
[$([N;H2;X3][CX4]),$([N;H3;X4+][CX4])]; secondary aliphatic amine, 
[$([CX4][N;H1;X3][CX4]),$([CX4][N;H2;X4+][CX4])]; tertiary aliphatic amine, 
[NX3]([CX4])([CX4])[CX4]; carboxylic acid: [CX3]( = O) [OX1H0−,OX2H1].  
Globularity calculation 
def calc_glob(mol): 
    """ 
    Calculates the globularity (glob) of a molecule 
 
    glob varies from 0 to 1 with completely flat molecules like benzene having a 
    glob of 0 and spherical molecules like adamantane having a glob of 1 
 
    Arguments: 
        mol: pybel molecule object 
    Returns: 
        glob: globularity of molecule 
    """ 
    points = get_atom_coords(mol, heavy_only = False) 
    if points is None: 
        return 0 
    points = points.T 
 
    # calculate covariance matrix 
    cov_mat = np.cov([points[0,:],points[1,:],points[2,:]]) 
 
    # calculate eigenvalues of covariance matrix and sort 
    vals, vecs = np.linalg.eig(cov_mat) 
    vals = np.sort(vals)[::-1] 
 
    # glob is ratio of last eigenvalue and first eigenvalue 
    if vals[0] != 0: 
        return vals[-1]/vals[0] 
    else: 
        return 0 
 
def get_atom_coords(mol, heavy_only = False): 
    """ 
    Retrieve the 3D coordinates of all atoms in a molecules 
 
    Args: 
        mol: pybel molecule object 
    Returns: 
        points: numpy array of coordinates 
    """ 
 
    num_atoms = len(mol.atoms) 
    pts = np.empty(shape = (num_atoms,3)) 
 
    for a in range(num_atoms): 
        pts[a] = mol.atoms[a].coords 
 
    return pts 
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Plane of best fit calculation 
def svd_fit(X): 
    """ 
    Find (n - 1) dimensional standard (e.g. line in 2 dimension, plane in 3 
    dimension, hyperplane in n dimension) via solving Singular Value 
    Decomposition. 
     
    Example: 
        >>> XY = [[0, 1], [3, 3]] 
        >>> XY = np.array(XY) 
        >>> C, N = svd_fit(XY) 
        >>> C 
        array([ 1.5,  2. ]) 
        >>> N 
        array([-0.5547002 ,  0.83205029]) 
    Args: 
        X: n x m dimensional matrix which n indicate the number of the dimension 
            and m indicate the number of points 
    Returns: 
        [C, N] where C is a centroid vector and N is a normal vector 
    """ 
    # Find the average of points (centroid) along the columns 
    C = np.average(X, axis=0) 
    # Create CX vector (centroid to point) matrix 
    CX = X - C 
    # Singular value decomposition 
    U, S, V = np.linalg.svd(CX) 
    # The last row of V matrix indicate the eigenvectors of 
    # smallest eigenvalues (singular values). 
    N = V[-1] 
    return C, N 
 
def distance(x, C, N): 
    """ 
    Calculate an orthogonal distance between the points and the standard 
    Args: 
        x: n x m dimensional matrix 
        C: n dimensional vector whicn indicate the centroid of the standard 
        N: n dimensional vector which indicate the normal vector of the standard 
    Returns: 
        m dimensional vector which indicate the orthogonal distance. the value 
        will be negative if the points beside opposite side of the normal vector 
    """ 
    return np.dot(x - C, N) 
 
def calc_avg_dist(points, C, N): 
    """ 
    Calculates the average difference a given set of points is from a plane 
 
    Args: 
        points: numpy array of points 
        C: centroid vector of plane 
        N: normal vector of plane 
    Returns: 
        Average distance of each atom from the best-fit plane 
    """ 
    sum = 0 
    for xyz in points: 
        sum += abs(distance(xyz, C, N)) 




    """ 
    Uses SVD to fit atoms in molecule to a plane then calculates the average 
    distance to that plane. 
 
    Args: 
        mol: pybel molecule object 
    Returns: 
        pbf: average distance of all atoms to the best fit plane 
    """ 
    points = get_atom_coords(mol) 
    c, n = svd_fit(points) 
    pbf = 12 
    pbf = calc_avg_dist(points, c, n) 
    return pbf 
 
Analysis of conformer generation methods 
Balloon was run with MMFF94 force-field and the following command line options: “--nconfs 
200 --nGenerations 300 --maxtime 60000 -t 0.1 --maxiter 1000”. Confab was run through obabel 
with the following command line options: “--confab --conf 100000”. OpenBabel genetic algorithm 
was run with the following command line options: “--conformer --nconf 200 --score rmsd –
writeconformers”. RDkit using the AllChem.EmbedMultipleConfs function with the following 
options: numConfs=100, maxAttempts=1000, pruneRmsThresh=0.1, 
useExpTorsionAnglePrefs=True, userBasicKnowledge=True, enforceChirality=True, 
numThreads=0. 
All-atom molecular dynamics simulations 
The simulation model was constructed using CHARMM-GUI55 and composed one OmpF 
monomer (PDB: 3POX), 108 (90%) 1-palmitoyl-2-oleoyl-sn-glycero- 3-phosphoethanolamine 
(POPE) lipid molecules, 12 (10%) 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) 
(POPG), and solvated with 8,234 water molecules in 150 mM NaCl (36 Na+ and 15 Cl−) for a total 
of 45,402 atoms. Hexagonal periodic boundary conditions were applied with a distance of 77.3 Å 
in the xy-direction and 92.8 Å in the z-direction. Electrostatic interactions were calculated using 
the particle-mesh Ewald (PME) method. Protein residues E296, D312, and D127 were protonated. 
50,56,57 The simulations were performed at constant pressure (1 atm) and temperature (303 K) with 
a time step of 2 fs. Each small-molecule under investigation was manually placed directly above 
the pore. Restraints were initially applied to protein backbone and small-molecule analyte atoms 
and then removed to equilibrate the system. For SMD production simulations, each small-molecule 
analyte was pulled at the molecules centre of mass (5 kcal mol−1 Å−2) at a constant velocity (10 
Å ns−1) along the z-axis for 4 ns. The all-atom CHARMM force field was used for protein and 
lipids. TIP3P was used for water. 58 All the molecular dynamics simulations were carried out using 
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the NAMD 2.11 scalable molecular dynamics program and run on Stampede at TACC. CHARMM 
residue topology and parameter files for the small molecules were constructed using CGenFF59. 
SMD trajectories were analysed and visualized using VMD 1.9.2 and rendered using Pov-Ray 3.6. 
Data availability 
Source code for data analysis and model training can be found at 
https://github.com/HergenrotherLab/GramNegAccum. 
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CHAPTER 3 CONVERSION OF NARROW SPECTRUM ANTIBIOTICS 
There is an abundance of antibiotics with gram-positive-only activity at different stages of 
development. These compounds represent an untapped potential for treating antibiotic-resistant 
gram-negative pathogens. Until recently, there was no rational method for converting these 
compounds into agents with broad-spectrum activity. Here, the eNTRy rules (described in Chapter 
2) are applied to four compound classes to deliver newfound gram-negative accumulation 
3.1. Afabicin 
Afabicin is a candidate antibiotic currently in the clinical pipeline. For a more complete 
discussion of the selection of afabicin as a conversion candidate, see Chapter 1. Briefly, afabicin 
is a gram-positive-selective antibiotic that targets FabI, an essential component of fatty acid 
synthesis. Afabicin is a phosphate prodrug that is processed by alkaline phosphatase to release the 
active component, Debio-1452. The implementation of this prodrug strategy was necessary 
because of the poor solubility and bioavailability of Debio-1452 (7-9 fold improvement in 
bioavailability). As the introduction of a primary amine typically improves the solubility of 
compounds, we pursued derivatization of Debio-1452 rather than afabicin, as the prodrug would 
be unnecessary. 
 
Figure 3.1 Release of Debio-1452 by serum phosphatases. 
3.1.1. Alternative FabI inhibitors 
Although Debio-1452 has advanced the farthest among FabI inhibitors in the clinic, several 
other inhibitors have been reported (Table 3.1). While several of these compounds have been 
inspired by triclosan, some novel chemotypes have been described as well. Several of these 
compound classes demonstrated some activity against gram-negative organisms such as the 
diazaborines and diphenylethers. In general, however, these compounds are not selective inhibitors 
of FabI and have poor drug-like properties, limiting their use to topical applications. The pyridones 
(e.g. CG40059 and PT173) display selectivity for saFabI over ecFabI which results in no activity 
in efflux-deficient E. coli. Of the remaining FabI inhibitors, Debio-1452 is the most promising for 
conversion due to its potent activity in efflux-deficient E. coli  (MIC = 0.016 µg/mL) while also 




















Table 3.1 Summary of bioactivity of reported FabI inhibitors. 
Agent In vitro Inhibition Antimicrobial Activity 
 
Debio-1452 
Ki = 13 nM (saFabI)1 MIC90 = <0.008 µg/mL (S. aureus)2  
MIC = >32 µg/mL (E. coli)2 
MIC = 0.016 µg/mL (E. coli ∆acrAB)2 
 
Triclosan 
Ki = 50 pM (saFabI) 
Ki = 7 pM (ecFabI)3 
Ki = 220 nM (InhA)4 
MIC = 0.03-0.25 µg/mL (S. aureus) 5-8 
MIC = 4 µg/mL (E. coli)7 
 
Hexachlorophene 
IC50 = 4 µM (saFabI) 8 
IC50 = 4 µM (ecFabI) 8 
MIC = 1 µg/mL (S. aureus)8 
MIC = >64 µg/mL (E. coli) 8 
 
MUT056399 
IC50 = 12 nM (saFabI)9 
IC50 = 58 nM (ecFabI) 9  
MIC90 = 0.03 – 0.12 µg/mL (S. aureus)9 
MIC = 0.5 µg/mL (E. coli)10 
 
CG40059 
Ki = 1 nM (saFabI)11 
Ki = 82 nM (ecFabI)11 
MIC90 = 0.015 µg/mL (S. aureus)12,13 
MIC = >128 µg/mL (E. coli ∆acrAB)11 
 
Isoniazid (INH) 
Ki = 750 pM (InhA)4,14 MIC = 0.05 µg/mL (M. tuberculosis)4 
 
diazaborine 
Ki = 200 µM (ecFabI)15 MIC = 1.56 µg/mL (E. coli)16  
 
PT01 
Ki = 2.3 nM (saFabI)11 
Ki = 0.2 nM (ecFabI)11 
MIC = 0.5 µg/mL (S. aureus)11 
MIC = 0.125 µg/mL (E. coli ∆acrAB)11 
 
PT166 
Ki = 2.7 nM (saFabI)11 
Ki = 7.0 nM (ecFabI)11 
MIC = 0.25 µg/mL (S. aureus)11 
MIC = 2 µg/mL (E. coli ∆acrAB)11 
 
PT173 
Ki = 2.0 nM (saFabI)11 
Ki = 203 nM (ecFabI)11 
MIC = 2 µg/mL (S. aureus)11 
MIC = >128 µM (E. coli ∆acrAB)11 
 
Imidazole 
IC50 = 250 nM (saFabI)6 
IC50 = 6.4 µM (ecFabI)6 
MIC = 8 µg/mL (S. aureus)6 
 
Indole 
IC50 = 110 nM (saFabI)7 
IC50 = 4.2 µM (ecFabI) 7 
MIC = 0.5 µg/mL (S. aureus)7 

































































Table 3.1 (cont.) 
Agent In vitro Inhibition Antimicrobial Activity 
 
4-pyridinone 
IC50 = 220 nM (ecFabI)17 MIC = 0.25 µg/mL (S. aureus)17 
 
benzimidazole 
Ki = 16 nM (saFabI)18 MIC = 3.13 µg/mL (S. aureus)18 
 
thiopyridine 
IC50 = 3.0 µM (ecFabI)19 MIC = 0.75 µg/mL (S. aureus)19 
 
pyrrolidine 24 
IC50 = 0.42 µM (abFabI)20 
IC50 = 3.5 µM (saFabI)20 
MIC = 12.5 µg/mL (S. aureus)20 
MIC = 0.75 µg/mL (E. coli ∆tolC)20 
MIC = 50 µg/mL (A. baumannii 
cotreated with PMBN)20 
3.1.2. Design of derivatives 
As discussed in Chapter 1, extensive data is available on the SAR of Debio-1452. Further, 
crystal structures have been solved for Debio-1452 bound to both E. coli (PDB 4JQC) and S. 
aureus (PDB 4FS3) FabI. Examination of existing SAR data indicated the most promising sites 
for primary amine introduction would be on the naphthyridone ring. Additionally, some limited 
SAR is available for modifications at this position. Ring expansion and addition of polar 
heterocycles are both tolerated (Figure 3.2).21,22 With this precedent, we sought to design 
modifications at this site that would introduce a primary amine. Potential inhibitors are evaluated 
by molecular docking (Figure 3.3 and Figure 3.4). While amines attached to the naphthyridone 
ring were predicted to be well tolerated, introducing them on the benzofuran ring or restricting 
flexibility appeared to be disfavored. The series of alkyl amines were prioritized for synthesis and 
evaluation. 
 
Figure 3.2 Abbreviated SAR of Debio-1452. Inhibition of FabI and antimicrobial activity are maintained 
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Figure 3.3 Structure-based design of amine-containing inhibitors of FabI. A. Solvent exposure of the 
naphthyridone of Debio-1452 when bound to S. aureus FabI (PDB: 4FS3) suggests sites for modification. B. 
Molecular docking of amine-containing derivative, Debio-1452-NH3. Additional derivative docking and 
docking scores are shown in Figure 3.4.  C. Ligand interaction diagram of interaction shown in panel A. 
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Figure 3.4 Molecular docking of Debio-1452 derivatives into E. coli and S. aureus FabI (PDB codes 4JQC 
and 4FS3, respectively). Docking was performed with Glide XP (Schrodinger Inc.). Docking scores estimate 





























































































































































3.1.3. Synthesis of FabI inhibitors 
The synthesis of derivatives of Debio-1452 was executed by Dr. Erica Parker. This work 
is described here to demonstrate the modular nature of their assembly. Briefly, a late stage Heck 
coupling of benzofuran 3-1 and bromonaphthyridone 3-2 assembled the Debio-1452 scaffold, 3-3 
(Figure 3.5). Deprotection of the amines with HCl in dioxane provided the final compounds with 
varying linker lengths (n = 0, Debio-1452-NH3; n = 1, 3-4, n = 2, 3-5). As a control to evaluate 
the effect of the amine in some experiments, Debio-1452-NH3 was acetylated to give Debio-1452-
acetamide. 
 
Figure 3.5 Synthesis of Debio-1452 analogues. 
This synthetic manifold allowed rapid access to a small collection of derivatives that were 
then evaluated in a battery of bioassays. Other derivatives with modifications on benzofuran were 
also made through a similar manner. 
3.1.4. Antimicrobial susceptibility to Debio-1452-NH3 
Derivatives of Debio-1452 were tested in a series of laboratory strains of gram-negative 
bacteria as well as clinical isolates. The standard measure of antimicrobial activity is the minimal 
inhibitory concentration (MIC), the lowest concentration at which no bacterial growth is observed 
after 16-20 hr incubation. Concentrations are typically on a log-2 scale. As expected, the 
introduction of an amine onto the Debio-1452 scaffold resulted in a dramatic improvement in 
accumulation (Table 3.2). In a time-course accumulation experiment, it appeared that placement 
of the amine further from the core ring systems resulted in more rapid penetrance but provided no 
significant increase in accumulation once equilibrated. This improvement in accumulation resulted 
in improved bioactivity. Debio-1452-NH3 was active in wild-type strains of E. coli and E. cloacae 
but not P. aeruginosa. This activity in lab strains of gram-negative pathogens led us to investigate 



























































Table 3.2 Lab strain accumulation and susceptibility to Debio-1452 and derivatives. 




E. coli (MG1655) 
84±8 410±10 1300±300 1800±500 
1 h 260±20 1000±100 1580±70 1400±200 
2 h 330±40 1560±60 1800±200 1400±100 
MIC 
(µg/mL) 
 S. aureus (ATCC29213) 0.008 0.03 0.03 0.125 
 E. coli (JW5503a) 0.031 0.062 0.125 0.062 
 E. coli (MG1655) >32 4 8 8 
 E. cloacae (ATCC 29893) >32 8 4 32 
 P. aeruginosa (PAO1) >32 >64 >64 >64 
a∆tolC       
 
Clinical isolates of gram-negative priority pathogens were obtained from ATCC, CDC, and 
the University of Illinois at Chicago Medical School. We were primarily interested in carbapenem 
resistant Enterobacteriaceae (CRE) due to their significant health care burden. The resistance 
genotype had been determined for many of the obtained strains. Carbapenem resistance is typically 
conferred by two plasmid-bound carbapenemases (KPC and NDM-1), which were found in many 
of these strains (Table 3.3). The susceptibility of clinical isolates to Debio-1452, Debio-1452-NH3, 
3-4, meropenem (a carbapenem), tigecycline, and tobramycin was determined. Resistance to 
meropenem correlated with the presence of carbapenemases, which confirms that the majority of 
these strains are CRE. Debio-1452-NH3 was broadly effective against all strains tested and clearly 
outperformed Debio-1452 (Figure 3.6). 
Table 3.3 Clinical isolate susceptibility to Debio-1452 and derivatives. 
Species Strain Debioa 3-4b NH3c MERd TIGe TOBf Resistanceg 
A. baumannii F19521h >32 16 4 >64 0.25 >64 KPCl 
A. baumannii KB304i >32 64 64 4 1 8 Unk.m 
A. baumannii KB343i >32 >64 64 1 1 >64 Unk. 
A. baumannii KB357i >32 >64 64 1 1 >64 Unk. 
A. baumannii M13100h >32 16 16 0.125 1 16 - n 
A. baumannii W41979h >32 16 4 >64 0.25 >64 KPC 
A. baumannii WO22i >32 >64 64 0.5 1 6 Unk. 
E. cloacae BAA-2341j >32 16 8 32 1 16 KPC 
E. cloacae BAA-2468j >32 8 8 2 1 >64 NDM-1o 
E. cloacae S28901.1h >32 8 16 0.25 4 0.5 - 
E. coli AR-0346k >32 4 8 0.125 0.125 >64 mcr-1p, ESBLq 
E. coli AR-0349k 4 2 2 0.125 0.5 64 mcr-1, ESBL 
E. coli AR-0493k >32 4 4 0.125 0.25 0.5 mcr-1, ESBL 
E. coli AR-0495k 8 2 4 0.125 0.125 8 mcr-1, ESBL 
E. coli BAA-2340j >32 4 4 4 0.25 64 KPC 
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Table 3.3 (cont.) 
Species Strain Debioa 3-4b NH3c MERd TIGe TOBf Resistanceg 
E. coli BAA-2469j 4 2 2 4 0.5 >64 NDM-1 
E. coli BAA-2471j 8 4 4 >64 0.125 >64 NDM-1 
E. coli F20987h >32 16 4 >64 0.25 16 KPC 
E. coli M66623h >32 8 8 0.125 1 32 - 
K. pneumoniae AR-0347k >32 8 16 >64 2 32 KPC 
K. pneumoniae BAA-1705j >32 16 8 32 1 32 KPC 
K. pneumoniae BAA-2342j >32 16 16 16 1 16 KPC 
K. pneumoniae BAA-2470j 8 4 4 8 0.5 >64 NDM-1 
K. pneumoniae BAA-2472j >32 16 16 >64 1 >64 NDM-1 
K. pneumoniae BAA-2473j >32 16 16 >64 2 >64 NDM-1 
K. pneumoniae M14723h >32 16 18 >64 0.5 >64 KPC 
K. pneumoniae M67198h >32 32 32 32 4 32 KPC 
K. pneumoniae M67297h >32 32 32 32 4 32 KPC 
K. pneumoniae S20595h >32 16 16 >64 2 32 KPC 
K. pneumoniae S47889h >32 8 8 16 1 16 KPC 
aDebio-1452, bDebio-1452-CH2NH3, cDebio-1452-NH3, dMeropenem, eTigecyclin,  fTobramycin, gDetermined by 
PCR,  hObtained from UIC, iObtained from John Quale, jObtained from ATCC, kObtained from CDC, lKlebseilla 
pneumoniae carbapenemase, mNot determined, nNone detected, oNew Delhi metallo-beta-lactamase, pMobilized 
colistin resistance, qExtended spectrum beta-lactamase. 
 
 
Figure 3.6 Cumulative MIC of Enterobacteriaceae clinical isolates to Debio-1452 and Debio-1452-NH3. 
3.1.5. Resistance to FabI inhibitors 
Having identified a compound with good activity against gram-negative bacteria, it was 
important to verify that Debio-1452-NH3 still acted through the same mechanism in gram-negative 
as gram-positive bacteria. Mechanism of action studies can be difficult for drugs that operate in 
























human cells. This process is more straightforward for antibiotics as resistance generation and 
whole genome sequencing will often identify mutations within the target of the antibiotic with 
which resistance was genereated. The FabI inhibitors currently in the clinic generate resistance via 
active site mutation in FabI (Table 3.4). These data combined with in vitro enzymology and 
metabolomics data support the conclusion that these compounds act primarily through inhibition 
of FabI. 
Table 3.4 Mutations in FabI that confer resistance to inhibitors. 
Agent Species FabI Mutation MIC Fold Change 
Debio-1452-NH3 E. coli A116V 16 G148S >16 













Diazaborine E. coli G93S - 
 
Resistance to Debio-1452-NH3 was generated in E. coli MG1655 via the large-inoculum 
method. At moderate antibiotic concentrations (4-fold the MIC), low level resistance was 
observed. Colony PCR and sequencing showed a point mutation in FabI (A116V) was associated 
with this low level resistance. One colony at this concentration still retained wild-type FabI. At 
higher Debio-1452-NH3 concentrations, higher resistance was observed albeit at a lower 
frequency. Sequencing of FabI revealed that a different mutation (G148S) was associated with 
higher level resistance. The sites of mutation mapped to sites near the binding site for Debio-1452 
(Figure 3.7A). The mutated residues were more distant compared to those caused by triclosan. The 
increased resistance came at a fitness cost, however, that was not observed for A116V (Figure 
3.7B). 
Table 3.5 Generation of resistant mutants to Debio-1452-NH3. 
[Debio-1452-NH3] 
(µg/mL)a 
Fold MICa FabI Mutation MIC 
(µg/mL)b 
Colony Count Frequency 
16 4 A116V 64 7/8 4.5x10-9 WT 32 1/8 
32 8 G148S >64 2/2 1.1x10-9 
64 16 G148S >64 1/1 5.6x10-10 





Figure 3.7 A. Mapping of observed mutants on E. coli FabI crystal structure (PDB: 4JQC). Mutations that 
cause resistance to triclosan are shown in blue. Mutations caused by Debio-1452-NH3 are shown in red. 
Debio-1452 is shown in green. NADH cofactor is shown in pink. B. Fitness of E. coli strains resistant to 
Debio-1452-NH3. Overnight cultures were diluted 100-fold and grown at 37 °C with 250 rpm shaking. 
Growth was monitored by absorbance at 600 nm. Data represents average of four independent replicates. 
Error bars represent standard error of mean. 
3.1.6. In vitro FabI assay 
To further validate that Debio-1452-NH3 kills gram-negative bacteria through inhibition 
of FabI, direct inhibition of FabI was evaluated in a reconstituted in vitro assay. In cells, FabI 
reduces ACP-bound unsaturated thioesters (Figure 3.8). While these substrates have been 
synthesized previously, expression and purification of ACP followed by enzymatically loading on 
the desired fatty acid is a laborious process.25 A much more expedient method is to use an enoyl-
CoA. Crotonoyl-CoA is commonly used due to its commercial availability, but improved activity 
is possible with longer chain fatty acids such as trans-2-dodecenoyl-CoA.26 
 
Figure 3.8 Differences between FabI-catalyzed reaction in cells and reconstituted in vitro assay. In cells, 
substrates are loaded onto acyl carrier proteins (ACPs). ACP can be substituted for coenzyme A with some 
lose in activity. 
Expression vectors for E. coli and S. aureus FabI were obtained from Prof. Peter Tonge 
(Stonybrook University). E. coli FabI was easily expressed and purified after minor modification 
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of previously reported procedures.5,27,28 Sufficient activity was observed with 20 nM FabI when 
conducted in half-area 96-well plates. Because Debio-1452 is such a potent inhibitor of FabI, the 
concentration of free Debio-1452 is no longer independent of enzyme concentration at inhibitor 
concentrations near the IC50. Consequently, data must be fit to Morrison’s quadratic to get accurate 
measures of potency. Despite these complications, Debio-1452 and derivatives were shown all to 
be similarly potent inhibitors of E. coli FabI (Figure 3.9). 
 
Figure 3.9 In vitro activity of Debio-1452 and derivatives against wild-type E. coli FabI. 
3.1.7. In vivo activity 
Given the promising activity demonstrated in cell culture, Debio-1452-NH3 was moved 
forward into animal models. This work was performed by Dr. Hyang Yeon Lee and Prof. Gee Lau. 
After determining the maximum tolerated dose to be 50 mg/kg, the pharmacokinetics of Debio-
1452-NH3 was determined with two routes of administration (Figure 3.10). Although similar, 
retro-orbital injection provided a slightly better exposure than intraperitoneal injection. Retro-
orbital injection is operationally easier to perform than tail-vein injection, has a lower rate of 
complication, and can be regarded as equivalent to intravenous injection.29 
 
Figure 3.10 Pharmacokinetics of Debio-1452-NH3 in CD-1 mice via retro-orbital or intraperitoneal injection 
(50 mg/kg, n = 3 mice per timepoint). Retro-orbital IV AUC = 14,757 µM•min; IP AUC = 12,074 µM•min. 









































Satisfied with the level of exposure provided by this route of administration, we moved 
forward with an acute bacteremia mouse model. In this model, a lethal inoculum of bacteria is 
injected IV. Four hours post-infection, mice are treated with antibiotics to prevent succumbing to 
infection. In the first model, the A. baumannii clinical isolate W41979 was chosen as this strain is 
highly resistant to carbapenems and tobramycin while Debio-1452-NH3 showed good activity 
(MIC = 4 µg/mL, Table 3.3). The activity of Debio-1452-NH3 was compared to the tosylate salt 
of Debio-1452. Rapid mortality was observed among mice treated with Debio-1452 (13 of 15 dead 
at 48 hr) while Debio-1452-NH3 successfully attenuated the lethality of infection (2 of 15 dead at 
48 hr, Figure 3.11). This initial positive result in mice is encouraging and suggests that Debio-
1452-NH3 or another amine-containing derivative will be an effective gram-negative antibiotic. 
Additional model of infection will be performed in the future to further evaluate Debio-1452-NH3. 
 
Figure 3.11 Kaplan-Meier survival curve of in vivo efficacy model of A. baumannii sepsis. Seven-week old 
CD-1 mice were infected with A. baumannii W41979 (2.6x108 CFU/mouse, 15 mice per group) via retro-
orbital IV. Mice were treated once-a-day for 4 days with compound (retro-orbital IV, 50 mg/kg). Log-rank 
test, p < 0.0001. Drugs were formulated in 20% sulfobutyl ether(7) b-cyclodextrin from solid immediately 
before treatment. 
3.2. Zoliflodacin 
DNA gyrase inhibitors are a mainstay of antibiotic therapy. The fluoroquinolones are the 
most prescribed drug class and have an outsized impact on the successes and failures of antibiotic 
use. DNA gyrase inhibitors work by forming a ternary structure with DNA gyrase and cleaved 
DNA. This ultimately results in the formation of double-strand breaks in DNA that can lead to cell 
death. Critical to the success of fluoroquinolones is their ability to hit two targets in bacteria: GyrB 
and ParC. For other antibiotic mechanisms of action, redundant targets can be problematic and 
limit efficacy (e.g. FabI and FabK in P. aeruginosa resists Debio-1452 analogues). Since 
fluoroquinolones rely on the activity of a DNA gyrase, mutations must occur in both genes in order 



















for high-level resistance.30 Despite this higher barrier to resistance, fluoroquinolones are 
increasingly less effective, especially in gram-negative organisms. Several efforts have been made 
to find new chemotypes that can hit DNA gyrases while evading fluoroquinolone-induced cross-
resistance. The most promising of these new antibiotics are the spiropyrimidenetriones, which 
features zoliflodacin (see Section 1.5.1). 
Zoliflodacin has recently completed a Phase III clinical trial against MDR N. gonorrhoeae. 
Although a gram-negative bacterial species, N. gonorrhoeae has an atypical outer-membrane, so 
zoliflodacin is not effective against other priority pathogens such as CRE.  
 
Figure 3.12 Structure of zoliflodacin and proposed derivatives. 
3.2.1. Synthesis of zoliflodacin and derivatives 
Several approaches to the synthesize spiropyrimidenetriones have been described 
previously.31-36 As derivatives of the oxazolidinones were of primary interest, a route that featured 
late introduction of this moiety was chosen (Figure 3.13). Briefly, ortho-directed hydrolysis of 
2,3,4-trifluorobenzoic acid (3-8) gave the hydroxybenzoic acid (3-9), which was subsequently 
methylated to provide ester 3-10. The isoxazole was assembled by reaction with hydroxylamine 
followed by CDI induced cyclization to give 3-12. Existing methods for chlorination of 3-12 
performed in lower yield than reported. After briefly screening conditions, addition of sub-
stoichiometric H2PO4 was found to be critical for complete conversion to 3-13. The scalability of 
3-13 synthesis was excellent and could routinely be performed on multi-decagram scale. Although 
limited in scalability, fluorine-directed lithiation and formylation of 3-13 provided 3-14. SNAr with 

















































Figure 3.13 Synthesis of key chlorobenzisoazole intermediate 3-16. Scale of each step is shown in 
parentheses. 
Intermediate 3-16 was an excellent diversification point for introducing different 
oxazolidinones (Figure 3.14). Introduction of the necessary amine was accomplished by late 
transformation of an alcohol as most amine protecting groups were found to not be stable in the 
oxazolidinone coupling reaction. Coupling of 3-16 with the appropriate TBS-protected 
oxazolidinone under strongly basic conditions provided 3-17 which was subsequently deprotected 
with TBAF to give alcohol 3-18. This alcohol was converted to azide 3-20 through the 
intermediacy of tosylate 3-19. Reaction with barbituric acid provided the spiropyrimidenetrione 
azide 3-21 via a tert-amino effect reaction. Finally, Staudinger reduction gave 3-6. 
In an effort to access a non-oxazolidinone containing derivative, 3-7, nucleophilic 
displacement of 3-16 with N-Boc-ethanolamine was attempted. In situ formation of 2-
oxazolidinone lead to limited formation of intermediate 3-22. Instead, ethanolamine was 
introduced with N-(2-hydroxyethyl)phthalimide that smoothly provided 3-24. Cyclization with 




































































































Figure 3.14 Synthesis of amine containing zoliflodacin derivative 3-6. 
 

















































































































































































































3.2.2. Evaluation of zoliflodacin derivatives 
The derivatives of zoliflodacin were evaluated for both accumulation and antimicrobial 
activity. Gratifyingly, introduction of a primary amine significantly increased bacterial 
accumulation for compounds 3-6 and 3-7 (Figure 3.16). Unfortunately, the introduction of an 
amine was also associated with a loss of activity in S. aureus, likely due to an inability to bind to 
DNA gyrase. These data both support our hypothesis that advanced clinical candidates can be 
modified to gain the ability to penetrate gram-negative bacteria and also highlight the challenge of 
introducing a charged functional group on a highly optimized structure. 
  
Figure 3.16 Microbial susceptibility to zoliflodacin derivatives. 
3.3. Indolmycin 
Indolmycin is a natural product antibiotic that targets bacterial tryptophanyl-tRNA 
synthetase (TrpRS).37-39 Amino acid tRNA ligases are unexploited antibacterial targets that have 
low homology with human orthologs; mupirocin is the only approved antibiotic that targets a 
tRNA ligase (isoleucine). Indolymcin was briefly evaluated by Takeda as a new antibiotic under 
the name TAK-083 for the treatment of H. pylori due to its surprising potency (MIC = 0.008-0.031 
µg/mL) and improved acid stability over current standard of care (clarithromycin and 
amoxicillin).40,41 Limited SAR information is available for indolmycin (Table 3.6), and a recently 
disclosed X-ray structure of indolmycin bound to TrpRS provides some guidance for compound 
design.42 Another natural product antibiotic, chuangxinmycin, has been shown to target TrpRS but 
little bioactivity data has been reported.43 The C-5 epimer of indolmycin, also called iso-
indolmycin, is completely inactive but is rapidly formed in basic media.44,45 While modification at 
C-6 is limited to small functional groups, modification at N-2 and C-5’ was much more tolerated. 











































3-23 3-21 3-6 3-7
Accumulation (nmol/1012 CFUs)
 105 
Table 3.6 Structure-activity relationship of antibiotics that target TrpRS. 
Compound In vitro activity Antimicrobial activity 
 
Indolmycin 
IC50 = 16 ng/mL (saTrpRSa)45 
IC50 = 12.2 nM (hpTrpRSb)41 
IC50 = 9.25 nM (ecTrpRSc)41 
IC50 = 4.04 mM (btTrpRSd)41 
MIC = 0.125-2 µg/mL (S. aureus)41,45 
MIC = 0.016 µg/mL (H. pylori)41 
MIC = >128 µg/mL (E. faecalis)41 
MIC = 32 µg/mL (E. coli, WT)41 
MIC = 0.3 µg/mL (E. coli, DC2e)46 
MIC = >128 µg/mL (K. pneumoniae)41 
 
Chuangxinmycin47,48 
IC50 = 30 nM (saTrpRS)43 Not reported 
 
IC50 = 250 ng/mL45 MIC = 64 µg/mL (S. aureus)45 
 
IC50 = 46 ng/mL45 MIC = 0.25 µg/mL (S. aureus)45 
 
IC50 “5 times greater than that 




MIC = 0.78 µg/mL (H. parahaemolyticusf)50 
MIC <0.39 µg/mL (P. multocidag) 50 




MIC = 10 µg/mL (E. coli, WT)46 
MIC = 0.3 µg/mL (E. coli, DC2)46 
 
aS. aureus, bH. pylori, cE.coli, dBos taurus, ePermeability mutant,51 fHaemophilus parahaemolyticus, gPasteurella 
multocida, hDose that protects 50% mice from acute bacterecemia 
 
Several synthetic routes have been described for indolmycin. Early methods mimic 
biosynthesis by assembling the oxazolone ring last (Figure 3.17).52,53 Most racemic methods rely 
on a coupling of 2-(dimethylamino)oxazol-4(5H)-one (3-30, Figure 3.18). Attempts towards 
making this coupling enantioselective or even diastereoselective have been unsuccessful.54 While 
enantioselective routes to indolmycin have been reported,53,55 the ability to rapidly assemble 























































Figure 3.17 Biosynthesis of indolmycin. 
Briefly, indole-3-carboxaldehyde (3-26) was Cbz protected and reacted with methyl 
Grignard to give alcohol 3-28 (Figure 3.18). Chlorination with thionyl chloride provided 3-29 
which was coupled with the lithium enolate of 3-30 to give methyl indolmycin (3-31). Amine 
exchange was successful with saturated aqueous methyl amine to give indolmycin. The route was 
brief and scalable enough to provide gram quantities of rac-indolmycin for derivatization. 
 
Figure 3.18 Racemic synthesis of indolmycin. Abbreviations: Cbz = carboxybenzyl, LDA = lithium 
diisopropylamide. 
With indolmycin in hand, its bioactivity was further evaluated. While it has been described 
as active against an E. coli strain with increased permeability, the characterization of this strain 
was not clear. In our hands, rac-indolmycin had comparable activity against S. aureus ATCC 
29213 and E. coli ∆tolC both with MIC 4 µg/mL. The poor activity against wild-type E. coli was 
confirmed to be 64 µg/mL (approximately twice of that described in literature reports for 
enantiopure indolmycin). Importantly, indolmycin had very low mammalian toxicity as 
demonstrated by the lack of activity even at 500 µM (Figure 3.19). While the potency against 
∆tolC E. coli could be better, we felt confident that indolmycin was a promising conversion 
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Figure 3.19 Cytotoxicity of indolmycin to HFF-1 cells. Seeded 3000 cells/well in 96-well plate. Cells treated 
for 72 hr then cell viability assessed by SRB assay. Doxorubicin IC50 = 150 nM, indolmycin IC50 > 500 µM. 
Several derivatives of indolmycin were envisioned, particularly at the oxazolone ring 
(Figure 3.20). Replacing methylamine with ethylenediamine gave primary amine 3-32 albeit with 
epimerization. The intriguing example of benzoyl substituted indolmycin (Table 3.6) led to the 
synthesis of a series of amides from indolmycin (Figure 3.20). Most common amide coupling 
reagents (EDC, HATU, PyBop) failed to efficiently provide product or caused significant C-5 
epimerization. Fortunately, acid chlorides smoothly provided the desired benzamides (3-33 to 3-
36). Several Boc-protected amines could be introduced via this method (3-36 and 3-37). 
Unfortunately, the indolmycin scaffold was found to be sensitive to acid as it underwent 
degradation to 3-38 even under strictly anhydrous conditions. Several other protecting group 
schemes were briefly surveyed (Fmoc, Cbz, and NVOC) but all were prone to hydrolysis to 3-38 
or indolmycin (not shown). 



















Figure 3.20 Synthesis of amide derivatives of indolmycin. 
The apparent tolerance of C-5’ substitution led to attempts to introduce a benzylic amine 
at this position. Synthesis of this derivative was envisioned to be possible through reduction of 5’-
cyanoindolmycin (Figure 3.21). 5’-cyanoindole-3-carbaldehyde (3-39) is commercially available 
and was easily carried forward through the same synthetic route as indolmycin (Figure 3.18) to 
provide 5’-cyanoindolmycin (3-43). Poor antimicrobial activity was observed for 3-43 (discussed 
below), so methods for selective reduction were not explored.  
 




































































































































The primary bioactivity endpoints for evaluating indolmycin derivatives were bacterial 
accumulation and antimicrobial activity. As expected, indolmycin had a much higher MIC in wild-
type E. coli than ∆tolC and ∆rfaC strains. Unfortunately the only primary amine tested, 3-32, did 
not show any antimicrobial activity and amides had comparable activity in S. aureus as 
indolmycin. The inactivity of 3-43 determined that making the equivalent primary amine would 
not likely be fruitful. 
 
Figure 3.22 Summary of bioactivity of indolmycin and derivatives. TolC is a component of a major efflux 
pump and RfaC is a glycosyltransferase essential for constructing a competent LPS. All compounds are 
racemic.  
 As the bioactivity of indolmycin amides was not intuitive when analyzing the co-crystal 
structure of indolmycin bound to TrpRS, the stability of these compounds was examined in buffer 
and media. Indeed, these indolmycin amides degraded to indolmycin when incubated in PBS at 37 
°C (t1/2 = 12 h for 3-33, Figure 3.23A). The rate of hydrolysis was significantly greater in cation-
adjusted MH broth (media used for MIC experiments) with half-lives for all compounds tested 
under one hour. The rate of hydrolysis showed both pH and electronic dependence (Figure 
3.23B,C). The inherent instability of N2 amides explains the aberrant activity in S. aureus (Figure 
3.22). In these MIC experiments, the N2 amides are rapidly converted to indolmycin, so the 
resulting MIC is the same as the parent compound. This unique feature of indolmycin could be 
leverage to design prodrugs on indolmycin, but compound instability has so far frustrated efforts 





















































Figure 3.23 A. Hydrolysis of indolmycin amides in MH media. B. Hydrolysis of benzoyl-indolmycin (3-33) 
in phosphate buffer as a function of pH. Hydrolysis is also assessed in cation-adjusted MH broth. C. Time 
course of hydrolysis of substituted indolmycin amides. 
3.4. Zantrin Z3 
As discussed in Chapter 1, FtsZ is a compelling target for new antibiotics. FtsZ is a 
homolog of tubulin and plays an important structural role in bacteria.56 Most critically, FtsZ 
initiates the formation of Z-rings at the midpoint of cells and provides the mechanical force 
necessary to divide them.57,58 Recent studies have also shown that FtsZ is critical in regulating 
peptidoglycan synthesis.59 Inhibitors of FtsZ causes Z-ring mislocation, and cells do not divide, 
growing into long filaments that eventually lyse (Figure 3.24).  
 
Figure 3.24 Observation of filamentation of B. subtilis FG347 bacteria expressing a GFP-tagged Z-ring 
marker protein (ZapA) by fluorescence microscopy. The bacteria were cultured for 2 h in the presence of 
DMSO vehicle (left) or 4 µg/mL TXA707 (8x MIC) (right). The arrows in the left panel indicate septal FtsZ 
Z-rings at midcell. Figure reused with permission from Ref. 60 © 2015 American Society for Microbiology. 
Despite some interesting and potent FtsZ inhibitors being developed, no compounds have 
entered the clinic. Although many compounds have been reported to be selective FtsZ inhibitors, 































































bona fide FtsZ inhibitors are the difluorobenzamides for which extensive SAR, structural biology, 
microbiology, and in vivo data exists.60,62-76 This class of compounds has been limited by poor 
solubility, but a series of prodrugs have been developed with improved solubility and 
bioavailability (Table 3.7). One prodrug, TXA709, developed by Taxis Pharmaceuticals has been 
designated a Qualified Infectious Disease Product and is reportedly slated to enter the clinic. Early 
work suggested that the selectivity observed by PC190723 was primarily due to target 
conservation, and improved accumulation in gram-negative bacteria would not confer activity.62,67 
These findings were confounded by a more recent study finding that TXY436 is moderately 
bactericidal in E. coli, K. pneumoniae, and A. baumannii when treated in combination with efflux 
pump inhibitors (Table 3.7).72 With the prospect of converting a difluorobenzamide into a gram-
negative-active agent unclear, we focused on other scaffolds. 
Table 3.7 Bioactivity of FtsZ inhibitors. 
Compound In vitro activity Antimicrobial activity 
 
PC190723 
Kd = 2.2 µM (saFtsZ)72 
Kd = 18.9 µM (ecFtsZ)72 
MIC = 1 µg/mL (S. aureus)62  
MIC = 1 µg/mL (B. subtilis)62  
MIC >64 µg/mL (E. faecalis)62  





MIC = 2 µg/mL (S. aureus)69 
MIC >64 µg/mL (E. coli WT)72 
MIC = 8 µg/mL (E. coli ∆acrAB)72 
MIC = 8 µg/mL (E. coli WT, with PAbN)72 
 
TXY541 
 MIC = 2 µg/mL (S. aureus)68 
 
TXA707 
PDB: 5XDT MIC = 1 µg/mL (S. aureus FtsZ
WT)60,75 




MIC = 0.5-1 µg/mL (S. aureus)60 




Aq. Solubility = 12.5 µg/mL71 
PDB: 5XDU 
PDB: 5XDV 
MIC = 0.125 µg/mL (S. aureus FtsZWT)75 
MIC = 1 µg/mL (S. aureus FtsZG196S)75 
 
Zantrin Z3 
IC50 = 20 µMa,61 
MIC = 5 µM (S. aureus)77 MIC = 2.5 µM 
(B. subtilis)77 
MIC = >80 µM (E. coli WT)77 




























































Table 3.7 (cont.) 
Compound In vitro activity Antimicrobial activity 
 
3-44 
IC50 = 12 µMa,61 Not reported 
 
3-45 
IC50 = 9 µMa,78 Not reported 
 
3-46 
IC50 = 27 µMa,78 Not reported 
aE. coli FtsZ GTPase activity 
 
In a critical 2012 study, Anderson and coworkers surveyed eight classes of compounds 
with alleged FtsZ inhibitory activity under standardized conditions.61 The majority of compounds 
were found to be aggregators or were significantly less potent than initially reported. Interestingly, 
PC190723 was found to be an activator of FtsZ’s GTPase activity. This finding was independently 
confirmed by Merck researchers.79 Only zantrin Z3 was shown to be a robust inhibitor in the 
presence of detergent. Zantrin Z3 was discovered in a high-throughput screen that measured GTP 
hydrolysis by FtsZ.77 In vitro FtsZ polymerization experiments suggest zantrin Z3 stabilizes FtsZ 
polymers as observed by electron microscopy and sedimentation. Curiously, zantrin Z3 does not 
cause filamentation despite disrupting Z-ring formation by immunofluorescence microscopy in E. 
coli lacking acrAB. No resistant mutants against zantrin Z3 or structural biology have been 
reported. This body of data points to zantrin Z3 acting through a distinct mechanism from the 
difluorobenzamides. 
Despite a slightly unclear mechanism of action, zantrin Z3 appeared to be an interesting 
candidate for conversion because of some recently reported SAR data. Shortening or removal of 
the pendent ethyl groups increases activity in a GTPase activity assay.61,78 While the activity of 
these compounds has not been reported in cell culture, we anticipated they would be active in 
gram-negative bacteria due to their conformity to the eNTRy rules. 
Zantrin Z3 and derivatives were synthesized as described previously.61,78 Briefly, 3-amino-
2-naphthoic acid (3-47) was acetylated and condensed with ammonia to give benzoquinazolinone 

















3-49, which was reacted with a variety of substituted ethylene diamine derivatives. A primary 
amine derivative was synthesized via Boc-protected intermediate 3-50 that was deprotected with 
anhydrous HCl to give 3-45. 
 
Figure 3.25 Synthesis of benzoquinazoline derivatives. 
Truncated versions of zantrin Z3 have been described with comparable activity such as 6-
methylquinazoline 3-46 (Table 3.7). These derivatives are synthesized as above but starting with 
5-methylanthranilic acid (3-51, Figure 3.26). Again, different derivatives were accessed by 
reacting chloroquinazoline 3-53 with various protected amines to yield dimethyl (3-54), 
monomethyl (3-57), and primary amine (3-46) derivatives. Primary amine 3-46 was acetylated to 
give amide 3-58. 
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Having synthesized quite a few compounds, these derivatives were evaluated by a battery 
of bioassays, summarized in Figure 3.27. Due to the poor solubility of the benzoquinazolines, most 
experiments were performed with the 6-methylquinazolines. As reported previously, zantrin Z3 
was active in S. aureus. Zantrin Z3 was able to achieve moderate accumulation in E. coli, but this 
did not translate into antimicrobial activity in most gram-negative species. Removal and truncation 
of the ethyl groups resulted in a dramatic increase in accumulation in both E. coli and P. 
aeruginosa. This increase in accumulation resulted in sensitization of several gram-negative 
species to FtsZ inhibitors. Interestingly, although 3-46 accumulated to a similar extent, E. coli was 
much more sensitive to FtsZ inhibition than P. aeruginosa as indicated by a 4-fold difference in 
MIC. Enthusiasm for this series of compounds was tempered by cytotoxicity in mammalian cells. 
Both A549 (lung cancer) and HFF-1 (human foreskin fibroblast) cells were sensitive to zantrin Z3 
derivatives as measured by a 72 h IC50. Cytotoxicity was not associated with the introduction of a 
primary amine as demonstrated by the activity of 3-58. These compounds are not likely membrane 
disruptors since only minimal hemolysis was observed at high concentration.  
 
Figure 3.27 Summary of zantrin Z3 derivative bioactivity. Bacterial accumulation was determined by Emily 
Geddes. nd – not determined. 
Anticipating that zantrin Z3 and analogues may be hitting the homolog of FtsZ, tubulin, in 
mammalian cells, we examined the time dependence of cytotoxicity. Cells can often recover from 
brief exposure to tubulin stabilizers or destabilizers. As shown in Figure 3.28A, the potency of 
paclitaxel (a tubulin stabilizer) is highly dependent upon the period of exposure. In contrast, the 
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that zantrin Z3 derivatives may be inducing mammalian toxicity through additional mechanisms 
other than tubulin stabilization.  
 
Figure 3.28 Mammalian and bacterial killing kinetics. A. Human cells were exposed to FtsZ inhibitors or 
paclitaxel for variable times before washout and recovery. After a total of 48 h, cell viability was determined 
by SRB. Data is shown as average IC50 from three independent biologic replicates. In 96-well plate: A549 
plated at 3000 cells/well, HFF-1 plated at 5000 cells/well. B. Bacterial killing kinetics was performed in E. 
coli MG1655. Cells were diluted into media containing 3-57 at various concentrations. Cell growth was 
monitored by CFU determination by serial dilution and plating. Representative data is shown from two 
independent replicates. 
This rapid mechanism of action was also observed in bacteria where 3-57 caused greater 
than 1-log kill after 2 h when planktonic E. coli cells were treated at their MIC (Figure 3.28B). At 
the 2-fold MIC concentration, quantitative cell death was observed after 30 min. This phenotype 
is inconsistent with FtsZ inhibition which typically involves filamentation and gradual lysis over 
several cell division cycles. Concerned that zantrin Z3 and derivatives do not achieve their 
antimicrobial activity through FtsZ inhibition, several experiments were performed to interrogate 
their mechanism of action. In the first experiment, the generation of resistant mutants was 
attempted. Curiously, both E. coli MG1655 and S. aureus ATCC 29213 cells produced lawns when 
plated on LB agar impregnated with 3-57 at 64 µg/mL (8-fold MIC). An alternative method of 
resistance generation was implemented in which cells are exposed to gradually increasing 
concentration of antibiotic (Figure 3.29). This approach has been used previously to generate 
resistance to ciprofloxacin, 80 which was accomplished here with a 64-fold increase in MIC. Only 
modest resistance (4-fold) was observed against 3-57 even after twelve generations. Sequencing 
of these cells showed FtsZ was still wild-type. 
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Figure 3.29 Generation of resistant mutants of E. coli MG1655 through repeated exposure. A. Overview of 
experiment. A standard MIC experiment is conducted. The cells from the well with the highest concentration 
of antibiotic with observed growth are expanded and used to setup a new MIC experiment. This process is 
repeated for several generations or until resistance is observed. B. Dose-response data from individual 
generations. Two lineages were maintained with exposure to ciprofloxacin (CIPa and CIPb). Four lineages 
were maintained with exposure to 3-57. C. MIC of lineages as a function of generation. 
Although it seemed clear at this point 3-57 hits an unknown target in addition to FtsZ, it 
was important to determine if FtsZ is part of the mechanism at all. To address this question, we 
turned to B. subtilis as a model system for studying Z-ring formation. By utilizing a gram-positive 
organism, the bifluorobenzamide PC190723 could be used as a positive control. An engineered 
strain of B. subtilis in which a mNeonGreen-tagged copy of ftsZ is incorporated into the genome 
was obtained from the Prof. Ethan Garner (Harvard University).81 Confocal microscopy confirmed 
filamentation and Z-ring disruption in PC190723-treated cells (Figure 3.30). This same phenotype 
was observed in cells treated with 3-57 in liquid culture but not agar. 
No Visible Growth
64 32 16 8 4 2 1 0.5
MIC = 4 µg/mL























































Figure 3.30 Fluorescence live imaging of B. subtilis bAB185 upon treatment with FtsZ inhibitors. B. subtilis 
bAB185 express a FtsZ fusion-tagged to mNeonGreen. Overnight cultures was diluted in chemically defined 
media (CDM) and grown to OD600 = 0.2. Cells were treated with FtsZ inhibitor and either incubated in liquid 
media for 1 h or mounted on agar pad immediately. Images were acquired on Zeiss LSM 700 equipped with 
63x/1.4 NA objective. Scale bar represents 20 µm. 
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Derivatives of zantrin Z3 were synthesized with dramatically improved gram-negative 
accumulation. This increased accumulation translated into antimicrobial activity, making these 
compounds the first putative FtsZ inhibitors with gram-negative cellular activity. Unfortunately, 
the high degree of mammalian toxicity prevents moving these compounds forward as candidate 
drugs. Further, the precise mechanism by cell death occurs remains unclear. Although fluorescence 
imaging provides evidence that Z-ring disruption is occurring, the unusual dependence on liquid 
versus solid media and rapid cell death are not consistent with only FtsZ inhibition. The structural 
similarity to a class of non-b-lactam inhibitors of penicillin-binding protein suggests the possibility 
for polypharmacology.82 Application of the eNTRy rules successfully converted zantrin Z3 into a 
gram-negative-active antibiotic. However, this conversion is a clear example of how the 
underlying mechanism of an antibiotic is a more important driver of overall value. 
3.5. Conclusion 
The literature is rife with example of antibiotic development projects that yielded 
interesting gram-positive-only antibiotics. Among these are compounds that hit novel targets or 
old targets but in new ways. The potential for enabling these compound classes with gram-negative 
accumulation would transform the antibiotic pipeline. Here the eNTRy guidelines for gram-
negative accumulation were applied to four compound classes. In three cases (Debio-1452, 
zoliflodacin, and zantrin Z3), high accumulating compounds were discovered by introducing a 
primary amine. Two of these classes (Debio-1452 and zantrin Z3) gained activity in gram-negative 
bacteria. If this rate of success is indicative of other compound classes, then this rational approach 
for gaining gram-negative activity represents an exciting new paradigm for drug discovery. 
3.6. Materials and methods 
3.6.1. Biology assays 
Antimicrobial susceptibility (MIC determination, microbroth dilution method) 
Susceptibility testing was performed in biological triplicate, using the micro-dilution broth method 
as outlined by the Clinical and Laboratory Standards Instituted. Cation-adjusted Muller-Hinton 
broth was used. 
Selection of resistance mutants 
Resistant mutants were selected via the large inoculum method. Briefly, E. coli MG1655 (1.8x109 
CFU) were plated on 100 mm plates of LB agar containing 64, 32, and 16 µg/mL Debio-1452-
NH3. Colonies were visible after incubating at 37°C for 48 h. Resistant colonies were confirmed 
by streaking on selective media with the same concentration of Debio-1452-NH3. 
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Sequencing of FabI 
FabI was amplified by colony PCR. Colonies were picked and diluted in 100 µL sterile H2O. PCR 
reactions are setup by combining 25 µL MiFi Mix (Bioline, London, UK), 1 µL 20µM primer mix 
(EcFabI-PCR-FOR and EcFabI-PCR-REV), 10 µL template, and 14 µL H2O. Reaction was 
performed on C1000 Thermal Cycler (Bio-Rad, Hercules, CA) with the following conditions: 
initial denature 95°C, 3 min; denature 95°C, 15 s; anneal 57°C, 15 s; extend 72°C, 30 s; final 
extend 3 min; 35 cycles. 5 µL portion of PCR reaction mixture was analyzed by agarose gel to 
confirm single 1.4 kbp product. PCR reaction was purified using GeneJET PCR Purification Kit 
(Thermo Scientific). PCR amplicons were submitted to the Core DNA Sequencing Facility at the 
University of Illinois at Urbana-Champaign for Sanger sequencing with overlapping internal 
primers (EcFabI-Seq-REV and EcFabI-Seq-REV). All primers were obtained from Integrated 
DNA Technologies (Coralville, IA).  
Primer Sequence 
EcFabI-PCR-FOR 5’- GGGGCCAGCGTTTCTTTTTC -3’ 
EcFabI-PCR-REV 5’- AAACATGGAGACGGTGCTGG -3’ 
EcFabI-Seq-FOR 5’- ATAGCTACTCACAGCCAGGT -3’ 
EcFabI-Seq-REV 5’- GAAGGGGAGAAAGACGGATC -3’ 
 
Plasmids 
Expression vectors for FabI were a generous gift from Peter Tonge (Stonybrook University, NY). 
Site directed mutagenesis was performed with NEB Q5 Site Directed Mutagenesis Kit according 
to kit instructions with the primers and annealing temperatures listed below. Mutations were 
confirmed by Sanger sequencing using T7 promoter and T7 terminator primers. 
Species Mutation Forward Primer Reverse Primer Ta 
E. coli A116V TTCAAAATTGTCCACGACATCAGCTC GCCTTCACGGGTAACGGC 67 
E. coli G148S TTCCTACCTTAGCGCTGAGCG AGGGTCAGCAGGGCAGAA 67 
E. coli G93V ACACTCTATTGTTTTTGCACCTG ACGAAACCGTCAAATTTC 58 
E. coli M159T CTACAACGTTACGGGTCTGGCAAAAG TTCGGGATAGCGCGCTCA 67 
E. coli F203L TATCAAAGACCTCCGCAAAATGCTGGC CCGGAGGCCGCCAGAGTA 67 
S. aureus M99T TTTGCTAATACGGAAGACTTACG TGCGATTGAATGATATACAC 58 
S. aureus Y147H TGCAACAACACATTTAGGTGG ACAATGCTACCACCTTCTG 58 
S. aureus A95V CATTCAATCGTATTTGCTAATATG ATATACACCATCAATATTGC 58 
S. aureus F252L AGATAGCGGACTCCACGCAAT ACATGAATATTTTCACCTGTAACGC 67 
 
Expression and purification of E. coli FabI 
E. coli BL21 (DE3) pLysS were transformed with pET15-ecFabI. Overnight culture (10 mL) in 
LB supplemented with 50 µg/mL ampicillin from single colony was diluted into 1 L LB + 50 
µg/mL ampicillin. Cells were grown at 37°C, 250 rpm until OD600 reached 0.8. Culture was cooled 
to 18°C and induced with 0.5 mM IPTG for 18 h at 18°C. Cells were harvested by centrifugation 
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(5,000xg, 10 min, 4°C). Cell pellets were flash frozen and store at -20°C pending purification. 
Frozen cell pellets were thawed on ice and resuspended (5 mL per gram wet pellet, typically 20-
30 mL) with 0.5% CHAPS, 1 mM PMSF, 1 µg/mL leupeptin, 1 µg/mL pepstatin A, and 2 µg/mL 
aprotinin in binding buffer [20 mM Tris (pH 7.9), 500 mM NaCl, 5 mM imidazole]. Cells were 
lysed by sonication on ice (30%, 10 s pulse, 20 s rest, 5 min total). Lysate was clarified by 
centrifugation (35,000xg, 1 h, 4°C) and filtration through 0.2 µm syringe filter. Lysate was 
incubated with 5 mL Co-NTA agarose (pre-equilibrated with binding buffer) for 30 min at 4°C 
with gentle rocking. Agarose-containing lysate was transferred to column and flow through 
discarded. Column was washed with 2 column volumes of binding buffer followed by 10 column 
volumes of wash buffer [20 mM Tris (pH 7.9), 500 mM NaCl, 60 mM imidazole]. Protein was 
eluted with 15 mL elution buffer [20 mM Tris (pH 7.9), 500 mM NaCl, 300 mM imidazole]. 
Fractions containing protein were identified by SDS-PAGE, subjected to dialysis against FabI 
storage buffer [60 mM PIPES (pH 8.0), 150 mM NaCl, 1 mM EDTA], and concentrated with 
Amicon spin filter. Protein solution was aliquoted, flash frozen in liquid nitrogen, and stored at -
80°C. 
Expression and purification of S. aureus FabI 
E. coli BL21 (DE3) pLysS were transformed with pET16-saFabI. Overnight culture (10 mL) in 
LB supplemented with 50 µg/mL ampicillin from single colony was diluted into 1 L LB + 50 
µg/mL ampicillin. Cells were grown at 37°C, 250 rpm until OD600 reached 0.6. Culture was 
cooled to 18°C and induced with 0.5 mM IPTG for 18 h at 18°C. Cells were harvested by 
centrifugation (5,000xg, 10 min, 4°C). Cell pellets were flash frozen and store at -20°C pending 
purification. Frozen cell pellets were thawed on ice and resuspended (5 mL per gram wet pellet, 
typically 20-30 mL) with 0.5% CHAPS, 1 mM PMSF, 1 µg/mL leupeptin, 1 µg/mL pepstatin A, 
and 2 µg/mL aprotinin in binding buffer [50 mM HEPES (pH 7.5), 500 mM NaCl, 5 mM 
imidazole, 5% glycerol]. Cells were lysed by sonication on ice (30%, 10 s pulse, 20 s rest, 5 min 
total). Lysate was clarified by centrifugation (35,000xg, 1 h, 4°C) and filtration through 0.2 µm 
syringe filter. Lysate was incubated with 5 mL Ni-NTA agarose (pre-equilibrated with binding 
buffer) for 30 min at 4°C with gentle rocking. Agarose-containing lysate was transferred to column 
and flow through discarded. Column was washed with 10 column volumes of binding buffer. 
Protein was eluted with 15 mL elution buffer [50 mM HEPES (pH 7.8), 500 mM NaCl, 400 mM 
imidazole, 5% glycerol]. Fractions containing protein were identified by SDS-PAGE, subjected to 
dialysis against FabI storage buffer [10 mM HEPES (pH 7.8), 300 mM NaCl, 1 mM EDTA, 5% 
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glycerol], and concentrated with Amicon spin filter. Protein solution was aliquoted, flash frozen 
in liquid nitrogen, and stored at -80°C. 
In vitro FabI inhibition assay 
NADH and crotonoyl-CoA were both diluted into activity buffer [100 mM potassium glutamate 
(pH 7.8)], and working solution was dispensed into two columns of standard 96-well plate (330 
µL per well). Inhibitors, dissolved in DMSO at 200X final concentration, were added to each well 
via multichannel pipette (2.48 µL per well). After thorough mixing, this mixture was transferred 
to UV-transparent half-area 96-well plate (100 µL per well, three technical replicates per inhibitor 
concentration). Plate was placed in plate reader under temperature control (25°C), and temperature 
was allowed to equilibrate. Fresh aliquot of enzyme from -80°C was thawed on ice and diluted in 
activity buffer. Enzyme working solution was added to plate (50 µL per well, 20 nM enzyme final). 
After shaking for 5 s, reaction progress was monitored by absorbance at 340 nm every 15 s for 90 
min. Linear portion of reaction progress curve was fit. Percent activity was calculated relative to 
DMSO-only and no-enzyme controls in each plate. Percent activity curves were fit to Morrison’s 
quadratic using Graphpad Prism to obtain apparent Ki. 
Indolymcin amide stability 
DMSO solutions were prepared for each amide (10 mM). Each amide was combined 1:1 with Me-
indolmycin (3-31). Diluted 2 µL of DMSO solution into 98 µL MH2 broth. Incubated for variable 
amount of time at 37 C. Reaction was quenched with addition of 0.4 mL acetonitrile and 
centrifuged. Supernatent was analyzed by LCMS to assess reaction progress. 
FtsZ inhibitor cytotoxicity time course 
Cells were plated (50 µL) in 96-well plates (A549 3000 cells/well, HFF-1 5000 cells/well) and 
allowed to attach overnight. Cells were treated with compound of interest in media (50 µL, 0.5% 
DMSO final) and incubated for a variable period of time at which point media was aspirated, cells 
were washed with media once, and allowed to incubate with fresh media for a total of 48 h 
(treatment plus recovery time). Raptinal (5 µM) was used as a positive control and was not washed 
out. Cells were fixed with the addition of 100 µL cold 10% trichloroacetic acid and incubated at 4 
°C for 1 h. Plates were washed with tap water 4x (typically filling a basin in sink and submerging 
to prevent detachment). Excess water was removed by tapping inverted plates on blotting paper 
and allowed to dry 1 h. SRB (Sulforhodamine B) solution (100 µL, 0.057% w/v in 1% acetic acid) 
was added to each well and incubated at room temperature for 30 min. Free SRB dye was removed 
by washing plates with 1% acetic acid 4x. Excess water was removed by blotting on paper and 
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allowed to dry completely. Protein-bound SRB dye was dissolved with addition of 10 mM Tris 
(200 µL per well). Absorbance was read at 564 nm (or 510 nm if saturated). Percent cell death was 
calculated based on positive control (5 µM raptinal) and negative control (DMSO). 
Bacterial killing kinetics 
Overnight culture of bacteria in MH broth was diluted 100 µL into 10 mL MH broth. Culture was 
grown at 37 °C, 250 rpm until OD600 reached 0.10 and 5 mL portion was diluted into 50 mL broth. 
This diluted culture was divided into five tubes (10 mL each) containing DMSO solutions of the 
antibiotic being tested. At appropriate timepoints, 100 µL aliquot of each tube was removed and 
CFU/mL was determined by serial dilution in sterile PBS and plating on LB agar. 
Hemolysis assay 
Whole human blood in citrate phosphate dextrose was obtained from Bioreclamation LLC. Whole 
blood (100 µL) was combined with 500 µL saline (0.9% NaCl) and centrifuged 5 min, 300xg, 4 
°C. Supernatent was aspirated and cells were washed 3x with 500 µL saline. Pellet was 
resuspended in red blood cell buffer [10 mM Na2HPO4 (pH 7.4), 150 mM NaCl, 1 mM MgCl2]. 
To a PCR plate added 19 µL red blood cell buffer and 1 µL 30X DMSO solution of compound of 
interest. 30% Triton X-100 was used as positive control. Plate was centrifuged briefly to combine. 
To each well was added 10 µL washed erythrocytes. Plate was sealed with AeroSeal and incubated 
at 37 °C for 2 h. Cells were pelleted by centrifuging plate 5 min, 300xg. Supernatent (20 µL) was 
carefully transferred to wells of clear bottomed 384-well plate. Absorbance was read at 540 nm. 
Sequencing of FtsZ 
Sequencing of ftsZ was performed by colony PCR and Sanger sequencing as described for fabI but 
with different primers. The ftsZ gene is much larger than fabI, so it had to be sequenced in pieces 
with multiple primers. 
Primer Sequence 
EcFtsZ-PCR-FOR 5’- ACGTGTTACAGCATCAGTTGGC -3’ 
EcFtsZ-PCR-REV 5’- AGTGTCCTTTGTTTGATCATCGT -3’ 
EcFtsZ-SeqA-FOR 5’- ACGTGTTACAGCATCAGTTGGC -3’ 
EcFtsZ-SeqA-REV 5’- CAATGCATCGCGATCCTCATCA -3’ 
EcFtsZ-SeqB-FOR 5’- TTTGGGTATCCTGACCGTTGCT -3’ 
EcFtsZ-SeqB-REV 5’- TCGATATCTTCCAGCAGCGGAG -3’ 
EcFtsZ-SeqC-FOR 5’- AACGCGACTGTGGTTATCGGTA -3’ 
EcFtsZ-SeqC-REV 5’- AGTGTCCTTTGTTTGATCATCGT -3’ 
 
Fluorescence microscopy of Z-rings 
B. subtilis bAB185 was obtained from Prof. Ethan Garner (Harvard University).81 Chemically 
defined media (CDM) was prepared and sterilized by filtration [62 mM K2HPO4, 44mM KH2PO4, 
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15 mM (NH4)2SO4, 6.5 mM sodium citrate, 0.8 mM MgSO4, 2.2mM glucose, 2.1 mM L-glutamic 
acid, 6 μM L-tryptophan, 7.5 μM MnCl2, 0.15x metal mix (prepare 50x metal mix stock which 
contains: 0.2 M MgCl2, 70 mM CaCl2, 5 mM MnCl2, 0.1 mM ZnCl2, 0.2 mM thiamin 
hydrochloride, 2 mM HCl, 0.5 mM FeCl3)].83  Agar pad for mounting was prepared by dissolving 
150 mg (1.5%) high resolution low-temp agarose (Sigma) in 10 mL CDM. Molten agarose was 
pipetted onto clean glass slide and carefully sandwiched with another glass slide using two #1 
coverslips as spacers. Once the agar pad was set, the top glass slide was removed and agar pad was 
trimmed to approximately 1 cm by 1 cm using a scalpel. Overnight culture of bAB185 in LB broth 
was diluted 100 µL into 10 mL CDM and grown at 30 °C, 250 rpm until OD600 reached 0.2. Culture 
was divided and treated with antibiotic or DMSO. Cell suspension (2 µL) was mounted onto agar 
pad immediately for after incubating in liquid media for 1 h. Clean glass #1 coverslip was placed 
over agar pad. Corners of coverslip were fixed with clear nail polish. Cells were imaged on Zeiss 
LSM 700 with Plan-Apochromat 63X/1.4 oil DIC M27 objective. Excitation: 488 nm, Emission: 
518 nm. 
3.6.2. Synthesis of zoliflodacin derivatives 
 
2-Hydroxy-3,4-difluorobenzoic acid (3-9) To a 1L three-necked round-bottom flask equipped 
with overhead stirrer and reflux condenser added 2,3,4-trifluorobenzoic acid (50.0 g, 284 mmol, 1 
eq). 1,3-Dimethyl-2-imidazolidinone (200 mL, 1.4 M) was added and material was dissolved. To 
stirring solution at room temperature sodium hydroxide (25 g, 1125 mmol, 4 eq) was added in two 
portions. Reaction vessel was heated to 130°C over 30 min while stirring at 250 rpm. After stirring 
at 130°C for 3 hr, reaction mixture was cooled to 0°C. While maintaining temperature at 0°C, 
reaction mixture was acidified with 4 M HCl until pH reached 2 (approx. 600 mL total reaction 
volume). Slurry was filtered through medium sintered glass funnel and washed with excess MilliQ 

































Methyl 2-hydroxyl-3,4-difluorobenzoate (3-10) To a 500 mL round-bottom flask added 3-9 
(43.4 g, 250 mmol) and dissolved in methanol (200 mL). Concentrated sulfuric acid (40 mL) was 
slowly added to stirring solution at room temperature. Reaction mixture was heated at reflux for 
12 hr. Mixture was cooled to room temperature, diluted with water, and extracted with diethyl 
ether. Organic layer was washed with saturated aq. NaHCO3, water, and then brine. Combined 
aqueous layers were extracted with diethyl ether twice. These additional organic layers were 
washed with NaHCO3, water, and brine. The combined ether layers were dried over MgSO4, 
filtered through celite, and evaporated to give a white solid (36.2 g, 77%). 1H NMR was consistent 
with previous report.32 
 
 
3,4-Difluoro-N,2-dihydroxybenzamide (3-11) To a 1 L round-bottom flask added 3-10 (36.1 g, 
192 mmol, 1 eq) and dissolved in methanol (500 mL). Hydroxylamine hydrochloride (26.7 g, 384 
mmol, 2 eq) was added followed by potassium hydroxide (43.1 g, 768 mmol, 4 eq). Mixture was 
stirred at 60°C for 16 hr. Reaction mixture was cooled to 0°C and acidified with 2 M HCl (250 
mL). White precipitate was collected by filtration. Filtrate was extracted with ethyl acetate three 
times. Combined organic layers were washed with brine, dried over Na2SO4, and evaporated. 
Original filtrand was further washed with water and dried (34.0 g, 94%). 1H NMR was consistent 
with previous report.32 
 
6,7-Difluoro-1,2-benzisoxazol-3(2H)-one (3-12) To a 2 L three-necked flask added 3-11 (33.4 g, 
176 mmol). Dry THF (800 mL, 0.2 M) was added via cannula. To stirring solution at room 
temperature, was added 1,1’-carbonyldiimidazole (57.2 g, 353 mmol) in two portions. After 
stirring at room temperature for 15 min, reaction mixture was heated to reflux and stirred 3 hr. 
Reaction mixture was cooled to 0°C and cautiously diluted (significant gas evolution) with water 
(1 L) and ethyl acetate (1 L). Diphasic mixture was acidified with concentrated HCl (50 mL) and 



































was washed with water then brine. Combined organic layers were dried over MgSO4, filtered, and 
evaporated to give tan solid (29.1 g, 96%). 1H NMR was consistent with previous report.32 
 
 
3-Chloro-6,7-difluorobenzo[d]isoxazole (3-13) Synthesized via a modified method for non-
fluorinated analogue. 85 Briefly, to a 500 mL round-bottom flask equipped with reflux condenser 
added 3-12 (28.5 g, 167 mmol). Phosphoryl chloride (43 mL, 1.645 g/mL, 461 mmol) and H2PO4 
(2.0 mL, 34 mmol) were subsequently added. Anhydrous pyridine (13.5 mL, 167 mmol) was 
slowly added. Once gas evolution ceased and material was mostly dissolved, reaction mixture was 
heated to 100°C and stirred for 7 hr. Reaction mixture was cooled to 0°C and quenched by 
transferring via cannula to a stirring mixture of methyl tert-butyl ether (100 mL), heptane (100 
mL), and water (150 mL). Mixture was stirred vigorously for 1 hr at room temperature. Organic 
layer was washed with brine, dried over Na2SO4, and evaporated. Residue was purified by silica 
gel chromatography (gradient 20:80 to 40:60 CH2Cl2:hexane, Rf = 0.57 in final composition) to 
provide tan solid (24.6 g, 78%). 1H NMR were consistent with previous report.32 
 
 
3-Chloro-6,7-difluorobenzo[d]isoxazole-5-carbaldehyde (3-14) To a 250 mL round-bottom 
flask added diisopropylamine (freshly distilled from Na, 15.5 mL, 111 mmol, 1.5 eq) and dissolved 
in THF (150 mL). Cooled to -78°C and n-BuLi (1.6 M in hexane, 64 mL, 102 mmol, 1.4 eq) was 
added in two portions. After stirring for 15 min at -78°C, reaction mixture was warmed to 0°C for 
10 min and cooled again to -78°C. Solution of LDA was transferred dropwise via cannula to 500 
mL round-bottom flask containing a stirring solution of 3-13 (14.0 g, 73.9 mmol, 1 eq) in THF 
(150 mL) at -78°C. Mixture was stirred for 30 min before addition of DMF (12 mL, 156 mmol, 
2.1 eq) and continued stirring for 1 hr. Reaction mixture was quenched by transferring via cannula 
to a solution of acetic acid (17 mL, 297 mmol, 4 eq) in diethyl ether (250 mL) and mixture was 
warmed to room temperature. Diluted with ethyl acetate and washed with brine. Combined 




































organic layers were dried over Na2SO4 and evaporated. Residue was purified by silica gel 
chromatography (20:80 to 60:40 CH2Cl2:hexane) to provide 3-14 as a white solid (6.2 g, 39%). 1H 
and 19F NMR was consistent with previous report.32 
Note: This reaction proceeds in slightly higher yield (~50%) with lithium tetramethylpiperidide, 
but the availability of tetramethylpiperidine limits scale. 
 
 
3-chloro-6-(2,6-dimethylmorpholino)-7-fluorobenzo[d]-isoxazole-5-carbaldehyde (3-15) To a 
200 mL round-bottom flask added 3-14 (4.74 g, 21.8 mmol) and dissolved in acetonitrile (54 mL). 
To stirring solution at room temperature added diisopropylethylamine (3.84 mL) followed by cis-
2,6-dimethylmorpholine (26.2 mmol). Mixture was heated at reflux for 6 hr. Cooled to room 
temperature and solvent was removed by rotary evaporation. Residue was dissolved in ethyl 
acetate and washed with brine. Aqueous layer was extracted again with ethyl acetate, and extract 
was washed with brine. Combined organic layers were dried over Na2SO4 and evaporated. 
Residue was purified by silica gel chromatography (98:2 CH2Cl2:EtOAc) to provide 3-15 as a 




16) To a 50 mL round-bottom flask added 3-15 (4.74 g, 15.2 mmol), ethylene glycol (4.2 mL, 7.5 
mmol), and toluene (150 mL). To stirring solution added p-toluenesulfonic acid (150 mg, 0.8 
mmol). Flask was attached to Dean-Stark trap and reaction mixture was heated at reflux for 4 hr. 
Reaction was cooled to room temperature and solvent was removed by rotary evaporation. Residue 
was dissolved in diethyl ether and washed with Na2CO3 and brine. Organic layer was dried over 
MgSO4, filtered, and evaporated to give 3-16 as a yellow solid (4.98 g, 92%). 1H NMR was 
















































Compound 3-17: To a 25 mL round-bottom flask added (R)-4-[[(tert-
butyldimethylsilyl)oxy]methyl]oxazolidin-2-one86 (84.3 mg, 0.364 mmol) and dissolved in DMF 
(3.5 mL). Sodium hydride was added as a 60% mineral oil dispersion (16.5 mg, 0.413 mmol) and 
stirred at room temperature for 15 min. To stirring mixture was added 3-16 (169.5 mg, 0.475 
mmol) and heated reaction mixture to 80 °C. After stirring at 80 °C for 4 h, reaction mixture was 
cooled to room temperature and quenched with satd aq NH4Cl. Volatiles were removed in vacuo. 
Residue was dissolved in diethyl ether and washed with water twice and brine once. Combined 
aqueous layers were extracted with diethyl ether which was subsequently washed with water and 
brine. Combined organic layers were dried over Na2SO4 and evaporated. Residue was purified by 
silica gel chromatography (25% EtOAc:hexane) to provide 3-17 as a white solid (128.8 mg, 64%). 
1H NMR was consistent with previous report.33 
1H NMR (500 MHz, CDCl3) δ 8.46 (d, J = 1.0 Hz, 1H), 6.24 (s, 1H), 4.83 (ddt, J = 9.0, 5.8, 3.4 
Hz, 1H), 4.20 (dd, J = 9.8, 8.7 Hz, 1H), 4.17 – 4.09 (m, 3H), 4.05 – 3.98 (m, 2H), 3.95 (dd, J = 
11.5, 3.7 Hz, 1H), 3.85 – 3.73 (m, 3H), 3.07 – 2.92 (m, 4H), 1.18 (dd, J = 6.2, 1.1 Hz, 6H), 0.81 
(s, 9H), 0.06 (d, J = 0.9 Hz, 5H). 
13C NMR (126 MHz, CDCl3) δ 153.89, 153.79, 153.70, 153.68, 145.40, 143.38, 138.91, 138.86, 
133.55, 119.69, 119.65, 114.31, 100.06, 100.04, 75.18, 72.53, 65.39, 65.35, 63.37, 57.48, 57.45, 
46.46, 25.73, 18.92, 18.20, -5.38, -5.41. 
























































Compound 3-18: To a stirring solution of 3-17 (186.2 mg, 0.338 mmol) in THF (4 mL) at room 
temperature, added Bu4NF as a 1 M solution in THF (0.5 mL, 0.5 mmol, 1.5 eq). Stirred at room 
temperature for 1.5 hr. Reaction mixture was quenched with satd aq NH4Cl and extracted with 
ethyl acetate. Organic layer was washed with brine, dried over Na2SO4, and evaporated. Residue 
was purified by silica gel chromatography (50:50 hexane:EtOAc) to provide 3-18 as a white solid 
(152 mg, 100%). 
1H NMR (500 MHz, Chloroform-d) δ 8.33 (d, J = 1.0 Hz, 1H), 6.21 (s, 1H), 4.71 – 4.63 (m, 2H), 
4.59 – 4.53 (m, 1H), 4.20 – 4.11 (m, 3H), 4.01 (td, J = 5.5, 2.8 Hz, 2H), 3.86 (dd, J = 12.2, 2.6 Hz, 
1H), 3.86 – 3.76 (m, 3H), 3.06 – 3.00 (m, 2H), 2.97 (ddt, J = 12.1, 9.9, 2.8 Hz, 2H), 1.20 (dd, J = 
6.3, 3.1 Hz, 7H). 
13C NMR (126 MHz, CDCl3) δ 154.58, 153.76, 153.66, 153.32, 153.29, 145.42, 143.40, 139.25, 
139.20, 133.81, 119.48, 119.44, 114.70, 99.98, 99.96, 72.60, 72.59, 66.44, 65.49, 65.42, 60.78, 
58.31, 57.53, 57.49, 57.46, 18.95. 





Compound 3-19: To a stirring solution of 3-18 (123.8 mg, 0.283 mmol) in CH2Cl2 (3 mL) at 0°C 
added p-toluenesulfonyl chloride (80.6 mg, 0.423 mmol) and 4-dimethylaminopyridine (68.4 mg, 
0.560 mmol). Allowed mixture to warm to room temperature and stirred for 2 hr. Reaction mixture 
was diluted with CH2Cl2 and quenched with the addition of satd aq NH4Cl. Organic layer was 
washed with water and satd aq NaHCO3, dried over Na2SO4, and evaporated. Residue was purified 
by silica gel chromatography (75:25 hexane:EtOAc) to give 3-19 as a white solid (150.5 mg, 90%). 
1H NMR was consistent with previous report.33 
1H NMR (500 MHz, CDCl3) δ 8.34 (s, 1H), 7.64 (d, J = 8.1 Hz, 2H), 7.11 (d, J = 8.0 Hz, 2H), 
6.23 (s, 1H), 4.80 – 4.73 (m, 1H), 4.68 – 4.55 (m, 3H), 4.29 (dd, J = 11.3, 2.2 Hz, 1H), 4.23 – 4.15 
(m, 2H), 4.08 – 4.00 (m, 2H), 3.88 – 3.76 (m, 2H), 3.13 – 2.90 (m, 4H), 2.27 (s, 3H), 1.21 (dd, J 































Compound 3-20: To a Schlenk tube added 3-19 (101.8 mg, 0.172 mmol) and dissolved in DMF 
(1.7 mL). Added sodium azide (69.3 mg, 1.07 mmol) and sealed tube. Reaction mixture was stirred 
at 90°C for 3 hr. Reaction was cooled to room temperature, quenched with water, and extracted 
with EtOAc. Organic layer was dried over Na2SO4 and evaporated. Residue was purified by silica 
gel chromatography (60:40 hexane:EtOAc) to give 3-20 as a white solid (61.0 mg, 77%). 1H NMR 
was consistent with previous report. 33 
1H NMR (500 MHz, CDCl3) δ 8.36 (s, 1H), 6.22 (s, 1H), 4.75 (dtd, J = 8.5, 4.9, 2.5 Hz, 1H), 4.65 
(t, J = 8.7 Hz, 1H), 4.47 (dd, J = 8.9, 4.7 Hz, 1H), 4.19 – 4.14 (m, 2H), 4.08 (dd, J = 13.0, 5.1 Hz, 
1H), 4.03 – 3.99 (m, 2H), 3.80 (tt, J = 8.4, 5.8 Hz, 2H), 3.70 (dd, J = 13.0, 2.6 Hz, 1H), 3.08 – 2.93 
(m, 4H), 1.19 (d, J = 6.3 Hz, 6H). 
13C NMR (126 MHz, CDCl3) δ 153.89, 153.87, 153.76, 152.90, 152.88, 145.43, 143.40, 139.27, 
139.22, 133.94, 119.37, 119.33, 114.45, 99.96, 99.94, 72.54, 66.52, 65.43, 65.41, 57.48, 57.44, 
55.47, 49.92, 18.94. 
19F NMR (470 MHz, CDCl3) δ -145.14. 
 
 
Compound 3-21: To a 4 mL reaction vial added 3-20 (8.9 mg, 0.0192 mmol) and barbituric acid 
(5.0 mg, 0.039 mmol). Material was dissolved in acetic acid (0.2 mL), vial was sealed, and mixture 
stirred at 120°C for 12 hr. Mixture was cooled to room temperature and solvent was evaporated. 
Residue was purified by reverse phase chromatography on Combiflash to provide 3-21 as a 
mixture of diastereomers (6.7 mg, 66%). 1H NMR was consistent with previous report.33 
1H NMR (500 MHz, CD3OD) δ 7.65 (d, J = 2.1 Hz, 1H), 4.76 (ddtd, J = 12.6, 8.4, 4.2, 2.3 Hz, 


























































(dd, J = 8.9, 4.0 Hz, 1H), 3.90 (ddd, J = 13.3, 7.0, 3.5 Hz, 1H), 3.80 (dq, J = 9.0, 6.4 Hz, 1H), 3.64 
(ddd, J = 13.9, 13.1, 2.3 Hz, 2H), 3.17 – 3.05 (m, 2H), 2.16 (s, 1H), 1.21 (d, J = 6.2 Hz, 3H), 0.99 
(dd, J = 6.4, 1.0 Hz, 3H). 




Compound 3-6: To a 4 mL reaction vial was added 3-21 (16.1 mg, 0.031 mmol) and 
triphenylphosphine (18.0 mg, 0.0686 mmol). Material was dissolved in methanol and stirred at 
reflux for 2 hr. Reaction mixture was cooled and solvent removed. Residue was purified by reverse 
phase chromatography on Combiflash to provide 3-6 as a mixture of diastereomers (2.6 mg, 17%).  
LCMS (ESI-TOF) m/z: [M+H]+ Calcd for C22H24FN6O7 503.1685; Found 503.1571. 
 
 
Compound 3-22: To a 25 mL round-bottom flask added N-Boc-ethanolamine (50 µL, 0.323 
mmol) and dissolved in DMF (3.0 mL). Sodium hydride was added as a 60% mineral oil dispersion 
(22.3 mg, 0.56 mmol) and stirred at room temperature for 15 min. To stirring mixture was added 
3-16 (102.1 mg, 0.286 mmol) and heated reaction mixture to 80 °C. After stirring at 80 °C for 4 h, 
reaction mixture was cooled to room temperature and quenched with satd aq NH4Cl. Volatiles 
were removed in vacuo. Residue was dissolved in diethyl ether and washed with water twice and 
brine once. Combined aqueous layers were extracted with diethyl ether which was subsequently 
washed with water and brine. Combined organic layers were dried over Na2SO4 and evaporated. 
Residue was purified by silica gel chromatography (25% EtOAc:hexane) to provide 3-22 as a 
white solid (7.9 mg, 6.8%). 
1H NMR (500 MHz, Chloroform-d) δ 8.46 (s, 1H), 6.25 (s, 1H), 4.65 (t, J = 7.9 Hz, 3H), 4.26 (dd, 
J = 8.5, 7.3 Hz, 3H), 4.20 – 4.15 (m, 3H), 4.07 – 3.98 (m, 3H), 3.86 – 3.77 (m, 3H), 3.08 – 2.93 



























































19F NMR (470 MHz, Chloroform-d) δ -145.15. 




Compound 3-23: To a 4 mL reaction vial added 3-22 (7.1 mg, 0.016 mmol) and barbituric acid 
(5.0 mg, 0.039 mmol). Dissolved in acetic acid (0.3 mL), sealed vial with Teflon cap, and heated 
at 120 °C. After stirring at 120 °C for 12 h, solvent was evaporated. Residue was dissolved in 
CH3OH and purified by C18 Combiflash (4.2 mg, 51%). 
LCMS (ESI-TOF) m/z: [M+H]+ Calcd for C21H21FN5O7 474.1420; Found 474.1203. 
 
Compound 3-24: To a 5 mL round-bottom flask added N-(2-hydroxyethyl)phthalimide (125.6 
mg, 0.657 mmol) and dissolved in DMF (2.5 mL). Sodium hydride (28.0 mg, 0.70 mmol) was 
added to stirring solution at room temperature. Reaction mixture was stirred for an additional 30 
min before the addition of 3-16 (244.1 mg, 0.684 mmol). Stirred at 80°C for 2 hr. Reaction mixture 
was cooled to room temperature and purified by silica gel chromatography to give 3-24 as a orange 
solid (175.9 mg, 52%). 
1H NMR (500 MHz, Chloroform-d) δ 7.83 (dd, J = 5.4, 3.1 Hz, 2H), 7.71 (dd, J = 5.5, 3.0 Hz, 
2H), 7.53 (d, J = 0.8 Hz, 1H), 6.16 (s, 1H), 4.66 (t, J = 5.4 Hz, 2H), 4.19 (t, J = 5.4 Hz, 2H), 4.15 
– 4.10 (m, 2H), 4.02 – 3.97 (m, 2H), 3.77 (dq, J = 13.4, 6.7 Hz, 2H), 2.97 – 2.92 (m, 4H), 1.16 (d, 
J = 6.3 Hz, 6H). 



























































Compound 3-25: To a 4 mL reaction vial added 3-24 (49.0 mg, 0.096 mmol) and barbituric acid 
(13.4 mg, 0.105 mmol) and dissolved in acetic acid (1 mL). Vial was sealed and stirred at 120°C 
for 12 hr. Reaction mixture was cooled to room temperature, and solvent was evaporated. Residue 
was purified by silica gel chromatography (3% CH3OH:CHCl3) to provide 3-25 as a orange solid 
(48.5 mg, 87%). 
1H NMR (500 MHz, DMSO-d6) δ 11.83 (s, 1H), 11.43 (s, 1H), 7.91 – 7.81 (m, 4H), 6.96 (s, 1H), 
4.65 – 4.52 (m, 2H), 4.13 – 3.97 (m, 3H), 3.91 (d, J = 8.8 Hz, 1H), 3.80 – 3.71 (m, 1H), 3.71 – 
3.53 (m, 2H), 3.07 (t, J = 12.2 Hz, 1H), 2.86 (d, J = 14.2 Hz, 1H), 1.12 (d, J = 6.2 Hz, 3H), 0.87 
(d, J = 6.4 Hz, 3H). 
13C NMR (126 MHz, DMSO) δ 170.88, 167.73, 167.63, 149.46, 135.19, 134.49, 131.56, 123.16, 
122.83, 113.72, 105.14, 72.01, 71.67, 67.64, 64.36, 53.08, 36.92, 18.19, 18.11. 




Compound 3-7: To a suspension of 3-25 (20.0 mg, 0.035 mmol) in ethanol (0.5 mL) was added 
hydrazine monohydrate (30 µL, 25 mg, 0.35 mmol). Suspension immediately dissolved. Mixture 
was heated at 50 °C for 2 h. Volatiles were removed in vacuo and residue was purified by silica 
gel chromatography (90:9:1 CHCl3:CH3OH:NH3OH) to give 3-7 as a white solid (15.1 mg, 90%). 
1H NMR (499 MHz, CD3OD) δ 8.20 (dd, J = 6.0, 3.3 Hz, 1H), 7.85 (dd, J = 6.0, 3.3 Hz, 1H), 6.72 
(d, J = 6.9 Hz, 1H), 4.53 (dd, J = 5.7, 4.4 Hz, 1H), 3.96 (p, J = 6.5 Hz, 1H), 3.73 (d, J = 5.1 Hz, 
1H), 3.52 (d, J = 1.2 Hz, 1H), 3.45 (dt, J = 13.9, 4.1 Hz, 1H), 3.38 – 3.33 (m, 2H), 1.17 (d, J = 6.5 
Hz, 3H), 1.12 (d, J = 6.1 Hz, 3H). 
























































LCMS (ESI-TOF) [M+H]+ Calcd for C20H23FN5O6 448.1627; Found 448.1516. 
 
3.6.3. Synthesis of indolmycin derivatives 
 
N-Carbobenzoxy-indole-3-carboxaldehyde (3-27) To a 500 mL flame-dried round-bottom flask 
was added sodium hydride as a 60% dispersion in mineral oil (5.0 g, 125 mmol, 1.2 eq). Mineral 
oil was washed away with hexane. Sodium hydride was suspended in THF (150 mL) and cooled 
to 0 °C. To stirring suspension was added 3-26 (15.1 g, 104 mmol, 1.0 eq) as a solid in three 
portions. Once gas evolution ceased, mixture was heated to 40 °C for 30 min. Mixture was cooled 
to 0 °C and benzyl chloroformate (15.0 mL, 1.195 g/mL, 17.9 g, 105 mmol, 1.0 eq) was added by 
addition funnel slowly. Reaction mixture was stirred at room temperature for 12 hr. Reaction 
mixture was quenched by pouring into water (500 mL). Once gas evolution ceased, mixture was 
extracted with CH2Cl2. Combined organic layers were washed with NH4Cl and brine, dried over 
Na2SO4, and evaporated to give dark red oil. Residue was redissolved in 50 mL diethyl ether at 
room temperature. Mixture of hexane and EtOAc (9:1 v:v) was slowly added until slightly cloudy. 
Mixture was heated with steam batch and cooled slowly to 0 °C. Yellow precipitate was collected 
by filtration and washed with cold hexane to provide 3-27 (21.61 g, 78%). 1H NMR was consistent 
with literature report.87 Note this transformation can also be accomplished in comparable yield 
with phase-transfer catalysis (CbzCl, Bu4NHSO4, NaOH, CH2Cl2). 88 
1H NMR (500 MHz, CDCl3) δ 10.09 (s, 1H), 8.29 (d, J = 7.6 Hz, 1H), 8.25 (s, 1H), 8.19 (d, J = 
8.2 Hz, 1H), 7.53 – 7.35 (m, 7H), 5.51 (s, 2H). 
13C NMR (126 MHz, CDCl3) δ 185.83, 150.26, 136.12, 136.10, 134.37, 129.32, 129.07, 128.93, 
126.53, 126.17, 125.07, 122.42, 122.38, 115.28, 69.97. 
 
 
1-(N-carbobenzoxyindol-3-yl)ethanol (3-28) To a 250 mL round-bottom flask added 3-27 (3.86 
g, 13.8 mmol) and dissolved in THF (72 mL). Reaction vessel was cooled to -78°C and methyl 





























mixture was stirred at -78°C for 2 hr. Reaction mixture was poured into a stirring solution of NH4Cl 
and then extracted with chloroform. Organic layer was dried over MgSO4, filtered, and evaporated. 
Residue was purified by silica gel chromatography (20:80 EtOAC:CHCl3, Rf = 0.52) to give 3-28 
as a white solid (3.56 g, 87%). 1H NMR was consistent with previous report.54 
1H NMR (500 MHz, CDCl3) δ 8.19 (s, 1H), 7.69 (dt, J = 7.8, 1.1 Hz, 1H), 7.57 (s, 1H), 7.52 – 
7.46 (m, 2H), 7.45 – 7.36 (m, 3H), 7.34 (t, J = 7.3 Hz, 1H), 7.27 (td, J = 7.6, 1.1 Hz, 1H), 5.44 (s, 
2H), 5.16 (dt, J = 11.0, 6.2 Hz, 1H), 1.83 (d, J = 4.0 Hz, 1H), 1.64 (d, J = 6.5 Hz, 3H). 
 
 
N-Carbobenzoxy-3-(1-chloroethyl)indole (3-29) To a stirring solution of 3-28 (3.05 g, 10.3 
mmol) in THF (80 mL) at -78 °C was added thionyl chloride (1.88 mL, 25.9 mmol). Reaction 
mixture was stirred for 30 min at -78 °C and then allowed to warm to room temperature. After 
stirring at room temperature for 2 h, solvent was removed by rotary evaporator and residue was 
redissolved in CHCl3. Activated carbon was added to solution and suspension was filtered through 
celite. Filtrate was evaporated to give 3-29 as a red oil (3.21 g, 99%). 3-29 was immediately carried 
forward into the next reaction without further purification.  
 
2-(dimethylamino)oxazol-4(5H)-one (3-30) To a 200 mL round-bottom flask added sodium 
hydride (804 mg, 20.1 mmol). Under an atmosphere of nitrogen, sodium hydride was washed with 
hexane to remove mineral oil and then suspended in toluene (100 mL). Ethyl glycolate (9.6 mL, 
101.4 mmol) was added slowly. Once gas evolution ceased and solution clarified, dimethyl 
cyanamide (8.1 mL, 100.2 mmol) was added in two portions. Reaction mixture was stirred at 87 
°C for 1 hr. Reaction mixture was hot filtered through sintered glass. Filtrate was evaporated to 
give 3-30 as white crystals (7.3 g, 57%). 1H NMR was consistent with previous report. 54 Product 
was conformationally stable enough to observe distinct resonances for both methyl groups. 
1H NMR (500 MHz, CDCl3) δ 4.57 (s, 2H), 3.19 (s, 3H), 3.08 (s, 3H). 





























Methyl indolmycin (3-31 To a 200 mL round-bottom flask was added THF (60 mL) and 
diisopropylamine (2.90 mL, 20.7 mmol, 2.0 eq), and mixture was cooled to 0 °C. To stirring 
solution was added n-butyllithium as a 1.6 M solution in hexane (13.0 mL, 20.8 mmol, 2.0 eq). 
Mixture was cooled to -78 °C and 3-30 (2.68 g, 20.9 mmol, 2.1 eq) was added in one portion as a 
solid to stirring solution. Reaction mixture was allowed to briefly warm to room temperature 
before cooling again to -78 °C. Freshly prepared 3-29 was added as a solution in THF (20 mL) via 
cannula. After stirring at -78 °C for 10 min, reaction mixture was allowed to warm to room 
temperature and stir overnight. Reaction mixture was quenched with the addition of water and 
extracted with EtOAc. Combined organic layers were dried over MgSO4 and evaporated. Residue 
was purified by silica gel chromatography with gradient elution (2% to 5% CH3OH:CHCl3). The 
desired diastereomer, 3-31, elutes first (1.03 g, 37%) followed by undesired diastereomer (964.4 
mg, 35%). 
1H NMR (500 MHz, DMSO-d6) δ 10.96 – 10.87 (m, 1H), 7.58 (dd, J = 7.9, 1.1 Hz, 1H), 7.38 – 
7.34 (m, 1H), 7.19 (dd, J = 2.5, 0.7 Hz, 1H), 7.08 (ddd, J = 8.0, 6.9, 1.2 Hz, 1H), 6.99 (ddd, J = 
8.0, 6.9, 1.1 Hz, 1H), 4.96 (d, J = 2.6 Hz, 1H), 3.63 – 3.56 (m, 1H), 3.02 (s, 3H), 3.01 (s, 3H), 1.22 
(d, J = 7.2 Hz, 3H). 
13C NMR (126 MHz, DMSO-d6) δ 186.17, 174.45, 136.13, 126.24, 122.43, 121.00, 118.50, 
118.36, 115.11, 111.48, 86.98, 79.17, 37.93, 35.26, 31.69, 13.63. 
 
Indolmycin: To a 20 mL reaction vial added 3-31 (77.7 mg, 0.286 mmol). Material was dissolved 
in aqueous methyl amine (2.0 mL, 40% v/v). Mixture was let to stand at 4 °C overnight. Solvent 
was removed to dryness by rotary evaporator with a room temperature water bath. Residue was 
purified by silica gel chromatography (5% CH3OH:CHCl3) to provide indolmycin as a white solid 
(74.6 mg, 100%). Note: prolonged incubation under basic conditions or elevated temperature 
erodes diastereomeric ratio. Two tautomers are observed by NMR as is often the case for 






































1H NMR (600 MHz, DMSO-d6) δ 10.97 – 10.85 (br s, 1H both), 8.71 (br s, 1H minor), 8.63 (q, J 
= 4.8 Hz, 1H major), 7.60 – 7.56 (m, 1H both), 7.37 – 7.34 (m, 1H both), 7.19 (d, J = 2.4 Hz, 1H, 
minor), 7.15 (d, J = 2.2 Hz, 1H major), 7.08 (dddd, J = 8.1, 6.9, 4.1, 1.1 Hz, 1H both), 6.99 (ddd, 
J = 8.0, 6.9, 1.0 Hz, 1H both), 4.94 (d, J = 2.6 Hz, 1H major), 4.91 (d, J = 2.7 Hz, 1H minor), 3.62 
(qd, J = 7.2, 2.8 Hz, 1H minor), 3.57 (qd, J = 7.2, 2.7 Hz, 1H major), 2.80 (d, J = 4.1 Hz, 3H 
major), 2.77 (s, 3H minor), 1.25 (d, J = 7.2 Hz, 3H minor), 1.19 (d, J = 7.1 Hz, 3H major). 
13C NMR (151 MHz, DMSO-d6) δ 186.73, 186.56, 175.79, 175.37, 136.20, 136.10, 126.35, 
126.07, 122.46, 122.38, 121.01, 120.96, 118.53, 118.51, 118.45, 118.32, 115.35, 114.99, 111.45, 
85.86, 85.34, 31.70, 31.64, 28.82, 27.08, 13.67, 13.57.  
 
 
To a 20 mL reaction vial added 3-31 (11.0 mg, 0.041 mmol), ethylenediamine (3.5 mL) and THF 
(5.0 mL). Reaction mixture was stirred at room temperature for 16 h then volatiles were removed 
in vacuo. Residue was purified by reverse phase chromatography (4.3 g C18 Combiflash column, 
water:CH3CN) to provide 3-32 as a mixture of diastereomers (6.1 mg, 53%). 
LCMS (ESI-TOF) m/z: [M+H]+ Calcd for C15H19N4O2 287.1503; Found 287.1568 
 
General Method A: 
 
To a 4 mL reaction vial added carboxylic acid (1.3 eq), pyridine (7.5 eq), and CH2Cl2 (0.1 M). 
Mixture was cooled to 0 °C and thionyl chloride (1.5 eq) was added slowly to stirring solution. 
Reaction mixture was stirred at room temperature for 3 hr and then cooled to 0 °C. To cooled 
stirring solution was added indolmycin (1.0 eq) as a solution in CH2Cl2 (0.1 M). Mixture was 
stirred at room temperature overnight. Reaction was quenched with addition of water and extracted 
with CH2Cl2, dried over Na2SO4, filtered, and evaporated. Residue was purified by silica gel 








































Compound 3-33: Synthesized via General Method A (40.3 mg, 53%) 
1H NMR (500 MHz, CDCl3) δ 8.30 (s, 1H), 7.79 (dd, J = 8.2, 1.4 Hz, 1H), 7.53 (dd, J = 8.2, 3.7 
Hz, 2H), 7.47 – 7.42 (m, 1H), 7.41 – 7.35 (m, 5H), 7.20 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 7.17 – 7.10 
(m, 2H), 6.54 (d, J = 2.4 Hz, 1H), 4.92 (dd, J = 3.0, 1.0 Hz, 1H), 3.80 (qd, J = 7.3, 3.0 Hz, 1H), 
3.42 (d, J = 1.0 Hz, 3H), 3.03 (dd, J = 4.8, 1.0 Hz, 2H), 1.39 (d, J = 7.3 Hz, 3H). 
13C NMR (126 MHz, Chloroform-d) δ 187.00, 176.99, 171.12, 135.96, 134.47, 132.90, 131.52, 
128.77, 128.70, 128.57, 126.96, 126.60, 122.35, 121.80, 119.74, 118.57, 115.10, 111.42, 87.98, 




Compound 3-36: Synthesized via General Method A (20.0 mg, 49%). 
1H NMR (500 MHz, CDCl3) δ 9.60 (s, 1H), 7.56 (d, J = 7.9 Hz, 2H), 7.49 (d, J = 7.9 Hz, 1H), 
7.34 (d, J = 8.2 Hz, 1H), 7.31 (d, J = 7.9 Hz, 2H), 7.15 (t, J = 7.6 Hz, 1H), 7.07 (t, J = 7.5 Hz, 1H), 
5.68 (d, J = 2.5 Hz, 1H), 5.30 (t, J = 6.6 Hz, 1H), 4.91 (d, J = 2.2 Hz, 1H), 4.47 (d, J = 6.4 Hz, 
2H), 3.73 (q, J = 7.1 Hz, 1H), 3.58 (s, 3H), 1.57 (s, 9H), 1.16 (d, J = 7.1 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 186.80, 176.82, 170.78, 156.90, 144.21, 136.02, 134.17, 128.98, 
126.06, 125.64, 121.81, 121.70, 119.24, 118.09, 115.43, 111.53, 88.82, 80.95, 43.85, 35.58, 31.63, 
28.63, 14.47. 
 
Compound 3-37: Synthesized via General Method A (8.0 mg, 20%). 
1H NMR (500 MHz, CDCl3) δ 8.36 (s, 1H), 7.63 (d, J = 7.9 Hz, 1H), 7.36 (d, J = 8.1 Hz, 1H), 
7.22 – 7.16 (m, 1H), 7.15 – 7.09 (m, 2H), 5.05 (d, J = 3.1 Hz, 1H), 4.32 (d, J = 8.2 Hz, 1H), 3.94 





















































1H), 1.82 (d, J = 11.5 Hz, 2H), 1.60 (s, 1H), 1.52 (d, J = 7.3 Hz, 3H), 1.45 (s, 11H), 1.30 – 0.82 
(m, 5H). 
13C NMR (126 MHz, CDCl3) δ 187.79, 177.53, 176.38, 155.33, 136.16, 126.72, 122.63, 121.95, 
119.82, 118.71, 114.98, 111.55, 86.50, 79.38, 49.13, 43.43, 32.40, 32.35, 32.09, 28.59, 14.11. 
 
Compound 3-35: Synthesized via General Method A (19.7 mg, 46%) 
1H NMR (500 MHz, CDCl3) δ 8.37 (s, 1H), 7.97 (d, J = 9.0 Hz, 2H), 7.60 (d, J = 7.9 Hz, 1H), 
7.46 (dt, J = 8.1, 0.9 Hz, 1H), 7.23 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 7.15 (ddd, J = 8.0, 7.0, 1.0 Hz, 
1H), 6.94 (d, J = 8.3 Hz, 2H), 6.87 (d, J = 2.5 Hz, 1H), 4.96 (d, J = 3.4 Hz, 1H), 3.87 (qd, J = 7.4, 
3.4 Hz, 1H), 3.42 (s, 3H), 1.53 (d, J = 7.4 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 186.28, 176.51, 169.63, 149.52, 140.19, 136.05, 132.92, 129.01, 
126.87, 123.42, 122.78, 122.28, 119.92, 118.74, 114.10, 111.59, 87.46, 33.67, 32.17, 14.33. 
 
 
Compound 3-34: Synthesized via General Method A (26.4 mg, 61%) 
1H NMR (500 MHz, CDCl3) δ 8.25 (s, 1H), 7.53 – 7.47 (m, 1H), 7.40 – 7.34 (m, 1H), 7.28 (d, J 
= 8.1 Hz, 2H), 7.18 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 7.14 (d, J = 7.9 Hz, 2H), 7.09 (ddd, J = 8.0, 
7.0, 1.0 Hz, 1H), 4.90 (d, J = 3.0 Hz, 1H), 3.78 (qd, J = 7.3, 3.0 Hz, 1H), 3.37 (s, 3H), 2.38 (s, 3H), 
1.38 (d, J = 7.3 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 187.10, 176.97, 171.03, 144.05, 135.93, 131.38, 130.30, 129.30, 




N-Carbobenzoxy-5-cyano-indole-3-carboxaldehyde (3-40): To a 100 mL round-bottom flask 


































THF (40 mL). Suspension was cooled to 0 °C and 5-cyano-indole-3-carboxaldehyde (2.0 g, 11.8 
mmol, 1.0 eq) was added. Once gas evolution ceased, benzyl chloroformate (1.8 mL) was added 
slowly and reaction mixture was stirred at room temperature for 12 hr. Reaction mixture was 
poured into water then diluted with CH2Cl2 and NH4Cl. Aqueous layer was extracted with CH2Cl2. 
Combined organic layers were dried over Na2SO4 and evaporated. Residue was purified by silica 
gel chromatography (3:1 to 3:2 hexance:EtOAc). (653.6 mg, 18%) 
1H NMR (500 MHz, CDCl3) δ 10.10 (s, 1H), 8.66 (dd, J = 1.7, 0.7 Hz, 1H), 8.37 (s, 1H), 8.30 (d, 
J = 8.7 Hz, 1H), 7.67 (dd, J = 8.7, 1.7 Hz, 1H), 7.52 – 7.48 (m, 2H), 7.48 – 7.42 (m, 3H), 5.53 (s, 
2H). 
13C NMR (126 MHz, CDCl3) δ 185.15, 149.68, 137.83, 137.25, 133.82, 129.74, 129.64, 129.20, 
129.16, 127.37, 126.36, 121.69, 119.05, 116.34, 108.95, 70.71. 
 
1-(N-carbobenzoxy-5-cyanoindol-3-yl)ethanol (3-41):To a 50 mL round-bottom flask added 3-
40 (303.6 mg, 1.0 mmol) and suspended in THF. Mixture was heated to 50 °C to fully dissolve 
material and cooled to -78 °C. To stirring solution at -78 °C methyl magnesium bromide was added 
as a 3 M solution in diethyl ether (0.35 mL, 1.05 mmol). Reaction mixture was stirred for 2 h at -
78 °C then poured into an aqueous solution of NH4Cl. Mixture was extracted with CHCl3, dried 
over Na2SO4, and evaporated. Residue was purified by silica gel chromatography (3% 
CH3OH:CHCl3). Dry loading method was necessary due to poor solubility. (201.7 mg, 63%). 
1H NMR (500 MHz, DMSO-d6) δ 8.26 (d, J = 1.7 Hz, 1H), 8.22 (d, J = 8.6 Hz, 1H), 7.74 (dd, J = 
8.6, 1.7 Hz, 1H), 7.69 (d, J = 1.1 Hz, 1H), 7.57 – 7.51 (m, 2H), 7.47 – 7.36 (m, 3H), 5.49 (s, 2H), 
5.33 (d, J = 5.0 Hz, 1H), 5.01 (p, J = 6.4, 6.2, 5.6 Hz, 1H), 1.46 (d, J = 6.4 Hz, 3H). 
13C NMR (126 MHz, DMSO-d6) δ 149.88, 137.19, 135.08, 128.73, 128.66, 128.62, 128.44, 
127.67, 127.29, 125.52, 123.24, 119.49, 115.72, 105.17, 68.83, 61.58, 24.07. 
 
5’-Cyano-2-methylindolmycin (3-42): To a 50 mL round-bottom flask added 3-41 (133.6 mg, 
0.417 mmol) and dissolved in THF (6.0 mL). Mixture was cooled to -78 °C before adding SOCl2 






























for 2 hr. Solvent was removed by rotary evaporator. Residue was redissolved in CHCl3, incubated 
with activated charcoal, filtered through celite, and evaporated. Crude alkyl chloride was dried 
under vacuum for 3 hr. To a 50 mL round-bottom flask was added 3-30 (106.3 mg, 0.83 mmol) 
and dissolved in THF (5 mL). Lithium diisopropylamide was added as a 2 M solution in heptane 
(0.46 mL, 0.92 mmol). Mixture was stirred at room temperature for 1 hr then cooled to -78 °C. 
Intermediate indole chloride was added slowly as a solution in THF (5 mL). After stirring at -78 
°C for 10 min, reaction mixture was allowed to warm to room temperature and stir overnight. 
Reaction mixture was quenched with the addition of water and extracted with EtOAc. Combined 
organic layers were dried over MgSO4 and evaporated. Residue was purified by silica gel 
chromatography with gradient elution (2% to 5% CH3OH:CHCl3) to provide 3-42 as a mixture of 
diastereomers (78.0 mg, 63%). 
1H NMR (500 MHz, CDCl3) δ 9.66 (s, 1H), 9.59 (s, 2H), 8.07 – 8.04 (m, 1H), 8.01 – 7.98 (m, 
1H), 7.45 (dd, J = 8.6, 0.7 Hz, 1H), 7.42 (dd, J = 8.4, 0.7 Hz, 1H), 7.37 (dd, J = 8.5, 1.5 Hz, 2H), 
7.33 (dd, J = 8.4, 1.5 Hz, 1H), 7.09 (d, J = 2.4 Hz, 2H), 7.02 (d, J = 2.4 Hz, 1H), 4.97 (d, J = 2.9 
Hz, 1H), 4.95 (d, J = 3.5 Hz, 2H), 3.81 (qd, J = 7.8, 3.6 Hz, 1H), 3.70 (qd, J = 7.4, 2.9 Hz, 1H), 
3.14 (s, 3H), 3.03 (s, 4H), 2.95 (s, 3H), 2.93 (s, 5H), 1.66 (d, J = 7.4 Hz, 3H), 1.57 (d, J = 7.4 Hz, 
5H). 
13C NMR (126 MHz, CDCl3) δ 187.33, 187.09, 174.65, 174.41, 138.57, 137.97, 127.11, 126.43, 
126.27, 125.64, 124.86, 124.71, 124.59, 124.33, 121.14, 121.03, 115.46, 113.53, 112.96, 112.79, 
101.98, 101.77, 88.75, 87.74, 38.64, 38.56, 36.06, 35.92, 34.32, 32.44, 17.42, 14.95. 
 
Cyano-indolmycin: To a 4 mL reaction vial added 3-42 (10.1 mg, 0.0341 mmol). Material was 
dissolved in aqueous methyl amine (0.3 mL, 40% v/v). Mixture was let to stand at 4 °C overnight. 
Solvent was removed to dryness by rotary evaporator with a room temperature water bath. Residue 
was purified by silica gel chromatography (5% CH3OH:CHCl3) to provide 3-43 as a white solid 
(7.5 mg, 78%). 
 
3.6.4. Synthesis of FtsZ inhibitors 
 




















2-Amino-3-naphthoic acid or 2-amino-3-benzoic acid (1 eq) was dissolved in acetic anhydride (0.2 
M final) and heated to reflux. After stirring a reflux for 4 h, reaction mixture was cooled to room 
temperature and solvent was removed by rotary evaporator. Concentrated NH4OH (0.2 M final) 
was added to residue and the solution was heated at 100 °C for 12 h. Once cooled to room 
temperature, the resulting precipitate was collected by filtration and washed with H2O and 
methanol yielding a solid. 
 
General Method C: 
 
Lactam (1 eq) was dissolved in acetic acid (0.1 M). 4-chlorobenzaldehyde (1.1 eq) was added and 
mixture was heated to reflux. After stirring at reflux for 16 h, reaction mixture was cooled to room 
temperature and precipitate was collected by filtration and dried under vacuum. Residue was 
suspended in toluene (0.04 M). N,N-dimethylaniline (2 eq) was added followed by POCl3 (2 eq) 
and mixture was heated to reflux. After stirring at reflux for 8 h, reaction mixture was cooled to 
room temperature and decanted into separate round-bottom flask. Solvent was removed by rotary 
evaporator to give a purple residue which was recrystallized from dichloromethane or purified by 
silica gel chromatography. 
 
General Method D: 
 
 
Chloroquinazoline (1 eq) and DMAP (0.2 eq) were dissolved in toluene (0.1 M). Triethylamine 
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for 16 h. Reaction mixture was cooled to room temperature, and solvent was removed by rotary 




2-methylbenzo[g]quinazolin-4(3H)-one (3-48) – Synthesized via general method B (1.72 g, 
72%). 1H and 13C NMR were consistent with previous reports.61 




(E)-4-chloro-2-(4-chlorostyryl)benzo[g]quinazoline (3-49) – Synthesized via general method C 
(321.6 mg, 48%). 1H NMR consistent with previous reports.61 
1H NMR (500 MHz, CDCl3) δ 8.85 (s, 1H), 8.55 (s, 1H), 8.16 – 8.07 (m, 3H), 7.67 (dd, J = 8.3, 
6.6 Hz, 1H), 7.64 – 7.59 (m, 3H), 7.42 – 7.38 (m, 2H), 7.33 (d, J = 15.8 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ 163.71, 158.68, 138.78, 137.31, 135.33, 134.60, 132.54, 129.50, 
129.28, 129.15, 129.13, 128.45, 127.42, 127.11, 126.56, 120.50. 




Zantrin Z3 – Synthesized via general method D (83.3 mg, 95%). 1H NMR was consistent with 
previous reports.61 
1H NMR (500 MHz, DMSO-d6) δ 8.88 (s, 1H), 8.68 (s, 1H), 8.26 (s, 1H), 8.04 (dd, J = 23.7, 8.4 
Hz, 2H), 7.95 (d, J = 15.9 Hz, 1H), 7.72 (d, J = 8.2 Hz, 2H), 7.60 (ddd, J = 8.3, 6.7, 1.2 Hz, 1H), 
7.54 (ddd, J = 8.1, 6.6, 1.2 Hz, 1H), 7.51 – 7.44 (m, 2H), 7.21 (d, J = 15.9 Hz, 1H), 3.83 (s, 2H), 
















13C NMR (126 MHz, DMSO) δ 159.44, 159.42, 145.58, 135.39, 135.06, 134.83, 133.11, 130.48, 
129.01, 128.92, 128.68, 127.66, 125.75, 124.30, 122.75, 114.25, 50.50, 47.01. 
HRMS (ESI) m/z: [M+H]+ Calcd for C26H28N4Cl 431.2002; Found 431.1984. 
 
 
3-50 – Synthesized via general method D (29.6 mg, 90%). 
HRMS (ESI) m/z: [M+H]+ Calcd for C27H28N4O2Cl 475.1901; Found 475.1899. 
 
 
(E)-N1-(2-(4-chlorostyryl)benzo[g]quinazolin-4-yl)ethane-1,2-diamine (3-45): 3-50 (28.2 mg, 
0.06 mmol) was dissolved in 4 M HCl in dioxane (1 mL) and heated to 40 °C. After stirring for 1 
h, reaction was basified with 10% NaOH and extracted with EtOAc. Organic layer was washed 
with brine, dried over Na2SO4, and evaporated. Residue was purified by silica gel chromatography 
(95:4.5:0.5 CH2Cl2:CH3OH:NH4OH) to give 3-45 as an orange solid (23.6 mg, 96%) 1H NMR was 
consistent with previous reports.78 
1H NMR (500 MHz, Methanol-d4) δ 8.66 (s, 1H), 8.17 (s, 1H), 8.00 (m, 3H) 7.64 (dd, J = 8.5, 1.5 
Hz, 2H), 7.57 (ddd, J = 8.2, 6.6, 1.3 Hz, 1H), 7.49 (ddd, J = 8.1, 6.7, 1.2 Hz, 1H), 7.40 (d, J = 8.5 
Hz, 2H), 7.11 (d, J = 15.7 Hz, 1H), 3.92 (t, J = 6.3 Hz, 2H), 3.12 (t, J = 6.3 Hz, 2H). 
13C NMR (126 MHz, MeOD) δ 161.67, 161.53, 146.05, 137.87, 137.39, 136.48, 135.61, 132.64, 
130.01, 129.96, 129.64, 129.03, 128.72, 126.96, 124.50, 123.70, 115.30, 44.39, 41.76. 
HRMS (ESI) m/z: [M+H]+ Calcd for C22H20N4Cl 375.1376; Found 375.1368. 
 
 
2,6-dimethylquinazolin-4(3H)-one (3-52) – Synthesized via general method B (880.4 mg, 38%). 




























1H NMR (500 MHz, DMSO-d6) δ 12.08 (s, 1H), 7.86 (s, 1H), 7.58 (dd, J = 8.3, 2.1 Hz, 1H), 7.47 
(d, J = 8.3 Hz, 1H), 2.41 (s, 3H), 2.32 (s, 3H). 
HRMS (ESI) m/z: [M+H]+ Calcd for C10H11N2O 175.0871; Found 175.0872. 
 
(E)-4-chloro-2-(4-chlorostyryl)-6-methylquinazoline (3-53) – Synthesized via general method 
C (1.745 g, 71%). 1H NMR was consistent with previous reports.78 
1H NMR (500 MHz, CDCl3) δ 7.95 (d, J = 16.0 Hz, 1H), 7.89 (dt, J = 1.8, 0.9 Hz, 1H), 7.80 (d, J 
= 8.5 Hz, 1H), 7.66 (dd, J = 8.6, 2.0 Hz, 1H), 7.50 – 7.46 (m, 2H), 7.30 – 7.26 (m, 2H), 7.17 (d, J 
= 15.9 Hz, 1H), 2.50 (d, J = 1.0 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 161.52, 159.47, 150.35, 138.94, 137.81, 137.32, 135.10, 134.61, 
129.21, 128.98, 128.28, 127.35, 124.87, 122.28, 22.00. 





54) – Synthesized via general method D (20.3 mg, 96%). 1H NMR was consistent with previous 
reports.78 
1H NMR (500 MHz, CDCl3) δ 7.90 (d, J = 15.8 Hz, 1H), 7.68 (d, J = 8.1 Hz, 1H), 7.55 – 7.45 (m, 
4H), 7.34 – 7.28 (m, 2H), 7.16 (d, J = 15.8 Hz, 1H), 6.53 (t, J = 4.6 Hz, 1H), 3.77 (q, J = 5.5 Hz, 
2H), 2.66 (t, J = 5.9 Hz, 2H), 2.45 (s, 3H), 2.33 (s, 5H). 
13C NMR (126 MHz, CDCl3) δ 159.81, 158.74, 148.35, 135.49, 135.32, 135.06, 134.43, 134.06, 
129.98, 128.90, 128.61, 127.96, 120.36, 113.88, 57.70, 45.33, 38.25, 21.70. 





















tert-butyl (E)-(2-((2-(4-chlorostyryl)-6-methylquinazolin-4-yl)amino)ethyl)carbamate (3-55) 
– Synthesized via general method D (231.4 mg, 42%). 1H NMR was consistent with previous 
reports.78 
1H NMR (500 MHz, CDCl3) δ 7.90 (d, J = 15.9 Hz, 1H), 7.70 (d, J = 8.4 Hz, 1H), 7.59 – 7.50 (m, 
4H), 7.33 (d, J = 8.4 Hz, 2H), 7.16 (d, J = 15.8 Hz, 1H), 6.99 (s, 1H), 5.32 (d, J = 6.4 Hz, 1H), 
3.80 (dd, J = 7.0, 3.9 Hz, 2H), 3.57 (q, J = 5.8 Hz, 2H), 2.47 (s, 3H), 1.43 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 159.80, 159.31, 158.17, 135.74, 135.37, 135.28, 134.57, 134.22, 
129.84, 128.99, 128.74, 127.91, 120.77, 113.93, 80.30, 43.97, 40.27, 28.48, 21.75. 




yl)amino)ethyl)(methyl)carbamate (3-56) – Synthesized via general method D (124.5 mg, 86%). 
 
1H NMR (500 MHz, Methanol-d4) δ 7.89 (dd, J = 42.0, 15.8 Hz, 1H), 7.72 (d, J = 49.5 Hz, 1H), 
7.53 (t, J = 7.1 Hz, 4H), 7.33 (d, J = 8.3 Hz, 2H), 7.06 – 6.97 (m, 1H), 3.78 (t, J = 6.1 Hz, 2H), 
3.63 (t, J = 5.6 Hz, 1.11H major), 3.56 (t, J = 6.4 Hz, 0.87H minor), 2.93 (s, 3H), 2.43 (d, J = 4.1 
Hz, 3H), 1.36 (s, 4H minor), 1.07 (s, 5H major). 
HRMS (ESI) m/z: [M+H]+ Calcd for C25H30N4O2Cl 453.2057; Found 453.2057. 
 
 
(E)-N1-(2-(4-chlorostyryl)-6-methylquinazolin-4-yl)ethane-1,2-diamine (3-46) – 3-55 was 
dissolved in 4 M HCl in dioxane and heated to 40 °C. After stirring for 1 h, reaction was basified 
with 10% NaOH and extracted with EtOAc. Organic layer was washed with brine, dried over 
Na2SO4, and evaporated. Residue was purified by silica gel chromatography (90:9:1 
CH2Cl2:CH3OH:NH4OH) to give 3-46 as a white solid (52.5 mg, 97%). 1H NMR was consistent 


























1H NMR (500 MHz, CD3OD) δ 7.84 (d, J = 15.8 Hz, 1H), 7.76 (s, 1H), 7.52 (dd, J = 8.6, 6.3 Hz, 
4H), 7.30 (d, J = 8.1 Hz, 2H), 6.99 (d, J = 15.8 Hz, 1H), 3.78 (t, J = 6.4 Hz, 2H), 3.01 (t, J = 6.4 
Hz, 2H), 2.44 (s, 3H). 
13C NMR (126 MHz, CD3OD) δ 160.95, 160.82, 148.61, 137.07, 136.97, 136.41, 135.52, 135.33, 
129.87, 129.76, 129.43, 127.30, 122.55, 115.21, 44.30, 41.81, 21.66. 
HRMS (ESI) m/z: [M+H]+ Calcd for C19H20N4Cl 339.1376; Found 339.1375. 
 
 
(E)-N1-(2-(4-chlorostyryl)-6-methylquinazolin-4-yl)-N2-methylethane-1,2-diamine (3-57) – 
3-56 was dissolved in 4 M HCl in dioxane and heated at 40 °C. After stirring for 1 h, the reaction 
mixture was basified with 10% NaOH and extracted with EtOAc. Organic layer was ashed with 
brine, dried over Na2SO4, and evaportated. Residue was purified by silica gel chromatography 
(90:9:1 CH2Cl2:CH3OH:NH4OH)  to give 3-57 as a white solid (76.4 mg, 99%) 
1H NMR (500 MHz, CD3OD) δ 7.91 (d, J = 15.7 Hz, 1H), 7.80 (s, 1H), 7.62 – 7.51 (m, 4H), 7.35 
(d, J = 8.5 Hz, 2H), 7.04 (d, J = 16.0 Hz, 1H), 3.87 (t, J = 6.4 Hz, 2H), 2.97 (t, J = 6.3 Hz, 2H), 
2.49 (s, 3H), 2.47 (s, 3H). 
13C NMR (126 MHz, CD3OD) δ 161.00, 160.81, 148.67, 137.19, 137.09, 136.46, 135.63, 135.43, 
129.95, 129.81, 129.45, 127.35, 122.60, 115.25, 51.39, 40.92, 35.88, 21.64. 
HRMS (ESI) m/z: [M+H]+ Calcd for C20H22N4Cl 353.1533; Found 353.1524. 
 
 
(E)-N-(2-((2-(4-chlorostyryl)-6-methylquinazolin-4-yl)amino)ethyl)acetamide (3-58) – To a 
stirring solution of 3-46 (27.4 mg, 0.081 mmol) in CH2Cl2 (1.0 mL) was added triethylamine (15 
µL, 0.11 mmol) followed by acetic anhydride (10 µL, 0.11 mmol). After stirring at room 
temperature for 1 h, reaction mixture was quenched with the addition of satd aq NH4Cl and 
extracted with EtOAc. Organic layer was washed with brine, dried over Na2SO4, and evaporated. 
Residue was purified by silica gel chromatography (2-5% CH3OH:CH2Cl2) to give 3-58 as a white 

































1H NMR (500 MHz, CDCl3+MeOD) δ 7.92 (dq, J = 14.8, 4.5 Hz, 1H), 7.75 – 7.68 (m, 1H), 7.64 
(dd, J = 8.4, 2.2 Hz, 1H), 7.57 (s, 3H), 7.41 – 7.33 (m, 2H), 7.11 (dd, J = 15.8, 2.3 Hz, 1H), 3.91 
– 3.82 (m, 2H), 3.62 – 3.55 (m, 2H), 2.52 (s, 3H), 1.96 (s, 2H). 
13C NMR (126 MHz, CDCl3+MeOD) δ 172.56, 159.51, 159.30, 147.30, 136.03, 135.78, 134.73, 
134.38, 128.84, 128.53, 128.32, 126.54, 121.03, 113.74, 41.25, 40.10, 22.49, 21.34. 
HRMS (ESI) m/z: [M+H]+ Calcd for C21H22N4OCl 381.1482; Found 381.1477. 
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CHAPTER 4 PROBES FOR POLY(ADP-RIBOSE) REGULATORS 
Portions of this Chapter are reprinted with permission from Drown, B.S.; Shirai, T.; Rack, J.G.M.; 
Ahel, I.; Hergenrother, P.J. Monitoring Poly(ADP-ribosyl)glycohydrolase Activity with a 
Continuous Fluorescent Substrate. Cell Chem. Biol. 2018, doi:10.1016/j.chembiol.2018.09.008 © 
2018 Elsevier and Rack, J.G.M.; Ariza, A.; Drown, B.S.; Henfrey, C.; Bartlett, E.; Shirai, T.; 
Hergenrother, P.J.; Ahel, I. Structural basis for the differential substrate recognition and inhibition 
of ADP-ribosyl hydrolases. Cell Chem. Biol. 2018, doi:10.1016/j.chembiol.2018.11.001 © 2018 
Elsevier. Contributions of others are noted where applicable. 
4.1. Introduction 
Many biological processes are regulated by post-translational modifications (PTMs), with 
ADP-ribosylation being one of the most thoroughly studied nucleotide-containing modifications. 
This modification includes a collection of “writers”, “readers”, and “erasers”. The writers, 
poly(ADP-ribosyl) polymerases (PARPs), modify protein substrates with adenine diphosphate 
ribose (ADP-ribose or ADPr, Figure 4.1). Nearly all nucleophilic amino acids have been shown to 
be modified: glutamate, aspartate, cysteine, lysine, and serine.1-5 While the majority of PARPs can 
only transfer a single ADPr unit from b-NAD+,6 the founding member of the family, PARP1 (also 
PARP2 and tankyrases), can synthesize large polymers termed poly(ADP-ribose) (PAR).4 A 
wealth of literature over several decades has established PARylation as central for proper DNA 
damage response,7-9 chromatin maintenance,10 cell division,11 and DNA replication.12 The most 
well-studied role of PAR is in the context of DNA damage repair. 
 
Figure 4.1 Overview of PAR signaling. ADP-ribosyltransferases such as PARP1 utilize b-NAD+ to modify 
themselves and neighboring proteins with polymers of varied length and branching. These modifications are 
removed by the activity of PARG, ARH3, and other hydrolases to produce oligomers and eventually 
monomeric ADP-ribose. 
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4.1.1. Canonical PAR signaling 
Mammalian cells are under constant onslaught from DNA-damaging agents. As a check 
against accumulating mutational load and tumorigenesis, cells have evolved numerous 
mechanisms to repair DNA lesions. One of the first responders to the site of single-strand DNA 
breaks is poly(ADP-ribose) polyermase-1 (PARP1 or ARTD1). Upon directly binding to the site 
of damage, PARP1 undergoes a conformational change activating its catalytic domain (Figure 
4.2).13 PARP1 synthesizes poly(ADP-ribose) from b-NAD+ and covalently appends this polymer 
to nucleophilic amino acid residues within its own automodification domain and histones adjacent 
to the site of damage. Nearly all nucleophilic residues have been shown to be modified: glutamate, 
aspartate, cysteine, lysine, and serine.1-5 This modification serves two purposes by recruiting DNA 
repair elements through mediation by PAR-binding proteins such as XRCC1 and inducing a major 
conformational reorganization in chromatin that allows DNA repair proteins to directly access the 
damaged bases. Once PARP1 becomes heavily auto-modified, the electrostatic repulsion of the 
covalently attached PAR and DNA leads PARP1 to dissociate from DNA. In order for PARP1 to 
deal with subsequent DNA damage, the PAR must be removed from PARP1. 
In the event of extensive DNA damage, hyperactivated PARP1 can initiate a controlled 
cell death pathway named parthanatos. Large quantities of PAR polymers accumulate and then 
escape the nucleus. These PAR polymers interact with apoptosis-inducing factor (AIF) on the outer 
membrane of the mitochrondria, which then migrates to the nucleus. There, AIF can activate 
macrophage migration inhibitory factor (MIF), which acts as a nuclease leading to large-scale 
DNA fragmentation and cell death.7 This pathway is responsible for cell death observed in 
ischemia-reperfusion injury after stroke and myocardial infarction, inflammatory injury, ROS–




Figure 4.2 PARP1-mediated DNA repair and induction of parthanatos. 
4.1.2. PAR-hydrolyzing enzymes 
In contrast, much is still unknown about the regulation of ADPr erasure. Several families 
of enzymes are responsible for removal and degradation of PARylation. Poly(ADP-ribose) 
glycohydrolase (PARG) hydrolyzes the 2',1'' glycosidic linkage (Figure 4.3, highlighted in red) of 
polymers mainly in an exo manner.15 PARG modifies PARylated proteins by removing polymers 
down to the last unit, which it is incapable of removing.16 ADP-ribosyl hydrolase 3 (ARH3 or 
ADPRHL2) is also capable of degrading PAR polymers, albeit at a reduced rate.17-20 Until recently, 
neither of these proteins were believed capable of removing the last ADPr unit directly bonded to 
the protein side chain. This hydrolysis is carried out by ARH1 or an enzymatic member of the 
macrodomain family (terminal ADP-ribosyl protein glycohydrolase (TARG1), MacroD1, and 
MacroD2 in mammals).1,6,21-25 Recently ARH3 was shown to be the sole enzyme capable of 
hydrolyzing mono-ADP-ribosyl serine.26,27 Beyond substrate recognition, little is known about 
how these ADPr erasers are regulated or the relative importance of different erasers in various 
biological contexts. In particular, study of PAR cleavage has been limited by the challenge of 
separating contributions to PAR degradation by PARG and by ARH3. Several reports suggest that 
the specific activity of PARG is significantly greater than ARH3; however, the cellular 
distributions of these two enzymes differ as do their regulatory domains.17 Genetic knockout of 
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ARH3 does not affect the lifetime of long polymers but does result in longer lived short polymers,26 
thus much more detailed information on the relative contribution of PAR-degrading enzymes is 
needed. 
4.1.3. PARG assays 
The most widely employed enzyme assays for measuring PARG/ARH3 activity rely on 
radioisotopically labelled and enzymatically produced PAR.22,28-31 The production and isolation of 
labelled PAR is limited to 0.3-2 mg scale.28 After treatment with PARG, reaction mixtures are 
separated by TLC or HPLC and quantified by autoradiography or liquid scintillation counting. 
This technique, while sensitive, is laborious and not scalable. Recent efforts to develop more 
scalable PARG activity assays have been modestly successful, for example, a four-component 
FRET system to detect the interaction between a PARylated protein and XRCC1.32,33 While this 
approach has been implemented in microtiter format to discover a first-in-class PARG inhibitor, it 
suffers from the inability to accurately measure enzyme kinetics and cannot operate in cell lysate.34 
There clearly is still an unmet need for a facile and continuous activity assay for PAR-degrading 
enzymatic activity. 
Selective enzyme assays are powerful for assessment of the differential contribution of 
enzyme family members to the total enzymatic activity.  The potential impact such experiments 
can have is apparent in the widespread use of a variety of compounds as caspase substrates.  For 
caspases, specificity can be imbued through use of peptide sequences known to be specifically 
recognized by different caspases isozymes, and such tool compounds have been widely employed 
to understand conditions under which specific caspases are activated, and have been critical to 
mapping the apoptotic cell death pathway.35,36  The lack of analogous reagents for monitoring of 
PAR processing has necessitated reliance on non-ideal methods such as isozyme-general 
processing of radiolabeled substrates.  In the case of PAR-processing enzymes, the development 
of specific substrates is considerably more complicated than for a protease (where specificity can 
be built in though understanding of the endogenous protein substrates).  The recently solved X-ray 
structures of ARH3 and PARG, and subsequent docking studies, has now allowed for the design 
of reporter substrates, one that is general for ARH3 and PARG, and one that is specific for ARH3. 
4.2. Design and synthesis of PARG substrates 
PARG and ARH3 selectively cleave the alpha glycosidic bond of PAR (Figure 4.3A, 
highlighted in red). Similar to synthetic activity probes for other glycohydrolases, a substrate 
reporter can be constructed by replacing the aglycone with a phenolic chromaphore or a 
 158 
fluorophore. While several moieties could be considered, p-nitrophenol (pNP) and 4-
(trifluoromethyl)-umbelliferone (TFMU) were chosen for the ready availability and spectral 
properties. Retrosynthetic analysis of these compounds identified a late-stage pyrophosphate 
formation and a 1,2-cis selective glycosylation as the primary synthetic challenges. Given recent 
success with applying these transformations towards the synthesis of dimeric PAR, we felt 
confident that these hurdles could be cleared in short order.37 
 
Figure 4.3 Design and retrosynthesis of substrate reporters for PARG and ARH3. A. PAR is cleaved by 
PARG and ARH3 via hydrolysis of the glycosyl bond (red). B. Synthetic PARG/ARH3 substrates mimic 
ADP-ribose and release a chromophore or fluorophore upon hydrolysis. Synthesis of these compounds 
requires a late-stage pyrophosphate formation and 1,2-cis selective glycosylation. 
While 1,2-cis selective glycosylations with ribose can typically be accomplished with non-
participating neighboring protecting groups (Figure 4.4), the stereoselectivity of these reactions is 
highly dependent upon donor,38 nucleophile,39,40 solvent,41 and promoter.42 Further complicating 
matters, glycosyl triflates can be sufficiently stable to act as reactive intermediates.43,44 As a result, 
there is no reliable reaction manifold to predictably obtain the desired stereochemical outcome 
without significant optimization. In most cases, the glycosylation of secondary alcohols (e.g. for 
the assembly of oligosaccharides) can be achieved with high stereochemical selectivity. In the case 
of poorly soluble and weakly nucleophilic phenols, many of the preferred conditions are not 
available.45 Instead, O-aryl glycosylations have been accomplished with Mitsunobu 
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Figure 4.4 Two-conformer model for furanose glycosylation proposed by Woerpel. Furanosyl oxocarbenium 
ions largely populate the 3E and E3 conformers. From these intermediate conformers, “inside” nucleophilic 
attack is favored so as to minimize eclipsed interactions. Substitution around the ring greatly impacts the 
relative stabilities of 3E and E3. Alkoxy substituents at C2 and C3 contribute to the electronic stability of 3E 
despite being sterically unfavored. 
We found that acceptable a-selectivity could be achieved under Mitsunobu conditions. 
These glycosylation conditions were most effective with a hemi-acetal with bulky protecting 
groups. As outlined in Figure 4.5, this strategy was employed using orthogonally protected ribose 
4-4, prepared in three steps from D-ribonic g-lactone (4-1)37; subsequent removal of the trityl group 
proceeded smoothly under strictly anhydrous conditions to prevent hydrolysis of the glycoside, 
producing 4-5. Although direct phosphorylation with POCl3 was possible, we found 
phosphoramidite coupling followed by fluorenylmethyl removal more amenable on scale to give 
phosphate 4-8 (Figure 4.5). Pyrophosphate formation was accomplished via in situ oxidative 
chlorination of H-phosphonate 4-11 (Figure 4.6), to produce 4-12, followed by global desilylation 
to provide pNP-ADPr.  
  
Figure 4.5 Synthesis of glycosyl donor and pNP-ribose phosphate. Abbreviations: DMAP = 4-
dimethylaminopyridine, TBDMSCl = t-butyldimethylsilyl chloride, ADDP = 1,1’-
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Figure 4.6 Synthesis of adenosine H-phosphonate and pNP-ADPr. Abbreviations: NCS = N-
chlorosuccinimide, DBU = 1,8-diazabicycloundec-7-ene, TBS = t-butyldimethylsilyl.  
A similar synthetic route was executed to achieve assembly of TFMU-ADPr. This 
synthetic route was smoothly translated to incorporate 4-(trifluoromethyl)-umbelliferone. TFMU 
has poor solubility in most organic solvents, largely limited to ethereal solvents. After a brief 
solvent screen, dimethoxyethene (DME) was found to effectively provide the glycoside 4-13 when 
performing the Mitsunobu reaction with DIAD and Ph3P (Figure 4.7). In a sequence of reactions 
similar to above, the required TFMU-ribose phosphate, 4-16, could be obtained in short order. 
Pyrophosphate formation with the same protected H-phosphonate gave 4-17, which was globally 
deprotected to reach TFMU-ADPr. 
 
Figure 4.7 Synthesis of TFMU-ADPr. 
4.2.1. Design of an ARH3-selective substrate 
At the same time we were working on evaluating the substrates described above, our 
collaborator Ivan Ahel (Oxford University) had solved the first X-ray co-crystal structure of ADP-
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4-17, R = TBS, X = DBUH










































so the Ahel lab utilized L. chalumnae ARH3 after screening orthologs for crystallinity. Upon 
seeing this crystal structure, we were struck by how different nucleobase recognition is compared 
to PARG (Figure 4.8A,B). 37 Different atoms on the base participate in H-bond interactions in 
these two structures (e.g. N1 and N10). Consequently, several nucleobases were docked into this 
binding site using Glide XP. While several sugar nucleotides predicted to have differential binding 
affinities (Table 4.1), IDPr was predicted to have weaker binding to PARG while maintaining 
strong binding to ARH3. This profile was accomplished by reversing two H-bond interactions in 
PARG (Ile726 backbone to N1 and Glu727 sidechain to N10, Figure 4.8C,D). 
Table 4.1 Docking scores for sugar nucleotides in PARG and ARH3. 








L. chalumnae ARH3 
ADPr -7.539 - -6.254 - 
IDPr -6.729 0.810 -7.000 -0.746 
GDPr -6.692 0.847 -6.131 0.123 
XDPr -7.100 0.439 -6.732 -0.478 
H. sapiens PARG 
ADPr -12.229 - -8.262 - 
IDPr -10.332 1.897 -6.613 1.649 
GDPr -10.906 1.323 -6.323 1.939 
XDPr -11.292 0.937 -6.090 2.172 
 
The synthesis of inosine-containing substrates was accomplished with little modification 
of the above synthetic route. Starting from inosine, the necessary protected H-phosphonate was 
obtained in 4 steps (Figure 4.9A). Pyrophosphate coupling with the appropriate ribose phosphate 
and deprotection provided pNP-IDPr and TFMU-IDPr (Figure 4.9B). The pyrophosphate 
forming reaction was slightly lower yielding than with adenine-containing substrates. While this 
undesired pathway could be mitigated through protection of the nucleobase or reaction condition 
optimization, this route provided sufficient material for the desired biochemical studies. 
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Figure 4.8 Recognition of sugar nucleotides by hPARG and LchARH3. A. ADPr bound to hPARG (PDB: 
5A7R). B. ADPr bound to LchARH3 (PDB: 6G1Q). C. ADPr (blue) and IDPr (yellow) are docking into 
hPARG. D. ADPr (blue) and IDPr (yellow) are docking into LchARH3. 
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4.3. Utilizing PARG substrates 
4.3.1. In vitro processing of substrates 
Using pNP-ADPr and TFMU-ADPr, the first continuous PARG and ARH3 activity 
assays were developed. Enzymatic hydrolysis of phenolic glycosides was easily monitored by an 
increased absorbance or fluorescence (Figure 4.11A, B). Kinetic parameters for human PARG and 
ARH3 were determined by non-linear fitting of initial reaction rates (Table 4.2 and Figure 4.10A, 
B). A commonly used ortholog of PARG from T. thermophila (ttPARG)15,37,50 was also 
characterized and found to effectively hydrolyze pNP-ADPr and TFMU-ADPr (Table 4.2 and 
Figure 4.11A). The measured KM of ARH3 was similar to the enzyme’s reported activity against 
O-acetyl-ADP-ribose51. The kinetic parameters of pNP-ADPr and TFMU-ADPr were quite 
similar likely due to the leaving groups having similar pKas (7.15 and 7.26). Gratifyingly, the 
predicted selectivity of TFMU-IDPr for ARH3 over PARG was confirmed (Figure 4.10C). 
Further, both PARG and ARH3 selectively hydrolyzed the a anomer of pNP-ADPr over the b 
anomer as is consistent with their natural substrates (Figure 4.11C, D). Hydrolysis of substrates 
depends on catalytically active protein; inactivating mutations in hPARG (the E756N mutant)37 
and hARH3 (the D77N/D78N mutant),26 abolish substrate processing (Figure 4.11F, G). 
 
Figure 4.10 Michaelis-Menton kinetics of recombinantly expressed human PARG and ARH3. A. Kinetics of 
human PARG processing TFMU-ADPr. B. Kinetics of human ARH3 processing TFMU-ADPr. C. 
Selectivity of TFMU-IDPr for processing by human ARH3 over human PARG. Error bars indicate SEM, n 
= 3. 
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Table 4.2 Kinetic parameters derived for ADP-ribosylhydrolase substrates. 
Substate Enzyme KM (µM) Vmax (µmol/min/mg) 
TFMU-ADPr hPARGa 66.2±15 0.84±0.05 
  ttPARGb 210±13 28.6±0.6 
  hARH3c 6.3±0.2 1.61±0.02 
TFMU-IDPr hPARG >1500 n.d. 
  ttPARG >1500 n.d. 
  hARH3 312±30 1.79±0.06 
pNP-ADPr ttPARG 210±10 16.9±0.5 
  hARH3 3.2±0.6 1.7±0.1 
pNP-IDPr ttPARG >1500 n.d. 
  hARH3 410±20 5.2±0.2 
aH. sapiens full length PARG 
bT. thermophila full length PARG 
cH. sapiens full length ARH3 
 
 
Figure 4.11 A. Reaction progress curves of ttPARG-catalyzed hydrolysis of pNP-ADPr. Enzyme (50 nM) 
was incubated with varying concentration of pNP-ADPr in 50 µL of appropriate reaction buffer in a 384-
well plate. Reaction was monitored every 2 s for 60 min. B. Same as A but with hARH3. C. Stereoselectivity 
















































































































































































of PARG and ARH3 for a glycosidic bonds. ttPARG (50 nM) was incubated with varying concentrations of 
a and b pNP-ADPr in 50 µL of appropriate reaction buffer in a 384-well plate. Initial reaction rates were 
obtained by monitoring reaction progress using an absorbance plate reader (405 nm). D. Same as C but with 
hARH3. E. Structures of a and b pNP-ADPr. F. Processing of TFMU-ADPr by catalytically active (WT) 
and inactive (E756N) hPARG. G. Processing of TFMU-ADPr by catalytically active (WT) and inactive 
(D77N/D78N) hARH3. Error bars represent SEM, n = 3. 
In the course of evaluating TFMU-ADPr as a substrate for ARH3, a strong dependence on 
Mg2+ concentration was observed. ARH3 is a metalloenzyme that has two Mg atoms coordinated 
in its active site. While paralogs in other species are capable of other metals, hARH3 has been 
described as metal-specific.17,19  To our knowledge, however, ARH3 has not been evaluated with 
other metals. The activity of ARH3 was determined against a panel of other divalent metals (Figure 
4.12B). Surprisingly, several metals inhibited ARH3 more potently than EDTA, suggesting that 
they bind more tightly to ARH3 than Mg2+ while not being catalytically active. This hypothesis is 
supported by shifts in the thermal stability of ARH3 in the presence of these metals (Figure 4.13). 
MnCl2 appears to bind tightly to ARH3 yet does not disrupt activity, possibly suggesting that Mn2+ 
is a competent catalyst as is the case for some ARH3 paralogs.52 Indeed, Mn2+ restores activity 
when ARH3 is stripped of Mg2+ (Figure 4.14). 
 
Figure 4.12 Metal dependence of ARH3. A. Dose-response activation of ARH3 with increasing Mg2+ 
(MgSO4) concentration. B. Panel of divalent metals were evaluated for their ability to inhibit hydrolysis of 



















































Figure 4.13 Assessment of the effect of metal substitution on ARH3 stability by DSF. A. Mg2+-depleted 
hARH3 and LchARH3 were supplemented with 100 µM of the indicated metal salt prior to the start of the 
assay. Curves represent normalized averages of triplicate (hARH3) or sextuplicate (LchARH3) 
measurements. B. Kd values were determined by DSF approach. Sixteen metal salt dilutions were distributed 
around the estimated Kd value. Melting temperature data were fitted using single site ligand binding model. 
Note, that the two highest calcium concentrations (open diamonds) were excluded from the fit as they 
consistently showed signs of increased protein instability. The represented data are derived from triplicate 
measurements ± SD. C. Calculated Kd values of the data shown in B. Experiments were performed by 
Johannes Rack (Oxford University). 
 
Figure 4.14 In vitro activity of Mg-deficient ARH3 in the presence of other metals. Mg2+ was stripped form 
hARH3 and LchARH3 as described in the methods section and activity assay performed in presence of 100 
µM of the indicated metal salt. Experiments were performed by Johannes Rack (Oxford University). 
4.3.2. Measuring ARH3 activity assay in cell culture 
The ability of TFMU-IDPr to selectively report on ARH3 activity within the cellular milieu 
would be an important application of these probes.  While the experiments in Figure 4.10 
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demonstrate the selectivity of this substrate for ARH3 over PARG in a purified enzymatic system, 
in cells other hydrolases that recognize ADP-ribose could potentially process this substrate. Thus, 
two experiments were conducted to assess the activity of ARH3 and PARG with these substrates 
in cell lysate.  First, the hydrolysis of TFMU-IDPr was evaluated in cell lysate from a ARH3 
knockout isogenic cell line pair derived from U2OS cells.26 Knockout of ARH3 resulted in near 
complete loss of TFMU-IDPr activity (Figure 4.15A) while TFMU-ADPr hydrolysis was only 
partially decreased (Figure 4.15B). Second, substrate processing was evaluated in the presence of 
the selective PARG inhibitor PDD00017273.34 Hydrolysis of TFMU-ADPr was completely 
abolished by PDD00017273 in ARH3-/- cell lysate, but TFMU-IDPr was unaffected by the PARG 
inhibitor. Taken together, these experiments indicate that TFMU-IDPr is selectively cleaved by 
ARH3 in cell lysate, and TFMU-ADPr is cleaved only by ARH3 and PARG. While PARG appears 
to contribute more substantially to total TFMU-ADPr cleavage, ARH3 is making a substantial 
contribution. 
 
Figure 4.15 Measurement of PARG activity in cell lysate and validation of TFMU-IDPr selectivity. A. 
Selectivity for ARH3 by TFMU-IDPr validated by CRISPR-Cas9 knockout of ARH3 in U2OS cells. PARG 
activity was measured in the presence and absence of PARG inhibitor PDD00017273 using TFMU-IDPr at 
200 µM. Error bars indicated SEM, n=3. Significance levels are given by asterisks: p<0.05 (*), p<0.01 (**), 
p<0.001 (***), p>0.05 (n.s.). B. Same as A but with 200 µM TFMU-ADPr. C. Validation of ARH3 knockout 
in U2OS as measured by Western blotting. D. Western blotting to determine ARH3 expression levels in 
various indicated cell lines; representative blot of two independent replicates shown, see Figure S4 for all 
replicates.  E. Correlation of ARH3 expression (measured by Western blotting) with ARH3 activity 
(measured by TFMU-IDPr hydrolysis). Data points reflect average values from different mammalian cell 
lines. Red indicates MCF10A. ARH3 activity was measured with 200 µM TFMU-IDPr. 
PARGi (µM) 0 10 0 10
+/+ -/-
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4.3.3. Survey of cancer cell lines 
As the activity of ARH3 in various cell types is unknown, experiments were conducted to 
assess ARH3 activity in a variety of cancer cell lines.  Twenty cell lines were analyzed for ARH3 
activity, measured using TFMU-IDPr, and compared to ARH3 abundance (measured by Western 
blot, Figure 4.15D); in general ARH3 activity and abundance are well correlated (Figure 4.15E). 
Strikingly, no ARH3 activity is observed with MCF10A cells despite the obvious presence of 
ARH3 by Western blot. Thus, it was hypothesized that in this cell line ARH3 is mutated or being 
affected by an endogenous inhibitor. 
A unique feature of MCF10A cells are the particular additives in the growth media, and 
most notable is the inclusion of cholera toxin (CTX), a known ADP-ribosyltransferase.53,54 
Suspecting that the presence of CTX may impact ARH3 activity, MCF10A cells were passaged 
five times in the absence of CTX, and ARH3 activity was restored (Figure 4.16A). This recovery 
of activity was reversed (in a dose and time-dependent manner) with subsequent addition CTX, 
and this phenotype was reproduced in other cell lines (MCF7 and MIA PaCa-2) (Figure 4.16A, 
B). In all these cell lines, CTX-mediated ARH3 inhibition occurred rapidly (t1/2 < 60 min, Figure 
4.16B). The treatment of cells with CTX appears to be the first example of selective ARH3 
inhibition in cells.   
 
Figure 4.16 Cellular ARH3 inhibition by CTX treatment. A. MCF10A cells were cultured in the absence of 
CTX for five passages. Cells were plated 1x105 cells/well in 6-well plate. Cells were treated with varied 
concentration of CTX for 48 h. Remaining ARH3 activity was measured with 200 µM TFMU-IDPr. B. Cells 
were plated 3x105 cells/well in 6-well plate. Cells were treated with 100 ng/mL CTX for the indicated period 
of time. Remaining ARH3 activity was measured with 200 µM TFMU-IDPr. C. In vitro activity of purified 











































































































































ARH3 in the presence or absence of 100 ng/mL CTX. D. Dose-response curve of ARH3 inhibition by cAMP 
using 200 µM TFMU-IDPr. E. MCF10A cells treated with forskolin for 1 h. F. A549 cells treated with various 
bacterial toxins for 24 h. Following treatment, ARH3 activity in cell lysate was assessed. CTX, cholera toxin 
100 ng/mL; CDT, C. difficile toxin 200 ng/mL CDTa 400 ng/mL CDTb; PT, pertussis toxin 100 ng/mL. 
 
Figure 4.17 Canonical mechanism of action for cholera toxin and involvement of ARH3. Cholera toxin is 
secreted as a binary toxin by Vibrio cholera within the intestinal lumen. Subunit B binds to GM1 receptor 
and is endocytosed. Subunit A contains an ADP-ribosyltransferase domain that ADP-ribosylates Gsa. This 
PTM causes constitutive activitation of Gsa, which activates AC leading to cAMP synthesis. Increased cAMP 
concentrations lead to cystic fibrosis transmembrane conductance regulator (CFTR) activation and efflux of 
chloride. Tight junctions are weakened leading to sodium and water leakage through the intercellular space, 
resulting in dehydration and loss of electrolytes 55. Pertussis toxin acts through a similar manner by ADP-
ribosylation of Gi which also gives rise to increased cAMP synthesis. 
4.3.4. Mechanism of ARH3 inhibition by ADP-ribosyl-arginine 
Having identified cholera toxin as causing ARH3 inhibition in cell culture, several 
experiments were performed to elucidate the toxin's mechanism of action. CTX was first found to 
have no direct effect on ARH3 in vitro (Figure 4.16C). The canonical mechanism of CTX involves 
mono-ADP-ribosylation of an active-site arginine (Arg187) on Gas (G-protein alpha subunit); this 
post-translational modification results in the constitutive activation of adenylyl cyclase (AC), 




































































ARH3 inactivation were investigated. cAMP was found to only weakly inhibit ARH3 (IC50 = 
2.96±0.05 mM, Figure 4.16D). Furthermore, treatment with forskolin, a known activator of 
AC,59,60 did not result in ARH3 inhibition (Figure 4.16E). Finally, other ADP-ribosyltransferase 
bacterial ecto-toxins that target other amino acid residues do not inhibit ARH3 activity (Figure 
4.16F). With these experiments pointing upstream of AC, direct interaction with ADP-ribosyl 
arginine (ADPr-Arg) was considered.  To make assessments, ADPr-Arg was synthesized as 
described previously61 and assessed in the in vitro assay.   This compound was found to potently 
inhibit ARH3 in vitro, with a Ki value of 18±2 nM (Figure 4.18A, B).  Interestingly, ADPr-Arg 
demonstrates markedly reduced activity against PARG (Figure 4.18C).  This differential inhibition 
is in contrast to the results for the substrate analogue inhibitor of PARG, the compound ADP-
HPD;62-64  analysis of ADP-HPD shows that this compound inhibits both PARG and ARH3 (Figure 
4.18C).  
 
Figure 4.18 Selective inhibition of ARH3 by ADP-ribosylated arginine. A. Kinetics of inhibition of ARH3 
by ADPr-Arg. B. Lineweaver-Burke plot of ADPr-Arg inhibition of ARH3. C. Selectivity of ADPr-Arg for 
ARH3 over hPARG is indicated by a shift in dose-response curve. D. Structure of ADPr-Arg. 
Importantly, ADPr-Arg substantially accumulated in MCF7 cells following CTX 
treatment, from concentrations below the limit of detection in untreated cells to 2.62±0.05 µM in 
the treated cells (Figure 4.19A). Changes in related metabolites were also observed: cAMP 
concentration increased as expected for the canonical activity of CTX, NAD+ concentration 
decreased as it is a substrate for ADPr-Arg synthesis, but arginine remained unchanged, perhaps 


































































































due to the presence of exogenous arginine in media. The same trend for these metabolic changes 
was also observed in U2OS cells (Figure 4.19B). 
While the background ADP-ribosylation of arginine by CTX has been observed with 
isolated protein,61 the activity of CTX has largely been regarded to be highly selective for 
proteinaceous arginine. We observe and quantify ADP-ribosylation of free arginine for the first 
time in cell culture at concentrations that rationalize ARH3 inhibition. The absence of ARH3 
inhibition following CDT treatment, despite creating the same PTM, may result from differential 
propensities to produce free and proteinaceous ADPr-arginine. However, the possibility remains 
that the observed ADPr-arginine results from proteolytic breakdown of ADP-ribosylated G 
proteins rather than direct ADP-ribosylation. In this case, the differential activities of bacterial 
toxins can be attributed to stabilities of their respective protein targets. Some of the phenotypes 
described upon treatment by bacterial toxins (i.e. lose of tight junctions) has also been described 
for PAR overproduction.65-68 While the exact mechanism by which these processes operate is yet 
unknown, inhibition of ARH3 may assist in toxins’ ability to elevate PAR concentrations. 
 
Figure 4.19 A. Metabolic profiling of MCF7 cells treated with 100 ng/mL CTX for 6 h. Metabolites (ADPr- 
Arg, cAMP, ADP-ribose, NAD+, and arginine) in methanolic cell extract were quantified by LC-MS/MS. 
Samples below the limit of detection are indicated by open points. Error bars represent standard deviation, n 









































































































To further interrogate the mode of inhibition by ADPr-Arg, we again collaborated with the 
Ahel lab to obtain a crystal structure of ADPr-Arg bound to LchARH3 (Figure 4.20). In this 
structure, the guanidinium makes close interactions with Glu33 residues and may contribute to 
tight binding. The rest of the arginine moiety makes limited contacts with the protein and may be 
dispensable for binding. 
 
Figure 4.20 X-ray crystal structure of ADPr-Arg bound to LchARH3 (PDB: 6HH4). 
4.4. Synthesis and evaluation of ADP-HPD and analogues 
The first potent, validated inhibitors of PARG and ARH3 were obtained by mimicking the 
oxocarbenium intermediate through introduction of an amine in the ring, a common approach for 
glycosidases.69 The first compound, ADP-HPD has broad activity against ADP-ribosyl hydrolases 
(Figure 4.21).62,63 Despite being unable to penetrate the cell membrane, ADP-HPD has garnered 
wide use among researchers for different applications: proteomics,5,26,70-76 structural biology,16,77,78 
and in vitro studies.29,31,79,80 Several derivatives have been made, and while most modifications 
lead to a significant loss in activity, ADP-HPM remains active.64 These compounds are difficult 
to synthesize however as evidenced by the high commercial price for ADP-HPD ($185 for 60 µg, 
EMD Millipore). ADP-HPM is not commercially available, so its activity has not been evaluated 
in other contexts after the initial publication. The first and only reported synthesis of ADP-HPM 
was accomplished in 9 steps (9% overall yield) and relied on poor-yielding pyrophosphate 
formation that required 5 days to complete. Our lab’s recent foray into sugar nucleotide synthesis 
provided some confidence that these compounds could be assembled more efficiently and that 
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some interesting biology could be discovered. The initial work on ADP-HPD synthesis was 
performed by Dr. Tomohiro Shirai, a visiting scholar. I performed some optimization of conditions 
on scaleup and adapted the synthetic route for producing ADP-HPM. 
 
Figure 4.21 Structures of PARG inhibitors ADP-HPD and ADP-HPM. 
4.4.1. Synthesis of ADP-HPD 
The synthesis of ADP-HPD features two key synthetic hurdles: installation of the diol and 
pyrophosphate formation. While the amino sugar could be synthesized from a linear precursor, 
starting from trans-4-hydroxy-L-proline has generally been a better strategy. In our approach, we 
introduce three major improvements: a streamlined protecting group scheme, more rapid 
dihydroxylation, and higher yielding pyrophosphate formation. Previous approaches to 
dihydroxylproline have proceeded via dihydroxylation of 3,4-dehydro-L-proline. Dehydration of 
hydroxyproline is typically accomplished via Chugaev elimination81 or selonoxide elimination82 
due to the propensity for 4,5-dehydro-L-proline to form under other dehydrating conditions (Figure 
4.22).83 These toxic intermediates could be avoided through direct dehydration by Martin’s 
Sulfurane Dehydrating Agent as discovered by a former post-doctoral fellow Dr. Bryan Yestrepsky 
(Figure 4.22). 
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This improved method for dehydration was incorporated into a route with a more 
streamlined protecting group scheme. Several protecting groups were evaluated and found Fmoc 
for the pyrrolidine and silyl ethers for the alcohols was most effective in maintaining solubility 
and chemical compatibility throughout the route (Figure 4.23). Dehydration of Fmoc-protected 4-
hydroxy-L-proline methyl ester (4-22) provided the desired constitutional isomer (4-23). 
Gratefully, Upjohn dihydroxylation provided diol 4-24 in high diastereoselectivity. Alcohol 
protection as silyl ethers and ester reduction provided the necessary HPD building block 4-26. 
While the H-phosphonate chlorination method described for pNP-ADPr synthesis above could be 
used for pyrophosphate formation, Dr. Tomohiro Shirai found that phosphoramidite coupling was 
most effective because unprotected adenosine monophosphate (AMP) could be used as a coupling 
partner. The enabling discovery was that the counter-ion of AMP greatly affected its solubility and 
that the tetrabutylammonium salt was sufficiently soluble in DMF. This salt form could be 
obtained via ion exchange with Dowex 50W resin, first to triethylammonium then 
tetrabutylammonium. Thus, 4-26 was coupled to a fluorenylmethyl-protected phosphorodiamidite 
to give phosphoramidite 4-27, which was subjected to a P(III)-P(V) coupling with 
tetrabutylammonium AMP (4-28). In the same pot, oxidation to a pyrophosphate and 
fluorenylmethyl protecting groups removal provided TBS-protected ADP-HPD 4-29. The silyl 
ethers provided sufficient lipophilicity to enable efficient purification by reverse phase 
chromatography and were removed under acidic conditions to give ADP-HPD. In all, ADP-HPD 
was obtained in 8 steps, 5% overall yield. 
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Figure 4.23 Improved synthesis of ADP-HPD. 
4.4.2. Synthesis of ADP-HPM 
Few modifications were required for the synthesis of ADP-HPM (Figure 4.24). In this case, 
4-hydroxy-L-proline was orthogonally protected as 4-30. The same reaction sequence was 
followed to provide ADP-HPM in 6 steps, 37% overall yield. 
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4.4.3. Differential inhibition by ADP-HPD and ADP-HPM 
Amino sugar inhibitors of ADP-ribosyl hydrolases have only been carefully evaluated 
using an endpoint TLC PARG assay.63 This has made mechanism of inhibitions challenging as it 
is difficult to accurately measure initial rates.62 Further, the selectivity of these inhibitors has not 
been carefully studied with ARH1 or ARH3 due to their recent discovery. With a robust continuous 
enzyme assay (Section 4.3.1.  above) and newly developed synthetic route, we were in good 
position to evaluate both inhibitors with ARH3. Our collaborators in the Ahel lab were also 
interested in studying ARH1. Gratifyingly, ARH1 was capable of hydrolyzing TFMU-ADPr, 
albeit at a reduced rate.  
Initially, inhibition was evaluated at a single TFMU-ADPr concentration with varying 
inhibitor concentration to construct dose-response curves (Figure 4.25). ARH3 was potently 
inhibited by ADP-HPD as previously reported,31 but surprisingly ADP-HPM was 50-fold less 
active than the reaction product, ADP-ribose (Table 4.3). ARH1 was not much affected by ADP-
HPD or ADP-HPM. 
 
Figure 4.25 Inhibition of ARH1 and ARH3 by amino sugar nucleotides. 
 
Table 4.3 Kinetic parameters of hARH1 and hARH3 inhibition. 
 hARH1 hARH3 
Inhibitor Ki [μM] IC50 [μM] Ki [μM] IC50 [μM] 
ADPr n.d. 228 1.08 ± 0.08 3.2 
ADP-HPD n.d. n/a 0.58 ± 0.12 0.587 
ADP-HPM n.d. 164 54.2 ± 4 480 
CaCl2 n/a n.d. n/a 13.7 
(a) All samples measured in triplicates 
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4.5. Future directions 
4.5.1. Improved substrate design 
While the fluorescent substrate TFMU-ADPr demonstrates excellent performance within 
its intended applications, the fluorophore TFMU has several shortcomings. Specifically TFMU is 
highly sensitive to pH and is not convenient for use with confocal microscopy. Several 
fluorophores may perform better while retaining good reactivity and selectivity. Perhaps most 
interesting would be the implementation of aniline-containing dye. While PARG and ARH3 are 
incapable of cleaving a N-glycoside, aniline dyes could be coupled to ADPr through a quinone 
methide or trimethyl lock linker. 
4.5.2. Screen for synthetic lethality with ARH3 
The degradation of PAR provided by ARH3 is a checkpoint against parthanatos. Removal 
of this protection could increase cell death through this pathway. As demonstrated by the viability 
of ARH3 knockout cells and mice, removal of ARH3 is not sufficient for initiation of parthanatos. 
This viability may be due to the compensatory activity of PARG or that PAR formation is not 
initiated in resting cells. Although a cell permeable inhibitor of ARH3 is not available today, 
several experiments can be performed to explore the therapeutic potential of such a compound. A 
synthetic lethal genetic screen could be performed in ARH3-/- U2-OS cells to identify targets to hit 
in combination with ARH3 inhibitors. If another cancer histology is of interest, treatment with 
CTX may be an appropriate surrogate for ARH3 depletion. As it may be difficult to differentiate 
effects due to CTX-mediated ARH3 inhibition and the canonical activity of CTX, a counter screen 
with forskolin (a direct adenylyl cyclase activator) would be necessary. Finally, a chemical screen 
can be performed in ARH3-depleted cells (either genetically or with CTX) to identify synergistic 
interactions. Although this screen could be conduct with an unbiased compound library, it may be 
more practical to focus on DNA damaging agents, kinase inhibitors, and recently developed DNA 
repair inhibitors.84 The use of CTX-mediated ARH3 inhibition will be useful for interrogating the 
role of ARH3 in forestalling parthanatos while ADPr-Arg will be a good template for drug design. 
4.5.3. ARH3 inhibitors inspired by ADPr-Arg 
The discovery that ADPr-Arg is a potent and selective ARH3 inhibitor opens the door for 
the potential to design ARH3 inhibitors with improved drug-like properties. ADPr-Arg is highly 
polar and expected to have poor membrane permeability as is the case for other pyrophosphates. 
A cell-permeable inhibitor may be possible by removing problematic functional groups or 
replacing them with more permeable bioisosteres. Several modifications to ADPr-Arg were 
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considered and docked into the co-crystal structure of ARH3 and ADPr-Arg (Figure 4.26). 
Docking poses were refined and relative binding energies estimated with MM-GBSA. The arginine 
moiety was substituted with various function groups that donate two hydrogen bonds. Of the 
neutral groups, 2-aminopyridine appears to be the most favorable. Since ARH1 is capable of 
hydrolyzing ADP-Arg, it may be necessary to design non-hydrolyzable compounds. A similar 
strategy has been employed for nucleoside analogues (e.g. entecavir and neplanocin). A 
cyclopentene derivative was predicted to have tighter binding than ADPr-Arg. Finally, 
modification of the pyrophosphate was explored. Replacement with a methylene phosphonate was 
favorable, and removal of adenosine was tolerated. However, truncation down to the ribose 
monophosphate appears disfavored. Some combination of these approaches (guanidine 
substitution, sugar mimicry, and pyrophosphate) may provide a compelling drug lead. 
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Figure 4.26 Molecular docking of potential inhibitors of ARH3. 
4.5.4. MacroD1 substrates 
While PARG is capable of rapidly degrading PAR polymers attached to proteins, it is 
ultimately incapable of removing the final ADPr moiety thereby leaving a MARylated protein. 
Additionally several members of the PARP family of enzymes are only capable of MARylating 
proteins. These PTMs on Asp and Glu are removed by MacroD1. Unlike PARG, MacroD1 is an 



































































































































































































Figure 4.27 APDr acyl migration and hydrolysis by MacroD1. 
We currently lack a reliable and robust activity assay for MacroD1. Consequently, no 
inhibitors have been disclosed for MacroD1. The development of a continuous fluorogenic 
substrate for MacroD1 would be beneficial for assisting in understanding the role of MacroD1. 
Designing a fluorogenic probe for MacroD1 poses some challenges, however. The literature is 
well populated with esterase substrate probes, but these compounds almost exclusively design the 
fluorophore on the “alcohol-side” of the ester. In the case of MacroD1, the “alcohol-side” must be 
ADPr in order for proper substrate recognition. This strategy can be accomplish either by utilizing 
recently described BODIBY-based probes85 or incorporating a self-immolating carbamate (Figure 
4.28). Carbamates have been used in carboxylesterase-activated prodrugs such as capecitabine and 
irinotecan.86,87 Although a more straightforward design, the BODIPY probe is less favorable due 
to the possible steric clashes introduced by the proximity of the fluorophore to ADPr. 
 
Figure 4.28 Proposed MacroD1 substrates. BODIPY containing substrate senses electronic of carbonyl at 
meso position. Carbamate substrate contains self-immolating linker to allow release of phenolic fluorophores. 
4.6. Materials and methods 
Reagents 
Mouse anti-ARH3 was purchased from Santa Cruz Biotech (Cat# sc-374162). Rabbit anti-beta-
actin (Cat# 4970), rabbit anti-PARP1 (Cat# 9542), HRP-conjugated goat anti-rabbit (Cat# 7074), 
and HRP-conjugated horse anti-mouse (Cat# 7076) were purchased from Cell Signaling. 
PDD00017273 was purchased from Tocris (Cat# 5952). 4-(trifluoromethyl)umbelliferone was 
purchased from Enamine Building Blocks (Cat# EN300-05279). 1,1’-(azodicarbonyl)dipiperidine 
was purchased from Accela ChemBio Inc. (Cat# SY001006). 1,2-dimethyoxyethane was 



























































Aldrich or Fisher Scientific in the highest available purity. Protease Inhibitor Cocktail Set III was 
purchased from Calbiochem (Cat# 539134). Cholera toxin from Vibrio cholerae (Cat# 100B), 
Binary Toxin from Chlostridium difficile (Cat# 157A/B), and Pertussis Toxin from B. pertussis 
(Cat# 180) were purchased from List Biological Labs. 
Buffer composition 
PARG Activity Lysis Buffer: 30 mM Tris (pH 7.5), 500 mM NaCl, 20% glycerol, 1% Triton X-
100, 1:500 protease inhibitor cocktail 
Lysate Activity Buffer: 50 mM K2HPO4 (pH 7.4), 50 mM KCl, 5 mM MgCl2, 5 mM DTT 
T. thermophila PARG reaction buffer: 50 mM K2HPO4, 50 mM KCl, 10 mM b-mercaptoethanol, 
pH 7.40 
Human PARG reaction buffer: 50 mM K2HPO4, 50 mM KCl, 10 mM b-mercaptoethanol, pH 7.40 
Human ARH3 reaction buffer: 50 mM Na2HPO4, 10 mM MgCl2, 5 mM DTT, pH 7.40 
PARG Purification Lysis buffer: 50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, 0.5 mg/mL 
lysozyme, 1 ug/mL leupeptin, 1 ug/mL pepstatin A, 2 ug/mL aprotinin, 1 mM PMSF, pH 8.0 
PARG Purification Wash buffer: 50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0 
PARG Purification Elution buffer: 50 mM NaH2PO4, 300 mM NaCl, 300 mM imidazole, pH 8.0 
PARG Purification Dialysis buffer: 25 mM Tris, 50 mM NaCl, 1 mM DTT, 10% glycerol, pH 7.5 
Towbin Transfer Buffer: 20% CH3OH, 192 mM glycine, 50 mM Tris, pH 8.3 
In vitro enzyme kinetics 
10X dilutions of substrate were prepared from 10 mM stock solutions in MilliQ H2O into reaction 
buffer. 5 µL 10X substrate was added to a 384-well plate. 45 µL 2.2 nM enzyme solution in 
reaction buffer was added to a single column of the 384-well plate via 16-channel Matrix pipet. 
Plate was placed into plate reader. After shaking for 5 s, absorbance or fluorescence was recorded 
at 2 s intervals for 5 min. Initial reaction rates were determined by fitting the linear portions of 
reaction progress curves using SoftMax Pro 6.4. Initial rates were plotted against substrate 
concentration and fit to the Michaelis-Menton equation using a non-linear curve-fitting algorithm 
with GraphPad Prism 6. For pNP detection, plate reader was configured: absorbance at 405 nm. 
For TFMU detection, plate reader was configured: Excitation 385 nm, Cutoff 495 nm, Emission 
502 nm, 6 reads/well, Low Gain. 
Cell lysate ARH3 activity assay 
Cells were cultured in T75 flasks in appropriate medium. Cells were trypsinized, and scrapped (if 
necessary), and counted. 1x106 cells were harvested and washed with cold PBS 2x. Cell pellet was 
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lysed by addition of activity lysis buffer (150 µL) and incubated on ice for 30 min. Lysate was 
clarified by centrifugation at 14,300xg at 4°C for 10 min. Supernatant was transferred to chilled, 
empty 500 µL tube. Total protein content of lysate was evaluated by BCA assay. ARH3 expression 
level was determined by western blotting analysis. 5 µL lysate was added to well of 384-well black 
plate. 45 µL TFMU-IDPr (200 µM final) in reaction buffer was added to well. Reaction progress 
was monitored by fluorescent plate reader (ex 385 nm, cutoff 495, em 502 nm, 6 reads/well, high 
gain). 
ADP-ribosylated arginine enzymatic synthesis 
CTX (100 µL, 500µg/mL, 10µg/mL final) was added to 5 mL buffer (400 mM K2HPO4, 20 mM 
DTT, pH 7.2) containing 200 mM arginine and 10 mM NAD. Mixture was incubated at 37°C for 
16 h. Protein was removed from reaction mixture by filtration through 3k MWCO spin filter. 
Filtrate was direction subjected to ion-pairing preparative HPLC using Luna C18 21.5x150mm 
column (Cat# 00F-4252-P0-AX). Solvent A: 20 mM Et3N•HOAc (pH 7.2), solvent B: acetonitrile. 
Gradient (A:B, 20 mL/min): 98:2, 0 min; 98:2, 2 min; 75:25, 16 min; 75:25, 23 min; 40:60, 27 
min, 40:60, 30 min. ADP-ribosylated arginine eluted at ~5 min as two separate anomers. Individual 
anomers gradually interconverted in ~1 h, so characterization and inhibition experiments were 
performed with mixture of anomers. Product-containing fractions were determined by LCMS and 
lyophilized to yield flocculent white solid (7.8 mg, 21%). 1H NMR was consistent with previous 
reports.61 
Cell culture 
A549, D54, HCC1937, HCC38, HCT-116, Jurkat, and U937 cells were grown in RPMI 1640 
supplemented with 10% fetal bovine serum (Benchmark, Gemini) and 1% pen/strep. U2OS, 
Daudi, HEK293TN, HeLa, Hs578t, MEF, MIA PaCa-2, and SK-MEL-5 cells were grown in 
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum and 1% 
pen/strep. HFF-1 cells were grown in Dulbecco’s modified Eagle’s medium supplemented with 
15% fetal bovine serum and 1% pen/strep. HepG2, MCF7, T98G, and U87 cells were grown in 
Eagle's Minimum Essential Medium supplemented with 10% fetal bovin serum and 1% pen/strep. 
MCF10A cells were grown in Dulbecco’s modified Eagle’s medium supplemented with 2% horse 
serum, 20 ng/mL EGF, 0.5 µg/mL hydrocortisone, 10 µg/mL insulin, 100 ng/mL cholera toxin, 
and 1% pen/strep. Phenol red was added to all media except for MCF10A as a pH indicator. All 
cells were cultured at 37°C in a 5% CO2 environment. Media were prepared by the University of 
Illinois School of Chemical Sciences Cell Media Facility. Sex of cell lines: A549 (Male, 58 years 
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old), CA46 (Male, age unknown), D54 (Female, age unknown), Daudi (Male, 16 years old), 
HCC1937 (Female, 23 years old), HCC38 (Female, 50 years old), HCT-116 (Male, age unknown), 
HEK293TN (Female, fetus), HeLa (Female, 31 years old), HepG2 (Male, 15 years old), HFF-1 
(Male, newborn), Hs578t (Female, 74 years old), MCF7 (Female, 69 years old), MCF10A 
(Female, 36 years old), MEF (sex and age unknown), MIA PaCa-2 (Male, 65 years old), Jurkat 
(Male, 14 years old), SK-MEL-5 (Female, 24 years old), T98G (Male, 61 years old), U2OS 
(Female, 15 years old), U87 (Male, age unknown), U937 (Male, 37 years old). 
Metabolic profiling 
Six-well plates were seeded with cells at 3x105 cells/well. When cells were ~80% confluent, cells 
were treated with 100 ng/mL CTX for 6 h. Cells were washed with PBS once and detached with 
trypsin, quenching trypsin with media with 10% FBS. Cell viability was verified by Trypan Blue 
exclusion. Cells were centrifuged at 400xg at 4°C for 4 min and washed with PBS twice. Cell 
pellets were resuspended with cold 70:30 methanol:water and placed on ice. Cell suspension was 
sonicated on ice (20%, 10 s on, 10 s off, 30 s total) and continued to be incubated on ice for 30 
min. Lysate was clarified by centrifugation at 14,300xg at 4°C for 30 min. Supernatent was 
transferred to an empty 0.5 mL tube and stored at -80°C until analysis. Samples were analyzed 
with the 5500 QTRAP LC/MS/MS system (Sciex, Framingham, MA) in Metabolomics Lab of 
Roy J. Carver Biotechnology Center, University of Illinois at Urbana-Champaign. Software 
Analyst 1.6.2 was used for data acquisition and analysis.   The 1200 series HPLC system (Agilent 
Technologies, Santa Clara, CA) includes a degasser, an autosampler, and a binary pump. The LC 
separation was performed on an Agilent SB-Aq (4.6 x 50mm, 5μm) with mobile phase A (0.1% 
formic acid in water) and mobile phase B (0.1% formic acid in acetontrile). The flow rate was 0.3 
mL/min. The linear gradient was as follows: 0-3min, 100%A; 5-10min, 2%A; 11-15min, 100%A. 
The autosampler was set at 10°C. The injection volume was 5 μL. Mass spectra were acquired 
under positive electrospray ionization (ESI) with the ion spray voltage of +5500 V. The source 
temperature was 450 °C. The curtain gas, ion source gas 1, and ion source gas 2 were 36, 65, and 
60, respectively. Multiple reaction monitoring (MRM) was used for quantitation: Arg m/z 175.1 -
-> m/z 70.1; ADP-Arg m/z 716.2 --> m/z 428.1; cAMP m/z 330.2 --> 232.0; ADP-ribose m/z 
560.1 --> m/z 348.1; NAD m/z 664.2 --> m/z 136. Limit of quantitation (LOQ) for the compounds 
were: 10 ng/mL ADPr-Arg, 10 ng/mL ADP-ribose, 10 ng/mL arginine, 20 ng/mL cAMP, and 100 
ng/mL NAD+. 
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Recombinant protein expression and purification 
Human ARH3 was expressed as previously described.15,29 Briefly, human ARH3 cloned 
into a pDEST vector with an N-terminal His6-tag was obtained from Hening Lin (Cornell 
University, Cornell, NY) was transformed into Rosetta2 (DE3) E. coli cells. 500 mL culture of LB 
(100 µg/mL ampicillin and 20 µg/mL chloramphenicol) was inoculated with 10 mL of overnight 
culture. The culture was grown at 37°C to mid-log phase (OD600 = 0.5) and cooled to 18°C. Protein 
expression was induced with 0.1 mM IPTG for 18 h and harvested. Pellet was resuspended in 13 
mL lysis buffer and lysed by sonication. Lysate was clarified by centrifugation (35,000xg, 30 min, 
4°C). Supernatent was purified on Ni-NTA beads by batch protocol. Fractions containing pure 
protein were combined, dialyzed, and stored at -80°C. Protein concentration was determined by 
BCA assay. 
T. thermophila PARG enzyme was expressed using a modified protocol a previously 
reported.50 Briefly, T. thermophila PARG2 cloned into a pET28a vector was obtained from Ivan 
Ahel (University of Oxford, Oxford, UK) and transformed into Rosetta2 (DE3) E. coli. 500 mL 
culture of LB (100 µg/mL kanamycin and 20 µg/mL chloramphenicol) was inoculated with 10 mL 
of overnight culture. The culture was grown to mid-log phase (OD600 = 0.7). Culture was induced 
with 0.3 mM IPTG at 30°C for 3 h and harvested. Pellet was resuspended in 13 mL lysis buffer 
and lysed by sonication. Lysate was clarified by centrifugation. Protein was purified on Ni-NTA 
beads by batch protocol. Fractions containing pure protein were combined, dialyzed, and stored at 
-80°C. Protein concentration was determined by BCA assay. 
Human PARG cloned into a pColdTF vector was obtained from Ivan Ahel (University of 
Oxford, Oxford, UK) and transformed into Rosetta2 (DE3) E. coli. Culture of Terrific Broth 
supplemented with appropriate antibiotics was grown to an OD600 = 0.6-0.8 at 37°C. Culture was 
induced with 0.1 mM IPTG at 18°C for 16 h and harvested. Pellet was resuspended in lysis buffer 
(40 mM HEPES, 300 mM NaCl, 20 mM imidazole, 10% glycerol, 1 mM TCEP, pH 8.0) 
supplemented with benzonase, lysozyme and protease inhibitor (Roche Complete EDTA-free 
protease inhibitor tablet) and lysed by freeze/thaw. Lysate was clarified by centrifugation. Protein 
was purified on Ni-NTA beads by batch and eluted with lysis buffer supplemented with 500 mM 
imidazole. 
Western blot analysis 
Samples loading was normalized based on total protein content as assessed by BCA assay and 
subjected to SDS-PAGE. Protein was transferred to PVDF membranes (Merck Millipore). 
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Membranes were cut along molecular weight markers and then blocked with TBS-T buffer (25 
mM Tris-HCl, 150 mM NaCl, 0.05% Tween 20, pH 7.5) supplemented with either 5% BSA 
(PARP1) or 5% non-fat dried milk (ARH3) for 1 h. Membrane strips were incubated overnight 
with primary antibodies in blocking buffer at 4°C with gentle rocking. Membranes were washed 
3x with TBS-T and incubated with HRP-conjugated secondary antibody in TBS-T for 1 h. 
Membranes were washed 3x with TBS-T, developed using SuperSignal West Pico and imaged 
using a ChemiDoc MP system. Membrane strip containing ARH3 bands was stripped and 
reimaged with anti-actin antibody. Dilutions for antibodies were: anti-PARP1 (1:3000), anti-
ARH3 (1:1000), anti-actin (1:3000), anti-rabbit (1:3000), and anti-mouse (1:3000). Band 
quantification was performed using FIJI. 
Molecular docking 
Protein and ligand preparation, docking, and scoring was performed using the Schrodinger 
Suite 2018-1. Proteins were prepared using the Protein Prep Wizard using standard settings with 
pH set to 7.4. Receptor grids were generated based on bound ADP-ribose. Additional positional 
constraints were applied so that the nucleobase occupies the adenine binding site and the ribose 
ring occupies the active site. Sugar nucleotide protonation state and tautomer form was determined 
using LigPrep. Docking was performed with Glide using both standard precision (SP) and extra 
precision (XP). Docking poses were exported and rendered using PyMOL. In the case of ADPr-
Arg derivatives, docking poses were further refined with Prime MM-GBSA using the OPLS3e 
force field and VSGB solvation model. Flexibility was allowed with hierarchical sampling. 
Differential scanning fluorimetry 
Assays were performed essentially as earlier described.88 Briefly, 10 µM LchARH3 WT EDTA-
treated, 10x SYPRO® Orange (ThermoFisher Scientific) and indicated amounts of metal salts in 
assay buffer (50 mM TrisHCl [pH 8], 200 mM NaCl, and 1 mM DTT) were thermal denaturated 
in MicroAmp® Fast plates (Life Technologies) in a StepOne qPCR instrument (ThermoFisher 
Scientific). The initial temperature of 24 °C was hold for 2.5 min, followed by a ramp to 97.5 °C 
at 0.5 °C/45 sec, and then 2 min pause at 98 °C. Curves were fit using GraphPad Prism 6. For 
analysis recorded data were cropped two data points after recorded fluorescence signal maximum 
and the resulting curves fitted using the Boltzman equation: 






For the inference of the binding constant the determined TM’s were plotted and analysed using a 
single binding site model: 

























with P, protein concentration; M, metal salt concentration; Kd dissociation constant. 
General chemical synthetic methods 
All reactions were run in flame or oven dried glassware under and atmosphere of dry 
nitrogen unless otherwise noted. Acetonitrile, tetrahydrofuran, methanol, dimethylformamide, 
toluene, and methylene chloride using in reactions were obtained from a solvent dispensing 
system. 4 Å molecular sieves were dried at 150°C on high vacuum overnight. Pyridine, 
diazabicyclo[5.4.0]undec-7-ene, diisopropylethylamine, and trimethylamine were distilled from 
CaH2 and stored on 4 Å sieves. All other reagents were of standard commercial purity and were 
used as received. Analytical thin-layer chromatography was performed on EMD Merck silica gel 
plates with F254 indicator. Plates were visualized with UV light (254 nm) or staining with p-
anisaldehyde. Silica gel for column chromatography was purchased from Macherey-Nagel (40-63 
µm particle size). 
Unless otherwise indicated, 1H, 13C, 19F, and 31P NMR spectra were recorded at 500, 126, 
470, and 202 MHz, respectively. 1H and 13C NMR spectra were referenced to the residual solvent 
peak. 19F NMR spectra were referenced using absolute referencing based on 1H spectra. 31P NMR 
spectra were externally referenced to 85% H2PO4 (0.00 ppm) in water. Chemical shifts are reported 
in ppm and multiplicities are reported as s (singlet), d (doublet), t (triplet), q (quartet), p (pentet), 
h (hextet), m (multiplet), and br (broad). For annotated NMR spectra see Data File S1. Mass 
spectrometry analysis was performed by the University of Illinois Mass Spectrometry Center.  
Preparative C18 chromatography was performed using a Teledyne Isco Combiflash Rf 
system with RediSep Gold columns. Silyl ether protected intermediates were separated using a 
gradient of H2O/CH3CN beginning with 95% H2O:5% CH3CN, ramping to 65% H2O:35% CH3CN 
over 6 min, ramping to 100% CH3CN over 6 min, and holding 100% CH3CN for 5 min. 
Unprotected substrates were separated using a gradient of 10 mM Et3N•HOAc (pH 7.2)/CH3CN 
beginning with 100% buffer, ramping to 15% buffer:85% CH3CN over 10 min, ramping to 50% 
buffer:50% CH3CN over 6 min, and holding 50% buffer:50% CH3CN for 4 min. 
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4.6.2. Synthesis of PARG substrates 
 
5-O-trityl-D-ribono-1,4-lactone (4-2): Synthesized with modification of previous reports.89 
Specifically, to a 250 mL round bottom flask was added D-ribonic acid g-lactone (2.15 g, 14.5 
mmol, 1 eq), 4-dimethylaminopyridine (360 mg, 2.9 mmol, 0.2 eq), and pyridine (42 mL). Once 
fully dissolved, triphenylmethyl chloride (4.86 g, 17.4 mmol, 1.2 eq) was added as a solid in one 
portion to the stirring reaction mixture at room temperature. The solution was stirred at 70°C for 
16 h. The cooled reaction mixture was diluted with dichloromethane and washed with 1 M HCl 
twice and satd aq NaHCO3 once. The organic layer was dried over MgSO4, filtered through a pad 
of celite, and concentrated in vacuo. The residue was purified by silica gel chromatography, eluting 
with 1:1 hexanes-EtOAc, yielding compound 4-2 as a white solid (5.0 g, 88%). 
1H NMR (500 MHz, DMSO-d6) δ 7.41 – 7.24 (m, 15H), 5.93 (d, J = 7.6 Hz, 1H), 5.45 (d, J = 4.0 
Hz, 1H), 4.54 (dd, J = 7.6, 5.5 Hz, 1H), 4.39 – 4.34 (m, 1H), 4.02 (ddd, J = 5.3, 4.0, 1.2 Hz, 1H), 
3.41 – 3.33 (m, 1H), 3.14 (dd, J = 11.0, 3.8 Hz, 1H). 
13C NMR (126 MHz, DMSO-d6) δ 176.2, 143.2, 128.2, 128.1, 127.3, 86.7, 83.4, 69.4, 68.6, 63.0. 
HRMS (ESI-TOF) m/z: [M+Na]+ Calcd for C24H22O5Na 413.1365; Found 413.1362 
 
2,3-bis-O-tert-butyldimethylsilyl-5-O-trityl-D-ribono-1,4-lactone (4-3): Synthesized with 
modification of previous reports.89 Specifically, to a 100 mL round bottom flask was added 4-2 
(2.0 g, 5.1 mmol, 1 eq), imidazole (1.9 g, 27 mmol, 5 eq), and dimethylformamide (20 mL). The 
solution was cooled to 0°C. Tert-butyldimethylsilyl chloride (2.9 g, 19 mmol, 4 eq) was added as 
a solid in one portion. Solution was allowed to warm to room temperature and was stirred for 16 
h. Reaction mixture was diluted with diethyl ether and quenched with the addition of satd aq 
NH4Cl. Organic layer was washed with satd aq NaHCO3 thrice and brine once. Organic layer was 
dried over Na2SO4, filtered, and concentrated. Residue was purified by silica gel chromatography, 
eluting with 5% Et2O-hexane, to yield compound 4-3 as a white foam (3.1 g, 97%). 
1H NMR (500 MHz, CDCl3) δ 7.40 (d, J = 8.4 Hz, 6H), 7.31 (t, J = 7.6 Hz, 6H), 7.25 (t, J = 7.1 
























J = 11.0, 3.7 Hz, 1H), 3.21 (dd, J = 11.0, 2.8 Hz, 1H), 0.93 (s, 9H), 0.80 (s, 9H), 0.18 (s, 3H), 0.11 
(s, 3H), 0.01 (s, 3H), -0.06 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 175.27, 143.19, 128.63, 128.18, 127.49, 84.70, 77.16, 72.16, 
70.44, 62.39, 25.96, 25.75, 18.51, 18.20, -3.45, -4.47, -4.70, -5.04. 
HRMS (ESI-TOF) m/z: [M+Na]+ Calcd for C36H50O5Si2Na 641.3094; Found 641.3093 
 
2,3-bis-O-tert-butyldimethylsilyl-5-O-trityl-D-ribose (4-4): A 1 M solution of (i-Bu2AlH)2 in 
hexane (17.5 mL, 17.5 mmol, 1.5 eq) was added dropwise via addition funnel over 5 min to a 
stirring solution of 4-3 (7.25 g, 11.7 mmol, 1 eq) in CH2Cl2 (120 mL) at -78 °C. The resulting 
solution was stirred at -78 °C for 3 h. Reaction was quenched with the addition of CH3OH (4 mL) 
added dropwise via addition funnel and allowed to warm to 0 °C. After stirring for 30 min, 200 
mL 0.5 M potassium sodium tartrate was added and mixture was stirred until aluminum salts were 
fully dissolved. Extracted mixture with CH2Cl2 three times. The combined organic layers were 
dried over MgSO4, filtered through a pad of celite, and concentrated. The residue was purified by 
silica gel chromatography, eluting with 10% Et2O-hexanes, to yield an interconverting mixture of 
diastereomers of compound 4-4 as a white foam (6.5 g, 90%). 
b anomer (major) 
1H NMR (500 MHz CDCl3) δ 7.50 – 7.43 (m, 6H), 7.35 – 7.30 (m, 6H), 7.29 – 7.24 (m, 3H), 5.13 
(dd, J = 11.4, 4.3 Hz, 1H), 4.24 (d, J = 11.4 Hz, 1H), 4.16 (t, J = 4.5 Hz, 1H), 3.92 (d, J = 4.6 Hz, 
1H), 3.26 (dd, J = 10.4, 4.9 Hz, 1H), 3.11 (dd, J = 10.4, 3.3 Hz, 1H), 0.93 (s, 9H), 0.85 (s, 9H), 
0.13 (s, 3H), 0.10 (s, 3H), 0.04 (s, 3H), -0.02 (s, 3H) 
a anomer (minor) 
1H NMR (500 MHz CDCl3) δ 7.50 – 7.43 (m, 6H), 7.35 – 7.30 (m, 6H), 7.29 – 7.24 (m, 3H), 5.19 
(d, J = 4.6 Hz, 1H), 4.40 (dd, J = 7.3, 4.0 Hz, 1H), 4.20 (t, J = 4.0 Hz, 1H), 4.11 (ddd, J = 7.0, 3.8, 
2.6 Hz, 1H), 3.97 (d, J = 4.1 Hz, 1H), 3.49 (dd, J = 10.3, 2.7 Hz, 1H), 3.10 (dd, J = 10.2, 3.9 Hz, 
1H), 2.71 (d, J = 4.6 Hz, 1H), 0.91 (s, 9H), 0.75 (s, 9H), 0.11 (s, 3H), 0.09 (s, 3H), -0.03 (s, 3H), -
0.19 (s, 3H) 
Both anomers 
13C NMR (126 MHz, CDCl3) δ 143.80, 129.01, 128.77, 128.01, 127.95, 127.26, 127.23, 102.19, 
97.90, 87.05, 87.01, 84.43, 81.78, 77.06, 74.56, 72.58, 71.74, 63.77, 63.31, 26.06, 25.96, 25.92, 











HRMS (ESI-TOF) m/z: [M+Na]+ Calcd for C36H52O5NaSi2 643.3251; Found 643.3251 
 
4-nitrophenyl 2,3-bis-O-tert-butyldimethylsilyl-5-O-trityl-D-ribofuranoside (4-5): To a 250 
mL round bottom flask, were added 4-4 (3.80 g, 6.11 mmol, 1 eq), 4-nitrophenol (2.51 g, 18.1 
mmol, 3 eq), 4 Å molecular sieves (200 mg), and toluene (100 mL). Cooled mixture to 0 °C. Added 
n-Bu3P (3.80 mL, 0.81 g/mL, 3.1 g, 15 mmol, 2.5 eq) dropwise via syringe. Added 1,1’-
(azodicarbonyl)dipiperidine as a solid in one portion. Mixture was stirred at 0 °C for 30 min and 
then allowed to warm to room temperature and stirred for an additional 4 h. The reaction mixture 
was cooled to 0 °C, and 30% H2O2 (5 mL) was added to fully quench phosphine. After stirring for 
30 min, the reaction mixture was diluted with hexane (100 mL). The resulting yellow precipitate 
was removed by filtration through a pad of celite. The filtrate was washed with satd aq NaHCO3 
five times, dried over Na2SO4, filtered, and concentrated. The residue was purified by silica gel 
chromatography, eluting with 5% Et2O-hexanes, to yield compounds 4-5 (a mixture of anomers, 
a:b 69:31) as a pale yellow foam (2.87 g, 63%). 
a-anomer 
1H NMR (500 MHz, CDCl3) δ 8.21 (d, J = 9.0 Hz, 2H), 7.48 – 7.43 (m, 6H), 7.32 (t, J = 7.7 Hz, 
6H), 7.29 – 7.24 (m, 3H), 7.13 (d, J = 9.3 Hz, 2H), 5.65 (d, J = 4.1 Hz, 1H), 4.38 (t, J = 4.7 Hz, 
1H), 4.18 (q, J = 3.0 Hz, 1H), 4.05 (dd, J = 5.2, 2.2 Hz, 1H), 3.42 (dd, J = 10.5, 3.5 Hz, 1H), 3.12 
(dd, J = 10.6, 3.1 Hz, 1H), 0.92 (s, 9H), 0.84 (s, 9H), 0.09 (s, 3H), 0.08 (s, 3H), 0.04 (s, 3H), -0.12 
(s, 3H). 
13C NMR (126 MHz, CDCl3) δ 162.98, 143.82, 142.01, 128.79, 128.04, 127.33, 125.94, 116.35, 
100.21, 86.98, 86.66, 73.83, 72.23, 63.43, 26.00, 25.86, 18.44, 18.17, -4.37, -4.39, -4.40, -4.73. 
HRMS (ESI-TOF) m/z: [M+Na]+ Calcd for C42H55NO7Si2Na 764.3415; Found 764.3413 
b-anomer 
1H NMR (500 MHz, CDCl3) δ 8.20 (d, J = 9.2 Hz, 2H), 7.38 – 7.33 (m, 6H), 7.20 – 7.13 (m, 11H), 
5.59 (d, J = 1.4 Hz, 1H), 4.41 (dd, J = 6.9, 4.1 Hz, 1H), 4.30 (dd, J = 4.1, 1.4 Hz, 1H), 4.23 (ddd, 
J = 6.9, 4.1, 2.6 Hz, 1H), 3.38 (dd, J = 10.6, 2.7 Hz, 1H), 3.00 (dd, J = 10.6, 4.2 Hz, 1H), 0.92 (s, 
9H), 0.76 (s, 9H), 0.13 (s, 3H), 0.13 (s, 3H), 0.02 (s, 3H), -0.16 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 162.09, 143.74, 142.27, 128.82, 127.75, 127.09, 125.87, 116.26, 




















HRMS (ESI-TOF) m/z: [M+Na]+ Calcd for C42H55NO7Si2Na 764.3415; Found 764.3414 
 
4-nitrophenyl 2,3-bis-O-tert-butyldimethylsilyl-D-ribofuranoside (4-6): To a stirring solution 
of compound 4-5 (5.26 g, 7.09 mmol, 1 eq) in dichloromethane (60 mL) at 0 °C was added 
trifluoroacetic anhydride (4.00 mL, 1.487 g/mL, 5.95 g, 28.3 mmol, 4 eq) as a 2 M solution in 
CH2Cl2 dropwise via addition funnel. Trifluoroacetic acid (1.6 mL, 1.489 g/mL, 2.38 g, 20.9 mmol, 
3 eq) was added as a 2 M solution in CH2Cl2 dropwise via addition funnel. Reaction was stirred at 
room temperature for another 10 min. Reaction mixture was quenched with the addition of Et3N 
(4 mL, 0.7255 g/mL, 2.9 g, 29 mmol, 4.1 eq) followed by CH3OH (30 mL). Mixture was stirred 
for an additional 15 min at room temperature before being diluted with H2O. Extracted three times 
with CH2Cl2. Combined organic layers were dried over Na2SO4 and concentrated in vacuo. 
Resulting residue was purified by silica gel chromatography (5:1 Hexane:EtOAc) to yield 
compound 4-6 (2.15 g, 61%) and undesired anomer (0.96 g, 27%). 
a-anomer (4-6) 
1H NMR (500 MHz, CDCl3) δ 8.17 (d, J = 9.2 Hz, 2H), 7.10 (d, J = 9.3 Hz, 2H), 5.60 (d, J = 3.6 
Hz, 1H), 4.20 – 4.15 (m, 3H), 3.81 (ddd, J = 12.2, 4.5, 2.5 Hz, 1H), 3.67 (ddd, J = 12.3, 7.0, 3.1 
Hz, 1H), 1.94 (dd, J = 7.4, 4.5 Hz, 1H), 0.91 (s, 18H), 0.12 (s, 3H), 0.09 (s, 3H), 0.07 (s, 6H). 
13C NMR (126 MHz, CDCl3) δ 162.65, 142.13, 125.91, 116.34, 100.21, 86.99, 77.16, 73.96, 
71.45, 62.32, 25.96, 25.90, 18.42, 18.20, -4.30, -4.39, -4.40, -4.71. 
HRMS (ESI-TOF) m/z: [M+Na]+ Calcd for C23H41NNaO7Si2 522.2314; Found 522.2297 
b-anomer 
1H NMR (500 MHz, CDCl3) δ 8.15 (d, J = 9.2 Hz, 2H), 7.07 (d, J = 9.2 Hz, 2H), 5.46 (d, J = 1.3 
Hz, 1H), 4.36 (dd, J = 7.0, 4.1 Hz, 1H), 4.21 (dd, J = 4.2, 1.3 Hz, 1H), 4.15 (dt, J = 6.7, 3.1 Hz, 
1H), 3.80 (ddd, J = 12.5, 4.4, 2.7 Hz, 1H), 3.54 (ddd, J = 12.4, 8.8, 3.5 Hz, 1H), 1.68 (dd, J = 8.8, 
4.3 Hz, 1H), 0.91 (s, 9H), 0.91 (s, 9H), 0.13 (s, 6H), 0.10 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 161.52, 142.47, 125.92, 116.23, 105.00, 84.24, 77.16, 76.85, 
70.72, 61.21, 25.94, 25.85, 18.20, 18.17, -4.15, -4.45, -4.46, -4.90. 

















4-nitrophenyl 2,3-bis-O-tert-butyldimethylsilyl-a-D-ribose-5-(difluorenylmethyl phosphate) 
(S5): To a 20 mL reaction vial, 4-6 (71.1 mg, 0.142 mmol, 1 eq) and bis-(9H-fluoren-9-ylmethyl)-
N,N-diisopropylamidophosphite37 (95.5 mg, 0.183 mmol, 1.3 eq) were added. Dissolved material 
by addition of CH2Cl2 (1.25 mL). Cooled solution to 0 ºC. 4,5-dicyanoimidazole (24.0 mg, 0.203 
mmol, 1.4 eq) was added as a solution in acetonitrile (0.25 mL). After stirring at 0 ºC for 15 min, 
mixture was allowed to warm to room temperature and was stirred for an additional 2 h. Once 
starting material was consumed as indicated by TLC (75:25 hexane:EtOAc), mixture was cooled 
to 0 ºC and subjected to dropwise addition of tert-butyl hydroperoxide (0.14 mL, 0.70 mmol, 5 eq) 
as a 5 M solution in decane. Mixture was stirred for an additional 1 h and quenched with H2O. 
Mixture was extracted with CH2Cl2 three times. Combined organic layers were dried over Na2SO4, 
concentrated, and purified by silica gel chromatography eluting with 60:40 hexane:EtOAc to yield 
compound 4-7 as a white foam (111.5 mg, 84%). 
1H NMR (500 MHz, CDCl3) δ 8.00 (d, J = 9.2 Hz, 2H), 7.77 – 7.70 (m, 4H), 7.57 (dd, J = 18.2, 
7.5 Hz, 2H), 7.52 (dd, J = 7.3, 6.3 Hz, 2H), 7.44 – 7.34 (m, 4H), 7.32 – 7.24 (m, 4H), 6.91 (d, J = 
9.2 Hz, 2H), 5.26 (m, 1H), 4.38 – 4.26 (m, 4H), 4.22 – 4.12 (m, 3H), 4.06 (ddd, J = 11.4, 5.8, 3.1 
Hz, 1H), 4.04 – 4.00 (m, 2H), 3.91 (ddd, J = 11.1, 7.0, 3.8 Hz, 1H), 0.91 (s, 9H), 0.90 (s, 9H), 0.11 
(s, 3H), 0.05 (s, 3H), 0.03 (s, 6H). 
13C NMR (126 MHz, CDCl3) δ 162.23, 143.16, 143.10, 142.98, 142.94, 142.10, 141.47, 141.44, 
128.10, 128.08, 128.06, 127.27, 127.22, 125.78, 125.21, 125.17, 125.13, 125.07, 120.19, 120.18, 
120.15, 116.09, 99.76, 83.93, 83.87, 77.16, 73.46, 71.13, 69.56, 69.51, 69.48, 69.43, 66.55, 66.51, 
48.03, 48.00, 47.97, 47.93, 25.90, 25.86, 18.38, 18.12, -4.25, -4.37, -4.47, -4.80. 
31P NMR (202 MHz, CDCl3) δ -0.41. 
HRMS (ESI-TOF) m/z: [M+Na]+ Calcd for C51H62NO10NaSi2P 958.3548; Found 958.3554. 
 
Triethylammonium 4-nitrophenyl 2,3-bis-O-tert-butyldimethylsilyl-a-D-ribose-5-phosphate 
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acetonitrile (5 mL) and triethylamine (freshly distilled from CaH2, 1 mL) successively. Stirred at 
room temperature for 16 h. Added 1 mL toluene to stirring solution and concentrated in vacuo. 
Residue was redissolved in methanol (0.5 mL) and purified by C-18 chromatography to yield the 
triethylammonium salt of compound 4-8 as a tan foam (241 mg, 71%). 
1H NMR (500 MHz, CD3OD) δ 8.20 (d, J = 9.3 Hz, 2H), 7.17 (d, J = 9.3 Hz, 2H), 5.71 (d, J = 4.2 
Hz, 1H), 4.39 (dd, J = 5.4, 4.2 Hz, 1H), 4.31 (dd, J = 5.4, 2.3 Hz, 1H), 4.20 (dq, J = 3.9, 1.9 Hz, 
1H), 3.99 (ddd, J = 10.1, 4.4, 3.1 Hz, 1H), 3.95 (ddd, J = 9.1, 4.6, 3.4 Hz, 1H), 3.17 (q, J = 7.3 Hz, 
6H), 1.31 (t, J = 7.3 Hz, 9H), 0.94 (s, 9H), 0.93 (s, 9H), 0.16 (s, 3H), 0.13 (s, 3H), 0.13 (s, 3H), 
0.10 (s, 3H). 
13C NMR (126 MHz, CD3OD) δ 164.14, 143.13, 126.62, 117.36, 101.35, 87.69 (d, J = 8.9 Hz), 
74.75, 73.14, 65.98 (d, J = 5.2 Hz), 47.40, 26.49, 26.46, 19.15, 18.96, 9.11, -4.10, -4.31 (2C), -
4.43. 
31P NMR (202 MHz, CD3OD) δ 0.77 
HRMS (ESI-TOF) m/z: [M-H]- Calcd for C23H41NO10PSi2 578.2012; Found 578.2017. 
 
2’,3’,5’-tris-O-(tert-butyldimethylsilyl)-adenosine (Precursor to 4-9):  To a 100 mL round-
bottom flask, adenosine (5.0 g, 19 mmol, 1 eq), imidazole (6.9 g, 102 mmol, 5.4 eq), and 
dimethylformamide (40 mL) were added. Once fully dissolved, solution was cooled to 0 °C. Tert-
butyldimethylsilyl chloride (12.2 g, 81 mmol, 4.2 eq) was added to the stirring solution. Once fully 
dissolved, reaction vessel was allowed to warm to room temperature. Stirred at room temperature 
for 16 h. Reaction was quenched by the addition of satd aq NH4Cl. Extracted three times with 
CH2Cl2. Combined organic layers were dried over MgSO4, filtered through a pad of celite, and 
evaporated. Residue was purified by silica gel chromatography eluting with 50:50 hexane:EtOAc 
to yield Precursor to 4-9 as a white foam (12.5 g, 96%). 
1H NMR (500 MHz, CDCl3) δ 8.32 (s, 1H), 8.15 (s, 1H), 6.11 (bs, 2H), 6.02 (d, J = 5.2 Hz, 1H), 
4.68 (t, J = 4.8 Hz, 1H), 4.31 (t, J = 3.9 Hz, 1H), 4.12 (q, J = 3.5 Hz, 1H), 4.02 (dd, J = 11.4, 4.2 
Hz, 1H), 3.77 (dd, J = 11.3, 2.9 Hz, 1H), 0.94 (s, 9H), 0.92 (s, 9H), 0.78 (s, 9H), 0.13 (s, 3H), 0.12 
(s, 3H), 0.09 (s, 3H), 0.09 (s, 3H), -0.06 (s, 3H), -0.24 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 155.70, 153.03, 150.05, 139.69, 120.19, 88.41, 85.58, 75.89, 
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HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C28H56N5O4Si3 610.3640; Found 610.3647 
 
2’,3’-bis-O-(tert-butyldimethylsilyl)-adenosine (4-9): A 500 mL round-bottom flask was 
charged with Precursor to 4-9 (4.4 g, 7.2 mmol, 1 eq). Compound was dissolved in wet 
tetrahydrofuran (120 mL). Solution was cooled to 0 ºC. To vigorously stirring solution, 
trichloroacetic acid (56 g, 340 mmol, 47 eq) was added as an ice-cold solution in H2O (25 mL). 
Stirred reaction mixture at 0 ºC for 3 h. Quenched reaction by slowly cannulating reaction mixture 
into ice cold satd aq NaHCO3. Once evolution of gas ceased, extracted three times with EtOAc. 
Dried organic layer over Na2SO4, filtered, and evaporated. Residue was purified by silica gel 
chromatography eluting with 95:5 CH2Cl2:CH3OH to yield compound 4-9 as a white solid (3.3 g, 
92%). 
1H NMR (500 MHz, 1:1 CDCl3:DMSO (v:v)) δ 8.24 (s, 1H), 8.11 (s, 1H), 7.29 (s, 2H), 6.08 (dd, 
J = 9.3, 3.3 Hz, 1H), 5.86 (d, J = 7.1 Hz, 1H), 4.87 (dd, J = 7.2, 4.5 Hz, 1H), 4.26 (dd, J = 4.4, 1.4 
Hz, 1H), 4.01 (q, J = 2.1 Hz, 1H), 3.75 (dt, J = 12.6, 3.2 Hz, 1H), 3.58 (ddd, J = 12.1, 9.4, 2.6 Hz, 
1H), 0.90 (s, 9H), 0.69 (s, 9H), 0.09 (s, 3H), 0.08 (s, 3H), -0.18 (s, 3H), -0.52 (s, 3H). 
13C NMR (126 MHz, 1:1 CDCl3:DMSO (v:v)) δ 156.22, 151.89, 148.40, 140.12, 119.86, 88.45, 
87.40, 73.99, 73.06, 61.60, 25.52, 25.33, 17.65, 17.36, -4.88, -4.97, -5.07, -6.02. 
HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C22H42N5O4Si2 496.2775; Found 496.2774 
 
Triethylammonium 2’,3’-bis-O-(tert-butyldimethylsilyl)-adenosin-5’-yl H-phosphonate (4-
10): To a 20 mL reaction vial was added compound 4-9 (324 mg, 0.654 mmol, 1 eq). Added dry 
pyridine (6.5 mL). Once fully dissolved, diphenyl phosphite (0.65 mL, 1.22 g/mL, 795 mg, 3.4 
mmol, 5 eq) was added, and reaction mixture was stirred at room temperature for 1.5 h. Then, 
water (0.5 mL) was added followed by triethylamine (0.5 mL). After stirring for an additional 30 
min, the reaction mixture was concentrated and purified by C-18 chromatography to yield the 
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1H NMR (500 MHz, CD3OD) δ 8.51 (s, 1H), 8.22 (s, 1H), 6.83 (d, 1JHP = 618.5 Hz, 1H), 6.10 (d, 
J = 6.7 Hz, 1H), 4.87 (dd, J = 6.7, 4.4 Hz, 1H), 4.41 (dd, J = 4.4, 1.9 Hz, 1H), 4.21 (td, J = 3.9, 2.1 
Hz, 1H), 4.14 (ddd, J = 11.0, 6.7, 4.2 Hz, 1H), 4.08 (ddd, J = 11.4, 6.7, 3.8 Hz, 1H), 3.15 (q, J = 
7.3 Hz, 6H), 1.27 (t, J = 7.3 Hz, 9H), 0.97 (s, 9H), 0.74 (s, 9H), 0.18 (s, 3H), 0.16 (s, 3H), -0.02 
(s, 3H), -0.31 (s, 3H). 
13C NMR (126 MHz, CD3OD) δ 157.20, 153.66, 151.00, 141.41, 120.32, 88.64, 86.71 (d, 3JCP = 
8.1 Hz), 77.07, 74.49, 64.22 (d, 2JCP = 4.5 Hz), 47.61, 26.44, 26.24, 18.90, 18.68, 9.16, -4.17, -
4.28 (2C), -5.08. 
31P NMR (202 MHz, CD3OD) δ 4.14 
HRMS (ESI-TOF) m/z: [M-H]- Calcd for C22H41N5O6PSi2 558.2338; Found 558.2323 
 
2’,3’-bis-O-(tert-butyldimethylsilyl)-adenosin-5’-yl 2-cyanoethyl phosphonate (4-11): To a 25 
mL round-bottom flask was added compound 4-10 (238 mg, 0.360 mmol, 1 eq). Dried material by 
co-azeotroping with dry acetonitrile three times. Pyridine was added (4 mL) and solution was 
cooled to 0 °C. 3-hydroxypropionitrile (0.070 mL, 1.04 g/mL, 73 mg, 1.0 mmol, 3 eq) was added 
to stirring solution. Pivaloyl chloride (0.09 mL, 0.98 g/mL, 88 mg, 0.73 mmol, 2 eq) was added 
dropwise. After stirring at 0 °C for 2.5 h, reaction mixture was concentrated, azeotroping with 
toluene. Resulting residue was redissolved in acetonitrile and purified by C-18 chromatography to 
yield compound 4-11 as a white solid as a mixture of diastereomers (159 mg, 72%). 
1H NMR (500 MHz, CDCl3) δ 8.30 (s, 1H), 8.30 (s, 1H), 8.00 (s, 1H), 7.98 (s, 1H), 6.91 (d, J = 
720.9 Hz, 1H), 6.83 (d, J = 723.5 Hz, 1H)  6.50 (d, J = 7.8 Hz, 2H), 5.87 (dd, J = 5.8, 4.2 Hz, 2H), 
4.89 (q, J = 4.1 Hz, 2H), 4.52 - 4.14 (m, 10H), 2.72 (t, J = 6.3 Hz, 2H), 2.69 (t, J = 6.2 Hz, 2H), 
0.90 (s, 9H), 0.90 (s, 9H), 0.80 (s, 18H), 0.10 (s, 3H), 0.09 (s, 3H), 0.09 (s, 3H), 0.08 (s, 3H), -0.03 
(s, 6H), -0.19 (s, 3H), -0.19 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 156.00, 155.96, 153.01, 149.52, 149.49, 140.14, 139.98, 120.54, 
116.33, 89.94, 89.83, 82.60, 82.57, 82.55, 82.52, 77.16, 74.42, 74.33, 71.68, 71.60, 64.90, 64.85, 
64.77, 64.73, 60.20, 60.16, 60.12, 60.08, 25.87, 25.76, 19.98, 19.93, 18.09, 17.94, -4.30, -4.31, -
4.61, -4.63, -4.75, -4.76, -4.83, -4.85. 































HRMS (ESI-TOF) m/z: [M-H]- Calcd for C25H44N6O6PSi2 611.2604; Found 611.2594 
 
a-1’’-O-(4-nitrophenyl)-2’,2’’,3’,3’’-O-tetrakis-(tert-butyldimethylsilyl)-ADP-ribose (4-12): 
To a 20 mL reaction vial was added 4-8 (158.6 mg, 0.233 mmol, 1.0 eq) and 4-11 (138.3 mg, 0.226 
mmol, 1.0 eq). Mixture was dried by co-azeotroping with dry acetonitrile three times and placing 
under vacuum over P2O5 for 12 h. The mixture was dissolved in acetonitrile (3.0 mL). Then, (i-
Pr2)2NEt (129 mg, 1.00 mmol, 4.4 eq) and N-chlorosuccinimide (90.8 mg, 0.68 mmol, 3 eq) were 
sequentially added as 1 M solutions in acetonitrile and stirred at room temperature for 1 h. 1,8-
diazabicycloundec-7-ene (350 mg, 2.3 mmol, 10 eq) was added as a 1 M solution in acetonitrile. 
After stirring for 30 min, reaction mixture was evaporated in vacuo and purified by C18 
chromatography to yield compound 4-12 as a white foam (287 mg, 88%). 
1H NMR (500 MHz, CD3OD) δ 8.67 (s, 1H), 8.18 (s, 1H), 8.14 (d, J = 9.2 Hz, 2H), 7.11 (d, J = 
9.2 Hz, 2H), 6.15 (d, J = 7.5 Hz, 1H), 5.64 (d, J = 4.3 Hz, 1H), 4.85 (dd, J = 7.5, 4.5 Hz, 1H), 4.46 
(d, J = 4.4 Hz, 1H), 4.37 (dd, J = 5.4, 4.2 Hz, 1H), 4.35 - 4.27 (m, 3H), 4.21 (ddt, J = 16.3, 4.3, 2.3 
Hz, 2H), 4.11 (hept, J = 5.7, 5.0 Hz, 2H), 3.58 - 3.53 (m, 4H), 3.50 (t, J = 6.5, 1.7 Hz, 4H), 3.36 
(t, J = 5.6 Hz, 4H), 2.73 - 2.67 (m, 4H), 1.99 (pd, J = 5.4, 1.3 Hz, 4H), 1.79 - 1.62 (m, 12H), 1.34 
(d, J = 6.5 Hz, 2H), 0.98 (s, 9H), 0.93 (s, 9H), 0.91 (s, 9H), 0.70 (s, 9H), 0.20 (s, 3H), 0.17 (s, 3H), 
0.15 (s, 3H), 0.13 (s, 3H), 0.11 (s, 3H), 0.08 (s, 3H), -0.01 (s, 3H), -0.38 (s, 3H). 
13C NMR (126 MHz, CD3OD) δ 167.42, 164.19, 157.30, 153.85, 151.17, 143.00, 141.66, 126.58, 
120.04, 117.32, 101.23, 87.89, 87.86, 87.82, 87.64, 87.56, 77.60, 74.87, 74.76, 73.28, 66.76, 66.71, 
66.66, 55.23, 49.53, 49.00, 39.34, 33.60, 30.01, 27.54, 26.49, 26.44, 26.21, 24.99, 20.43, 19.59, 
19.14, 18.97, 18.93, 18.65, -4.07, -4.09, -4.19, -4.26, -4.29, -5.26. 
31P NMR (202 MHz, CD3OD) δ -11.30 (d, J = 21.8 Hz), -11.67 (d, J = 21.6 Hz). 































































































pNP-ADPr: To a 25 mL round-bottom flask was added 4-12 (109.7 mg, 0.0761 mmol, 1 eq) and 
THF (3.0 mL). Once starting material was fully dissolve, triethylamine trihydrofluoride (0.5 mL) 
was added neat dropwise. Reaction vessel was sealed and heated to 65 ºC. Reaction was closely 
monitored by TLC (80:20 2-propanol:0.2% NH4OH(aq)) Once reaction had gone to completion, 
reaction mixture was cooled to room temperature and concentrated in vacuo. Remaining acid was 
quenched by dropwise addition of satd aq NaHCO3. Aqueous solution of crude product was 
purified by C18 chromatography utilizing ion-pairing reagent in the mobile phase (10 mM Et3N-
HOAc, pH 7.0) to yield compound 1 as a triethylammonium salt. The triethylammonium salt was 
eluted through Dowex 50W-8X (ammonium-form) to give the ammonium salt of pNP-ADPr as a 
white powder (53.8 mg, 98%). 
1H NMR (500 MHz, D2O) δ 8.36 (s, 1H, Ade-2), 8.03 (s, 1H, Ade-8), 7.92 (d, J = 9.2 Hz, 2H, 
pNP-3,5), 6.92 (d, J = 9.2 Hz, 2H, pNP-2,6), 6.04 (d, J = 5.7 Hz, 1H, Ade-1’), 5.67 (d, J = 4.4 Hz, 
1H, Rib-1’’), 4.62 (t, J = 5.7 Hz, 1H, Ade-2’), 4.46 (dd, J = 5.1, 3.6 Hz, 1H, Ade-3’), 4.41 (dd, J 
= 6.0, 4.6 Hz, 1H, Rib-2’’), 4.36 (m, 2H, Ade-4’, Rib-4”), 4.27 (dd, J = 6.2, 2.6 Hz, 1H, Rib-3’’), 
4.23 (m, 2H, Ade-5’), 4.08 (m, 2H, Rib-5’’). 
13C NMR (126 MHz, D2O) δ 161.8, 155.2, 152.5, 148.7, 141.5, 139.6, 125.6, 118.3, 116.3, 100.4, 
86.8, 84.7, 83.8, 74.5, 71.3, 70.4, 69.7, 65.7, 65.3. 
31P NMR (202 MHz, D2O) δ -11.2 




A 100 mL round bottom flask was charged with 4-(trifluoromethyl)umbelliferone (1.69 g, 7.36 
mmol, 1.5 eq), 2,3-di-(tert-butyldimethylsilyl)-5-(triphenylmethyl)-D-ribofuranose (4-3) (3.05 g, 
4.91 mmol, 1 eq), triphenylphosphine (1.93 g, 7.37 mmol, 1.5 eq), and 4 Å molecular sieves (600 
mg). Material was dissolved in dimethoxyethane (35 mL) and stirred for 15 min at room 
temperature. DIAD (1.45 mL, 7.36 mmol, 1.5 eq) was added dropwise. Reaction mixture was 
stirred at room temperature for 2 hours and then poured into hexane (400 mL). Resulting 
precipitate was removed by filtration. Filtrate was washed with satd aq NaHCO3 4x. Organic phase 






















give 4-13 (2.47 g, 60%) as a mixture of anomers. While anomers were could be separated by silica 
gel chromatography, the mixture of diastereomers was routinely carried into the next step as they 
were more easily separable with the trityl group removed. 
a-anomer 
1H NMR (500 MHz, CDCl3) δ 7.55 (dt, J = 9.1, 1.9 Hz, 1H), 7.39 – 7.34 (m, 6H), 7.27 – 7.21 (m, 
6H), 7.20 – 7.15 (m, 3H), 7.03 (d, J = 2.3 Hz, 1H), 6.95 (dd, J = 9.0, 2.4 Hz, 1H), 6.54 (s, 1H), 
5.55 (d, J = 4.2 Hz, 1H), 4.31 (dd, J = 5.3, 4.3 Hz, 1H), 4.08 (q, J = 3.1 Hz, 1H), 3.96 (dd, J = 5.2, 
1.9 Hz, 1H), 3.32 (dd, J = 10.6, 3.4 Hz, 1H), 3.03 (dd, J = 10.6, 3.1 Hz, 1H), 0.83 (s, 9H), 0.75 (s, 
9H), -0.00 (s, 6H), -0.05 (s, 3H), -0.21 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 161.79, 159.62, 156.25, 143.83, 141.75 (q, 2JCF = 32.8 Hz), 128.79, 
128.07, 127.34, 126.43 (d, 3JCF = 2.3 Hz), 121.79 (q, 1JCF = 275.5 Hz), 114.85, 112.50 (q, 3JCF = 
5.7 Hz), 107.61, 104.46, 100.23, 87.03, 86.87, 73.87, 72.25, 63.49, 26.01, 25.85, 18.44, 18.16, -
4.37, -4.41, -4.43, -4.72. 
19F NMR (471 MHz, CDCl3) δ -64.68. 
b-anomer 
1H NMR (500 MHz, CDCl3) δ 7.50 (dq, J = 8.9, 1.8 Hz, 1H), 7.25 – 7.20 (m, 6H), 7.06 – 7.01 (m, 
10H), 6.99 (dd, J = 9.0, 2.5 Hz, 1H), 6.48 (s, 1H), 5.45 (d, J = 1.3 Hz, 1H), 4.32 (dd, J = 6.9, 4.0 
Hz, 1H), 4.17 (dd, J = 4.1, 1.4 Hz, 1H), 4.09 (dt, J = 6.8, 3.3 Hz, 1H), 3.30 (dd, J = 10.6, 2.8 Hz, 
1H), 2.86 (dd, J = 10.7, 3.8 Hz, 1H), 0.80 (s, 9H), 0.63 (s, 9H), 0.00 (s, 3H), 0.00 (s, 3H), -0.11 (s, 
3H), -0.28 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 160.98, 159.37, 156.10, 143.77, 141.55 (q, 2JCF = 32.7 Hz), 128.85, 
127.75, 127.07, 126.43 (q, 3JCF = 2.4 Hz), 121.70 (q, 1JCF = 275.6 Hz), 114.14, 112.96 (q, 3JCF = 
5.7 Hz), 107.92, 105.19, 104.79, 86.55, 83.32, 76.62, 71.46, 62.51, 25.93, 25.90, 18.27, 18.11, -
3.98, -4.28, -4.37, -4.84. 
19F NMR (471 MHz, CDCl3) δ -64.75. 
HRMS (ESI-TOF) m/z: [M+Na]+ Calcd for C46H55O7F3NaSi2 855.3336; Found 855.3342. 
 
4-(trifluoromethyl)umbellifer-7-yl 2,3-bis-O-tert-butyldimethylsilyl-D-ribofuranoside (4-14) 
To a 100 mL-RBF equipped with addition funnel was added 4-13 (2.31 g, 2.77 mmol) and 



















mL of dichloromethane was added to stirring solution via addition funnel at room temperature. 
Trifluoroacetic acid (0.64 mL, 8.4 mmol, 3 eq) diluted with 5 mL of dichloromethane was added 
to stirring solution dropwise. Reaction mixture was stirred at room temperature for 20 min. 
Reaction mixture was neutralized by addition of neat triethylamine (5.0 mL, 36 mmol, 13 eq) via 
addition funnel followed by methanol (10 mL). Fuming mixture was stirred for 30 min and poured 
into satd aq NH4Cl. Layers were separated and aqueous layer extracted  3x with dichloromethane. 
Combined organic layers were dried over Na2SO4, filtered, and evaporated. Residue was purified 
by silica gel chromatography (6:1 hexane:EtOAc) to give separable anomers 4-14 (658 mg, 40%) 
and undesired anomer (767 mg, 47%) as white solids. 
a-anomer (4-14) 
1H NMR (600 MHz, CDCl3) δ 7.63 (dd, J = 9.0, 1.8 Hz, 1H), 7.09 (d, J = 2.4 Hz, 1H), 7.03 (dd, 
J = 9.0, 2.4 Hz, 1H), 6.62 (s, 1H), 5.60 (d, J = 3.7 Hz, 1H), 4.22 – 4.14 (m, 3H), 3.81 (dd, J = 12.3, 
2.7 Hz, 1H), 3.67 (dd, J = 12.2, 3.1 Hz, 1Hf), 1.82 (bs, 1H), 0.920 (s, 9H), 0.918 (s, 9H), 0.12 (s, 
3H), 0.09 (s, 3H), 0.08 (s, 3H), 0.08 (s, 3H). 
13C NMR (151 MHz, CDCl3) δ 161.44, 159.55, 156.17, 141.73 (q, 2JCF = 32.72 Hz), 126.49 (q, 
3JCF = 2.40 Hz), 121.74 (q, 1JCF = 275.62 Hz), 114.80, 112.68 (q, 3JCF = 5.68 Hz), 107.80, 104.46, 
100.25, 87.04, 74.01, 71.45, 62.34, 25.98, 25.91, 18.44, 18.21, -4.29, -4.36, -4.37, -4.69. 
19F NMR (564 MHz, CDCl3) δ -64.74. 
HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C27H42O7F3Si2 591.2421; Found 591.2437. 
b-anomer 
1H NMR (500 MHz, CDCl3) δ 7.64 (dd, J = 8.9, 1.9 Hz, 1H), 7.06 (d, J = 2.4 Hz, 1H), 7.01 (dd, 
J = 9.0, 2.4 Hz, 1H), 6.65 (s, 1H), 5.47 (d, J = 1.2 Hz, 1H), 4.38 (dd, J = 7.2, 4.1 Hz, 1H), 4.21 
(dd, J = 4.1, 1.2 Hz, 1H), 4.17 (dt, J = 7.2, 3.0 Hz, 1H), 3.86 – 3.79 (m, 1H), 3.56 (ddd, J = 12.4, 
9.1, 3.3 Hz, 1H), 1.46 (dd, J = 9.1, 4.2 Hz, 1H), 0.93 – 0.92 (s, 18H), 0.14 (s, 9H), 0.12 (s, 3H). 
13C NMR (151 MHz, CDCl3) δ 160.36, 159.23, 156.13, 141.54 (q, 2JCF = 32.82 Hz), 126.71 (q, 
3JCF = 2.40 Hz), 121.69 (q, 1JCF = 275.34 Hz), 114.34, 113.23 (q, 3JCF = 5.66 Hz), 108.27, 105.14, 
104.57, 84.23, 76.90, 70.68, 61.22, 25.99, 25.91, 18.28, 18.23, -4.08, -4.38, -4.41, -4.83. 
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(difluorenylmethyl phosphate) (4-15): To a stirring solution of compound 4-14 (373.9 mg, 0.633 
mmol) and N,N-diisopropyl bis(9-methylfluorenyl)phosphoramidite (403.8 mg, 0.774 mmol) in 
CH2Cl2 (12 mL). Dicyanoimidazole (151 mg, 1.3 mmol) was added as a solution in acetonitrile 
(4.8 mL). Stirred at room temperature for 3 h. Reaction mixture was cooled to 0 °C added t-
butylperoxide as a 5 M solution in decane (0.6 mL). Stirred at 0 °C for 1 h. Reaction mixture was 
quenched with water and extracted with CH2Cl2. Combined organic layers were dried over Na2SO4 
and evaporated. Residue was purified by silica gel chromatography (1:1 hexane:EtOAc) to give 
compound 4-15 as a yellow foam (579.5 mg, 90%). 
1H NMR (500 MHz, CDCl3) δ 7.76 – 7.68 (m, 4H), 7.58 – 7.46 (m, 5H), 7.43 – 7.32 (m, 4H), 7.31 
– 7.22 (m, 5H), 6.95 (d, J = 2.4 Hz, 1H), 6.86 (dd, J = 9.0, 2.4 Hz, 1H), 6.61 (s, 1H), 5.34 – 5.30 
(m, 1H), 4.34 (td, J = 6.3, 1.4 Hz), 4.29 (ddt, J = 9.9, 6.8, 3.7 Hz), 4.20 – 4.12 (m, 3H), 4.05 – 4.00 
(m, 3H), 3.90 (ddd, J = 11.1, 7.1, 3.8 Hz, 1H), 0.90 (s, 9H), 0.89 (s, 9H), 0.10 (s, 3H), 0.04 (s, 3H), 
0.02 (s, 3H), 0.02 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 161.13, 159.34, 156.03, 143.16 (d, J = 11.6 Hz), 143.04 (d, J = 
9.6 Hz), 141.53 (q, 2JCF = 32.8 Hz), 141.52, 141.47, 128.07 (d, J = 1.7 Hz), 127.28 (d, J = 1.2 Hz), 
127.26, 126.45 (q, 3JCF = 2.2 Hz), 125.22 (d, J = 6.8 Hz), 125.16 (d, J = 4.2 Hz), 121.72 (q, 1JCF = 
275.5 Hz), 120.19 (d, J = 1.9 Hz), 120.16, 114.20, 112.80 (q, 3JCF = 5.7 Hz), 107.81, 104.59, 99.82, 
84.30 (d, J = 7.4 Hz), 73.54, 71.26, 69.54 (t, J = 5.7 Hz), 66.66 (d, J = 5.8 Hz), 48.04 (dd, J = 7.9, 
5.7 Hz), 25.94, 25.88, 18.42, 18.15, -4.25, -4.36, -4.42, -4.74. 
19F NMR (471 MHz, CDCl3) δ -64.71. 
31P NMR (203 MHz, CDCl3) δ -1.55. 
HRMS (ESI-TOF) m/z: [M+Na]+ Calcd for C55H62O10F3NaSi2P 1049.3469; Found 1049.3500. 
 
Triethylammonium 4-(trifluoromethyl)umbellifer-7-yl 2,3-bis-O-tert-butyldimethylsilyl- -
D-ribose-5-phosphate (4-16): To a stirring solution of compound 4-15 (1.18 g, 1.00 mmol) in 
acetonitrile (10 mL) was added Et3N (freshly distilled from CaH2, 2.5 mL). Mixture was stirred at 
room temperature for 16 h. Reaction mixture was co-evaporated with toluene to dryness. Residue 

























1H NMR (500 MHz, CDCl3) δ 7.57 (dt, J = 9.0, 1.8 Hz, 1H), 7.04 (d, J = 2.4 Hz, 1H), 7.00 (dd, J 
= 9.0, 2.4 Hz, 1H), 6.56 (s, 1H), 5.54 (d, J = 4.1 Hz, 1H), 4.25 (dd, J = 5.4, 4.1 Hz, 1H), 4.22 (dd, 
J = 5.4, 1.9 Hz, 1H), 4.16 (dt, J = 4.0, 2.2 Hz, 1H), 3.98 (ddd, J = 11.3, 5.4, 3.8 Hz, 1H), 3.93 (ddd, 
J = 11.2, 5.6, 4.1 Hz, 1H), 3.06 (q, J = 7.3 Hz, 6H), 1.30 (t, J = 7.3 Hz, 9H), 0.86 (s, 9H), 0.86 (s, 
9H), 0.07 (s, 3H), 0.04 (s, 3H), 0.03 (s, 3H), 0.02 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 161.76, 159.58, 156.06, 141.72 (q, 2JCF = 32.6 Hz), 126.33 (q, 3JCF 
= 1.70 Hz), 121.66 (q, 1JCF = 275.6 Hz), 114.93, 112.20 (q, 3JCF = 5.7 Hz), 107.32, 104.07, 100.00, 
86.72 (d, 3JCP = 8.6 Hz), 73.52, 71.66, 64.78 (d, 2JCP = 4.8 Hz), 45.47, 25.90, 25.84, 18.29, 18.08, 
8.62, -4.46, -4.47, -4.49, -4.66. 
19F NMR (471 MHz, CDCl3) δ -64.74. 
31P NMR (203 MHz, CDCl3) δ 1.69. 
HRMS (ESI-TOF) m/z: [M+Na]+ Calcd for C27H42O10NaPF3Si2 693.1904; Found 693.1901. 
 
a-1’’-O-(4-(trifluoromethyl)umbellifer-7-yl)-2’,2’’,3’,3’’-O-tetrakis-(tert-
butyldimethylsilyl)-ADP-ribose (4-17): To a stirring solution of 4-16 (95.8 mg, 0.124 mmol) and 
4-11 (76.3 mg, 0.124 mmol) in dichloromethane (5 mL) was added DIPEA as a 1 M solution in 
CH3CN (0.74 mL, 0.74 mmol, 6 eq) and N-chlorosuccinimide as a 1 M solution in CH3CN (0.62 
mL, 0.62 mmol, 5 eq). Mixture was stirred for 30 min at room temperature and then 1,8-
diazabicycloundec-7-ene as a 1 M solution in THF (1 mL, 1 mmol, 8 eq) was added. After stirring 
for an additional 30 min, solvent was removed by rotavap. Residue was purified by C18 
chromatography to give 4-17 (124 mg, 70%) as a white solid. 
1H NMR (500 MHz, CD3OD) δ 8.29 (s, 1H), 7.81 (s, 1H), 7.24 (dd, J = 8.9, 2.0 Hz, 1H), 6.65 (m, 
2H), 6.29 (s, 1H), 5.73 (d, J = 7.2 Hz, 1H), 5.27 (d, J = 4.3 Hz, 1H), 4.42 (dd, J = 7.2, 4.4 Hz, 1H), 
4.05 (dd, J = 4.4, 1.3 Hz, 1H), 3.99 (dd, J = 5.4, 4.3 Hz, 1H), 3.95 – 3.87 (m, 3H), 3.85 – 3.80 (m, 
2H), 3.75 – 3.70 (m, 2H), 3.18 – 3.14 (m, 1H), 3.11 (t, J = 6.0 Hz, 2H), 2.96 (dd, J = 10.1, 4.4 Hz, 
2H), 2.91 (p, J = 1.6 Hz, 1H), 2.80 (q, J = 7.4 Hz, 3H), 2.33 – 2.27 (m, 2H), 1.60 (pd, J = 5.5, 1.1 
Hz, 2H), 1.38 – 1.24 (m, 4H), 0.97 (ddt, J = 14.4, 9.2, 5.2 Hz, 22H), 0.57 (s, 9H), 0.54 (s, 9H), 
0.51 (s, 9H), 0.31 (s, 9H), -0.21 (s, 3H), -0.24 (s, 3H), -0.25 (s, 3H), -0.28 (s, 3H), -0.29 (s, 3H), -




















































13C NMR (126 MHz, CD3OD) δ 163.03, 160.75, 157.36, 153.02, 151.00, 142.21, 141.85, 127.28, 
120.00, 115.77, 113.82, 108.45, 105.03, 101.34, 88.03, 87.46, 87.39, 77.72, 74.77, 73.27, 66.76, 
66.63, 55.43, 55.25, 43.49, 39.35, 33.62, 30.00, 27.54, 26.49, 26.48, 26.22, 24.99, 20.43, 19.57, 
19.14, 18.98, 18.92, 18.86, 18.65, 17.44, 13.05, 9.12, -4.09, -4.18, -4.20, -4.24, -4.28, -4.31, -5.21. 
19F NMR (470 MHz, CD3OD) δ -66.37. 
31P NMR (202 MHz, CD3OD) δ -10.38 (d, J = 21.2 Hz), -10.80 (d, J = 21.2 Hz). 
HRMS (ESI-TOF) m/z: [M-H]- Cald for C49H81F3N5O16P2Si4 1226.4188. Found 1226.4139. 
 
TFMU-ADPr: To a stirring solution of 4-17 (67.2 mg, 0.044 mmol) in THF (1 mL) was added 
triethylamine trihydrofluoride (0.3 mL). Mixture was heated to 65 °C and stirred for 2 h. Once 
cooled to room temperature, reaction was quenched with addition of satd aq NaHCO3. Aqueous 
mixture was purified by ion-pairing chromatography (10 mM Et3N-HOAc, C18) followed by ion 
exchange (Dowex 50W-8, ammonium form) to provide TFMU-ADPr as a white solid (33.8 mg, 
96%).  
1H NMR (500 MHz, D2O) δ 8.11 (s, 1H), 7.71 (s, 1H), 7.25 (dd, J = 9.1, 1.8 Hz, 1H), 6.70 (dd, J 
= 9.0, 2.5 Hz, 1H), 6.58 (d, J = 2.5 Hz, 1H), 6.50 (s, 1H), 5.76 (d, J = 5.6 Hz, 1H), 5.56 (d, J = 4.5 
Hz, 1H), 4.41 (t, J = 5.3 Hz, 1H), 4.33 – 4.28 (m, 2H), 4.28 – 4.25 (m, 1H), 4.22 (q, J = 4.1 Hz, 
1H), 4.15 (dd, J = 6.2, 2.8 Hz, 1H), 4.15 – 4.05 (m, 2H), 4.01 (ddd, J = 11.5, 5.0, 3.0 Hz, 1H), 3.94 
(dt, J = 11.4, 4.4 Hz, 1H). 
13C NMR (126 MHz, D2O) δ 161.71, 159.94, 154.33, 154.18, 151.56, 147.93, 141.37 (q, 2JCF = 
32.8 Hz), 139.31, 125.98, 121.09 (q, 1JCF = 275.1 Hz), 117.67, 114.65, 112.35 (q, 3JCF = 4.3 Hz), 
107.33, 103.50, 100.16, 86.90, 84.51 (d, 3JCP = 8.2 Hz), 83.42 (d, 3JCP = 8.3 Hz), 74.46, 71.13, 
70.10, 69.57, 65.66 (d, 2JCP = 4.0 Hz), 65.11 (d, 2JCP = 4.2 Hz). 
19F NMR (471 MHz, D2O) δ -64.43. 
31P NMR (203 MHz, D2O) δ -11.08 (d, J = 21.9 Hz), -11.28 (d, J = 21.5 Hz). 




































































2’,3’,5’-tris-O-(tert-butyldimethylsilyl)-inosine (4-18): Intermediate was prepared according to 
a modified version of a previous report 90. Briefly, a 100 mL round-bottom flask was charged with 
inosine (1.0 g, 3.7 mmol, 1 eq) and imidazole (1.7 g, 25 mmol, 6.7 eq). Material was dissolved in 
dimethylformamide (4 mL). Tert-butyldimethylsilyl chloride (2.8 g, 18.7 mmol, 5 eq) was added 
in one portion. The solution was stirred at room temperature for 16 h. Reaction mixture was diluted 
with CH2Cl2 and quenched with the addition of satd aq NaHCO3. Organic layer was washed two 
times with satd aq NaHCO3, dried over Na2SO4, filtered through a pad of celite, and evaporated to 
give 4-18 as a white solid (2.2 g, 96%) which was used in subsequent reactions without further 
purification. 1H NMR spectrum was consistent with literature. 
1H NMR (500 MHz, CDCl3) δ 12.94 (bs, 1H), 8.24 (s, 1H), 8.10 (s, 1H), 6.02 (d, J = 4.9 Hz, 1H), 
4.50 (t, J = 4.6 Hz, 1H), 4.30 (t, J = 4.0 Hz, 1H), 4.13 (q, J = 3.4 Hz, 1H), 4.00 (dd, J = 11.4, 3.7 
Hz, 1H), 3.79 (dd, J = 11.4, 2.5 Hz, 1H), 0.96 (d, J = 0.7 Hz, 9H), 0.93 (d, J = 0.7 Hz, 9H), 0.81 
(d, J = 0.7 Hz, 9H), 0.15 (s, 3H), 0.14 (s, 3H), 0.10 (s, 3H), 0.09 (s, 3H), -0.02 (s, 3H), -0.18 (s, 
3H). 
 
2’,3’-bis-O-(tert-butyldimethylsilyl)-inosine (4-19): A 100 mL round-bottom flask was charged 
with 4-18 (1.2 g, 2.0 mmol, 1 eq). Compound was dissolved in tetrahydrofuran (31 mL). Solution 
was cooled to 0 ºC. To vigorously stirring solution, trichloroacetic acid (15 g, 92 mmol, 47 eq) 
was added as an ice-cold solution in H2O (6.8 mL). Stirred reaction mixture at 0 ºC for 3 h. 
Quenched reaction by slowly cannulating reaction mixture into satd aq NaHCO3. Once evolution 
of gas ceased, extracted three times with EtOAc. Dried organic layer over Na2SO4, filtered, and 
evaporated. Residue was purified by silica gel chromatography eluting with 93:7 CH2Cl2:CH3OH 
to yield compound 4-19 as a white solid (641 mg, 66%). 
1H NMR (500 MHz, CDCl3) δ 13.34 (bs, 1H), 8.46 (s, 1H), 7.95 (s, 1H), 5.80 (d, J = 7.7 Hz, 1H), 
5.68 (bs, 1H), 4.87 (dd, J = 7.8, 4.6 Hz, 1H), 4.31 (d, J = 4.5 Hz, 1H), 4.16 (s, 1H), 3.93 (dd, J = 
12.9, 2.1 Hz, 1H), 3.72 (d, J = 13.0 Hz, 1H), 0.94 (d, J = 0.9 Hz, 9H), 0.75 (d, J = 0.9 Hz, 9H), 
0.12 (s, 3H), 0.11 (s, 3H), -0.12 (s, 3H), -0.52 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 158.90, 147.87, 145.79, 141.04, 126.72, 91.05, 89.33, 74.79, 73.84, 























HRMS (ESI-TOF) m/z: [M+H]+ Calc for C22H40N4O5Si2 497.2610; Found 497.2614 
 
Triethylammonium 2’,3’-bis-O-(tert-butyldimethylsilyl)-inosin-5’-yl H-phosphonate (4-20): 
A 100 mL round-bottom flask was charged with 4-19 (420 mg, 0.85 mmol, 1 eq) and pyridine (8.5 
mL). Diphenylphosphite (0.81 mL, 1.223 g/mL, 990 mg, 4.2 mmol, 5 eq) was added dropwise. 
After stirring reaction mixture at room temperature for 1.5 h, H2O (0.5 mL) and triethylamine (0.5 
mL) were added sequentially. Reaction was stirred for 30 min, then concentrated in vacuo. 
Remaining pyridine was removed by repeated azeotropic evaporation with toluene. Residue was 
purified by C18 chromatography to provide compound 4-20 as a white foam (464 mg, 83%). 
1H NMR (500 MHz, CD3OD) δ 8.48 (s, 1H), 8.16 (s, 1H), 6.84 (d, JHP = 620.8 Hz, 1H), 6.07 (d, 
J = 6.6 Hz, 1H), 4.83 (dd, J = 6.5, 4.4 Hz, 1H), 4.41 (dd, J = 4.4, 2.1 Hz, 1H), 4.24 - 4.20 (m, 1H), 
4.20 - 4.14 (m, 1H), 4.12 - 4.05 (m, 1H), 3.23 (q, J = 7.3 Hz, 6H), 1.30 (t, J = 7.3 Hz, 9H), 0.96 (s, 
9H), 0.77 (s, 9H), 0.17 (s, 3H), 0.15 (s, 3H), 0.00 (s, 3H), -0.27 (s, 3H). 
13C NMR (126 MHz, CD3OD) δ 158.78, 150.22, 146.99, 140.81, 125.52, 89.00, 86.60(d, JCP = 
8.0 Hz), 77.09, 74.17, 64.05 (d, J = 4.4 Hz), 47.49, 26.44, 26.26, 18.88, 18.67, 9.19, -4.18, -4.29, 
-4.31, -5.10. 
31P NMR (202 MHz, CD3OD) δ 4.11. 
HRMS (ESI-TOF) m/z: [M-H]- Calc for C22H41N4O7PSi2 559.2179; Found 559.2164. 
 
2’,3’-bis-O-(tert-butyldimethylsilyl)-inosin-5’-yl 2-cyanoethyl phosphonate (4-21): To a 20 
mL reaction vial was added compound 4-20 (246 mg, 0.372 mmol, 1 eq) and dry pyridine (4 mL). 
Solution was cooled to 0 ºC. 3-hydroxypropionitrile (0.070 mL, 1.04 g/mL, 73 mg, 1.0 mmol, 2.8 
eq) was added to stirring solution. Pivaloyl chloride (0.09 mL, 0.98 g/mL, 88 mg, 0.73 mmol, 2 
eq) was added dropwise. After stirring at 0 °C for 2.5 h, reaction mixture was concentrated, 






























































chromatography to yield compound 4-21 as a white solid as a mixture of diastereomers (166 mg, 
73%). 
1H NMR (500 MHz, CDCl3) δ 8.40 (s, 0.5H), 8.36 (s, 0.5H), 8.03 (s, 0.5H), 8.01 (s, 0.5H), 6.98 
(d, J = 722.4 Hz, 0.5H), 6.94 (d, J = 722.1 Hz, 0.5H), 5.90 (dd, J = 4.7, 3.2 Hz, 1H), 4.79 (t, J = 
4.5 Hz, 1H), 4.76 (t, J = 4.0 Hz, 1H), 4.52 – 4.23 (m, 7H), 2.87 – 2.75 (m, 2H), 0.92 (s, 9H), 0.91 
(s, 9H), 0.805 (s, 9H), 0.799 (s, 9H), 0.12 (s, 3H), 0.10 (s, 3H), 0.09 (s, 3H), -0.017 (s, 3 H), -0.022 
(s, 3H), -0.19 (s, 3H), -0.21 (s, 3H) 
13C NMR (126 MHz, CDCl3) δ 159.03, 148.66, 148.64, 145.75, 145.68, 139.73, 139.53, 125.75, 
125.69, 116.73, 116.60, 89.71, 89.64, 83.15, 83.10, 83.03, 82.97, 77.36, 74.94, 74.74, 71.73, 71.66, 
64.55, 60.60, 60.56, 60.53, 25.87, 25.75, 20.17, 20.12, 20.08, 18.10, 17.94, -4.30, -4.56, -4.58, -
4.69, -4.70, -4.90, -4.93. 
31P NMR (202 MHz, CDCl3) δ 8.66, 8.41. 
HRMS (ESI-TOF) m/z: [M-H]- Calc for C25H44N5O7PSi2 612.2444; Found 612.2448. 
 
a-1’’-O-(4-nitrophenyl)-2’,2’’,3’,3’’-O-tetrakis-(tert-butyldimethylsilyl)-IDP-ribose (TBS-
pNP-IDPr): To a 20 mL reaction vial was added 4-8 (41.1 mg, 0.0604 mmol, 1.0 eq) and 4-21 
(38.7 mg, 0.0630 mmol, 1.04 eq). Mixture was dried by co-azeotroping with dry acetonitrile three 
times and placing under vacuum over P2O5 for 12 h. The mixture was dissolved in acetonitrile (1.0 
mL). Then, (i-Pr2)2NEt (31 mg, 0.24 mmol, 4.0 eq) and N-chlorosuccinimide (24 mg, 0.18 mmol, 
3 eq) were sequentially added as 1 M solutions in acetonitrile and stirred at room temperature for 
1 h. 1,8-diazabicycloundec-7-ene (92 mg, 0.6 mmol, 10 eq) was added as a 1 M solution in 
acetonitrile. After stirring for 30 min, reaction mixture was evaporated in vacuo and purified by 
C18 chromatography to yield compound TBS-pNP-IDPr as a white foam (34.6 mg, 40%). 
1H NMR (500 MHz, CD3OD) δ 8.55 (s, 1H), 8.14 (d, J = 9.2 Hz, 2H), 8.08 (s, 1H), 7.12 (d, J = 
9.3 Hz, 2H), 6.08 (d, J = 7.5 Hz, 1H), 5.66 (d, J = 4.3 Hz, 1H), 4.46 (d, J = 4.3 Hz, 1H), 4.39 (dd, 
J = 5.4, 4.3 Hz, 1H), 4.35 – 4.28 (m, 3H), 4.23 (t, J = 4.8 Hz, 1H), 4.19 (dt, J = 4.3, 2.6 Hz, 1H), 
4.15 – 4.07 (m, 2H), 3.64 – 3.56 (m, 4H), 3.53 (t, J = 6.1 Hz, 4H), 3.36 (t, J = 5.6 Hz, 4H), 2.74 – 


















































0.91 (s, 9H), 0.73 (s, 9H), 0.20 (s, 3H), 0.17 (s, 3H), 0.15 (s, 3H), 0.13 (s, 3H), 0.11 (s, 3H), 0.08 
(s, 3H), -0.00 (s, 3H), -0.36 (s, 3H). 
31P NMR (202 MHz, CD3OD) δ -11.3 (d, J = 21.9 Hz), -11.6 (d, J = 21.8 Hz). 
13C NMR (126 MHz CD3OD) δ 167.50, 164.28, 159.27, 150.61, 147.02, 143.00, 141.44, 126.59, 
125.58, 117.36, 101.30, 88.57, 88.02 (d, J = 9.2 Hz), 87.70 (d, J = 9.3 Hz), 77.11, 74.81, 73.33, 
66.71 (d, J = 5.5 Hz), 66.52 (d, J = 5.4 Hz), 55.33, 49.57, 39.37, 33.70, 30.01, 27.53, 26.50 (3C), 
26.48, 26.22, 24.97, 20.44, 19.15, 18.99, 18.93, 18.68, -4.04, -4.11, -4.20, -4.23, -4.26, -4.30, -
4.32, -5.32. 
HRMS (ESI-TOF) m/z: [M-H]- Calc for C45H80N5O17P2Si4 1136.4107; Found 1136.4115. 
 
pNP-IDPr: To a 7 mL reaction vial was added TBS-pNP-IDPr (17.4 mg, 0.0121 mmol, 1 eq) and 
THF (1.0 mL). Once starting material was fully dissolve, triethylamine trihydrofluoride (0.2 mL) 
was added neat dropwise. Reaction vessel was sealed and heated to 60 ºC. Reaction was closely 
monitored by TLC (80:20 2-propanol:0.2% NH4OH(aq)). Once reaction had gone to completion, 
reaction mixture was cooled to room temperature and concentrated in vacuo. Remaining acid was 
quenched by dropwise addition of satd aq NaHCO3. Aqueous solution of crude product was 
purified by C-18 chromatography utilizing ion-pairing reagent in the mobile phase (10 mM Et3N-
HOAc) to yield compound pNP-IDPr as a triethylammonium salt. The triethylammonium salt was 
eluted through Dowex 50W-8X (ammonium-form) to give the ammonium salt of compound pNP-
IDPr  as a white powder (6.2 mg, 75%).  
1H NMR (500 MHz, D2O) δ 8.37 (s, 1H), 8.09 (s, 1H), 8.06 (d, J = 9.1 Hz, 2H), 7.06 (d, J = 9.0 
Hz, 2H), 6.06 (d, J = 5.9 Hz, 1H), 5.79 (d, J = 4.5 Hz, 1H), 4.70 (t, J = 5.5 Hz, 1H), 4.50 (dd, J = 
5.2, 3.5 Hz, 1H), 4.45 (dd, J = 6.2, 4.5 Hz, 1H), 4.42 - 4.37 (m, 2H), 4.31 (dd, J = 6.0, 2.5 Hz, 1H), 
4.29 – 4.22 (m, 2H), 4.16 - 4.05 (m, 2H) 
31P NMR (202 MHz, D2O) δ -11.14 (d, J = 21.8 Hz, 1P), -11.36 (d, J = 21.6 Hz, 1P) 
13C NMR (from 1H,13C-HMBC, 500 MHz, D2O) 162.04, 158.43, 148.37, 146.14, 141.63,139.60, 
125.85, 123.59, 116.73, 100.32, 87.36, 84.78, 83.97, 74.53, 71.21, 70.38, 69.64, 65.57, 64.86 















































butyldimethylsilyl)-IDP-ribose (TBS-TFMU-IDPr): To a stirring solution of 4-16 (93.6 mg, 
0.121 mmol) and 4-21 (75.5 mg, 0.123 mmol) in dichloromethane (1 mL) was added DIPEA as a 
1 M solution in CH3CN (0.73 mL, 0.73 mmol, 6 eq) and N-chlorosuccinimide as a 1 M solution 
in CH3CN (0.61 mL, 0.61 mmol, 5 eq). Mixture was stirred for 30 min at room temperature and 
then DBU as a 1 M solution in THF (1 mL, 1 mmol, 8 eq) was added. After stirring for an additional 
30 min, solvent was removed by rotary evaporator. Residue was purified by C18 chromatography 
to give TBS-TFMU-IDPr (126 mg, 68%) 
1H NMR (500 MHz, CD3OD) δ 8.56 (s, 1H), 8.09 (s, 1H), 7.65 (dd, J = 9.6, 2.0 Hz, 1H), 7.05 (dd, 
J = 6.8, 2.4 Hz, 3H), 6.70 (s, 1H), 6.07 (d, J = 7.4 Hz, 1H), 5.70 (d, J = 4.3 Hz, 1H), 4.89 (dd, J = 
7.4, 4.4 Hz, 1H), 4.44 (d, J = 4.5 Hz, 1H), 4.40 (dd, J = 5.4, 4.3 Hz, 1H), 4.35 – 4.25 (m, 6H), 4.22 
(q, J = 3.9 Hz, 4H), 4.12 (t, J = 4.7 Hz, 3H), 3.72 (hept, J = 6.7 Hz, 2H), 3.58 (m, 2H), 3.52 (t, J = 
5.9 Hz, 2H), 3.37 (t, J = 5.7 Hz, 2H), 3.20 (q, J = 7.4 Hz, 2H), 2.76 – 2.68 (m, 2H), 2.01 (pd, J = 
5.6, 1.3 Hz, 2H), 1.80 – 1.64 (m, 6H), 1.38 (t, J = 7.2 Hz, 14H), 0.96 (s, 9H), 0.94 (s, 9H), 0.91 (s, 
9H), 0.73 (s, 9H), 0.19 (s, 3H), 0.16 (s, 3H), 0.15 (s, 3H), 0.13 (s, 3H), 0.12 (s, 3H), 0.09 (s, 3H), 
-0.00 (s, 3H), -0.36 (s, 3H). 
13C NMR (126 MHz, CD3OD) δ 167.45, 163.08, 160.79, 158.93, 157.38, 150.54, 146.83, 142.33 
(q, 2JCF = 32.6 Hz), 141.41, 129.48, 127.29, 125.52, 123.23 (q, 1JCF = 274.9 Hz), 115.77, 113.81 
(q, 3JCF = 6.4 Hz), 108.44, 105.04, 101.36, 88.59, 88.12 (d, 3JCP = 9.2 Hz), 87.55 (d, 3JCP = 9.4 
Hz), 77.15, 74.79, 74.74, 73.31, 66.79 (d, 2JCP = 5.5 Hz), 66.54 (d, 2JCP = 5.4 Hz), 55.40, 55.27, 
43.49, 39.36, 33.64, 30.04, 27.56, 26.49, 26.49, 26.47, 26.22, 25.00, 20.44, 19.57 (d, J = 1.7 Hz), 
19.15, 19.00, 18.92, 18.67, 13.11, -4.06, -4.10, -4.20, -4.22, -4.24, -4.30, -4.32, -5.29. 
31P NMR (203 MHz, CD3OD) δ -11.41 (d, J = 21.3 Hz), -11.81 (d, J = 21.9 Hz). 

































































































TFMU-IDPr: To a stirring solution of TBS-TFMU-IDPr (119.9 mg, 0.78 mmol) in THF (1.0 
mL) was added triethylamine trihydrofluoride (0.5 mL, 3.1 mmol, 40 eq). Reaction mixture was 
sealed with Teflon cap and heated to 60 °C. After stirring at 60 °C for 2 h, solvent was removed 
by rotavap. Residue was neutralized with satd aq NaHCO3 and aqueous mixture was purified by 
ion-pairing chromatography (10 mM Et3N-HOAc, C18) followed by ion exchange (Dowex 50W-
8, ammonium form) to provide TFMU-IDPr (33.6 mg, 53%) as a white solid. 
1H NMR (500 MHz, D2O) δ 8.27 (s, 1H), 7.96 (s, 1H), 7.48 (dd, J = 9.1, 1.9 Hz, 1H), 6.93 (dd, J 
= 9.0, 2.4 Hz, 1H), 6.85 (d, J = 2.4 Hz, 1H), 6.70 (s, 1H), 5.95 (d, J = 5.6 Hz, 1H), 5.77 (d, J = 4.4 
Hz, 1H), 4.61 (t, J = 5.4 Hz, 1H), 4.49 – 4.42 (m, 2H), 4.44 – 4.39 (m, 1H), 4.37 (q, J = 3.8 Hz, 
1H), 4.30 (dd, J = 6.3, 2.8 Hz, 1H), 4.28 – 4.21 (m, 2H), 4.16 (ddd, J = 11.5, 5.1, 3.2 Hz, 1H), 4.09 
(dt, J = 11.3, 4.6 Hz, 1H). 
13C NMR (126 MHz, D2O) δ 161.91, 160.21, 157.82, 154.77, 148.22, 145.93, 141.55 (q, 2JCF = 
32.9 Hz), 139.48, 126.22, 123.33, 121.31 (q, 1JCF = 276.4, 275.8 Hz), 115.03, 112.72 (q, 3JCF = 8.2 
Hz), 107.67, 103.87, 100.30, 87.54, 84.77 (d, 3JCP = 8.2 Hz), 83.86 (d, 3JCP = 8.5 Hz), 74.62, 71.32, 
70.36, 69.71, 65.81 (d, 2JCP = 5.1 Hz), 65.29 (d, 2JCP = 5.3 Hz). 
31P NMR (202 MHz, D2O) δ -11.09 (d, J = 21.5 Hz), -11.31 (d, J = 21.3 Hz). 
19F NMR (470 MHz, D2O) δ -64.55. 
HRMS (ESI-TOF) m/z: [M-H]- Cald for C25H24F3N4O17P2 771.0569; Found 771.0566. 
4.6.3. Synthesis of amino sugar PARG inhibitors 
 
N-Fmoc-trans-4-hydroxyproline methyl ester (4-22): To a suspension of trans-4-
hydroxyproline methyl ester (900 mg, 4.95 mmol) in CH2Cl2 (25 mL) were added DIPEA (1.41 
mL, 10.9 mmol) and FmocCl (1.41 g, 5.45 mmol) at 0 ˚C. After stirring at room temperature for 
10 h, the reaction was quenched with water. The organic layer was separated and the aqueous layer 
was extracted with CH2Cl2. The combined organic layer was washed with brine, dried over 
MgSO4, filtered, and concentrated under reduced pressure. The residue was subjected to silica gel 
column chromatography (55% to 75% ethyl acetate/hexane) to afford N-Fmoc-trans-4-



















1H NMR (500 MHz, CDCl3): 7.75 (dd, J = 7.5, 2.5, 2H), 7.62-7.53 (m, 2H), 7.39 (t, J = 7.4 Hz, 
2H), 7.30 (t, J = 7.4, 2H), 4.55-4.38 (m, 3H), 4.37-4.28 (m, 1H), 4.28-4.22 (m, 0.5H), 4.17-4.12 
(m, 0.5H), 3.75-3.54 (m, 2H), 3.74 (s, 1.5H), 3.64 (s, 1.5H), 2.78 (br, 0.5H), 2.67 (br, 0.5H), 2.38-
2.27 (m, 1H), 2.12-2.04 (m, 1H). 
13C NMR (126 MHz, CDCl3) δ 173.20, 173.14, 155.14, 154.94, 144.10, 144.01, 143.85, 143.61, 
141.36, 141.31, 127.78, 127.75, 127.16, 125.19, 125.10, 124.97, 120.05, 120.04, 120.01, 70.11, 
69.24, 67.84, 67.69, 58.02, 57.66, 55.35, 54.72, 52.51, 52.45, 47.29, 47.21, 39.35, 38.46. 
HRMS (ESI): m/z calc. for C21H21NO5Na [M+Na]+: 390.1317, found: 390.1303. 
 
N-Fmoc-L-3,4-dehydroproline methyl ester (4-23): To a stirring solution of 4-22 (2.52 g, 6.85 
mmol) in CH2Cl2 (60 mL) at 0°C was added Martin’s Sulfurane dehydrating agent (4.93 g, 7.33 
mmol, 1.1 eq). Reaction mixture was stirred at 0°C for 1 h then allowed to warm to room 
temperature. After stirring for 3 h, the reaction mixture was quenched by the addition of satd aq 
NH4Cl. Aqueous layer was extracted with CH2Cl2. Combined organic layers were washed with 
brine, dried over anhydrous MgSO4, filtered, and evaporated. Residue was purified by silica gel 
chromatography (26% EtOAc/hexane) to provide expected alkene with some diphenyl sulfoxide 
contaminant. Diphenyl sulfoxide was removed by further purification via C18 chromatography, 
product eluting at ~60% H2O/THF (1.75 g, 73%). Observed rotamers in 52:48 ratio. 
1H NMR (500 MHz, CDCl3) δ 7.79 – 7.74 (m, 2H), 7.68 – 7.63 (m, 5H), 7.63 – 7.52 (m, 2H), 7.48 
– 7.42 (m, 7H), 7.40 (td, J = 7.4, 2.9 Hz, 2H), 7.32 (dddt, J = 7.4, 5.3, 2.5, 1.3 Hz, 2H), 6.03 – 5.96 
(m, 1H), 5.83 – 5.77 (m, 0.5H), 5.77 – 5.72 (m, 0.5H), 5.15 – 5.10 (m, 0.5H), 5.01 (ddd, J = 4.7, 
2.4, 1.2 Hz, 0.5H), 4.49 (ddd, J = 10.5, 6.6, 2.0 Hz, 1H), 4.44 – 4.35 (m, 1.5H), 4.35 – 4.26 (m, 
2H), 4.19 (t, J = 6.7 Hz, 0.5H), 3.76 (d, J = 0.9 Hz, 1.5H), 3.65 (d, J = 1.0 Hz, 1.5H). 
13C NMR (126 MHz, CDCl3) δ 170.53, 170.43, 154.43, 154.17, 145.72, 144.16, 144.13, 143.92, 
143.80, 141.42, 141.39, 131.13, 129.41, 129.23, 129.14, 127.81, 127.79, 127.74, 127.16, 127.14, 
127.12, 125.23, 125.14, 125.04, 124.97, 124.92, 124.87, 124.83, 124.80, 120.08, 120.06, 120.04, 
67.68, 67.62, 66.68, 66.23, 54.06, 53.50, 52.56, 52.53, 47.38, 47.30. 















N-Fmoc-(2S,3R,4S)-3,4-dihydroxyproline methyl ester (4-24): To a stirring solution of 4-23 
(1.59 g, 4.56 mmol) in t-BuOH (20 mL), THF (5 mL), and H2O (1 mL) was added OsO4 as a 0.2 
M solution in CH3CN (1.0 mL, 0.2 mmol, 4 mol %) and N-methylmorpholine-N-oxide (810 mg, 
6.9 mmol, 1.5 eq). Reaction mixture was stirred at RT for 3 h then quenched with satd aq Na2SO3 
and diluted with EtOAc (150 mL). Biphasic mixture was stirred for 1 h then separated. Organic 
layer was washed with satd aq NH4Cl and brine, dried over MgSO4, filtered, and evaporated. 
Residue was purified by silica gel chromatography (50% to 75% EtOAc/hexane) to provide 
expected product as a 9:1 mixture of diastereomers (1.597 g, 91%). 
1H NMR (500 MHz, CDCl3) δ 7.75 (dd, J = 7.6, 5.0 Hz, 2H), 7.61 – 7.50 (m, 2H), 7.39 (td, J = 
7.5, 3.5 Hz, 2H), 7.34 – 7.27 (m, 2H), 4.47 – 4.21 (m, 6H), 4.13 (td, J = 7.0, 4.0 Hz, 1H), 3.83 – 
3.78 (m, 1H), 3.76 (s, 1H), 3.73 (dd, J = 11.6, 5.3 Hz, 1H), 3.66 (s, 1H), 3.59 (ddd, J = 24.7, 11.4, 
4.3 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ 171.62, 155.22, 154.95, 143.96, 143.86, 143.79, 143.59, 141.37, 
127.88, 127.84, 127.22, 125.19, 125.17, 125.07, 124.96, 120.13, 120.09, 75.97, 74.89, 70.68, 
69.83, 68.01, 64.81, 64.58, 52.90, 52.80, 51.29, 51.02, 47.24, 47.16. 
HRMS (ESI): m/z calc. for C21H22NO6 [M+H]+: 384.1447, found: 384.1444. 
 
N-Fmoc-(2R,3R,4S)-3,4-bis((tert-butyldimethylsilyl)oxy)-proline methyl ester (4-25): To a 
stirring solution of 4-24 (1.52 g, 3.96 mmol) in CH2Cl2 at 0°C added 2,6-lutidine (1.40 mL, 1.30 
g, 12.1 mmol, 3 eq) and TBSOTf (2.74 g, 10.4 mmol, 2.6 eq). Reaction mixture was stirred at 0°C 
for 1.5 h and quenched with H2O. Mixture was extracted with CH2Cl2. Combined organic layers 
were washed with brine, dried over MgSO4, filtered and evaporated. Residue was purified by silica 
gel chromatography (10% EtOAc/hexane) to provide some fractions of a single diastereomer 
(1.569 g, 65%) and others as a mixture of diastereomers (459 mg, 19%). Two rotamers were 






























1H NMR (500 MHz, CDCl3) δ 7.76 (t, J = 6.9 Hz, 2H), 7.63 – 7.51 (m, 2H), 7.39 (q, J = 7.2 Hz, 
2H), 7.30 (td, J = 7.5, 2.9 Hz, 2H), 4.44 – 4.33 (m, 2H), 4.29 (t, J = 7.2 Hz, 0.55H), 4.24 (d, J = 
3.0 Hz, 0.55H), 4.22 – 4.12 (m, 3H), 3.78 (d, J = 1.2 Hz, 1.6H), 3.74 – 3.68 (m, 1H), 3.67 (d, J = 
1.2 Hz, 1.4H), 3.45 (dd, J = 10.2, 6.3 Hz, 0.44H), 3.40 (dd, J = 9.8, 6.4 Hz, 0.55H), 0.92 (s, 14H), 
0.89 (s, 4H), 0.10 (s, 9H), 0.08 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 171.53, 171.52, 155.10, 154.73, 144.28, 144.13, 144.04, 143.85, 
141.48, 141.45, 141.43, 141.41, 127.84, 127.82, 127.75, 127.22, 127.17, 127.14, 125.26, 125.23, 
125.16, 125.03, 120.11, 120.06, 77.02, 76.12, 71.82, 71.21, 67.74, 67.67, 65.65, 65.64, 52.57, 
52.52, 50.51, 50.49, 47.35, 47.29, 25.98, 25.96, 25.87, 18.28, -4.40, -4.42, -4.45, -4.52, -4.55, -
4.56, -4.98, -5.03. 
HRMS (ESI): m/z calc. for C33H50NO6Si2 [M+H]+: 612.3177, found: 612.3177. 
 
N-Fmoc-(2R,3R,4S)-3,4-bis((tert-butyldimethylsilyl)oxy)-2-(hydroxymethyl)pyrrolidine (4-
26): To a stirring solution of 4-25 (1485 mg, 2.43 mmol) in THF (24 mL) at 0°C was added lithium 
borohydride (305 mg, 14 mmol, 6 eq). Reaction mixture was stirred at 0°C for 2 h and then slowly 
warmed to RT and stirred for an additional 2 h. Reaction was cooled to 0°C and quenched by 
addition of 1 M HCl. Mixture was diluted with satd aq NH4Cl and extracted with EtOAc. 
Combined organic layers were washed with NaHCO3 and brine, dried over Na2SO4 and 
evaporated. Residue was purified by silica gel chromatography (25% EtOAc/hexane) to provide 
white solid (1.10 g, 78%). 
1H NMR (500 MHz, CDCl3) δ 7.77 (d, J = 7.5 Hz, 2H), 7.62 – 7.53 (m, 2H), 7.41 (t, J = 7.5 Hz, 
2H), 7.31 (t, J = 7.5 Hz, 2H), 4.67 – 4.54 (m, 0.5H), 4.44 (d, J = 6.9 Hz, 1.5H), 4.26 (t, J = 6.9 Hz, 
1H), 4.07 (td, J = 5.5, 3.6 Hz, 1H), 3.99 (s, 0.25H), 3.89 – 3.77 (m, 2.3H), 3.58 (dd, J = 11.1, 6.4 
Hz, 0.77H), 3.43 – 3.30 (m, 2H), 3.21 (t, J = 4.3 Hz, 0.74H), 0.95 – 0.88 (m, 9H), 0.86 (s, 3H), 
0.13 – 0.01 (m, 9H). 
13C NMR (126 MHz, CDCl3) δ 157.02, 144.07, 143.94, 141.55, 141.48, 127.88, 127.86, 127.21, 
127.16, 125.17, 125.09, 120.16, 120.10, 74.59, 71.22, 67.56, 66.05, 64.10, 51.48, 47.43, 25.98, 
25.96, 18.27, -4.10, -4.40, -4.47, -4.79. 


















fluorenylmethyl diisoproylphosphoramidite (4-27): To a stirring solution of 4-26 (40.3 mg, 
0.069 mmol) and 9-fluorenylmethyl tetraisopropylphosphorodiamidite (40.1 mg, 0.094 mmol, 1.4 
eq) in CH2Cl2 (2 mL) at 0°C was added tetrazole as a 0.45 M solution in CH3CN (0.18 mL, 0.081 
mmol, 1.2 eq). Reaction mixture was stirred at 0°C for 3 h. Solvent was removed by rotary 
evaporation, and residue was purified by silica gel chromatography (89:10:1 
hexane:EtOAc:diethylmethylamine) to provide phosphoramidite as a white foam (344.4 mg, 
89%). Despite appearing as two species by 31P NMR (likely rotamers), spectra of other nuclei 
reveal a complex mixture of rotamers. Compound decomposed analyzed by mass spectrometry. 
1H NMR (600 MHz, CDCl3) δ 7.79 – 7.72 (m, 4H), 7.72 – 7.53 (m, 5H), 7.45 – 7.22 (m, 8H), 4.57 
– 4.49 (m, 0H), 4.40 (ddd, J = 27.1, 10.4, 7.3 Hz, 1H), 4.36 – 4.12 (m, 4H), 4.00 (ddt, J = 18.7, 
8.6, 6.5 Hz, 1H), 3.87 – 3.74 (m, 2H), 3.69 (ddt, J = 14.5, 5.5, 3.7 Hz, 1H), 3.61 (ttt, J = 14.2, 6.9, 
3.7 Hz, 2H), 3.54 – 3.47 (m, 1H), 3.44 – 3.33 (m, 1H), 1.20 (d, J = 6.8 Hz, 2H), 1.18 – 1.10 (m, 
11H), 0.95 – 0.87 (m, 18H), 0.12 – 0.05 (m, 12H). 
13C NMR (151 MHz, CDCl3) δ 155.62, 155.58, 155.43, 155.42, 145.22, 145.14, 145.07, 144.86, 
144.80, 144.78, 144.45, 144.38, 144.36, 144.31, 144.26, 141.64, 141.61, 141.56, 141.54, 141.48, 
129.02, 128.32, 127.91, 127.74, 127.71, 127.34, 127.26, 127.14, 127.08, 125.79, 125.71, 125.46, 
125.33, 125.28, 125.25, 125.21, 120.21, 120.10, 120.03, 75.18, 74.92, 74.65, 74.44, 71.48, 71.46, 
71.03, 71.01, 67.58, 67.49, 67.32, 66.65, 66.52, 66.48, 66.44, 66.37, 66.32, 66.28, 65.99, 65.94, 
65.66, 65.60, 65.53, 65.43, 65.37, 62.27, 62.17, 61.98, 61.88, 61.57, 61.46, 61.30, 61.21, 50.96, 
50.85, 50.80, 50.69, 49.52, 49.47, 47.60, 47.55, 43.34, 43.31, 43.27, 43.24, 26.17, 25.03, 24.87, 
24.83, 18.50, -4.08, -4.22, -4.34, -4.40, -4.51, -4.60. 































































Tetrabutylammonium adenosine monophosphate (4-28): To a 20 mL syringe barrel was added 
Dowex 50Wx2, H-form (15 mL) and washed with MilliQ water (10 column volumns). In 2 mL 
portions, triethylamine was added to the top of the resin and washed with water until eluent was 
no longer basic. Adenosine monophosphate (2.0 g, 5.48 mmol) was dissolved in water (10 mL) 
and triethylamine (6 mL). Solution was added to the top of the resin and eluted with water (60 
mL). Solvent was removed from eluent by rotary evaporation (40 °C bath temperature) to provide 
triethylammonium adenosine monophosphate (2.37 g, 96%). A new 20 mL syringe barrel was 
loaded with Dowex 50Wx2, H-form (17 mL) and washed with MilliQ water (10 column volumns). 
In 2 mL portions, tetrabutylammonium hydroxide (40% w/v in water, 10 mL) was added to the 
top of the resin and washed with water until eluent was no longer basic. Triethylammonium 
adenosine monophosphate was dissolved in water (5 mL) and added to resin. Resin was washed 
with water (60 mL). Eluent was collected and lyophilized to give 4-28 as a white flocculent solid 
(2.26 g, 81%). 1H NMR indicates 1.3 molar equivalents of tetrabutylammonium cation. 
1H NMR (400 MHz, CD3OD) δ 8.61 (s, 1H), 8.19 (s, 1H), 6.11 (d, J = 6.2 Hz, 1H), 4.72 (dd, J = 
6.2, 5.0 Hz, 1H), 4.45 (dd, J = 5.0, 2.8 Hz, 1H), 4.26 – 4.20 (m, 1H), 4.15 – 4.03 (m, 2H), 3.27 – 
3.18 (m, 8H), 1.64 (dt, J = 11.5, 7.1 Hz, 8H), 1.40 (h, J = 7.4 Hz, 8H), 1.01 (t, J = 7.4 Hz, 12H). 
31P NMR (162 MHz, CD3OD) δ 1.44. 
 
Triethylammonium 3,4-bis((tert-butyldimethylsilyl)oxy)-ADP-HPD (4-29): To a 10 mL flask 
added 4-28 (292 mg, 0.497 mmol, 1.4 eq) and 4,5-dicyanoimidazole (76.1 mg, 0.644 mmol, 1.8 
eq). Dissolved in 4 mL DMF. 4-27 (320.8 mg, 0.353 mmol, 1 eq) was added as a solution in 4 mL 
DMF. Reaction mixture was stirred at RT for 1 h, then cooled to 0°C and t-BuOOH was added as 
a 5.5 M solution in decane (0.13 mL, 0.72 mmol, 2.0 eq). Reaction was stirred at 0°C for 1 h. 
Solvent was removed by rotary evaporation (60°C bath temp.). Residue was redissolved in CH3CN 
(5 mL) and H2O (5 mL). Triethylamine (3 mL) was added and mixture was stirred overnight at 
RT. Solvent was removed by rotary evaporation. Tetrabutylammonium cation was exchanged by 
elution through Dowex 50Wx2 resin (Et3N-form). Purification via C18 chromatography was 











































3. Et3N, CH3CN, H2O






1H NMR (500 MHz, CD3OD) δ 8.55 (s, 1H), 8.20 (s, 1H), 6.09 (d, J = 5.4 Hz, 1H), 4.64 (t, J = 
5.3 Hz, 1H), 4.45 (dd, J = 5.1, 3.5 Hz, 1H), 4.39 – 4.32 (m, 3H), 4.29 – 4.23 (m, 3H), 4.12 (dt, J = 
11.9, 4.9 Hz, 1H), 3.64 – 3.58 (m, 1H), 3.44 (dd, J = 12.2, 3.0 Hz, 1H), 3.19 (q, J = 7.3 Hz, 6H), 
3.14 (dd, J = 12.2, 1.8 Hz, 1H), 1.30 (t, J = 7.3 Hz, 9H), 0.94 (s, 9H), 0.93 (s, 9H), 0.18 (s, 3H), 
0.15 (s, 3H), 0.14 (s, 6H). 
13C NMR (126 MHz, CD3OD) δ 157.22, 153.77, 150.86, 141.11, 120.20, 89.12, 85.39 (d, J = 8.9 
Hz), 76.20, 73.88, 73.27, 71.84, 66.59 (d, J = 5.71 Hz), 62.79 (d, J = 4.7 Hz), 62.18 (d, J = 8.4 
Hz), 51.07, 47.76, 26.39, 26.35, 18.93, 18.82, 9.19, -4.00, -4.41, -4.48, -4.81. 
31P NMR (203 MHz, CD3OD) δ -11.25 (d, J = 22.5 Hz), -11.83 (d, J = 22.5 Hz). 
HRMS (ESI): m/z calc. for C27H53N6O12Si2P2 [M+H]+: 771.2735, found 771.2714. 
 
ADP-HPD: To a stirring solution of 4-29 (142 mg, 0.163 mmol) in 1:1 CH3OH:H2O (6 mL) was 
added trifluoroacetic acid (0.75 mL). Reaction mixture was stirred at RT for 2 h. Solvent was 
removed by rotary evaporation. Residue was purified by ion-pairing chromatography (40 mM 
Et3N•HOAc, pH 6.5). Product-containing fractions were combined and evaporated. 
Triethylammonium cation was exchanged for ammonium cation by elution through Dowex 50Wx2 
resin (NH4-form). After lyophilizing twice from H2O, obtained ADP-HPD as an adduct with one 
equivalent of ammonium acetate (28 mg, 31%). 
1H NMR (600 MHz, D2O) δ 8.43 (s, 1H, adenosyl H-8), 8.15 (s, 1H, adenosyl H-2), 6.09 (d, J = 
5.6 Hz, 1H, adenosyl H-1’), 4.73 (t, J = 5.4 Hz, 1H, adenosyl H-2’), 4.52 (dd, J = 5.1, 4.0 Hz, 1H, 
adenosyl H-3’), 4.42 – 4.34 (m, 4H), 4.26 – 4.18 (m, 3H), 3.79 – 3.75 (m, 1H), 3.49 (dd, J = 12.9, 
3.8 Hz, 1H, pyrrolidine H-5), 3.37 (dd, J = 12.9, 1.9 Hz, 1H, pyrrolidine H-5’), 1.92 (s, 3H, 
acetate). 
13C NMR (126 MHz, D2O) δ 181.34 (acetate C-1), 155.40 (adenosyl C-6), 152.74 (adenosyl C-
2), 148.90 (adenosyl C-4), 139.71 (adenosyl C-8), 118.49 (adenosyl C-5), 87.08 (adenosyl C-1’), 
83.66 (d, JCP = 8.7 Hz, adenosyl C-4’), 74.30 (adenosyl C-2’), 71.03, 70.32 (adenosyl C-3’), 69.60, 
65.40 (d, JCP = 5.5 Hz, pyrrolidine C-6), 62.26 (d, J = 4.9 Hz, adenosyl C-5’), 60.51 (d, J = 8.5 
Hz, pyrrolidine C-2), 49.76 (pyrrolidine C-5), 23.22 (acetate C-2). 
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HRMS (ESI): m/z calc. for C15H25N6O12P2 [M+H]+: 543.1006, found 543.1000. 
 
 1H 13C 1H-1H COSY 
Ado 1’ 6.09 (d, J = 5.6 Hz) 87.08 4.73 
Ado 2’ 4.73 (t, J = 5.4 Hz) 74.30 4.52 
Ado 3’ 4.52 (dd, J = 5.1, 4.0 Hz) 70.32 4.40 
Ado 4’ 4.40 83.66 (d, JP = 8.7 Hz) 4.52 
Ado 5’a 4.39 62.26 (d, JP = 4.9 Hz) 4.24 
Ado 5’b 4.24  4.39 
    
Ade 2 8.15 152.74 - 
Ade 4 - 148.90 - 
Ade 5 - 118.49 - 
Ade 6 - 155.40 - 
Ade 8 8.43 139.71 - 
    
HPD 2 3.77 60.51 (d, JP = 8.5 Hz) 4.21, 4.36 
HPD 3 4.36 71.03 3.77 
HPD 4 4.38 69.60 3.49, 3.37 
HPD 5a 3.49 (dd, J = 12.9, 3.8 Hz) 49.76 3.37, 4.38 
HPD 5b 3.37 (dd, J = 12.9, 1.9 Hz)  3.49, 4.38 
HPD 6a  65.40 (d, JP = 5.5 Hz)  
HPD 6b    
    
Acetate 1 - 181.34 - 
Acetate 2 1.92 23.22 - 
 
 
N-Fmoc-trans-4-O-TBS-proline methyl ester (4-30): To a solution of N-Fmoc-trans-4-
hydroxyproline methyl ester (1.49 g, 4.06 mmol) in DMF (24 mL) were added imidazole (552 mg, 
8.11 mmol) and TBSCl (795 mg, 5.27 mmol). After stirring at room temperature for 17 h, the 
reaction was diluted with diethylether and water. The organic layer was separated and the aqueous 
layer was extracted with diethylether. The combined organic layer was washed with brine, dried 
over MgSO4, filtered, and concentrated under reduced pressure. The residue was subjected to silica 
gel column chromatography (10% to 25% ethyl acetate/hexane) to afford N-Fmoc-trans-4-O-TBS-

















1H NMR (500 MHz, CDCl3): 7.77 (dd, J = 7.6, 2.3 Hz, 2H), 7.64-7.53 (m, 2H), 7.40 (t, J = 7.4 
Hz, 2H), 7.33-7.28 (m, 2H), 4.54-4.34 (m, 4H), 4.28 (t, J = 7.2 Hz, 0.6H), 4.19 (t, J = 6.8 Hz, 
0.4H), 3.77 (s, 1.8H), 3.73-3.65 (m, 1H), 3.65 (s, 1.2H), 3.55-3.46 (m, 1H), 2.29-2.19 (m, 1H), 
2.10-2.03 (m, 1H), 0.90 (s, 5.4H), 0.88 (s, 3.6H), 0.10-0.07 (m, 6H). 
13C NMR (126 MHz, CDCl3) δ 173.32, 173.25, 155.11, 154.67, 144.27, 144.12, 144.02, 143.83, 
141.42, 141.40, 127.78, 127.73, 127.19, 127.14, 125.23, 125.19, 125.14, 125.04, 120.08, 120.04, 
120.02, 70.60, 69.72, 67.68, 67.66, 58.13, 57.77, 55.32, 55.02, 52.47, 52.40, 47.39, 47.26, 40.13, 
39.09, 25.84, 18.10, -4.65, -4.70, -4.71, -4.74. 
HRMS (ESI): m/z calc. for C27H36NO5Si [M+H]+: 482.2363, found: 482.2350. 
 
N-Fmoc-trans-1-hydroxymethyl-4-O-TBS-pyrrolidine (4-31): To a solution of N-Fmoc-trans-
4-O-TBS-proline methyl ester (1.05 g, 2.18 mmol) in THF (11 mL) was added LiBH4 (237 mg, 
10.9 mmol) at 0 ˚C. The mixture was gradually warmed up to room temperature, and then 
quenched with 1 N HCl after 4 h. The organic layer was separated and the aqueous layer was 
extracted with ethyl acetate. The combined organic layer was washed with saturated aqueous 
NaHCO3 and brine, dried over MgSO4, filtered, and concentrated under reduced pressure. The 
residue was subjected to silica gel column chromatography (33% to 40% ethyl acetate/hexane) to 
afford N-Fmoc-trans-1-hydroxymethyl-4-O-TBS-pyrrolidine (953 mg, 96%) as a colorless gum. 
1H NMR (500 MHz, CDCl3): 7.77 (d, J = 7.6 Hz, 2H), 7.60 (dd, J = 7.5, 4.7, 2H), 7.41 (t, J = 7.5 
Hz, 2H), 7.32 (t, J = 7.4 Hz, 2H), 4.62 (m, 1H), 4.48-4.37 (m, 2H), 4.34 (m, 1H), 4.26 (t, J = 6.9 
Hz, 1H), 4.18 (m, 1H), 3.75 (d, J = 11.4 Hz, 1H), 3.59 (dd, J = 11.6, 7.1 Hz, 1H), 3.51-3.42 (m, 
2H), 2.02-1.96 (m, 1H), 1.68 (ddd, J = 13.1, 9.0, 4.4 Hz, 1H), 0.90 (s, 9H), 0.09 (s, 3H), 0.08 (s, 
3H). 
13C NMR (126 MHz, CDCl3) δ 157.25, 143.99, 143.89, 141.40, 141.38, 127.79, 127.12, 125.08, 
125.04, 120.07, 120.04, 69.83, 67.67, 66.50, 59.68, 56.11, 47.29, 38.00, 25.82, 18.07, -4.66, -4.75. 




































(iPr2N)(OFm)P-O-(Fmoc,TBS-HPM) (4-32): To a solution of N-Fmoc-trans-1-hydroxymethyl-
4-O-TBS-pyrrolidine (294 mg, 0.648 mmol) and (iPr2N)2P(OFm) (399 mg, 0.935 mmol) in 
CH2Cl2 (6.5 mL) was added tetrazole (0.45 M solution in CH3CN, 1.87 mL, 0.842 mmol) at 0 ˚C. 
After stirring at that temperature for 3 h, the mixture was diluted with hexane. Then white 
precipitate was filtered and the filtrate was concentrated under reduced pressure. The residue was 
subjected to silica gel column chromatography (short column, eluted rapidly with 15% ethyl 
acetate/hexane) to afford (iPr2N)(OFm)P-O-(Fmoc,TBS-HPM) (464 mg, 92%) as af white solid. 
Intermediate hydrolyzed easily, so was taken forward to next step immediately. 
1H NMR (500 MHz, CDCl3): 7.83-7.60 (m, 8H), 7.47-7.29 (m, 8H), 4.62-3.48 (m, 14H), 2.26-
2.16 (m, 1H), 2.09-1.99 (m, 1H), 1.27-1.17 (m, 12H), 0.96-0.91 (m, 9H), 0.14-0.09 (m, 6H). 
13C NMR (126 MHz, CDCl3) δ 155.04, 144.98, 144.70, 144.29, 144.23, 144.15, 141.41, 141.36, 
141.32, 141.27, 127.68, 127.65, 127.53, 127.50, 127.47, 127.43, 127.15, 127.10, 127.06, 127.02, 
126.96, 126.93, 126.89, 125.51, 125.47, 125.29, 125.26, 125.24, 125.19, 125.10, 125.07, 125.03, 
120.01, 119.99, 119.90, 119.84, 77.36, 70.57, 70.54, 69.96, 69.93, 67.29, 67.16, 66.41, 66.26, 
66.15, 66.07, 65.95, 65.90, 64.52, 64.42, 64.31, 63.62, 63.54, 63.42, 57.35, 57.30, 57.25, 56.82, 
55.52, 55.43, 55.33, 49.28, 49.22, 47.38, 43.11, 43.08, 43.02, 42.98, 38.58, 38.38, 37.67, 37.43, 
25.87, 24.80, 24.74, 24.68, 24.63, 18.09, -4.61, -4.69, -4.73. 
31P NMR (202 MHz, CDCl3): 148.8, 148.5, 147.6. 
HRMS (EI): m/z calc. for C46H59N2O5PSi [M+H]+: 778.3931, found: 778.3952. 
 
TBS-ADP-HPM triethylamine salt (4-33): To a solution of 4-28 (317 mg, 0.539 mmol) and 4,5-
dicyanoimidazole (81.8 mg, 0.693 mmol) in DMF (3.85 mL) was added 4-32 (300 mg, 0.385 
mmol, solution in 1.9 mL DMF). The mixture was stirred at room temperature for 30 min, and 
then TBHP (5.5 M in decane, 0.175 mL, 0.963 mmol) was added at 0 ˚C. The mixture was stirred 
at room temperature for further 30 min, and solvents were evaporated. This crude pyrophosphate 
was dissolved in CH3CN (3.85 mL) and water (3.85 mL), and then Et3N (1.92 mL) was added for 
the deprotection of Fmoc and Fm groups. After stirring at room temperature for 12 h, the mixture 
was diluted with 50% aqueous MeOH and washed with hexane. The aqueous layer was 










































3. Et3N, CH3CN, H2O




(Dowex 50WX8, pre-equilibrated with Et3N in 20% aqueous MeOH). The solvents were 
evaporated, and the residue was subjected to C18 column chromatography (0% to 100% 
CH3CN/water) to afford TBS-ADP-HPM triethylamine salt (198 mg, 69% for 2 steps) as a white 
solid. 
1H NMR (CD3OD, 500 MHz): 8.55 (s, 1H), 8.20 (s, 1H), 6.09 (d, J = 5.4 Hz, 1H), 4.66-4.63 (m, 
2H), 4.46 (dd, J = 5.1, 3.4 Hz, 1H), 4.35-4.23 (m, 4H), 4.14-4.05 (m, 2H), 3.38 (dd, J = 12.1, 3.4 
Hz, 1H), 3.15 (q, J = 7.3 Hz, 6H), 2.05 (dd, J = 8.3, 2.8 Hz, 2H), 1.30 (t, J = 7.3 Hz, 9H), 0.92 (s, 
9H), 0.11 (s, 6H). 
13C NMR (CD3OD, 125 MHz): 157.2, 153.8, 150.7, 141.0, 120.2, 89.2, 85.2 (d, 3JCP = 9.1 Hz), 
76.2, 72.9, 71.8, 66.5 (d, 2JCP = 5.1 Hz), 65.3 (d, 2JCP = 4.2 Hz), 59.6 (d, 3JCP = 8.4 Hz), 54.6, 47.4, 
37.0, 26.2, 18.8, 9.1, -4.8, -4.9. 
31P NMR (CD3OD, 202 MHz): -10.22 (d, J = 22.4 Hz), -10.58 (d, J = 22.4 Hz). 
HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C21H39N6O11P2Si 641.1921; Found 641.1917. 
 
ADP-HPM: TBS-ADP-HPM ammonium salt was prepared by the previous procedure with 
NH4OH for pre-equilibration in cation exchange step. To a solution of monoTBS-ADP-HPM (33.8 
mg, 0.0514 mmol) in MeOH (1 mL) and water (1 mL) was added TFA (0.5 mL). The mixture was 
stirred at room temperature for 4.5 h, and the solvents were evaporated. The residue was subjected 
to C18 column chromatography (0% to 100% CH3CN/40 mM NH4OAc aq) to afford ADP-HPM 
(22.8 mg, 82%) as a white solid. 
1H NMR (500 MHz, Deuterium Oxide) δ 8.38 (s, 1H), 8.09 (s, 1H), 6.03 (d, J = 5.6 Hz, 1H), 4.67 
(t, J = 5.4 Hz, 1H), 4.56 (t, J = 4.0 Hz, 1H), 4.45 (dd, J = 5.1, 3.8 Hz, 1H), 4.32 (br, 1H), 4.22 (dt, 
J = 11.7, 3.7 Hz, 1H), 4.16 (s, 1H), 4.09 (dtd, J = 9.7, 6.6, 2.9 Hz, 1H), 3.97 (dt, J = 11.5, 5.8 Hz, 
1H), 3.33 (dd, J = 12.6, 3.6 Hz, 1H), 3.24 (dt, J = 12.6, 1.5 Hz, 1H), 2.06 (ddt, J = 14.2, 7.2, 1.7 
Hz, 1H), 1.96 (ddd, J = 14.3, 10.4, 4.3 Hz, 1H).  
13C NMR (126 MHz, Deuterium Oxide) δ 155.34, 152.66, 148.82, 139.57, 118.38, 86.88, 83.61 
(d, 3JCP = 8.6 Hz), 74.17, 70.22, 69.70, 65.25 (d, 2JCP = 4.7 Hz), 64.14 (d, 2JCP = 4.6 Hz), 58.07 (d, 
3JCP = 8.0 Hz), 52.65, 34.29. 















































HRMS (ESI-TOF) m/z: [M+H]+ Cald for C15H25N6O11P2 527.1057; Found 527.1046. 
 
9-fluorenylmethyl tetraisopropylphosphorodiamidite:91 To a 100 mL round-bottom flask was 
added 9-fluorenylmethanol (2.01 g, 10.2 mmol, 1.0 eq) and dried under vaccum for 1 h. Material 
was dissolved in THF (5 mL) and diethyl ether (25 mL). Triethylamine (1.40 mL, 0.726 g/mL, 
10.0 mmol, 0.98 eq) was added and reaction mixture was cooled to 0 °C. 
Chlorodiisopropylphosphine (2.72 g, 10.2 mmol, 1.0 eq) was added in one portion and reaction 
mixture was stirred at 0 °C for 2.5 h. Precipitate was removed by filtration. Filtrate was diluted 
with hexane, washed with brine, dried over Na2SO4, and evaporated. Residue was partially purified 
by passing through a plug of neutral Al2SO3, eluting with 2:1 hexane:Et2O. After evaporation of 
the eluent, residue was recrystallized from Et2O to give white needles (2.66 g, 61%). 
1H NMR (600 MHz, CDCl3) δ 7.75 (d, J = 7.6 Hz, 2H), 7.69 (dd, J = 7.5, 1.0 Hz, 2H), 7.37 (t, J 
= 7.4 Hz, 2H), 7.30 (td, J = 7.4, 1.1 Hz, 2H), 4.20 (t, J = 6.7 Hz, 1H), 3.90 (t, J = 6.8 Hz, 2H), 3.54 
(dhept, J = 10.7, 6.7 Hz, 4H), 1.17 (d, J = 6.8 Hz, 12H), 1.15 (d, J = 6.6 Hz, 13H). 
13C NMR (151 MHz, CDCl3) δ 145.45, 141.48, 127.35, 126.86, 125.38, 119.84, 67.02 (d, J = 22.5 
Hz), 49.87 (d, J = 9.4 Hz), 44.64 (d, J = 12.3 Hz), 24.68 (d, J = 8.0 Hz), 24.06 (d, J = 5.9 Hz). 
31P NMR (243 MHz, CDCl3) δ 121.80. 
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